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ABSTRACT 
 
 
Protein phosphatases (PPases) are important enzymes which mediate dephosphorylation 
of proteins in eukaryotic cells. These enzymes are involved in a variety of cellular 
processes, and disruption of their activity has been shown to be involved in the 
development of diseases such as cancers and Alzheimer’s. Protein phosphatase inhibitors 
(PPIs) have been used to regulate the activity of these enzymes, and hence, control the 
development of the cellular processes related to them. However, the lack of potent and 
selective readily accessible PPIs is a major obstacle to the understanding of these complex 
biological pathways, and the development of reliable synthetic routes towards new PPIs 
has therefore generated a significant amount of interest. 
 
 
 
Figure 1. (2S,3S,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl- 
10-phenyldeca-4E,6E-dienoic acid (ADDA). 
 
Several naturally occurring PPIs possess the “ADDA” residue (Figure 1), which has been 
shown to be crucial for their inhibitory activity. We would like here to report the synthesis 
of “ADDA”-isoforms such as enantio-ADDA 1 and enantio-iso-ADDA 2 (Scheme 1) 
through a convergent approach taking advantage of cross-metathesis methodology, non-
aldol aldol and aza-Claisen rearrangements, as well as β-lactam chemistry.   
  
 
 
Scheme 1. enantio-ADDA and enantio-iso-ADDA residues. 
 
We envisage using our synthetic approaches as a platform to generate a wide range of 
novel “ADDA”-containing analogues, which might lead to the discovery of potent and 
selective PPIs, which could be generated in multi-gram scale. 
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1 - THE PROTEIN PHOSPHATASES (PPase)1 
 
1.1 – General introduction on PPases 
 
1.1.1 The phosphorylation/dephosphorylation cycle 
 
This reversible phosphorylation/dephosphorylation cycle (Scheme 2) is widely 
recognised as being critically involved in the regulation of countless eukaryotic cellular 
processes.2 It is mediated by protein kinases (PKs), which catalyse the phosphorylation of 
hydroxyl-bearing amino acid in using ATP as a phosphoryl donor, and protein 
phosphatases (PPs) which regulate the dephosphorylation process. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Reversible phosphorylation/dephosphorylation cycle. 
 
Both phosphatases and kinases act in opposition to mediate the 
phosphorylation/dephosphorylation process, represented by the simplified cycle above 
(Scheme 2). This process can be considered as a molecular « on-off » switch that acts to 
selectively modulate the activity of a myriad of other cellular processes, and signalling 
pathways such as cell division, gene expression, glycogen synthesis, muscle contraction, 
and neurotransmission. Indeed, the addition or the removal of a phosphate group may 
activate or de-activate an enzyme, or enable a protein-protein interaction to occur, and 
thus represents one of the most important means by which eukaryotic cells communicate 
in the body. To reverse the regulatory effect, the phosphate can be removed on its own by 
hydrolysis, or by protein phosphatase-mediated dephosphorylation. 
KINASES
NR
R
R OH
O
OH
NR
R
R OPO3H
-
O
OH
PHOSPHATASES
Phosphorylation
Dephosphorylation
Serine
Threonine
Tyrosine
 
 - 18 - 
1.1.2 Classification of protein phosphatases 
 
The phosphoprotein phosphatases represent a very broad family subdivided in five major 
subunits based upon their substrate specificity: 
 
- Serine/threonine specific PPases 
- Tyrosine-specific PPases 
- Dual Specificity PPases 
- Histidine PPases 
- Lipid PPases 
 
As part of this project, we are essentially interested in the synthesis of inhibitors of 
serine/threonine phosphatases. As such, the rest of the introduction will be focused 
around this specific class of PPases. 
 
1.1.3 Classical disorders 
 
The level of protein phosphorylation in cells is finely regulated by the complementary 
actions of protein kinases and protein phosphatases. This subtle balance is critical to 
maintaining both cellular and whole organism homeostasis, and even minor disturbance 
of this regulation process can lead to dramatic side effect on cell life. The abnormal 
phosphorylation levels have been shown to be narrowly linked to the development of 
cancers, diabetes, Alzheimer’s and inflammatory diseases. A better understanding of the 
mechanism by which the PPs and PKs catalyse and finely regulate the level of 
phosphorylation would lead to major discovery, and would enable the design of new 
therapeutic treatments. 
 
1.2 - Serine/threonine-specific protein phosphatases3 
 
At least 99% of protein phosphorylation in eukaryotic cells occurs on serine and threonine 
residues.4 Interestingly, while the human genome encodes an almost equal number of 
tyrosine kinases and tyrosine phosphatases (90 vs 107), there is a dramatic disparity 
between the number of serine/threonine kinases and phosphatases (428 vs 40).5 
Furthermore, the lack of selective protein phosphatases inhibitors available, which can be 
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used as biological probes,6 have considerably limited the number of studies on the 
functions of serine/threonine protein phosphatases, by comparison with protein kinases.6 
For these reasons, protein phosphatases represents a very challenging and fascinating 
research area largely under explored. 
 
1.2.1 Classification of Ser/Thr PPases 
 
Ser/Thr phosphatases are metalloenzymes which dephosphorylate their phosphoserine 
and/or phosphothreonine-containing substrates in a single reaction step, using a metal-
activated nucleophilic water molecule. They belong to the two major PPP and PPM (Mg2+-
dependent phosphatases) families of protein phosphatases, and are traditionally classified 
into several sub-families (PP1 to PP7), based upon fine and subtle characteristics such as 
their apparent sensitivity to inhibitors, their structural differences, and their in vitro 
substrate specificity.1 These different sub-families of PPases are themselves subdivided 
into different types (A, B, C), which in turn can contain distinct isoforms of catalytic and 
regulatory subunits (ex: α1, α2, β, γ1, γ2, etc…):  
 
- PP1 
- PP2 (A, B*, C**) 
- PP4 
- PP5 
- PP6 
- PP7 
 
*PP2B is also known as PP3, calcineurin and Ca2+/calmodulin-dependent protein phosphatase 
**PP2C is also known as ATP/Mg2+ -dependent protein phosphatase 
 
More recently, the new relatives of PP1 (PPZ1, PPZ2, PPQ), PP2A (PPV, PPG) and PP2B (rdgC) 
have been included in addition to the newly characterised catalytic subunits of PP4 (over-expressed 
in human breast and lung tumors),7 PP5, PP6 and PP7.  
 
1.2.2 PP1 and PP2 protein phosphatases3 
 
Although new catalytic subunits are regularly discovered, PP1 and PP2 subunits remain 
the most abundant, and generally account for most of the phosphoserine/threonine 
phosphatase activity in eukaryotic cells.8 They are typically found as heterodimers made 
of different variable subunits inducing fine and subtle structural differences responsible 
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for imparting substrate specificity. Type-I phosphatases (PP1) preferentially 
dephosphorylate the β-subunit of phosphorylase kinase, whereas type-2 phosphatases 
(PP2) preferentially dephosphorylate their α-subunit. Furthermore, Type-I phosphatases 
are inhibited by two heat-stable proteins, termed inhibitor-1 (I-1 or I1) and inhibitor-2 (I-2 
or I2), whereas type-2 phosphatases are insensitive to them. Type-2 phosphatases comprise 
three enzymes (PP2A, PP2B, and PP2C) that can be distinguished by their cation 
requirements. While PP2C belongs to the PPM family (Mg2+-dependent phosphatases), 
and exhibit a relatively narrow specificity against a number of protein substrates, PP1, 
PP2A and PP2B all belong to the PPP family and exhibit broad specificities. 
 
 
2 - INHIBITORS OF SER/THR PHOSPHATASES PP1 AND PP2A 
 
Since the first appearance of PP1 in the literature in 1943,9 more than 100 inhibitors, and 
targeting proteins,5 have been reported. A large number of of them have been tested 
against PP1 and PP2A, which shed further light on the structures, functions and roles of 
PP110 and PP2A11-13 in diverse processes. For instance, it is now known that PP1 activity is 
associated with abnormal calcium cycling, characteristic of experimental human heart 
failure.14 Additionally, a growing body of evidence indicates that PP2A has complex 
inhibitory and stimulatory effects on hormone, and growth factor signalling,4 and its 
activity is also believed to be a cause of the abnormal hyperphosporylation involved in 
Alzheimer’s disease.15 Inhibitors of PP1 and PP2A may represent attractive new 
therapeutic targets, and have consequently generated a growing interest. However, as 
their number is constantly increasing, notably through the use of modern technique such 
as virtual screening,16 the list of PPase inhibitors will be here strictly limited to some of the 
most significant ones. 
 
2.1 - Endogenous inhibitors 
 
PP1 and PP2A can be potently inhibited in vivo by the action of endogenous phosphatase 
inhibitors such as Inhibitor-1 (I1), Inhibitor-2 (I2), dopamine, cAMP regulated 
phosphoprotein (DARPP-32), and nuclear inhibitor of protein phosphatase 1 (NIPP-1).17  
The discovery of inhibitor-1 by Huang and Glinsmann in 1975 marked a turning point in 
the study of the protein phosphatases.18 Inhibitor-1 (together with its homolog, DARPP-
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32) was the first molecule discovered that was able to differentiate between the previously 
homologous PP1 and PP2A, and both have found great use in vitro as a result.17 Until 
recently, no known endogenous inhibitors that specifically targeted PP2A had been 
identified. This view changed with the discovery of I1PP2A and I2PP2A, which have both been 
determined to specifically inhibit PP2A in mammalian tissues without affecting the 
activity of the other serine-threonine phosphatases.15 Although the sequence of I1PP2A and 
I2PP2A has been determined, it is unknown whether they require phophorylation, or 
dephosphorylation to become activated.17 Regulation of PP1 and PP2A has also been 
proved to occur indirectly through their activation and deactivation by cellular secondary 
messengers such as cAMP, ATP, and glucose.17 
 
However, the use of endogenous inhibitors as effective PP1- and PP2A-specific inhibitors 
has been limited by their peptidic nature, which requires them to be microinjected directly 
into the cells under study. Thus, while such inhibitors may be mechanistically 
informative, they are also handicapped by the inherent shortcomings of peptides in 
general (i.e proteolytic degradation, poor membrane permeability, high molecular weight, 
and potential instability),17 and so it can be seen that the old medicinal chemists credo of 
“peptides don’t make good drugs” also extends to their use as in vitro inhibitors. The 
intrinsic deficiencies of using such endogenous phosphatase inhibitors as either biological 
probes or as potential drug leads have therefore prevented their widespread use. Hence, 
alternative inhibitors have had to be found in order for meaningful inhibition studies to be 
performed. 
 
2.2 - Exogenous inhibitors of PP1 and PP2A 
 
The difficulties posed by the use of the endogenous phosphatase inhibitors (quantity, 
stability, etc…) have been overcome by the use of small molecule inhibitors that are not 
compromised by the problems commonly associated with proteins.17 Many naturally 
occurring structural scaffolds have been found to mimic small areas of the three-
dimensional molecular surface presented by the endogenous protein inhibitors.17 This has 
allowed researchers to identify a diverse range of natural products that possess potent 
inhibitory activity against the serine-threonine protein phosphatases over the last twenty 
years. However, unlike protein-based endogenous inhibitors, these small molecules are 
often non-selective, and have a tendancy to inhibit several classes of PPases at a time.5 
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2.2.1 Okadaic acid (OA) 
 
This complex spirocycle, containing 16 stereocenters, was the first polyketide protein 
phosphatase inhibitor to be characterised (Figure 2). It was initially isolated from the 
marine sponges Halichondria okadaii, and Halichondria melanodocia, and was later proved to 
be produced by Prorocentrum lima too.19 However, subsequent investigation demonstrated 
that sponges tend to accumulate certain species of marine plankton, which are the true 
source of OA.17  
 
 
 
Figure 2. Okadaic Acid. 
 
OA is known to be an important tumor promoter,20 but also a potent and selective 
inhibitor of PP1 and PP2A (LD50 = 315 and 1.2 nM, respectively).17,21,22 Even at high doses, 
PP2B is only weakly inhibited, while PP2C is apparently unaffected. Several naturally 
occurring congeners, consisting of slight structural modifications to the parent OA 
skeleton, have since been isolated and shown to be equipotent with OA.17 
 
2.2.4 Calyculin A 
 
 
Figure 3. (-)-Calyculin. 
 
Calyculin A is a sophisticated spirocyclic polyene that possesses 15 stereocenters and 5 
(E)-double bonds (Figure 3). This octamethyl polyhydroxylated fatty acid, which was 
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isolated from several marine sponges, possesses similar phosphatase inhibition and 
tumour-promoting activities to OA. 
 
2.2.5 Tautomycin and Tautomycetin 
 
Tautomycin (Figure 4) possesses a simpler framework than either OA or calyculin, and 
contains 13 stereocentres. It was first isolated from the soil bacterium Streptomyces 
spiroverticillus in 1987, but it was not until 1993 that its structure was fully elucidated. It 
exhibits antifungal and hepatotoxic activity17 at low concentrations, and inhibits PP1 (IC50 
= 0.2 nM) and PP2A (IC50 = 1nM). As such, it is the only naturally-occurring small 
molecule inhibitor that is partially selective for PP1. 
 
 
Figure 4. Tautomycin (TM). 
 
Tautomycetin (Figure 5) is structurally related to tautomycin, but lacks the spiroketal 
moiety of the latter. This results in a simpler molecule to synthesize, as it contains only 8 
stereogenic centres. It was isolated from Streptomyces griseochromogenus, and induces the 
same morphological changes in cells as observed for TM exposure, although data 
pertaining to its protein phosphatase inhibition characteristics has not been published.17 
 
 
Figure 5. Tautomycetin. 
 
2.2.6 Cantharidin 
 
Cantharidin is a meso-symmetric molecule which is by far the simplest, and the most 
conformationnally rigid member of the PP inhibitors to date (Figure 6). 
 - 24 - 
 
 
Figure 6. Cantharidin. 
 
This meso-tricycle is a powerful vesicant, which was used in the 19th century to remove 
warts, although its high toxicity limited its general use. Indeed, human poisonings persist 
as a result of folklore surroundings its purported aphrodisiac and abortifacient properties. 
 
2.2.7 Microcystins and Nodularins 
 
The microcystins (Figure 7) are complex cyclic heptapeptides that are isolated from 
different Mycrocystis species of blue-green algae,23 whereas the nodularins (Figure 6) are 
cyclic pentapeptides isolated from Nodularia species of algae. 
 
 
 
 
Figure 7. General Structures of Microcystins XZ and Nodularins Z. 
 
Since their discovery, microcystins and nodularins have generated a lot of interest for 
biologists, ecologists, and chemists. They have been shown by a number of groups to 
possess potent inhibitory activity against PP1 and PP2A, but are also thought to be potent 
tumour promoters.24 Conversely they have only weak inhibitory activity against PP2B, 
and no impact at all on PP2C.6 They are the only known families of ADDA-containing 
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natural products (Figure 7) and represent therefore a major interest as part of this project 
and will then be discussed in further details in the next paragraphs. 
 
2.2.8 General Overall Bilan 
 
All of the natural products described above are collectively referred to as the Okadaic 
Acid-class of protein phosphatase inhibitors. They all exhibit competitive kinetics with 
okadaic acid, as do the endogenous protein inhibitors. The OA-class all inhibit PP1 and 
PP2A, and several members also affect PP4 and PP5. However PP2B (calcineurin) is only 
weakly inhibited, and PP2C remains unaffected. What is astonishing is that while all these 
inhibitors possess unrelated chemical structures, and come from very diverse origins, they 
all specifically and potently target the same protein phosphatases, supporting the 
contention that the phosphatases play an extremely important physiological role. 
 
The use of exogenous small molecule inhibitors described above has been an invaluable 
tool for understanding specific signalling pathways, and has helped elucidate a wide 
range of protein phosphatase functions within the cell. However, althought the OA-class 
PPIs are fairly potent and selective inhibitors, they clearly also have numerous drawbacks. 
Their lack of specificity, their toxicity and their difficulty to be isolated and/or 
synthesised, clearly limit the quantity of material available for biological studies.  
 
Such studies not only serve to increase our understanding of such complex biochemical 
pathways, but also uncover the potential for the development of novel drug therapies for 
a wide range of human and animal disorders. Thus, the development of more potent and 
highly selective phosphatase inhibitors has therefore become a priority for a number of 
research groups involved in the development of innovative therapies for the treatment of 
a range of illnesses as diverse as Alzeihmer’s Disease and Cancer.  
 
 
3 - ADDA-CONTAINING MICROCYSTINS & NODULARINS 
 
The serine/threonine phosphatases are inhibited by a variety of natural toxins, including 
the microcystins and nodularins, which are the only ADDA-containing natural products 
(Figure 7). Since their isolation from their natural sources, they have generated a lot of 
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scientific work, which has demonstrated that these cyanotoxins possess high toxicity as 
well as strong inhibitory activity towards protein phosphatases inhibitors, both being 
closely related. 
 
3.1 - The cyanobaterial origin25 
 
3.1.1 Cyanobacteria 
 
Cyanobacteria, also known as blue-green algae, are actually not true algae but rather 
photosynthetic bacteria that are believed to be among the first forms of life to exist on 
land. They are photosynthetic prokaryotes, and have been found to inhabit an extremely 
diverse range of habitats, ranging from sub-zero landscapes to hot deserts. They are 
capable of both aerobic and anaerobic photosynthesis, and utilise the enzyme nitrogenase 
to convert N2 directly to ammonia, allowing them to undertake the fundamental metabolic 
process of nitrogen fixation with great efficiency. They also contain several photosynthetic 
pigments including chlorophyll-a, carotene, xanthophyll, blue c-phycocyanin, and red c-
phycoerythrin, which translates into a wide range of colourful cyanobacterial 
waterblooms (Figure 8).  
 
     
 
Figure 8. Blue-green and Red Cyanobacterial Waterblooms. 
 
Many cyanobacterial species possess special gas vesicles which prevent them from 
developing vertically in a water column. In order to optimize their development, they 
spread horizontally, forming blooms at the surface of eutrophic slow-flowing waters 
during warm seasons (Figure 8). Their formation is a natural process linked to the climatic 
conditions as well as nitrogen- and/or phosphorous-containing nutrient levels, generally 
resulting from municipal wastewater discharge, and/or runoff from agricultural land. 
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Cyanobacterial waterblooms are found worldwide, and regularly cause animal poisoning, 
and pose risk to human health through the release of cyanotoxins.26 
 
Despite their toxicity, cyanobacteria possess many attractive applications, and represent 
one of the main natural source of novel bioactive compounds (Scheme 3).25,28 
 
 
 
Scheme 3. Types of chemical compounds isolated from marine Cyanobacteria and their reported 
biological activities.25,28 
 
Cyanobacteria have also been recognized as an important source of vitamins and proteins. 
They represent a very inexpensive food supplement, and can be found in health food 
stores. Dried Anthrospira (Spirulina), for instance, is sold as a health food with annual sales 
estimated at US $ 40 million. Edible blue-green algae (Nostoc, Spirulina and 
Aphanizomenon) have a very quick development rate, and their ease of cultivation is 
currently helping solve problems of malnutrition in Africa. Interestingly, cyanobacteria 
have also been used in the production of green fuel (ethanol, H2), and are the subject of 
active ongoing research.27 
 
3.1.2 Cyanobacterial toxins23 
 
The poisonous toxins produced by bloom-forming bacteria in the aquatic environment, 
are usually contained within the cyanobacterial cells. However, they may be released in 
fairly substantial quantities upon certain conditions, such as during cell lysis, and after cell 
death.28 Cyanotoxins are conveniently categorised according to the main organs, cells, or 
physiological systems affected in animals, and in vitro toxicity studies: hepatotoxins, 
neurotoxins, cytotoxins, dermatotoxins, and irritant toxins (lipopolysaccharides). 
Although cyanotoxins have generated a significant amount of scientific interest, 
surprisingly, the biological role of these toxins within the cyanobacteria remains poorly 
understood, and represents an active research area.29  
 - 28 - 
The overall toxicity of cyanobacterial extracts is commonly attributed to the 
microcystins30,31 and nodularins,32 which are considered to be the main toxic constituents 
produced by the algae. The hepatotoxicity of the microcystins and nodularins is closely 
related to their potent phosphatase inhibitory activity, which induces overall 
hyperphosphorylation of many cytosolic and cytoskeletal proteins, resulting in damage to 
cell structure and causing cytoskeletal disintegration. On the other hand, inactivation of 
protein phosphatases disturbs the normal balance of cell processes, resulting in cell 
proliferation and cancer production, or apoptosis and cell death. Hence, MCs detoxication 
of aquatic ecosystems by bacterial biodegradation have received a lot of interest, and 
certain strains of Sphingomonas sp. have proved to be effective.33 However, although the 
toxicity of MCs is widely recognised, it should be noted that a recent study published by I. 
R. Falconer in 2007,34 tends to moderate their role in the overall toxicity of cyanotoxins. 
 
3.1.3 Health impacts of cyanotoxin poisoning23 
 
Cyanobacterial toxins have been shown to be dangerous to humans, other mammals and 
invertebrates.35 Contact with, or ingestion of, water containing cyanotoxins can cause skin 
irritation, allergic responses, blistering of mucosa, hay fever symptoms, diarrhoea, acute 
gastroenteritis, muscular pain, and acute liver and kidney damage.36 They generally travel 
to the liver, via the bile acid transport system, where most of them get stored, though some 
toxins remain in the blood stream and may contaminate other tissue such as heart, lung, 
brain or kidney.37 In the most severe cases of intoxication, the consumption of drinking 
water containing cyanotoxins leads to death resulting from severe disruption of hepatic 
liver function. 
 
3.1.4 Historical human cyanotoxin poisoning23 
 
The negative effects of cyanobacterial toxins on health have been observed and reported 
repeatedly over the years. Over a century ago, the first documented case of lethal 
intoxication by drinking water from an Australian freshwater lake heavily infested with 
cyanobacteria, was published.38,17 However, the first recorded case of human illness 
resulting from cyanotoxin poisoning was not reported until an outbreak of gastroenteritis 
around Ohio in 1931.35 In this outbreak, a massive Microcystis bloom caused illness in 
between 5,000 and 8,000 people who drank water originating from the Potomac river. The 
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methods used to treat drinking water at the time (precipitation, filtration and chlorination) 
were insufficient to remove the cyanotoxins. 
 
In 1959, 12 people became ill after swimming in a Canadian lake contaminated by toxins 
from Anabaena. The affected people displayed symptoms such as headaches, nausea, 
muscular pain, and acute gastroenteritis. In 1989, 10 British soldiers became ill after 
swimming, and canoe-training in water with a heavy bloom of Microcystis. In Australia, a 
sickness known as Barcoo fever, which typically displays symptoms of diarrhoea and 
vomiting, is believed to be caused by the ingestion of cyanobacterial toxins. 
Cyanobacterial waterbloom toxicosis has been reported in both humans and animals, with 
mycrocystins being the most commonly implicated causative agent. 
 
However, the most serious human poisoning episode of late occurred in February 1996, 
when 56 patients who underwent dialysis at the Kidney Disease Institute in Caruaru, 
north-east Brazil, died as a result of toxic hepatitis that was eventually attributed to 
Microcystis toxins present in the dialysis water.39 Studies carried out in the People’s 
Republic of China have shown a higher incidence of human hepatocellular carcinoma 
(primary liver cancer), and colorectal cancer in regions where the population uses surface 
water containing microcystins for drinking than in neighbouring areas where 
groundwater is apparently uncontaminated.40,41 
 
Clearly, cyanobacterial toxins continue to pose a major risk to human health especially in 
areas of the world where surface water exists under conditions that are optimal for 
cyanobacterial blooms.  
 
3.2 - The ADDA fragment 
 
Microcystins and nodularins contain invariably the characteristic hydrophobic β-amino 
acid (2S,3S,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4E,6E-dienoic acid, 
often abbreviated as ADDA (Figure 1). The ADDA chain has not been found anywhere 
else other than in these two genera of toxins. This raises the prospect of using ADDA as 
marker for measuring the presence of microcystins and nodularins in environmental and 
clinical material, and thus determining the intoxication level. 
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Figure 1. (2S,3S,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10- 
phenyldeca-4E,6E-dienoic acid (ADDA). 
 
3.2.1 Role of ADDA in bioactivity of MCs & nodularins 
 
The ADDA residue plays a critical role in the bioactivity displayed by such cyanotoxins. 
Geometrical double-bond isomers of the (4E,6E)-1,3-diene do not exhibit biological 
activity, while additionally, ozonolysis or hydrogenation of the (4E,6E)-1,3-diene causes 
the microcystins and nodularins toxicity to cease.34,42-44  Interestingly, MC analogues with 
modifications of the ADDA C9 methyl ether, either as the corresponding hydroxyl45 or 
acetylated46 analogue, are fully active inhibitors. 
 
It is worth mentioning that the ADDA chain, as its free amino acid form (Figure 1), and 
the remaining peptidic macrocycle of microcystins and nodularins are both non-toxic 
compounds. These two units are therefore complementary and both essential for potent 
bioactivity. However, although the peptidic macrocycle has been shown to be crucial for 
the bioactivity of MCs and nodularins, crystallographic studies of MCs and nodularins-
protein phosphatase complexes show only a few binding interactions between the 
macrocyle and the enzymatic binding site (Figure 9). In Figure 9, the ADDA residue (in 
white) is situated deep in a pocket within the phosphatase, whereas half of the 
macrocyclic peptide (in orange) does not interact with the enzyme at all. These 
observations were also confirmed by extensive SAR studies, which demonstrated that 
ADDA analogues resulting from the replacement of peptidic macrocycles for smaller 
acyclic aminoacids, conserve significant inhibitory activity (SAR results will be further 
discussed in section 3).  
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3.2.2 Biosynthetic origin of ADDA 
 
In addition to the structural and computational studies, several groups have investigated 
the (non-ribosomal) biosynthesis of these cyclic peptides, with particular emphasis on the 
amino acid ADDA. Rinehart conducted feeding experiments using isotopically labelled 
biological building blocks to determine the source of ADDA carbon atoms in nodularin.47 
Rinehart’s work47 suggested that ADDA is produced through a polyacetate pathway, in 
which a late intermediate is methylated, and dehydrated to form ADDA. A polypeptide 
chain is then built up from the C-terminus of ADDA, and cyclised to give either the 
microcystins or nodularins.  
 
3.3 - The microcystins 
 
The microcystins are the most abundant group of cyanotoxins29 with more than 80 
different mycrocystins identified to date,48-52 from different genera of cyanobacteria. These 
cyanotoxins are known to be tumor promoters by inhibiting PP1 and PP2A, and are often 
reported as the most common and dangerous hepatotoxins.53 These cyclic nonribosomal 
heptapeptide compounds (Figure 10) are named after the first genus from which they 
were isolated, Microcystis aeruginosa, and they can be obtained not only from Microcystis 
 
Figure 9. Binding interactions between motuporin and PP1. 
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spp., but also from Anabaena, Nodularia, Nostoc, Oscillaria, Phanktotrix, and Umezakia, all of 
which are also known to form waterblooms.  
 
 
 
 
Figure 10. general structure of microcystins XZ. 
 
Microcystins are most commonly represented in the literature by microcystin-LA and 
microcystin-LR variants (Figure 15) [the suffix identifies two variable L-amino acids found 
at two non-conserved positions in the macrocycle (e.g Leu and Arg in microcystin-LR)]. 
The general structure of these potent hepatotoxins is cyclo [-D-Ala-L-X-D-MeAsp-L-Z-
ADDA-D-Glu-Mdha-] (Figure 10), which contains three D-aminoacids: Alanine (Ala), 
erythro-β-methylaspartic acid (MeAsp), glutamic acid (Glu), and two unusual amino acids: 
N-methyldehydroalanine (Mdha), and 3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-
4,6-dienoic acid (ADDA). The two variable residues X and Z (Figure 10) can be occupied 
by a wide variety of L-amino acids with little effect on biological activity.47 However, it 
should be noted that minor structural modifications have been detected in all seven amino 
acids units. Thus, a whole family of related heptapeptide cyanobacterial compounds exists 
through modification of amino acids.  
 
3.4 - The nodularins 
 
These cyclic pentapeptidic hepatotoxins (Figure 11) are closely related to microcystins, 
and are also known to be potent tumor promoters.54 They have been isolated from the 
brackish water-dwelling filamentous cyanobacterium Nodularia spumigena,55,56 and at least 
10 variants have been reported to date.57  
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Figure 11. General Structure of Nodularins Z. 
 
These cyclic pentapeptides are most commonly represented by the arginine variant 
nodularin-R, and bear a remarkable resemblance to the microcystins. They possess the 
ADDA subunit in addition to D-glutamate (D-Glu), L-araginine (Arg), D-β-methylaspartic 
acid (MeAsp) and D-N-methyl-dehydrobutyrin (Mdhb) (Figure 11). Structural variations 
characterised thus far include D-apartate nodularin, O-demethylAdda nodularin and L-
valine nodularin (also known as nodularin-V or motuporin (Figure 13)). The lack of 
reliable and productive source of material is an obstacle for the accumulation of more 
information and very little is actually known about the biology of nodularins. 
 
2.2.1 Motuporin 
 
More recently, a major member of nodularins containing L-valine, and commonly named 
motuporin, was isolated from the marine sponge Theonella swinhoei collected from Papua 
New Guinea (Figure 12).28 This discovery raised the possibility that cyanobacterial 
organism living in a symbiotic relationship with the marine sponge, may also account for 
this finding.58 It has also been suggested that sponges and bivalves may accumulate 
cyanobacteria through filter feeding. 
 
         
 
Figure 12. The three Theonella swinhoei phenotypes (with the kind permission of Prof. Phil Crews)59 
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This cyclic pentapeptide is one of the most potent PP1 inhibitors known, inhibiting at sub-
nanomolar concentrations (IC50 < 1.0 nM), and showing strong in vitro cytotoxicity against 
a variety of human cancer cells. Motuporin shows remarkable resemblance with previous 
microcystins, as it contains the ADDA residue, but also an α,β-unsaturated amino acid N-
methyldehydrobutyrine (N-MeΔBut or Mdhb), an isolinked D-glutamate, and a β–methyl 
D-aspartate (β-MeAsp or Masp) residue (Figure 13). 
 
 
 
Figure 13. Motuporin (Nodularin-V). 
 
Motuporin was isolated much later than other members of its class, and is derived from a 
much less readily accessible source. Consequently much of the information concerning its 
biology and chemistry is unknown. 
 
2.2.2 Iso-motuporin 
 
In 2007,59 further investigations on the remarkably prolific Indo-Pacific Theonella swinhoei 
sponges (Figure 12), which had already originated motuporin,28 shed further light on 
novel ADDA-containing analogues. Refinement of the observations published in 1998,60 
allowed isolating 15 natural compounds. 11 of them were already known such as 
motuporin, but more interestingly, 4 iso-motuporin analogues A, B, C and D, containing 
the (2R)-iso-ADDA residue, were identified (Figure 14).59 Until now all the ADDA-
containing inhibitors known, including microcystins, nodularins, and motuporin carried, 
with no exception, the (2S) stereochemistry (Figure 13).  
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Figure 14. iso-motuporins A, B, C and D. 
 
Due to the recent discovery, no biological or pharmaceutical work has been documented 
on ADDA isoforms, but their discovery reinforces the idea that more potent and selective 
PPIs can be generated from the chemical transformation of the ADDA chain. 
 
 
4 - TOWARDS SIMPLIFIED ADDA-CONTAINING PPIs 
 
Unlike PP2A which remains largely unknown, significant structural data has been 
accumulated about PP1 through the years.43,61 The application of techniques such as 
Structure-Relation-Activity (SAR), and crystallographic studies of OA-class inhibitors 
with PP1 has provided major information regarding the chemical PPIs features required 
for binding interactions, and potent bioactivity (Figure 15).62-66 The compilation of this 
information has led to the mapping of PP1, which has given crucial guidance for the 
modelling of novel PPIs,67 which greatly inspired our own work.  
 
 
 
Figure 15. Microcystin-LR binding contacts necessary for interaction with PP1. 
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Despite the many naturally occurring PPIs that have been isolated, the number of 
substrates for available SAR studies has been restricted by the small quantities available 
through isolation, and by the limited types of chemical transformations that can be 
performed on the natural products themselves. Moreover, toxicity and bioactivity being 
considered as highly related, much of the biological data have been reported in the form 
of LD50’s (general toxicity), and not IC50’s (PP1/PP2A inhibition). Thus, the PP1/PP2A 
inhibition potency of many MCs is inferred from LD50 data, which obviously is only a 
crude estimate, and provides no information about the selectivity among the various 
phosphatases.  
 
4.1 - First Structure-Activity-Relationship approach 
 
The first approach taken to prepare MC and nodularin analogues has been to synthesize 
truncated or linear versions of the natural toxins by removing, or simplifying amino acid 
residues. Among the truncated derivatives, there have been two trains of thought. The 
first approach involved the replacement of ADDA with a simpler residue, while the 
second one started with ADDA, which is progressively extended in adding as little as 
necessary for binding. 
 
The first reported attempt to make truncated MC analogues without ADDA, was by 
Abdel-Rahmen.68 The Abdel-Rahmen group made three linear hexapeptides 
corresponding to three MCs they had isolated (MC-RR, MC-YM, and MC-LA). Compared 
to the respective natural products, these peptides had, in effect, excised ADDA, 
substituted Ala for Mdha, and substituted α-linked Arg for Masp. None of these 
compounds had any toxicity, implying (but not proving) that they are not PP1 or PP2A 
inhibitors. 
 
Quinn has also reported a series of cyclic and acyclic analogues of the MCs and 
nodularins.69,70 In all of the compounds, ADDA was substituted by either β-alanine or L-
cysteine. The iso-linked D-Glu and β-methyl-D-aspartate were also replaced with D-
glutamate or D-aspartate, along with other changes. Most of these analogues showed no 
inhibition of PP2A, with a few having IC50’s in the low millimolar range (0.5 mM < IC50 < 
10 mM). Of the four most active compounds, three were cyclic and one was linear, tending 
to prove that the macrocylic structure was important, but not essential for toxicity. Overall 
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however, the inhibitory activity of all of these analogues against PP2A was very poor and, 
no further analogues were designed. 
 
Later, Chamberlin67b,71 prepared, and tested a series of truncated analogues as small as 
possible that could conserve potent inhibitory activity. Chamberlin’s approach, based on 
published crystallographic structures, demonstrated that the majority of the important 
contacts within the protein could be retained, even if most of the macrocycle was 
removed. However, it remained unclear how much of the parent structure could be 
excised without losing activity. Thus, Chamberlin decided to begin with the known, active 
tetrapeptide 3 (H2N-ADDA-isoGlu-Mdha-Ala-OH) (Figure 16), and gradually build up 
the structure. The initial targets were AcNH-ADDA-isoGlu-NMe2, AcNH-ADDA-D-Ala, 
and AcNH-ADDA-Gly. 
 
 
 
Figure 16. structure of tetrapeptide 3. 
 
Chamberlin’s compounds were evaluated as inhibitors of the catalytic subunit of both PP1 
and PP2A, and the results showed that all analogues retained inhibitory activity. 
However, the variants were several orders of magnitude less potent than the parent 
inhibitor, MC-LA, as well as tetrapeptide 3. Nevertheless, the shortest peptide 4 (AcNH-
ADDA-D-Ala), which bears the strongest resemblance to the parent compound of the 
analogues generated, retained high inhibitory potency (Figure 17). Interestingly, all 
derivatives showed partial selectivity for PP2A over PP1. The most PP2A selective, which 
is also the poorest inhibitor, was the “unnatural” L-alanine-containing variant 5, while the 
D-alanine variant 4 was the most potent and least selective of the group (Figure 17). 
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Figure 17. Respectively D-alanine variant 4 and L-alanine variant 5. 
 
The potency of the D-alanine containing variant was in the useful range, and this analogue 
has become the basis for the design, and synthesis of second-generation truncated MC 
analogues. These results demonstrated the importance of the stereochemistry for the 
bioactivity of ADDA-containing analogues, which reinforces our idea according to which 
ADDA-isoforms might lead to the discovery of more potent and selective PPIs. 
 
4.2 - Second Structure-Activity-Relationship approach 
 
The second approach to preparing MCs and nodularins analogues has been to synthesize 
“full-sized”, but non-natural versions of the toxins containing specifically modified amino 
acids.  
 
 
Figure 18. motuporin (Nodularin-V). 
 
Toogood72 used his synthesis of motuporin (Figure 18) as a platform for making analogues 
in which L-alanine replaced the Mdhb residue, via “chemical mutation” at specific 
positions.72 This change was paired either with D- or L-valine at the variable position Z 
(Figure 18). The analogue 6 (Figure 19) with L-valine inhibited PP1 less potently than 
motuporin (IC50 motuporin = 1 nM). This observation makes sense given the natural 
variations at this position in both the nodularins and MCs appear to have little effect on 
toxicity. Similarly, analogue 7 (Figure 19), in wich D-valine is at the variable position also 
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retained nanomolar activity (IC50 37.8 nM), reinforcing the idea that substantial structural 
variation is well-tolerated at this position. 
 
 
 
Figure 19. Full-sized variants 6 and 7 respectively. 
 
The Chamberlin group has also made several “full-sized” non-natural variants of the 
MCs.73 The goal, in this case, was not just to prepare new inhibitors for SAR studies, but 
especially to impart selectivity for PP1 over PP2A to these analogues, as the nodularins 
and MCs, for all of their variety, are essentially non-selective for PP1 versus PP2A. 
Gratifyingly, each of the compounds showed slightly better selectivity towards PP1, hence 
proving that chemical modifications can help direct the selectivity of MCs and nodularins 
towards PP1 or PP2A. 
 
4.3 - Summary of Structure-Activity-Relationship results 
 
The vast number of SAR experiments conducted on OA-class inhibitors over the past 
decades has allowed the accumulation of priceless information concerning the design of 
novel protein phosphatase inhibitors. McCluskey,67c published a very clear and concise 
review presenting a straightforward scale of the inhibitory activity of the key analogues 
generated for SAR studies. This scale gives a good overview of what must be kept in 
mind.  
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The SAR studies brought precious information, which confirmed that truncated or 
modified ADDA-containing inhibitors can retain potent bioactivity. These observations 
reinforced our idea according to which minor modifications of ADDA isoforms, would 
lead to the discovery of small inhibitors, possessing potent and selective inhibitory 
activity, but which could be synthesised in large amounts. 
 
 
5 – OUR PROPOSED STRATEGY 
 
As discussed so far, ADDA-containing protein phosphatase inhibitors have been 
generating an extraordinary amount of work through the past years. Despite the large 
number of promising results accumulated, as far as we know, no ADDA analogue 
combining potent inhibitory activity with high selectivity towards the different classes of 
PP has been developed yet. 
 
We believe that isomeric ADDA-containing analogues might display unexpected and 
significant biological activities. It should be noted that, whereas many syntheses have 
been designed towards (2S,3S,8S,9S)-ADDA,72,75-87 no work has been reported on the 
synthesis of enantiomeric ADDA, or any other isomeric forms. Hence, we decided to 
synthesise the enantio-ADDA chain through a novel convergent strategy, which can also 
be used to generate the naturally occurring (2S,3S,8S,9S)-ADDA isomer. We would also 
like to report the very first synthesis of enantio-iso-ADDA, which has been recently 
discovered as its iso-motuporin form.59  
 
The final goal of this project will be the preparation of short ADDA analogues, which we 
hope will help in the development of novel, easy-to-make and potent PPIs, which will be 
used to extend our understanding of protein phosphatase pathways. 
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1 - PREVIOUS REPORTED SYNTHESES 
 
The interesting biological properties of the MCs and nodularins have prompted a number 
of synthetic studies. Thus far, the synthesis of the unique amino acid ADDA has generated 
the most interest. Since the absolute stereochemistry of the aliphatic chain was 
elucidated,32 14 different syntheses have been reported.72,74-86 The synthetic challenges 
include efficient selective formation of the (E,E)-diene, and the establishment of the four 
non-contiguous stereogenic centers in a reasonable number of steps.  
 
1.1 - Rinehart’s approach74 
 
The first total synthesis of the (2S,3S,8S,9S)-3-amino-9-methoxy-2,6,8,-trimethyl-10-
phenyl-4,6-decadienoic acid (ADDA) was reported by K. L. Rinehart in 1989.74 The ADDA 
chain was prepared via a convergent synthesis involving purification by HPLC techniques 
to separate the different diastereoisomers generated. 
 
Rinehart’s synthesis started from a diasteroisomeric mixture of alcohols (2S,3R)-8 and 
(2S,3S)-8, which was used as a (1:1) mixture of diastereoisomers. A sequence including 
oxidation, Wittig olefination, and lithium aluminium hydride reduction afforded a 
diastereoisomeric mixture of allylic alcohol 9. Separation by preparative HPLC allowed 
the isolation of the (4S,5S)-isomer 9, which was then converted into the corresponding 
triphenylphosphonium bromide 10 in 35% overall yield and 6 steps in total (Scheme 4). 
 
 
 
Reagents and conditions i, PDC, DCM; ii, Ph3P=C(CH3)COOEt, PhMe, 81% from 1; iii, 
LiAlH4, THF, 91%; iv, HPLC separation, 50%; v, PPh3, CBr4, MeCN; vi, PPh3, MeCN, 94%. 
 
Scheme 4. Synthesis of triphenylphosphonium bromide 10. 
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The synthesis of the amino acid partner began with the optically active γ-butyrolactone 11, 
which was methylated to generate a (4:1) mixture of diastereoisomers, which could be 
separated by flash column chromatography. The minor diastereoisomer could be 
efficiently isomerised to the desired (2S,3R)-isomer 12 by heating it in a mixture of 
benzene/triethylamine over 2 days. The γ-butyrolactone 12 was then hydrolysed under 
basic conditions, and subsequently esterified to produce the ethyl ester 13 in 39% overall 
yield over the 2 steps (Scheme 5). 
 
 
 
Reagents and conditions i, LDA, THF, -78 °C then MeI, 54%; ii, NaOH, MeOH then EtI, KHCO3, DMF, 88%. 
 
Scheme 5. Synthesis of the alcohol 13. 
 
Alcohol 13 was then oxidized to the corresponding aldehyde, which was coupled with 
phosphonium bromide 10 via a Wittig olefination, to give the protected ADDA chain 14 in 
43% yield (from 13) (Scheme 6). Although no details were given regarding the generation 
of undesired (Z)-isomers, their formation was confirmed, as expected, by further literature 
examples.72,75,76,84,85  
 
 
Reagents and conditions i, Swern, then 10, DME, n-BuLi, 43% from 13. 
 
Scheme 6. Synthesis of the protected ADDA 14. 
 
Rinehart’s 7 steps synthesis provided the ADDA derivative 14 in a respectable 17% overall 
yield, but also and above all, provided a useful platform from which further optimized 
synthesis were designed. 
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1.2 - Chakraborty’s approach75 
 
The second synthesis of the ADDA residue was proposed by T. K. Chakraborty in 1990.75 
A convergent approach, involving the coupling of two partners via a Wittig olefination 
was also utilised.74 In Chakraborty’s synthesis, both ADDA fragments originated from 
epoxide 15, which was opened with Me2CuLi to generate diols 16 and 17. Both diols were 
ketal protected, and subsequently separated by flash column chromatography. Treatment 
of acetonides 18 and 19 in acidic conditions allowed re-generating diols 16 and 17 
separately in 63% and 86% respectively over the three steps (Scheme 8). 
 
 
 
Reagents and conditions i, a) Me2CuLi, Et2O, -40 °C or b) Me3Al, DCM, 0 °C; ii, Me2C(OMe)2, 
PTSA; iii, Et2O, HCl. 
 
Scheme 8. Synthesis of diols 16 and 17. 
 
The synthesis of the amino partner 21 started from diol 16, which was mono-protected. 
The remaining secondary alcohol was subjected to a Mitsunobu transformation, and the 
benzyl group of the protected alcohol 20 was removed. The resulting alcohol was oxidised 
to aldehyde 21, which was isolated in 41% overall yield and 7 steps from epoxide 15 
(Scheme 9). 
 
 
 
Reagents and conditions i, t-BuPh2SiCl, imidazole, DMF; ii, Phtalimide, DEAD, PPh3, THF, 72% (2 steps); iii, 
Pd/C, H2, EtOH; iv, Swern, 90% (2 steps). 
 
Scheme 9. Synthesis of aldehyde 21. 
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The synthesis of the aryl containing partner involved the use of diol 17, which was 
regioselectively turned into the mono tosylate, and subsequently cyclised into the 
corresponding epoxide 22. Addition of phenyl magnesium bromide onto the epoxide, 
followed by methylation of the resulting alcohol, led to the formation of ether 23. Removal 
of the benzyl group, followed by a subsequent Swern oxidation, and a Wittig olefination, 
afforded the (E)-conjugated ester 25, plus 8% of the (Z)-isomer (Scheme 10). The ester 25 
was subsequently converted to the corresponding phosphonium salt 10 through a classical 
3 steps sequence. Finally, the phosphonium salt was deprotonated, and then coupled to 
the aldehyde 21 via the same Wittig olefination used by Rinehart.74 The O-TBS diene was 
deprotected, and the resulting alcohol was oxidised to the carboxylic acid, and quenched 
with diazomethane to form the methyl ester 26 (Scheme 10). 
 
 
 
Reagents and conditions i,TsCl, pyridine; ii, MeONa, MeOH, 76% (2 steps); iii, PhMgBr, CuI, Et2O; 
iv, NaH, MeI, THF, 80% (2 steps); v, Pd/C, H2, EtOH; vi, Swern; vii, Ph3P=C(CH3)COOEt, PhH, 
57% (3 steps); viii, DIBAL-H, DCM; ix, CBr4, PPh3, DCM; x, PPh3, MeCN, 60% (3 steps); xi, n-BuLi 
then 7, 39%; xii, HF-pyridine; xiii, Jones oxidation then CH2N2 (no yields provided). 
 
Scheme 10. Synthesis of ADDA derivative (E,E)-26. 
 
It is worth noticing that the Wittig reaction provided the diene in 55% yield, and as a 7:3 
mixture of isomers (E,E)-26 and (E,Z)-26. The final ADDA methyl ester (E,E)-26 was 
isolated in 7% overall yield over 20 steps in total. 
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1.3 - Beatty’s approach76 
 
V. F. Beatty’s ADDA synthesis76 is closely related to that of K. L. Rinehart.74 Although 
parts of the synthesis were similar, the two coupling units were prepared in a 
stereocontrolled manner, and thus did not require the use of HPLC techniques to separate 
unwanted diastereoisomeric side products. 
 
The synthesis of the left hand side partner took advantage of Evan’s chiral oxazolidine 
template methodology to generate alcohol 8 as a single diastereoisomer. The rest of the 
synthesis was the same as proposed by Rinehart,74 giving allylic bromide 30 in 11% overall 
yield (Scheme 11). Importantly, for the first time, Beatty76 demonstrated the occurance of 
epimerisation during the Wittig olefination, resulting in the formation of small amount of 
undesired of C4-epimerised (4R,5S)-ester from (4S,5S)-ester 25. Furthermore, the same 
Wittig olefination also provide (4.5:1) (E)- and (Z)-isomeric mixture of ester 25. 
 
 
 
Reagents and conditions i, BuLi, THF; ii, EtCOCl, THF, 92%; iii, Bu2BOSO2CF3, DIPEA, DCM; iv, DIPEA, DCM; 
v, phenylacetaldehyde; vi, H2O2, MeOH, 73%; vii, Me3O+,BF4-, proton sponge, 60%; viii, LiBH4, 64%; ix, 
Py.SO3, DMSO, 73%; x, Ph3P=C(CH3)COOEt, DMF, 70%; xi, DIBAL-H, THF, 94%; xii, PPh3, CBr4, Et2O, 74%. 
 
Scheme 11. Synthesis of allylic bromide 5. 
 
The synthesis of the right hand side unit started from the enantiomerically pure aspartic 
acid derivative 32. Its non-diastereoselective methylation gave a (1:1.3) mixture of erythro 
vs threo diastereoisomers, where the major compound was the unwanted threo. The two 
isomers were separated, and the benzyl ester was cleaved to afford the carboxylic acid 33. 
 - 47 - 
The acid 33 was reduced to the corresponding alcohol 34, which was finally oxidized to 
the aldehyde 35 as a single diastereoisomer after 5 steps in 7% overall yield (from 32) 
(Scheme 12). 
 
 
 
Reagents and conditions i, LHMDS, THF, -78 °C; ii, MeI, THF; iii, H2/Pd, MeOH; iv, BH3.THF, 
MeOH, 0 °C; v, Py.SO3, DMSO, TEA. 
 
Scheme 12. Synthesis of aldehyde 35. 
 
Both partners were taken on crude, and coupled via the same Wittig olefination previously 
used by other workers.74,75 The outcome of the reaction was proved to be a mixture of four 
geometric isomers. Purification by preparative TLC afforded the fully protected ADDA in 
a modest 30% yield, which was then converted to the N-Boc carboxylic acid 31 after 14 
steps in total (Scheme 13). 
 
 
 
Reagents and conditions i, PPh3, PhH; ii, BuLi, THF; iii, 35, THF, 0 °C; iv, NH4Cl, 30%; v, NaOH, MeOH, 83%. 
 
Scheme 13. Synthesis of N-Boc-ADDA 31. 
 
In spite of the very modest 2% overall yield, the work reported by V. F. Beatty77 gave a 
large amount of precious information, which has been extremely useful for all future work 
realised on the ADDA chain. 
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1.4 - Schreiber’s approach77 
 
In 1995, S. L. Schreiber77 reported a novel synthesis of the ADDA chain, together with the 
first total synthesis of motuporin. Schreiber designed a convergent and efficient approach, 
in which all of the motuporin stereocenters are derived from the chiral pool, and from 
either common amino acids or D-mandelic acid.  
 
In the Schreiber’s synthesis, all the stereocenters of the ADDA fragment were installed 
through a Lewis acid promoted crotylstannane addition to benzyloxymethyl-protected 
mandelaldehyde. No details were given regarding the diastereoselectivities of the 
crotylstannane addition, the removal of the benzyloxymethyl protecting group, or the 
problems encountered by previous workers on the selectivity of the Wittig olefination.75,76 
The chain was then elaborated by standard methods to give sulfone 34 in 10 steps, and an 
excellent 30% overall yield (from 32) (Scheme 14). 
 
 
 
Reagents and conditions i, DIBAL-H; ii, crotylstannane, MgBr2, Et2O, 74% (2 steps); iii, NaH, MeI, 
98%; iv, OsO4, NMO; v, H2, Raney Ni, EtOH; vi, NaIO4; vii, Ph3P=C(CH3)COOEt, 68% (4 steps); 
viii, LiAlH4, 77%; ix, Ms2O, pyridine; x, Na(CH3C6H4SO2), Bu4NBr, DME, 78% (2 steps). 
 
Scheme 14. Synthesis of sulfone 34. 
 
The synthesis of the aminoacid partner was inspired by Rinehart’s work.74 Protected D-
threonine 35 was nicely converted to γ-butyrolactone 37 in five steps through the 
intermediate tosylaziridine 36. The γ-butyrolactone 37 was the same used by Rinehart,74 
but this time, it was generated as a single enantiomer without requiring any HPLC 
purification. The lengthy process, due to the numerous protection/deprotection steps, 
yielded alcohol 38 in an excellent 60% overall yield over 10 steps (Scheme 15). 
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Reagents and conditions i, Ms2O, pyridine; ii, NaBH4, THF, EtOH; iii, TBSCl, DIEA, 
DMAP; iv, NaCN, DMSO; v, HCl, MeOH, 81% (2 steps); vi, Ba(OH)2; vii, CH2N2; viii, 
TBSCl, DIEA, DMAP; ix, Boc2O, DMAP; x, HCl, MeOH, 93% (5 steps). 
 
Scheme 15. Synthesis of alcohol 38. 
 
A (E,E)-stereoselective diene-forming coupling was achieved through an alternative to the 
Wittig olefination74-76 for the first time. A modified Julia coupling between sulfone 34 and 
the aldehyde resulting from the Swern oxidation of alcohol 38, was followed by the 
treatment with sodium naphthalene, which gave protected ADDA 39. Ester hydrolysis 
was conducted to give the carboxylic acid form, which was taken on crude to generate 
motuporin (nodularin-V) (Scheme 16).  
 
 
 
Reagents and conditions i, Swern; ii, BuLi, THF, -78 °C then 34; iii, NaNapthalene, THF -78 °C, 65% (3 steps). 
 
Scheme 16. Synthesis of N-Boc-ADDA methyl ester 39. 
 
Schreiber77 reported the first synthesis of the ADDA chain involving an (E,E)-
stereoselective coupling reaction. The ADDA derivative 39 was obtained as a single 
isomer after 23 steps in total, and in an excellent overall yield of 20%. 
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1.5 – Toogood’s approach78 
 
Toogood completed the enantioselective synthesis of N-Boc-ADDA,78 using similar 
partners coupled through the same Wittig olefination, used previously by other groups.74-
76 However, each of the partners originated from a common precursor through a shorter 
approach. 
 
Toogood’s synthesis began with the propargylic alcohol 3-pentyne-2-ol (±)-40, which was 
resolved to access the (R)-alcohol (R)-40, and the (S)-alcohol (S)-40 separately. Each 
alkynol was reduced and esterified with methoxyacetyl chloride, providing R- and S- 
esters 41 (Scheme 17), which underwent an ester enolate Claisen rearrangement to yield 
both enantiomers of the acid 42 (Scheme 18). 
 
 
 
Reagents and conditions i, resolution then Na, NH3, Et2O, 90%; ii, methoxyacetyl 
chloride, pyridine, DCM, 83%. 
 
Scheme 17. Synthesis of ester 41. 
 
Synthesis of the aromatic-containing unit started from carboxylic acid 42, which was 
initially converted to phenyl ketone 43, which was in turn reduced to alkene 44. 
Ozonolysis of the olefin 44, followed by a Wittig olefination then produced the 
trisubstituted olefin 45. The akene 45 was then oxidized regioselectively by selenium 
dioxide to give the (E)-allylic alcohol 9 exclusively. It is worth mentioning that if this 
sequence avoided the formation of the (Z)-double bond isomer, nothing was reported 
concerning the epimerization of the C4 stereocenter observed by Beatty.76 The alcohol 9 
was finally converted into the corresponding bromide 30 after 7 steps, and 20% overall 
yield (from (R)-3-pentyne-2-ol (R)-40) (Scheme 18). 
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Reagents and conditions i, KHMDS, TMSCl, THF, 81%; ii, Ph2P(O)Cl, CH3NH(OCH3), THF, 95%; iii, PhMgBr, 
THF, 85%; iv, NaBH4, 97%; v, PhOC(S)Cl, pyridine, DCM, 90%; vi, AIBN, nBu3SnH, PhMe, 90%; vii, O3, DMS, 
MeOH, 86%; viii, Ph3P=C(CH3)2, THF, 80%; ix, SeO2, EtOH then NaBH4, 78%; x, PPh3, CBr4, Et2O, 74%. 
 
Scheme 18. Synthesis of allylic bromide 30. 
 
The synthesis of the amino partner started with methyl ether 41, which was reacted with 
LiHMDS, followed by diazomethane to generate methoxyester 46. The resulting ester 46 
was converted to the N-Boc protected amine 47 through a 4 steps sequence involving the 
use of a Mitsunobu substitution, with inversion of configuration (Scheme 19). Reduction 
of ester 47, followed by ozonolysis in methanol provided the lactone 48 in good yield. The 
lactone hydrolysis, followed by esterification of the resulting carboxylic acid, and Swern 
oxidation of the primary alcohol, generated the desired aldehyde 35 over a total of 6 steps, 
and in 10% overall yield (from (S)-3-pentyne-2-ol (S)-40) (Scheme 19). Other alternatives 
were also reported, leading to the same aldehyde 35 with similar ease and effectiveness. 
 
 
 
Reagents and conditions i, LiHMDS, TMSCl, THF, 81%; ii, CH2N2, Et2O, 100%; iii, BBr3, DCM, 65%; 
iv, DEAD, DPPA, THF; v, PPh3, H2O, THF; vi, (Boc)2O, 60% (3 steps); vii, LiBH4, MeOH; viii, O3, 
NaOH, MeOH, 63% (2 steps); ix, NaOH, MeOH, H2O; x, CH2N2, DCM; xi, Swern, 68% (2steps). 
 
Scheme 19. Synthesis of aldehyde 35. 
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Finally, both allylic bromide 30 and the aldehyde 35 were coupled through the Wittig 
olefination sequence previously employed, and was followed by saponification of the 
methyl ester 31 (Scheme 20). 
 
 
 
Reagents and conditions i, PPh3, PhH; ii, BuLi, THF; iii, 14, THF, 0 °C; iv, aq. NH4Cl, 30%; v, 
NaOH, MeOH, 83%. 
 
Scheme 20. Synthesis of the N-Boc-ADDA 31 
 
The N-Boc-ADDA 31 was successfully isolated after a total of 16 steps, and 3% overall 
yield (excluding the resolution of racemic 3-pentyne-2-ol (±)-40). It is worth noticing the 
inefficiency of the Wittig olefination74-76,78 compared to the previously reported (E,E)-
stereoselective Julia coupling.77 
 
1.6 – Mann’s approach79 
 
The approach followed by A. Mann79 in his convergent synthesis of the N-Boc-ADDA 
marked a turning point in the total synthesis history of the ADDA chain, as it was the first 
time that a palladium-catalysed coupling was employed to form the (E,E)-1,3-diene 
system selectively.  
 
The synthesis of the aryl containing partner started from readily accessible (S)-
phenyllactic acid 49. Acid 49 was transformed into the Weinreb amide 50, which was then 
converted into propargylic ketone 51 (Scheme 21). A syn-stereoselective reduction of 
ketone 51 was achieved in using K-Selectride to generate alcohol 52. The resulting alcohol 
52 was then turned into the corresponding bromoallene intermediate, which was reacted 
with MeCuCNLi to provide the desired alkyne 53, plus 5% of undesired trans-
diastereomer of 53. After separation of the two isomers, alkyne 53 was subjected to a 
hydrozirconation, and quenched with iodine to generate selectively the (E)-iodide 54 after 
7 steps, and in 17% overall yield (Scheme 21). 
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Reagents and conditions i, N,O-dimethylhydroxylamine.HCl, TEA, pyBOP, DCM, 81%; ii, MeI, 
Ag2O, DMF, 88%; iii, MeC≡CLi, THF, -78 °C, 89%; iv, K-Selectride, THF, -100 °C, 72%; v, 
BuLi, LiBr, TsCl, THF, then CuBr.DMS, LiBr, -60 °C, 75%; vi, MeCuCNLi, THF, -78 °C, 72%; 
vii, Cp2ZrCl(H), PhH, 43 °C, then I2 in CCl4, 70%. 
 
Scheme 21. Synthesis of iodoalkene 54. 
 
The synthesis of the amino partner began with acid 33, which was accessed from the 
commercially available (R)-aspartic acid 55. Acid 33 was converted to the corresponding 
ethylthioester, which was subsequently reduced to aldehyde 35, in turn transformed into 
stannane 56. The Stille partner 56 was thus obtained through a quick 4-step sequence in 
excellent 37% overall yield (from acid 33) (Scheme 22). 
 
 
 
Reagents and conditions i, EtSH, DCC, DMAP, DCM, 81%; ii, Et3SiH, Pd/C, acetone, 82%; 
iii, CHI3, CrCl2, THF, 75%; iv, (Me3Sn)2, Pd(PPh3)4, THF, 74%. 
 
Scheme 22. Synthesis of stannane 56. 
 
Vinyl iodide 54 and stannane 56 were coupled via a palladium-catalysed Stille coupling 
which provided the ADDA methyl ester derivative in a modest 58%, but with excellent 
(E,E)-regioselectivity (5% of the (E,Z)-isomer was still observed). A final saponification 
provided the carboxylic acid 31 over a total of 13 steps and 7% overall yield (Scheme 23). 
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Reagents and conditions i, 56, PdCl2(MeCN)2, DMF, 58%; ii, LiOH, DME, H2O, 70%. 
 
Scheme 23. Synthesis of N-Boc-ADDA 31. 
 
1.7 - Kallmerten‘s approach80 
 
J. Kallmerten80 reported the first linear asymmetric synthesis of N-trifluoroacetyl ADDA 
methyl ester 66 from the very inexpensive D-glucose. This linear strategy had nothing in 
common with the previous reported ADDA syntheses, and took advantage of a [2,3] 
Wittig rearrangement to produce the ADDA chain as its N-trifluoroacetyl protected form. 
 
In Kallmerten’s synthesis, the oxazoline 58 was accessed via the [2,3] Wittig rearrangement 
of the D-glucose-derived tertiary ether 57, made from D-glucose. Reductive cleavage of the 
oxazoline unit 58 afforded the corresponding diol, which underwent regioselective 
tosylation followed by base-induced cyclisation to furnish epoxide 59. Introduction of the 
aryl subunit of ADDA was achieved by addition of phenyl Grignard reagent to 59 and O-
methylation of the resulting alcohol yielded ether 60, comprising the complete carbon 
framework of ADDA (Scheme 24). 
 
 
 
Reagents and conditions i, BuLi, THF, -78 °C; ii, TFA, H2O, THF then LiAlH4; iii, TsCl, pyridine; iv, NaOH, 
MeOH, 83% (4 steps); v, PhMgBr, THF, 0 °C; vi, KH, MeI, DME, 83% (2 steps). 
 
Scheme 24. Synthesis of ether 60. 
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Deprotection of benzyl ether 60 afforded the corresponding alcohol, which was converted 
to the corresponding sensitive triflate, and treated with lithium azide in DMF to yield 
azide 61 (Scheme 25). Exposure of ether 61 to acidic methanol resulted in solvolytic 
cleavage of the methoxymethyl ether, followed by a thermodynamically driven furanose-
to-pyranose conversion, which provided the anomeric pyranose 62 (Scheme 25) as the 
major component of a complex mixture of isomers. 
 
 
 
Reagents and conditions i, H2, Pd(OH)2, MeOH; ii, Tf2O, pyridine, DCM, -20 °C; iii, LiN3, DMF, 77% (3 steps); iv, 
HCl, MeOH, 50 °C. 
 
Scheme 25. Synthesis of the alcohol 62. 
 
At this juncture, introduction of a halogen substituent at the C4 position was necessary for 
the proposed E,E-diene-generating Vasella reductive halogenation. Despite of a broad 
variety of conditions attempted, the halogenated substrate could not be produced, forcing 
the authors to add additional steps to the 14-step approach initially envisaged.  
 
In an alternative approach, the vicinal bis-mesylate 64 was prepared through a Lewis 
catalyzed thioketalization of mesylate 63, to give the acyclic dithiane derivative, followed 
by mesylation of the remaining C5 alcohol. Exposure of mesylate 64 to a THF solution of 
Na-anthracene, generated the desired (E,E)-diene 65 stereoselectively. Hydrolysis of the 
dithiane group yielded the corresponding aldehyde, which was then oxidised and 
esterified to the final ADDA methyl ester derivative 66 (Scheme 26) in 12% overall yield 
after 19 steps in total (from intermediate 57). 
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Reagents and conditions i, TFAA, pyridine; ii, H2, Pd-C, EtOAc, 73% (2 steps); iii, MsCl, pyridine, 
98%; iv, BF3.Et2O, HS(CH2)3SH, DCM; v, MsCl, pyridine, 45% (2 steps); vi, Na, anthracene, THF, 0 
°C; vii, AgNO3, MeCN, H2O, 89%; viii, CrO3, H2SO4, H2O; ix, CH2N2, Et2O, 0 °C, 91%. 
 
Scheme 26. Synthesis of N-trifluoroacetyl ADDA methyl ester 66. 
 
1.8 - Chamberlin’s approach81 
 
In 1996, A. R. Chamberlin81 reported the first total synthesis of Microcystin-LA including a 
new route towards the N-Boc-ADDA chain, involving a Suzuki coupling. This new 
convergent strategy was greatly inspired from the work described by A. Mann et al. in 
1996.79 
 
The synthesis of the aryl containing Suzuki partner began with the known Evans aldol 
product 67 originally synthesised by Beatty in 67% yield and 6 steps.76 Conversion of the 
alcohol 67 into the Weinreb amide was followed by methyl ether formation, and reduction 
to the aldehyde 68 (Scheme 27). The resulting aldehyde 68 was readily converted into the 
methyl alkyne 53 via the Corey-Fuchs protocol, but the subsequent transformation of 53 
into the requisite boronic acid 69 proved troublesome. Hydroboration of 53 followed by 
hydrolysis of the resulting dihaloborane gave an isomeric mixture of boronic acids, which 
were readily separated by chromatography. The unstable desired isomer 69 was prepared 
in 17% overall yield over 13 steps (from carbamate 27) (Scheme 27).  
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Reagents and conditions i, Me2AlN(OMe)Me, THF, 87%; ii, NaH, MeI, 95%; iii, DIBAL-H, 79%; iv, PPh3, CBr4; v, 
BuLi, MeI, 85% (2 steps); vi, HBBr2; vii, aq. citrate buffer, 45% (2 steps). 
 
Scheme 27. Synthesis of boronic acid 69. 
 
The synthesis of the second Suzuki coupling partner started from the 
benzyl/phenylfluorenyl protected dimethyl aspartate 70, which had been obtained in 
three steps and 78% overall yield from commercially available D-aspartic acid. Compound 
70 was then regio- and diastereoselectively methylated to give the syn-β-methyl 
diastereoisomer 71 exclusively. N-deprotection of the benzylphenylfluorenyl aspartate 71 
produced the hydrochloride salt 72, which was selectively saponified in nearly 
quantitative yield. N-Boc protection followed by ester formation, and in situ reduction led 
to the formation of alcohol 34, which can lactonized spontaneously above -15°C to form 
lactone 74 (Scheme 28). Swern oxidation of alcohol 34 gave the epimerization-prone 
aldehyde intermediate, which was used immediately to generate the trans iodoalkene 73 
exclusively via Takai’s procedure. The synthesis of the iodoalkene 73 proved to be very 
tricky, but was successfully achieved in 26% overall yield and 11 linear steps (from D-
aspartic acid) (Scheme 28). 
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Reagents and conditions i, LiHMDS; ii, MeI, 98% (2 steps); iii, H2, Pd-C, TFA, 91%; iv, 
CuCO3/Cu(OH)2, 97%; v, (Boc)2O, 98%; vi, DCC, HOSuc; vii, NaBH4, 73% (2 steps); viii, Swern; ix, 
CrCl2/CHI3, THF/dioxane, 53% (2 steps). 
 
Scheme 28. Synthesis of iodoalkene 73. 
 
Boronic acid 69 and iodoalkene 73 were reacted together, under the palladium-catalyzed 
Suzuki cross-coupling conditions. After a significant amount of optimization, the use of 
thallium ethoxide in the presence of water afforded the fully protected ADDA fragment, 
which was finally, saponified to the desired N-Boc-ADDA 31, thus obtained in a 
satisfactory 12% overall yield after 26 steps in total (Scheme 29). 
 
 
 
Reagents and conditions i, 73, Pd(PPh3)4, TlOEt, H2O, 82%; ii, LiOH, 88%. 
 
Scheme 29. Synthesis of N-Boc-ADDA 31. 
 
It should be noted that the total synthesis proposed by Chamberlin81 was the most 
efficient ADDA synthesis reported at that time. Nevertheless, it involved numerous side 
reactions, as well as numerous unstable intermediates, which made the synthesis very 
complicated to reproduce and scale up. 
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1.9 - Mann’s second approach82 
 
In 1997, A. Mann82 published an extension of his previous work published in 1996.79 The 
only difference was the presentation of a novel strategy for the generation of the 
aminoacid partner. 
 
Mann’s synthesis began with aldehyde 75, originated from the (S)-serine, and was 
converted to the propargylic alcohol 76, which was subsequently desilylated with TBAF. 
The resulting terminal alkyne was mesylated, and the corresponding mesylate was finally 
methylated to give the propargylic derivative 77 (Scheme 30). The terminal alkyne 77 was 
subsequently reduced to the corresponding olefin 78, which was in turn oxidised, and 
then esterified to methyl ester 79. Ring opening of the oxazolidine, followed by a Swern 
oxidation gave the aldehyde intermediate. The aldehyde was converted to the iodoalkene 
intermediate 73, which could be cleanly transformed into the stannane 56 (6% yield over 
12 steps from aldehyde 75) (Scheme 30). 
 
 
 
Reagents and conditions i, Me3SiCCLi, HMPT, THF, 85%; ii, TBAF, THF; iii, MsCl, TEA; iv, 
LiBr, CuBr.DMS, 38% (3 steps); v, MeMgBr, CuBr.DMS, LiBr, 80%; vi, H2, Pd/BaSO4, 
quinoline, 85%; vii, RuCl3, aq. NaIO4; viii, Me3OBF4, proton sponge, 61% (2 steps); ix, PPTS, 
EtOH; x, Swern, 85%; xi, CH2I2, CrCl2, 75%; xii, (Me3Sn)2, Pd(PPh3)4, 74%. 
 
Scheme 30. Synthesis of stannane 56. 
 
Mann initially attempted a Negishi coupling between alkyne 53 and iodoalkene 73, which 
unfortunately failed to give the expected ADDA unit (Scheme 31).  
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Reagents and conditions i, Cp2ZrClH, PhH; ii, 73, ZnCl2, various catalysts. 
 
Scheme 31. Unsuccessful Negishi cross-coupling to ADDA derivative 39. 
 
The successful coupling was finally achieved by reverting to a Stille coupling between 
vinylstannane 56 and iodide 54, as reported previously (Scheme 32).79 
 
 
 
Reagents and conditions i, PdCl2(MeCN)2, 56, DMF, 58%; ii, LiOH, DME, H2O, 70%. 
 
Scheme 32. Sucessful Stille coupling to N-Boc-ADDA 31. 
 
The second Mann’s synthesis afforded the N-Boc-ADDA side chain 31 in a modest 3% 
overall yield over 13 steps (from compound 76). 
 
1.10 - Panek’s approach83,87 
 
In, 1997, J. S. Panek83 reported a very efficient and sophisticated convergent synthesis of 
N-Boc-ADDA taking advantage of some of the previously reported approaches.78,79,81 In 
2002, he completed and published the total synthesis of (-)-motuporin87 using the 
methodology initially developed in 1997.83 A common precursor of chirality generated via 
Ireland-Claisen rearrangement,88 was used to generate of both side of the ADDA chain, 
which were assembled through a palladium-mediated cross-coupling. 
 
Panek’s synthesis started with the acetate 80, which was converted to the silane 81 
through the use of the Ireland-Claisen rearrangement.88 The condensation of silane (S)-81 
with phenylacetaldehyde dimethyl acetal afforded olefin 82 as a (10:1) diastereoisomeric 
mixture, which was then ozonolyzed, and converted to the corresponding dibromoolefin 
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via a Corey-Fuchs reaction. Finally the dibromoolefin was treated with n-BuLi and 
iodomethane to give alkyne 53 in 58% overall yield after a 6 steps sequence (Scheme 33). 
 
 
 
Reagents and conditions i, Ireland-Claisen rearrangement;88 ii, phenyl acetaldehyde dimethyl acetal, 
BF3.Et2O, -50 °C, 92%; iii, O3, DMS; iv, CBr4, PPh3, 88% (2 steps); v, nBuLi, THF, then MeI, 98%. 
 
Scheme 33. Synthesis of akyne 53. 
 
Silane 84 was prepared in 73% yield through a 3-step sequence involving the use of the 
Ireland-Claisen rearrangement. Treatment of silane 84 with trifluoroboron etherate 
produced the stereochemically pure tetrahydrofuran 85 as single product. Exposure of 
compound 85 to SbCl5, followed by O-TBS protection led to the formation of ester 86. 
Azide reduction, followed by N-Boc protection yielded the alkene intermediate, which 
was then ozonolysed and converted to the corresponding vinyl iodide 87 in 39% overall 
yield after 11 steps (Scheme 34). 
 
 
 
Reagents and conditions i, Ireland-Claisen rearrangement,88 73% (3 steps); ii, BF3.Et2O, -50 °C, 91%; iii, 
SbCl5, DCM, -50 °C, 96%; iv, TBSCl, imidazole, 99%; v, SnCl2, MeOH, 0 °C; vi, (Boc)2O, dioxane, aq. 
NaHCO3, 84% (2 steps); vii, O3, DMS; viii, CrCl2/CHI3, THF, 74% (2 steps). 
 
Scheme 34. Synthesis of iodoalkene 87. 
 
Unlike the results reported by Mann,83 Panek reported a modified Negishi-type coupling 
which successfully linked the two alkyne 53 and iodoalkene 87 together. Mechanistically, 
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alkyne 53 was first converted regioselectively to the vinylzirconium intermediate, which 
was then transmetallated to the vinylzinc species. The intermediate vinylzinc was reacted 
with the vinyl iodide 87 through a Negishi coupling to yield the (E,E)-1,3-diene as a single 
isomer. TBAF deprotection followed by oxidation provided the carboxylic acid 31 in 28% 
overall yield after 21 steps in total (Scheme 35). 
 
 
 
Reagents and conditions i, Cp2ZrHCl, THF; ii, ZnCl2, THF; iii, 87, Pd(PPh3)4, 84% (3 
steps); iv, TBAF, 99%; v, PDC, DMF, 86%. 
 
Scheme 35. Synthesis of N-Boc-ADDA 31. 
 
1.11 - McCarthy’s approach84,89 
 
T. D. McCarthy84,89 reported the synthesis of the ADDA chain using a convergent strategy 
based on some of the work initially developed by Rinehart and Beatty.74,76 The synthesis of 
the aromatic-containing unit started with the diastereo- and enantioselective Brown 
crotylation of phenylacetaldehyde 88, to generate the syn-homoallylic alcohol 
intermediate, which was then O-methylated to provide the alkene 89. Ozonolytic cleavage 
of alkene 89, followed by a Wittig olefination afforded the conjugated ester 25, which was 
subjected to an 1,2-reduction giving the allylic alcohol 9 (Scheme 36). It is important to 
notice that conjugated ester 25 was obtained as the major isomer of a mixture containing 
some (Z)-isomer and C4-epimer, as reported by Beatty.76  
 
 
 
Reagents and conditions i, 90, 95%; ii, NaH, MeI; iii, O3 then PPh3, 88% (3 steps); iv, Ph3PC=C(CH3)COOEt, 
85%; v, LiAlH4, 100%. 
 
Scheme 36. Synthesis of allylic alcohol 9. 
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The allylic alcohol 9 was then converted to the three intermediates 10, 91, and 92 through 
the use of classical techniques. Intermediates 91 and 92 were isolated over 6 and 5 steps in 
excellent 37 and 55% overall yields respectively. The ylide 10 was generated in situ, and 
taken on crude into the Wittig olefination (Scheme 37). 
 
 
 
Reagents and conditions i, CBr4, PPh3, 68%; ii, PPh3; iii, EtOPPh2, 73%; iv, 
BtSH, DEAD, PPh3 then Oxone or H2O2, 73%. 
 
Scheme 37. Synthesis of intermediates 10, 91 and 92. 
 
Although the synthetic sequence used to generate the aminoacid partner started, as many 
others,76,79,81 with D-aspartic acid, the β-lactam framework was used for the very first time. 
The synthesis began with the p-toluenesulfonic acid salt of D-dibenzylaspartate 93, which 
was N-TBS protected (Scheme 38). The resulting aminoester 94 was cyclised to the β-
lactam by treatment with tBuMgCl. The crude β-lactam intermediate was reduced under 
mild conditions to give alcohol 95, which was stereoselectively methylated, and then 
oxidised to the aldehyde 96. This very short 5-step sequence gave multigram quantities of 
aldehyde 96 as a single diastereoisomer in a very good 26% overall yield (Scheme 38). 
 
 
 
Reagents and conditions i, TBSCl, TEA, 90%; ii, tBuMgCl then NH4Cl; iii, NaBH4, 
LiBr, THF, H2O, 55% (3 steps); iv, n-BuLi then MeI, 53% (from 8); v, Swern, 90%. 
 
Scheme 38. Synthesis of aldehyde 96. 
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McCarthy reported extensive studies on the couplings of 10, 91, and 92 intermediates with 
aldehyde 96. Unfortunately the coupled products were obtained in poor to modest yields, 
and limited control of the double bond isomer geometry in all cases. The best results 
reported a 45% yield with an (3:1) (E/Z) ratio of diastereoisomers. The diene intermediate 
was N-TBS deprotected, and then was N-Boc re-protected to finally open the β-lactam 
ring, and isolate the N-Boc protected ADDA 31 after a total of 14 steps, and 11% overall 
yield (Scheme 39). 
 
 
 
Reagents and conditions i, 92, KHMDS; ii, KF, 45% (2 steps); iii, (Boc)2O, TEA, 93%; 
iv, LiOH, THF, 86% (2 steps). 
 
Scheme 39. Synthesis of N-Boc-ADDA 31. 
 
The route reported by McCarthy84,89 presented the quickest, and the most efficient way to 
generate the two coupling units. Unfortunately, the inefficiency of the coupling reaction 
ruined the final overall yield of the total synthesis. Switching the Wittig-type termination 
of the project for the organometallic coupling described by Panek83 would have 
significantly inproved the overall yield of the synthesis. 
 
1.12 - Armstrong’s approach85 
 
R. W. Armstrong85 reported the total synthesis of motuporin including an optimized 
synthesis of the ADDA chain based on a similar strategy to that used by McCarthy.84,89 
 
The synthesis of the phenyl containing unit was prepared via the classical 6-step sequence 
in 32% overall yield (Scheme 36), using the methodology described by T. D. McCarthy.84,89 
 
Armstrong’s synthesis of the opposite amino partner began with the metalation of 
chloroiodomethane with n-butyllithium in the presence of triisopropyl borate to give 
diisopropyl chloromethylborate. The latter was transesterified with (+)-pinanediol, and 
the chloride was then displaced in SN2 fashion with lithium p-methoxybenzyloxide in 
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THF, to produce protected alcohol 97 (Scheme 40). Chain extension of PMB-protected 
alcohol 97 by treatment with dichloromethyllithium, followed by addition of ZnCl2 gave 
α-chloroborate ester 98 as a single diastereoisomer. Stereospecific displacement of the 
chloride with methylmagnesium chloride afforded the α-methyl borate ester, which was 
converted to the corresponding bromide 99. The bromide was substituted cleanly via an 
SN2 insertion of the azide unit providing azido borate 100, which was then converted to 
aminoalcohol 101 via a borate oxidative cleavage and azide hydrogenation. A final N-Boc 
protection followed by a DMP oxidation yielded the aldehyde 102 in good 19% overall 
yield after 13 steps (Scheme 40). 
 
 
 
Reagents and conditions i, CH2ICl, BuLi, THF, -78 °C; ii, (+)-Pinanediol, Et2O; iii, LiOPMB, DMSO, 
THF, 62% (3 steps); iv, LiCHCl2, -100 °C then ZnCl2, 90%; v, MeMgCl, THF; vi, LDA, CH2Br2 then 
ZnCl2, 87% (2 steps); vii, NaN3, Aliquot 336, DCM, H2O; viii, BuLi, CH2ICl, THF, 74% (2 steps), ix, 
H2O2, THF then aq. NaOH; x, H2, Pd/C, MeOH; xi, (Boc)2O, DCM; xii, DMP, DCM, 54% (4 steps). 
 
Scheme 40. Synthesis of aldehyde 102. 
 
The Wittig coupling between the two partners was extensively explored, but as 
experienced by other groups,74-76,78,84,89 it could not provide efficient and selective (E,E)-
diene formation. The best results were obtained via the known triphenylphosphonium salt 
10, which provided the (E,E)-diene 103 in 67% yield, plus 16% of its undesired (Z,E)-
isomer. All attempts reported led to the formation of significant amounts of the (E,Z)-
diene as well as a diastereoisomeric mixture (up to 1:1) stemming from the epimerisation 
of aldehyde 102 (Scheme 40). Cleavage of the O-PMB group caused the unwanted loss of 
the N-Boc protecting group under the reaction conditions. The resulting amine, was N-Boc 
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protected once again, and the free alcohol subsequently oxidized to yield N-Boc-ADDA 31 
in a modest 8% overall yield after 24 steps in total (Scheme 41). 
 
 
 
Reagents and conditions i, LDA, THF then 102, 67%; ii, BF3.Et2O, EtSH, DCM then (Boc)2O, DCM; iii, DMP, 
DCM; iv, NaClO2, 2-methyl-2-butene, tBuOH, H2O, 60% (3 steps). 
 
Scheme 41. Synthesis of the N-Boc-ADDA 31. 
 
1.13 - Toogood’s second approach 72 
 
In 1999, P. L. Toogood achieved the total synthesis of motuporin, based on the strongest 
aspects of his previous work published in 1996.78 The strategy developed in his previously 
published approach to ADDA was considered to be too long for scale-up purposes. 
 
The synthesis of the aryl containing fragment employed the Evans aldol chemistry 
previously utilised by Rinehart and Beatty.74,76 The allylic bromide 30 was isolated in 24% 
overall yield after 13 steps from phenylacetaldehyde, using the same methodology 
described by Toogood in his previous paper (Schemes 11 & 42).78 
 
 
 
Reagents and conditions (refer to Scheme 11). 
 
Scheme 42. Synthesis of allylic bromide 30.78 
 
In Toogood’s synthesis, the amino unit was prepared from (R)-3-pentyn-2-ol (R)-40 
through a slightly modified version of the one previously reported.78 Acylation of the 
alkynol with N-Boc-L-glycine under standard DCC conditions, followed by 
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hydrogenation provided cis-olefin 104. Then, treatment of alkene 104 with LDA, in the 
presence of zinc chloride, promoted a highly stereoselective Claisen rearrangement to the 
methyl ester 47 (Scheme 43). Reduction of ester 47 followed by O-TBS protection, and 
subsequent ozonolytic alkene cleavage in methanol yielded the methyl ester 106. Removal 
of the TBS group, under extremely mild conditions, prevented lactonisation, and afforded 
the primary alcohol intermediate. The resulting alcohol was then oxidised to aldehyde 35 
in excellent 40% overall yield after 9 steps (from (R)-3-pentyn-2-ol (R)-40) (Scheme 43). 
 
 
 
Reagents and conditions i, a) N-Boc glycine, DCC, DMAP, 95%; b) H2, Pd/BaSO4 or CaCO3, EtOAc, 
91%; ii, LDA, -78 °C, ZnCl2, 75%; iii, NaH, MeI, 95%; iv, LiAlH4; v, TBSCl, 86% (2 steps); vi, O3, 
NaOH, MeOH, 90%; vii, NBS; viii, Swern, 84% (2 steps). 
 
Scheme 43. Synthesis of aldehyde 35. 
 
Toogood72 ambitiously tried to apply modified ylide chemistry to the Wittig-type coupling 
reactions previously used in previously reported ADDA syntheses.74-76,78,84,85,89 A number 
of derivatives, including phosphonates, phosphine oxides, phosphonium salts and 
alkylphosphoranes, were synthesized from allylic bromide 30. Unfortunately, the best 
results were obtained, once again, through the use of triphenylphosphonium salt 10, and 
no optimization of this olefination reaction could be achieved (Scheme 44).  
 
 
 
 Reagents and conditions i, nBuLi, 41%; ii, LiOH, 98%. 
 
Scheme 44. Synthesis of N-Boc-ADDA 31. 
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The Wittig olefination provided a (2:1) mixture of (E,E)- and (E,Z)-dienes in a poor 41% 
yield. Having failed to improve the reaction yield and selectivity, Toogood’s efforts were 
focused on the isomerisation of the unwanted (E,Z)-isomer into the (E,E)-diene 107, which 
was gratifyingly carried out in 51% yield through the use of light and iodine (Scheme 45). 
The (E,E)-diene methyl ester 107 was then saponified in nearly quantitative yield to 
provide the N-Boc-ADDA 31 in 10% overall yield over a 22 steps sequence. 
 
 
 
Reagents and conditions i, hυ, I2, 51%. 
 
Scheme 45. Isomerisation of (Z,E)-diene 107 to (E,E)-diene 107. 
 
1.14 - Rinehart’s second approach 86 
 
The second linear and most efficient total synthesis of the N-Boc-ADDA chain 31 was 
proposed by Rinehart,86 more than 10 years after his initial synthesis published in 1989.74  
 
Rinehart’s synthesis began with the use of the Evans aldol methodology used by 
Chamberlin81 and Beatty76 to generate amide 110. The amide 110 was reacted with a 
stabilised ylide to provide (E)-conjugated ester 25 (Scheme 46). No information was given 
about the formation of any isomers of 25, as reported by other workers.76 
 
 
 
Reagents and conditions i, Bu2BOTf, TEA, PhCH2CHO, 99%; ii, Me2AlN(OMe)Me; iii, 
NaH, MeI, 95% (2 steps); iv, DIBAL-H; v, Ph3P=C(CH3)COOEt), 86% (2 steps). 
 
Scheme 46. Synthesis of (E)-conjugated ester 25. 
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A second Dibal-H reduction of ester 25, followed by oxidation of the resulting allylic 
alcohol, gave the aldehyde intermediate, which was subjected to a second Wittig 
olefination to generate the (E,E)-conjugated ester, completing the (E,E)-diene system of 
ADDA. Another Dibal-H reduction, followed by MnO2 oxidation gave aldehyde 111, 
which upon an Evans aldol reaction in the presence of the opposite enantiomer of the 
acylated oxazolidinone 108 yielded alcohol 112. The treatment of oxazolidinone 112 with a 
mixture of NaH and tert-butyl-N-hydroxycarbamate gave N-Boc protected amine 113. The 
synthesis of N-Boc-ADDA 31 was finally completed via a Mitsunobu cyclization followed 
by SmI2 reduction in a “one-pot” process (Scheme 47). 
 
 
 
Reagents and conditions i, DIBAL-H; ii, MnO2, 97% (2 steps); iii, Ph3PCHCOOEt, 96%; iv, 
DIBAL-H; v, MnO2, 95% (2 steps); vi, (S)-108, Bu2BOTf, TEA, 91%; vii, NaH, HONHBoc, 
96%; viii, PPh3, DEAD, ix, SmI2, 64% (2 steps). 
 
Scheme 47. Synthesis of N-Boc-ADDA 31. 
 
The Rinehart synthesis86 yielded the N-Boc-ADDA chain in the best overall yield (40%) 
reported to this point, after only 13 linear steps from oxazolidinone 108. 
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2 - OUR PROPOSED APPROACH 
 
Many of the previously reported syntheses relied on similar strategies to prepare the 
ADDA residue. Although they presented a number of strong qualities, on the down side, 
they also contained major obstacles, which had to be taken into consideration to design an 
efficient new route towards ADDA. It is worth noticing that 8 of the 14 syntheses utilized 
the rather inefficient Wittig olefination to link the two coupling units, which generated the 
(E,E)-diene in low yield and with poor selectivity.72,75-76,78,84,85,89 Moreover, the Wittig 
olefination required the use of the amino unit as an aldehyde, which was shown to be 
sensitive to epimerisation during its preparation,72,81 but also under the coupling 
conditions,85 leading to complex isomeric mixtures. Several groups have successfully 
overcome these problems by using linear syntheses,80,86 or other coupling methodologies 
such as palladium-catalysed Stille79 and Suzuki81 reactions, or Julia olefination.77 However, 
these alternatives generally involved the use of unstable material generated through toxic 
and costly processes, which were not suitable for scale-up. 
 
2.1 – Cross-metathesis approach 
 
Chemically, the first goal of our approach was to find another method to assemble the two 
partners in by-passing the issues listed above. A cross-metathesis coupling methodology 
was envisaged, as it was known to be (E)-selective, and had not been employed to 
synthesise the ADDA framework before. Our proposed convergent synthesis towards 
enantio-ADDA, and enantio-iso-ADDA, involved the coupling of two cross-metathesis 
olefin partners, which were synthesised through the use of non-aldol aldol and aza-
Claisen rearrangements, as well as β-lactam chemistry, as described below (Scheme 48). 
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Scheme 48. Retrosynthesis of enantio-N-Boc-ADDA enant-31 and enantio-N-TAC-iso-ADDA 115. 
 
2.2 – Alkyne-alkyne coupling approach 
 
Is should be noted that an alternative to the cross-metathesis methodology had also been 
envisaged through an alkyne-alkyne coupling (Scheme 49). Although opposite 
enantiomers of alkynes enant-53 had already been synthesised in several previously 
reported ADDA syntheses,79,81,83,87 the alkyne-alkyne coupling had never been utilised to 
construct the (E,E)-1,3-diene motif selectively.90 With the prospect of using this coupling 
technique towards the synthesis of enantio-N-TAC-iso-ADDA 115, the route presented 
below was attempted (Scheme 49). However the process was rapidly discontinued to the 
benefit of the cross-metathesis methodology. 
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Scheme 49. Retrosynthesis of enantio-N-TAC-iso-ADDA 115 involving an alkyne-alkyne coupling. 
 
Despite the large amount of work accumulated over the past years, no ADDA-containing 
analogues combining potent inhibitory activities with high selectivities towards the 
different classes of PP have been developed yet. As an ultimate goal, we proposed to 
prepare small protein phosphatase inhibitors containing isomeric ADDA residue, such as 
enantio-ADDA and enantio-iso-ADDA, which might lead to the discovery of potent and 
selective inhibitory activity. 
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1 – SYNTHESIS OF ARYL CONTAINING UNIT 
 
1.1 - Initial methodology 
 
The synthesis of the aryl containing partner started with the treatment of commercially 
available phenylacetaldehyde 88 with 1-carbethoxyethylidene triphenylphosphorane 
(Scheme 51). Such stabilised ylide are well known for inducing regioselective formation of 
(E)-olefins in Wittig olefination,91 and have been successfully used by many groups 
towards the synthesis of ADDA.72,74,75,77,84-86,89 The Wittig olefination is a key reaction, 
which has been employed several times in our project. The intermediate oxaphosphetanes 
stemming from stabilised ylides have the ability to equilibrate, leading to the 
thermodynamic (E)-isomer, as shown in the mechanism below (Scheme 50). Although the 
Wittig olefination was discovered in 1954,92 the existence and interconversion of betaine 
intermediates is still under debate as there is evidence that phosphonium ylides can react 
with carbonyl compounds via a [2+2] cycloaddition to directly form the 
oxaphosphetanes.93 
 
 
 
 
Scheme 50. Mechanism of the Wittig olefination. 
 
As expected, the conjugated ester 124 (Scheme 51) was obtained as a single double bond 
isomer, which was then reduced with lithium aluminium hydride to provide the allylic 
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alcohol 125. The (E)-double bond geometry of olefins 124 and 125 was confirmed by 
comparison of 1H NMR chemical shifts with literature precedents.74-78,84-86,89 The allylic 
alcohol 125 reacted under Sharpless Asymmetric Epoxydation conditions to afford the 
enantiomerically enriched epoxyalcohol 116 in very good yield and high enantiomeric 
excess. The preparation of the racemic epoxyalcohol (±)-116 via a vanadium(III) acetyl 
acetonate-catalysed epoxidation, enabled the determination of the enantiomeric excess 
(90% ee) by chiral HPLC analysis (Scheme 51).  
 
 
 
Reagents and conditions i, Ph3P=C(CH3)COOEt, benzene, Δ, 84%; ii, LAH, Et2O, 90%; iii, t-BuOOH, Ti(O-
iPr)4, D-(-)-DIPT, DCM, -30 °C, 95%, 90% ee; iv, V(acac)2, t-BuOOH, toluene, rt, 1 h, 58%. 
 
Scheme 51. Synthesis of epoxides 116 and (±)-116. 
 
The epoxyalcohol 116 was then protected as the TBS silyl ether by treatment with TBSCl 
and imidazole in dimethylformamide to provide the compound 126 in excellent yield 
(Scheme 52). 
 
 
 
Reagents and conditions i, TBSCl, imidazole, DMF, rt, 2 h, 95%. 
 
Scheme 52. Synthesis of the epoxide 126. 
 
With the TBS-protected epoxyalcohol 126 in hand, the non-aldol aldol (NAA) 
rearrangement was attempted for the first time. This reaction, under represented in the 
literature, and developed by M. E. Jung,94 represents a very efficient way to generate aldol 
products via a non-aldol process. It only requires very mild conditions, and provides aldol 
products with excellent diastereoselectivity. As shown in the mechanism below (Scheme 
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53), the diastereoselectivity of the reaction is a result of the exclusive departure of the Hanti 
to the breaking C-O bond of the epoxide. This hydride then attacks the adjacent 
stereocenter in a SN2 fashion, resulting in an inversion of configuration of the stereocenter 
in α- of the carbonyl. The NAA rearrangement has also been successfully applied to 
secondary alcohols, and represents a very efficient route to ketones.95 
 
 
 
Reagents and conditions i, TMSOTf, DIPEA, DCM, -78 °C then work-up. 
 
Scheme 53. Mechanism of TMS-mediated non-aldol aldol rearrangement. 
 
The rearrangement was first envisaged with TMSOTf and DIPEA, as shown above 
(Scheme 53), and provided the rearranged aldehyde 127 very quickly (Scheme 54). 
However, this aldehyde was proved to be unstable, and spontaneously degraded into the 
conjugated aldehyde 128 via β-elimination, resulting in the loss of stereochemistry 
(Scheme 54). Another side-product was also formed during the reaction, but it could not 
be isolated due to its great instability. Further experiments (isolation of silyl enol ether 135 
in Scheme 56) demonstrated that the side product was in fact the TMS-enol ether 129 
stemming from the aldehyde 128 (Scheme 54). Modifications of reaction time, 
temperature, and amounts of reagents did not give any better results.  
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Reagents and conditions i, TMSOTf, DIPEA, DCM, 20 min, -78 °C. 
 
Scheme 54. TMS-mediated NAA rearrangement of epoxide 126. 
 
The aldehyde 127 was obtained in low yield and could not be purified due to its 
unstability. In order to by-pass this issue, the aldehyde 127 was taken on crude into the 
following reaction, which was, at that time, envisaged as a Corey-Fuchs olefination, with 
the prospect of the alkyne-alkyne coupling. Without any prior purification, the treatment 
of the crude aldehyde 127 under the Corey-Fuchs conditions provided the expected 
dibromoolefin 131 in poor yield, as a complex mixture of compounds (Scheme 55). The 
side dibromoolefin 133, stemming from the olefination of the aldehyde 128, was also 
isolated. In addition, during purification by flash column chromatography over 
neutralized silica gel, the desired dibromoolefin 131 partially degraded into the 
dibromoalkenol 132, making the purification process troublesome (Scheme 55). 
 
 
 
Reagents and conditions i, TMSOTf, DIPEA, DCM, -78 °C; ii, CBr4, PPh3, DCM, -78 °C. 
 
Scheme 55. TMS-mediated NAA rearrangement of epoxide 126 followed by Corey-Fuchs reaction. 
 
As the alcohol 132 was a key intermediate towards the generation of the methoxyolefin 
137, its formation via the preceding synthetic sequence (Scheme 55) was tried and 
optimized. The final reaction mixture, stemming from the NAA rearrangement (Scheme 
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55), was treated with a number of reagents such as TBAF, HF.pyridine, and silica 
gel/methanol, which unfortunately, all failed to give the alcohol 132. 
 
To overcome the stability problems induced by the use of the trimethyl silyl protecting 
group, the non-aldol aldol rearrangement of epoxide 126 was performed using TBSOTf. 
The reaction was much more difficult to monitor by TLC analysis, and required a much 
longer reaction time (3 h at -40 °C). However, the rearrangement worked well, and 
provided the desired aldelyde 134 as a single diastereoisomer in 70% yield (Scheme 56). 
The formation of the conjugated adduct 128 was still observed, but its formation was 
greatly reduced. Another side product, which had a similar TLC profile as the one 
observed during the TMSOTf rearrangement (silyl enol ether 129), was also formed 
during the reaction. This compound was ultimately isolated, and fully characterised as the 
TBS-enol ether 135 stemming from the aldehyde 128 (Scheme 56). 
 
 
 
Reagents and conditions i, TBSOTf, DIPEA, DCM, -45 °C, 70% (134). 
 
Scheme 56. TBS-mediated NAA rearrangement of epoxide 126. 
 
It is worth noting that, unlike the TMS-enol ether 129, the TBS-enol ether 135 was very 
stable and could easily be isolated without observable decomposition by flash 
chromatography. However, under mass spectrometry conditions, the silyl enol ether 135 
could not be observed entirely and decomposed to the aldehyde 128 instead. It should be 
noted that these very mild conditions (TBSOTf and DIPEA) might offer an efficient route 
towards series of useful TBS-enol ethers from epoxyalcohols. 
 
Interestingly, the aldehyde 134 was also successfully generated directly from the 
epoxyalcohol 116 with a better yield, and thus saved a step in the synthesis (Scheme 57). 
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Reagents and conditions i, TBSOTf, DIPEA, DCM, -60 to -20 °C, 77%. 
 
Scheme 57. TBS-mediated NAA rearrangement of epoxide 116. 
 
The TBS-protected aldol 134 proved to be fairly fragile upon storage and underwent 
partial decomposition. However, it could easily be purified by rapid flash column 
chromatography. Alternatively, the aldehyde 134 was usually taken on crude or semi-
pure in the subsequent Corey-Fuchs olefination to provide the dibromoolefin 136 in good 
yield. The TBS group was then cleaved off, and the resulting alcohol 132 was methylated 
to afford dibromoolefin 137 in low yield (Scheme 58). The data of olefin 137 were in full 
agreement with those of the opposite enantiomer previously reported in the 
literature,81,83,87 confirming the syn-stereochemistry of compound 137, and by extension the 
structures of the previously generated intermediates 127, 132 and 134. 
 
 
 
Reagents and conditions i, TBSOTf, DIPEA, DCM, -50 °C; ii, CBr4, PPh3, DCM, -78 °C, 
67% (2 steps);  iii, TBAF, THF, 81%; iv, NaH, MeI, THF, 0 °C, 43%. 
 
Scheme 58. Synthesis of dibromoolefin 137. 
 
Meanwhile, the synthesis of the opposite amino partner (section 1.4.2), conducted in 
parallel, failed to give satisfactory results. The approach involving the conversion of 
dibromoolefin 137 to alkyne enant-53 (Scheme 49) with the prospect of a later alkyne-
alkyne coupling, was consequently abandoned to the benefit of the cross-metathesis 
methodology. 
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1.2 - Synthesis of the aromatic containing CM partner 
 
As part of our new approach, the freshly purified TBS-protected aldol 134 had to be 
converted into a suitable diene for the CM coupling reaction. Initially, aldehyde 134 was 
subjected to a Wittig olefination by treatment with readily accessible stabilised ylide 2-
(triphenylphosphoranylidene)propionaldehyde. Unfortunately, several attempts all failed 
to generate the desired aldehyde 138, precursor of diene (E)-139 (Scheme 59).  
 
 
 
Reagents and conditions i, Ph3P=C(CH3)CHO, various conditions. 
 
Scheme 59. Synthesis of aldehyde 138. 
 
The TBS-protected diene 134 was instead obtained through a Horner-Wadsworth-
Emmons (HWE) olefination. Although being a well recognized method for the 
regioselective synthesis of (E,E)-1,3-dienes96,97 via the use of readily accessible 1-
methylallyldiphenylphosphine oxide 142,98 this method remains under-represented in 
organic synthesis (Scheme 62). 
 
The required phosphine oxide 14298 was accessed via two different and easily scalable 
methods (Scheme 60 & 61). In the first one, the inexpensive and readily available crotyl 
alcohol 140 and diphenylphoshine chloride were reacted together, and the resulting crude 
mixture was then thermally rearranged (Scheme 60).98 The pure phosphine oxide 142 was 
then obtained in multi-gram quantities after a subsequent purification by flash column 
chromatography. This purification method appeared to be much more straightforward 
than the classical recrystallisation technique used in previous work.98 
 
 
 
Reagents and conditions i, PPh2Cl, pyridine, Et2O; ii, thermal rearrangement at 130°C, 20% (2 steps). 
 
Scheme 60. Synthesis of 1-methylallyldiphenylphosphine oxide 142 from crotyl alcohol 140. 
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The second method started with commercially available allyldiphenylphosphine oxide 143 
which was methylated by treatment with n-BuLi and iodomethane. The desired 
methylated phosphine oxide 142 was obtained with comparable ease, but greater 
efficiency than in the first route. Nevertheless, it required a trickier purification by flash 
column chromatography due to the formation of the unwanted dimethylated phosphine 
oxide 144 (Scheme 61). However, residual amount of the over-methylated by-product 144 
were not considered as a problem for the WHE, as it could not be deprotonated during the 
reaction process. 
 
 
 
Reagents and conditions i, n-BuLi, THF, -78 °C then MeI, 85% (142), 15% (144). 
 
Scheme 61. Synthesis of 1-methylallyldiphenylphosphine oxide 142 from commercially available 
allyldiphenylphosphine oxide 143. 
 
As described by previous workers,96,97 the Horner-Wadsworth-Emmons olefination 
provided the expected 1,3-diene in good yield, but as a (3:1) mixture of (E)- and (Z)-
isomers (E)-139 and (Z)-139 (Scheme 62). The double bond geometry of each isomer was 
corroborated through nOe and NOESY analyses and by comparison with NMR data 
reported in the literature.96,97 
 
 
 
Reagents and conditions i, n-BuLi, HMPA, THF, -78 °C then 142, 73%, (E/Z 3:1). 
 
Scheme 62. Synthesis of dienes (E)-139 and (Z)-139 via a HWE olefination. 
 
Numerous conditions were explored in order to improve the (E/Z) ratio between 
coumponds (E)-139 and (Z)-139. The use of lower temperatures (< -78 °C) afforded a 
slightly better (E/Z) ratio, but also dramatically affected the yield which dropped below 
30%. Interestingly, the reaction performed at -100 °C in anhydrous diethyl ether enabled 
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the isolation of the non-eliminated phosphinyl alcohol intermediate 145 as a white 
crystalline solid (Scheme 63). Unfortunately, crystallographic analysis failed to provide 
precious structural information about these potentially useful intermediates, which have 
never been isolated, and characterized before. Thus, the stereochemistry of both newly 
created stereocenters could not be experimentally determined, and was therefore deduced 
from the Felkin-Ahn model. Treatment of phosphinyl alcohol 145 with n-BuLi at -78 °C 
afforded the diene (E)-139 as a single (E)-isomer exclusively (Scheme 63). However, this 
route was not extensively explored, due to lack of time.  
 
 
 
Reagents and conditions i, n-BuLi, THF, -78 °C, 71%, (E) only. 
 
Scheme 63. Synthesis of diene (E)-139 from phosphinyl alcohol 145. 
 
It is important to mention that the HWE process, although leading efficiently to the 
desired diene, was highly temperamental. After many unsuccessful attempts, which 
resulted in the waste of considerable amount of aldehyde 134, the more classic, but robust 
initial approach, previously used by Rinehart,86 was envisaged to bring more material 
through. The aldehyde 134 was olefinated through a Wittig olefination, and the (E)-
conjugated ethyl ester 146 was then reduced into the allylic alcohol 147. A subsequent 
MnO2 oxidation, followed by a second Wittig olefination provided the O-TBS protected 
diene (E)-139 as a single diastereoisomer (Scheme 64). 
 
 
 
Reagents and conditions i, Ph3P=C(CH3)COOEt, DCM, Δ, 2 days, 54%, (E) only; ii, LAH, Et2O, -78 °C, 
91%; iii, MnO2, DCM, rt, 1 h; iv, Ph3CH2I, LiHMDS, DCM, -78°C to rt, overnight, 60 %, (E) only.  
 
Scheme 64. Synthesis of diene (E)-139 via a Wittig olefination. 
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This process was chosen to provide the (E)-isomer (E)-139 exclusively, requiring no 
separation by flash chromatography of the (E)- and (Z)-isomers. Surprisingly, although 
the first microscale trials were very satisfying, for unclear reasons, scale-up of the process 
gave an unwanted (3:1) inseparable mixture of (E) and (Z)-isomers of ester 146 (Scheme 
64). However, unlike described by Beatty76 who encountered the same issue, the use of 
different solvents did not help change the (E/Z) ratio. The isomeric mixture of 146 was 
taken on crude to the next steps, and both double bond isomers (E)-139 and (Z)-139 were 
separated by flash column chromatography after the diene-forming reaction. 
 
 
 
Reagents and conditions i, Ph3P=C(CH3)COOEt, DCM, Δ, 2 days; ii, LAH, Et2O, -78 °C; iii, MnO2, DCM, rt, 1 
h; iv, Ph3CH2I, LiHMDS, DCM, -78°C to rt, overnight, 45 % (4 steps), (E/Z) (3:1).  
 
Scheme 65. Synthesis of dienes (E)-139 and (Z)-139. 
 
Isomers (E)-139 and (Z)-139 were usually separated by flash column chromatography at 
this point. However, it should be noted that the diene isomers have also been successfully 
separated by flash column chromatography (silica gel, 70% toluene in 40 - 60 petroleum 
ether) as their methyl ethers (E)-117 and (Z)-117. Unlike the situation described in the 
literature,97 purification of the (E)- and (Z)-isomeric mixture of diene 139 by flash column 
chromatography over silica gel coated with AgNO3 was shown to be ineffective for the 
separation. TBS-deprotection was performed by treatment of (E)-139 with TBAF under 
anhydrous conditions, and the resulting crude alcohol was then immediately methylated, 
without prior purification, to give final diene (E)-117 in good overall yield (Scheme 66). 
 
 
 
Reagents and conditions i, TBAF, THF; ii, KH, MeI, 92% (2 steps). 
 
Scheme 66. Synthesis of diene (E)-117. 
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2 - SYNTHESIS OF THE AMINO UNIT 
  
2.1 - Cross-metathesis methodology 
 
2.1.1 General information on cross-metathesis 
 
Olefin cross-metatheses are metal-catalysed coupling reactions leading to the formation of 
dimeric olefins via the fine balance of successive subtle thermodynamic equilibria. Cross-
metatheses are known to be preferentially (E)-double bond forming reactions, but the 
global regioselectivity of the CM reaction is poorly understood, and is still the subject of 
intense ongoing research. The mechanism proposed by Chauvin and Hérisson,99 via the 
formation of metallocyclobutane intermediates is the most widely accepted (Scheme 67). 
 
 
 
Scheme 67. Widely accepted cross-metathesis mechanism.99 
 
In recent years, olefin cross-metathesis has emerged as a powerful and convenient 
synthetic technique in organic chemistry. However, the use of CM as a general synthetic 
method has been limited by the lack of predictability in product selectivity and 
stereoselectivity. Cross-metathesis reactions are governed by the statistical formation of 
three possible dimers, separately available as their (E)- and (Z)-double bond isomers 
(Scheme 68). Two of them result from the homodimerization of each starting olefin with 
itself, while the third dimer is the heterodimeric product formed by the coupling of both 
starting olefins to one another. 
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Scheme 68. Statistical distribution of Cross-Metathesis dimers.100 
 
The outcomes of non-selective cross-metathesis reactions obey to statistical distribution 
(Scheme 68), and result in the formation of complex mixture of products, that are 
generally difficult to separate.100 Such CM reactions, producing the desired heterodimer 
AB in a maximum of 50% yield, and tangled up with a complex mixture of side products, 
do not represent an attractive coupling tool for organic chemists. This is the reason why 
many scientists have focused their efforts onto the control of CM selectivity.100 
 
Playing with the ratio between starting olefins100 is one of the few options which can be 
employed to direct CM selectivity. Using one of the two starting olefins in large excess can 
afford the desired heterodimer with very good conversion (> 95%) (Scheme 68). However, 
at least one of the two olefins has to be cheaply accessible, as it is common to use more 
than ten equivalents of one partner over the other. The choice of the olefin to use in excess 
is closely related to the ability of each olefin partner to undergo homodimerization, and as 
a result can be tricky to determine. Thus, the most valuable partner will be the one to use 
in excess sometimes, making the cross-metathesis of two sophisticated and elaborated 
partners unthinkable. 
 
The addition rate of the CM partner can also help direct the selectivity of cross-metathesis 
reactions. The olefin having the strongest ability to homodimerize can be added very 
slowly to the other olefin in solution with the catalyst, through the use of a syringe pump. 
Although this process can help improve the conversion towards the heterodimer, it 
usually requires the two olefins to have very different reactivity. 
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Finally, different modifications of the reaction conditions such as solvent, temperature, or 
the use of additives such as Lewis acids101 can also help increase the reactivity of partners 
in certain CM reactions. Alternatively, the use of olefin partners as their homodimers 
(Scheme 69),102 the addition of the catalyst neat or in solution, or the use of vacuum102a 
during the reaction to remove ethylene from the catalyst, thus helping drive the 
equilibrium to the right, are also factors which have to be taken into consideration. 
Although the effects of these factors on CM efficiency cannot be predicted, very time-
consuming screening of such parameters can nevertheless give significant results. 
 
 
 
Reagents and conditions i, first generation Grubbs catalyst (5 mol%), DCM, 40 °C, 12 h. 
 
Scheme 69. Effect of symmetric olefin partner on cross-metathesis.102a 
 
As the choice of the CM catalysts and olefin partners is absolutely crucial for the CM 
selectivity, it will be discussed in details in the next sections (II-2.1.2 and II-2.1.3). 
 
2.1.2 Choice of cross-metathesis allylic amino alkene partner100 
 
The choice of CM partners is by far the most important factor to be controlled in order to 
guarantee successful selective CM. Although being fairly unpredictable, two major 
features can be finely modified to direct the CM selectivity: 
 
- Steric effects 
The steric hindrance of each partner does affect their ability to undergo homodimerzation, 
and directly favours or disfavours the heterodimerization. Two different olefins A and B 
will tend to dimerize according to the statistical distribution discussed earlier (Scheme 
68). However, if the olefin A is made more hindered, this will reduce its propensity to 
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homodimerize with itself, and will consequently increase its probability to heterodimerize 
with B. Nevertheless, if the olefin A is made too hindered, the opposite olefin B will prefer 
homodimerize with itself rather than heterodimerize. For instance, the incorporation of 
additional bulky groups, such as protecting groups, can facilitate important geometrical 
modifications of a CM partner, affecting its propensity to homodimerize, and making its 
double bond more or less accessible for the coupling reaction (Scheme 70). 
 
 
 
Reagents and conditions i, second generation Grubbs catalyst (5 mol%), DCM, 40 °C, 24 h. 
 
Scheme 70. Effect of protecting groups on cross-metathesis.102b 
 
- Electronic effects 
The idea that two olefins possessing opposite electronic properties are more likely to 
heterodimerize, is widely accepted in metathesis. That is to say that an electron 
withdrawing olefin has more chance to heterodimerize with an electron rich olefin. 
Despite the fact that this common magnet-like principle is in total contradiction with 
homodimerization, which can be observed in very high yields sometimes, it remains a 
reliable scheme to use for the design of efficient CM couplings. 
 
It is difficult to accurately predict how the complex interplay of steric and electronic 
factors will determine the ability of various sets of olefins to participate in selective CM. In 
order to make this point clearer, R. H. Grubbs100 published a general model based, notably, 
on the ability of different class of olefins to homodimerize. It represents an interesting 
empirical tool for the prediction of competitive CM couplings, involving notably 
polyalkene partners with several competing C=C double bonds. However, it appeared to 
be rather limited by the number of substrates and catalysts listed, and in fact, did not help 
us find the optimal conditions in our case. 
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Cross-metathesis is a very powerful tool which can be employed to couple most types of 
olefin. However, to do so, it can require a significant amount of work to screen all the 
possible conditions. However, due to the lack of predictability in CM selectivity, this time-
consuming screening remains the only real way to significantly improve the efficiency of 
CM couplings, as illustrated below (Scheme 71). 
 
 
 
Reagents and conditions i, second generation Grubbs catalyst (5 mol%), DCM, 40 °C, 12 h. 
 
Scheme 71. Effect of alkene substitution on cross-metathesis.102a 
 
The use of 1,3-dienes as metathesis partners is known from the literature,103-107 and several 
groups have reported their use in metathesis couplings with allylic ethers,103,106,107 or allylic 
alcohols.105 However, the CM coupling of 1,3-dienes with allylic amines have never been 
reported before, and thus represented an opportunity to extend the scope of cross 
metathesis methodology. As a result, an important screening of conditions such as, CM 
partners, catalysts, solvents, and many other parameters was necessary to establish 
suitable CM conditions. It was first crucial to reduce the large choice of amino CM 
partners to a limited number of frameworks structurally similar to successful CM partners 
reported in the literature (Figure 20).108-114 
 
 
 
Figure 20. Possible frameworks for Cross-Metathesis coupling. 
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According to the preliminary results, the β-lactam scaffold appeared as one of the best 
candidates. It had already been used in cross-metatheses with success,113 and offered an 
internal protection of both amino and carboxylic groups masked as the β-lactam scaffold. 
As presented in McCarthy’s work,84,89 once coupled to the diene, the lactam could easily 
be cleaved in one step, and thus liberates both amine and carboxylic acid functions 
required in the final ADDA structure. Furthermore, the relative trans-stereochemistry, 
required in the final ADDA chain, had been demonstrated to be relatively easy to control 
through β-lactam chemistry.84,89 
 
2.1.3 Choice of cross-metathesis catalysts 
 
The selection of appropriate CM catalysts represents a difficult task which can have 
dramatic effects on the outcome of the coupling reaction, as illustrated below (Scheme 72).  
 
 
 
Reagents and conditions i, CM catalyst (3-5 mol%), DCM, 40 °C, 12 h. 
 
Scheme 72. Effect of catalyst on CM selectivity.102a 
 
Since the discovery of the cross-metathesis coupling reaction in the 1950s, the 
development of CM catalysts has become a very intense and productive area of research. 
Among the numerous catalysts designed, more than a dozen are now commercially 
available.115 Nevertheless they remain fairly expensive to use and so focusing our 
attention on the most promising candidates, was consequently considered as crucial. 
Moreover, it should be noted that metathesis catalysts have generally low activity in cross-
metathesis and require then to be used in fairly large amounts (> 30 mol%). This is due to 
the lack of enthalpic driving force in cross-metathesis unlike in Ring Closing Metathesis 
(RCM) (formation of favoured 5 or 6-membered ring) or Ring-Opening Metathesis (ROM) 
(ring-strain release). This obstacle has widely participated to the under-representation of 
CM compared with RCM or ROM. 
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In addition to the general model published by Grubbs,100 a review published in 2007115 
appeared to be extremely helpful for the selection of the five most adapted CM catalysts, 
listed below (Figure 21): 
 
 
 
Figure 21. Most promising selected CM catalysts.115 
 
The selection was based upon their price, their ability to catalyse cross-metathesis rather 
than other types of metathesis (RCM, ROM), their ability to catalyse CM of hindered 
olefins, and their reactivity at low temperatures. 
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2.2 - Synthesis of β–lactam CM partner 
 
2.2.1 Brief overview on β–lactam chemistry 
 
The chemistry related to the synthesis of β-lactams has generated a lot of interest since the 
discovery of penicillin and other β-lactam-containing antibiotics, and is frequently 
represented in the literature by two majors synthetic routes, presented below: 
 
-   [2+2] cycloadditions (Scheme 73)116 
 
 
 
Scheme 73. Synthesis of β-lactam via [2+2] cycloadditions.116 
 
-   Nucleophilic cyclisations (Scheme 74)117 
 
  
 
 
Scheme 74. Synthesis of β-lactam via nucleophilic cyclisations.117 
 
Many other methods, such as catalysed C-H insertion,118 are known to synthesise β-
lactams. However, they are not as widely reported as the two methods exposed above 
(Schemes 73 & 74). These well-known approaches can also be found in many different 
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variants, involving ketene precursors such as acyl chlorides or diazo-compounds, to name 
a few.119 
 
2.2.2 Synthesis of β-lactam (±)-119 
 
Before embarking on an enantioselective synthesis, it was first decided to focus on the 
preparation of the racemic β–lactam, which could allow the isolation of the enantio-ADDA, 
and its diasteromeric analogue simultaneously. The synthesis started with the [2+2] 
cycloaddition of vinyl acetate 148 and chlorosulfonyl isocyanate 149, which afforded the 
known acetoxy azetidinone (±)-118 in good yield compared with literature precedents.120 
This highly scalable reaction allowed the preparation of large amounts of lactam (±)-118 in 
an inexpensive manner (Scheme 75). The low yield obtained was essentially due to the 
non-trivial work-up required to cleave the chlorosulfonyl moiety of the intermediate 150 
to access the azetidinone (±)-118. Indeed, the chlorosulfonyl cleavage, which must be 
carried out at low temperature in pre-cooled glassware, releases one equivalent of 
hydrochloric acid and one equivalent of sulphuric acid. Although the majority of the acids 
were neutralized during the buffered work-up, the remaining acidic traces, and the 
elevation of the temperature induced the rapid decomposition of the β-lactam unit. 
 
  
 
Reagents and conditions i, neat, 0 °C, 1 h; ii, NaHCO3, Na2SO3, water, ice, 0 °C, 24% (2 steps). 
 
Scheme 75. Synthesis of acetoxy azetidinone (±)-118. 
 
The reaction required no purification to afford the unstable acetoxyazetidinone (±)-118 in 
very good purity. The azetidinone (±)-118 was then immediately converted into the vinyl 
azetidinone (±)-151 by treatment of the phenyl sulfone intermediate with vinyl 
magnesium bromide at -78 °C, as described in the literature.120ab The lactam (±)-151 was 
then protected as N-TBS azetidinone (±)-152 in quantitative yield, and an extra methyl 
group was incorporated α-position to the carbonyl group by treatment of azetidinone (±)-
152 with n-BuLi and methyl iodide. The resulting methylated vinyl azetidinone (±)-153 
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was thus obtained in good yield with the desired trans-relationship exclusively. The N-
TBS azetidinone (±)-153 was finally deprotected to yield the final trans-β-lactam (±)-119 
(Scheme 76). 
 
 
 
Reagents and conditions i, PhSO2Na, water, Δ, 20 min; ii, CH2=CHMgBr, THF, -78 °C, 
90%; iii, TBSOTf, DCM, rt, 10 min, 98%; iv, n-BuLi, THF, -78 °C, then MeI, 78%, 
trans only; v, KF, MeOH, 0 °C, 87%. 
 
Scheme 76. Synthesis of trans-azetidinone (±)-119. 
 
 
3 – THE CROSS-METATHESIS COUPLING 
 
3.1 – First attempts 
 
Although extensive work have been reported to better understand and predict cross-
metathesis selectivity,100 the screening of a broad range of conditions appeared necessary. 
With both the left and right hand side ADDA fragments in hands, the first CM test 
reactions could be attempted. However, before embarking on the initial cross-metathesis 
methodology, it was first decided to take advantage of the successful Horner-
Wadsworths-Emmons olefination used to construct the diene (E)-139 (Scheme 62). The 
idea was to turn the lactams (±)-119 and (±)-153 into the corresponding allylic phosphine 
oxides (±)-154, (±)-155, (±)-156, and (±)-157 through a cross-metathesis reaction (Scheme 
77). Surprisingly, cross-metathesis of phosphine oxides are barely represented in the 
literature,121,122 and a wide number of conditions was screened to find the best coupling 
conditions. A broad variety of conditions involving the use of different CM catalysts (GI, 
GII, HGII, 10 - 20 mol%), in different solvents (dichloromethane and toluene), and in the 
presence of titanium isopropoxide. Unfortunately, the coupling of racemic 1-
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methylallyldiphenylphosphine oxide 142 with lactams (±)-119 and (±)-153, proved 
fruitless, as it did not give even a trace of the expected heterodimer (Scheme 77).  
 
 
 
Reagents and conditions i, various conditions (see text). 
 
Scheme 77. Failed CM with between phosphine oxide 142 and β-lactams (±)-119 and (±)-153. 
 
Our attention was then drawn on literature precedents, which reported the use of 
allyldiphenylphosphine oxide 143 as a successful cross-metathesis partner.121,122 It was first 
decided to compare the reactivity of both phosphine oxides 142 and 143 with one another 
and thus determine the effect of the extra methyl group on the CM reactions. The 
previously reported methodology,122 involving the use of hexenylacetate 158, was 
rigorously followed as described, and reliably reproduced for both phosphine oxides 
(Scheme 78). The comparison brought precious information, highlighting the fact that the 
extra methyl caused dramatic effects on the CM selectivity (Scheme 78).  
 
 
 
Reagents and conditions i, Second generation Grubbs catalyst (6 mol%), DCM, Δ, 24 h. 
 
Scheme 78. Comparison of CM abilities of phosphine oxides 142 and 143. 
 
It should be noted that, although the formation of traces quantities of (Z)-isomers of 
olefins 159, 160, and 161 were expected, as described in the literature,122 this could not be 
confirmed by NMR analyses as the NMR signals of the side-products traces were mostly 
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unresolved. The phosphine oxide 143 was thus proved to be a much better CM partner 
than the 1-methylallyldiphenylphosphine oxide 142 (Scheme 78). CM test reactions were 
continued, and were all re-attempted with the allyldiphenylphosphine oxide 143. Among 
the numerous conditions employed, it should also be noted that the use of symmetrical 
(E)-allyldiphenylphosphine oxide homodimer 162 (Scheme 79), obtained through the 
method reported by V. Gouverneur,122 as CM partner, or the addition of Ti(O-iPr)4 did not 
give any better results.  
 
 
 
Reagents and conditions i, Second generation Grubbs catalyst (2 mol%), DCM, Δ, 24 h. 
 
Scheme 79. Homodimerization of allyldiphenylphosphine oxide 162. 
 
After a significant amount of optimization, the first promising results were obtained in 
toluene, at 80 °C, with either second generation Grubbs catalyst or second generation 
Hoveyda-Grubbs catalyst. Interestingly, the choice of β-lactam CM partner appeared 
important for the cross-metathesis efficiency (Scheme 80). Indeed, unprotected 
azetidinone (±)-119 was shown to undergo heterodimerization with phosphine oxide 142 
in a much better yield than N-TBS protected azetidinone (±)-153 (Scheme 80), which was 
since considered as a poor CM partner, and discarded from the future CM screenings. 
Traces of side products were also observed by NMR but could not be identified as they 
were mainly unresolved. Hence, the existence of the (Z)-isomers of (±)-163 and (±)-164 
heterodimers could not be demonstrated. 
 
 
 
Reagents and conditions i, Second generation Grubbs catalyst (19 mol%), toluene, 65 to 80 °C, 
38 h, 69%; ii, Second generation Hoveyda-Grubbs catalyst (31 mol%), toluene, 80 °C, 13 h, 
78%; iii, Second generation Hoveyda-Grubbs catalyst (10 mol%), toluene, 80 °C, 33 h, 31%. 
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Scheme 80. Heterodimersation of phosphine oxides (±)-163 and (±)-164. 
 
Both very polar heterodimers (±)-163 and (±)-164 were isolated after difficult purifications 
by flash chromatography, and pure phosphine oxide (±)-163 was taken into HWE 
coupling. The phosphine oxide (±)-163 was treated with n-BuLi, and then with freshly 
distilled propionaldehyde in using the same methodology previously utilised to generate 
the dienes (E)-139 and (Z)-139 via the Horner-Wadsworths-Emmons olefination (Scheme 
62 & 81). Unfortunately, the expected but unwanted side β-elimination followed by the 
opening of the lactam occurred, in place of the staighforward olefination designed to 
provide diene (±)-165. Another attempt, with catalytic amount of n-BuLi gave the same 
unwanted triene 166 (Scheme 81), and the process was consequently abandoned without 
trying the reaction with N-TBS protected hetrodimer (±)-164. The CM reactions seen above 
(Scheme 80) were therefore not optimized. The major (E,E,E)-geometry of the triene was 
deduced from NMR analyses reported in the literature for equivalent trienes.123 
 
 
 
Reagents and conditions i, n-BuLi, HMPA, THF, -78 °C, the EtCHO, -78 °C to rt, overnight, 66%. 
 
Scheme 81. Unsuccessful synthesis of diene (±)-165 through HWE olefination. 
 
It worth mentioning that the CM/HWE-sequence developed (Scheme 80 & 81), offers a 
novel interesting route to valuable polyenes commonly found in the literature.123 After 
failing to form the (E,E)-1,3-diene, the initial CM strategy was then re-envisaged, and the 
CM/HWE approach was left aside. 
 
3.2 – Towards the successful metathesis 
 
The statistical distribution of olefins (Scheme 68) can be significantly modified for cross-
metatheses involving polyalkenes possessing several competitive C=C double bonds. The 
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competition between the double bonds tends to increase the risk of forming undesired 
cross-dimers. This is one of the reasons why cross-metathesis of polyalkenes remains 
fairly under represented in the literature. 
 
In order to find the best cross-metathesis partners among all the olefin intermediates 
generated so far, a straightforward screening was operated. On one hand, the CM abilities 
of OMe-diene (E)-117 were compared with those of O-TBS diene (E)-139, in coupling them 
separately to β-lactam (±)-119. And, on the other hand, the CM abilities of lactam (±)-119 
and those of lactam (±)-151 were also compared in coupling them separately to diene (E)-
139. Thus, we expected to be able to determine, and better understand the effects of the 
TBS and methoxy groups on the reactivity of the dienes (E)-117 and (E)-139, as well as the 
effects of the extra methyl group of β-lactam (±)-119 compared with non-methylated β-
lactam (±)-151 (Scheme 82). 
 
 
 
Reagents and conditions i, HGII (11 mol%), toluene, Δ, 2 days, 37%; ii, HGII (16 mol%), toluene, Δ, overnight, 
37%; iii, HGII (10 mol%), DCM, Δ, 10 h, 11%. 
 
Scheme 82. First successful cross-metatheses between diene and β-lactam units. 
 
After trying many CM reactions under various conditions (solvents, temperatures and 
catalysts), interesting results were obtained. The coupling of diene (E)-139 with β-lactam 
(±)-119 using second generation Hoveyda-Grubbs catalyst, in toluene, at reflux, provided 
heterodimers 167 and 168 with a modest but encouraging 37% yield (Scheme 82). The 
same CM conditions were then applied to methoxy diene (E)-117, and provided 
heterodimers 169 and 170 with the same efficiency. Finally, the CM coupling of diene (E)-
117 with β-lactam (±)-151 yielded dienes 171 and 172 in very low yield (Scheme 82).  
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Interestingly, the preliminary results obtained showed that, unlike for the dienes (E)-117 
and (E)-139, which had almost identical CM abilities, the presence of the additional 
methyl of β-lactam (±)-119, compared with (±)-151, dramatically reduced the efficiency of 
the coupling metathesis. Based on these observations, the azetidinone (±)-119 was 
considered as the best CM partner, and our future efforts were essentially focused on the 
optimisation of its CM coupling with diene (E)-117. 
 
Before optimising the CM reaction, the inseparable heterodimers 169 and 170 were N-Boc 
protected by treatment with triethylamine, DMAP, and (Boc)2O, and the resulting N-Boc 
protected lactam intermediates were subsequently opened by addition of lithium 
hydroxide, as described by McCarthy.84,89 The sequence provided the final N-Boc 
carboxylic acids enant-31 and 173, which matched with the data previously reported for 
the opposite enantiomer (Scheme 83).72,76-79,81-89 
 
 
 
 
Reagents and conditions i, (Boc)2O, DMAP, TEA, DCM, rt, overnight, 70%; ii, LiOH, THF, rt, 23 h, 85%.  
 
Scheme 83. Synthesis of enantio-N-Boc-ADDA enant-31 and the ADDA isoform 173. 
 
3.3 – Optimisation of the coupling 
 
A large number of modifications were envisaged to optimize the actual cross-metathesis 
of the β-lactam (±)-119 and the diene (E)-117 (Scheme 82). The use of a suitable nitrogen 
protecting group was envisaged to make the azetidinone (±)-119 more hindered, and less 
electron rich in taking some of the electron density away from the nitrogen. In order to do 
this, the N-Boc and N-TAC protecting groups appeared as the most judicious options, and 
both racemic N-protected β-lactams (±)-174 and (±)-175 were generated from the 
unprotected azetidinone (±)-119  in quantitative yield (Scheme 84). 
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Reagents and conditions i, (Boc)2O, DMAP, TEA, DCM, rt, overnight, 100%; ii, 
Cl3CC(O)Cl, TEA, DCM, -78 °C, 10 min, 100%. 
 
Scheme 84. Synthesis of N-Boc and N-TAC protected β-lactams (±)-174 and (±)-175. 
 
McCarthy demonstrated that N-Boc protection was essential for the LiOH-based lactam 
hydrolysis,84,89 and for this reason, the N-Boc protected lactam (±)-174 was preferably 
engaged into the CM coupling. Gratifyingly, the N-Boc heterodimer was obtained as the 
(E,E)-isomer exclusively, in a much better yield, and the subsequent opening of the lactam 
via addition of lithium hydroxide was acheived in quantitative yield (Scheme 85). The 
spectral data of the final N-Boc carboxylic acid enant-31 matched with the data previously 
reported for the opposite enantiomer.72,76-79,81-89 
 
 
 
Reagents and conditions i, HGII (21 mol%), toluene, Δ, 22 h, 67%; ii, LiOH, THF, rt, 23 h, 85%. 
 
Scheme 85. Synthesis of enantio-N-Boc-ADDA enant-31 and the ADDA isoform 173. 
 
As a consequence of the satisfactory results obtained for the CM of diene (E)-117 and N-
Boc protected lactam (±)-174, the fragile N-TAC protected lactam (±)-175 was finally not 
utilised.  
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4 – COMPARISON OF COLLECTED DATA 
 
The final mixture of inseparable diastereoisomers enant-31 and 173 was fully 
characterised and the collected data, including 1H, 13C NMRs and [α]D, was thoroughly 
compared with the data available in the literature.72,76-79,81-89 Against the odds, the 
similarity was just astonishing. The obtained isomeric mixture had the same physical and 
spectral data as the N-Boc-ADDA chain reported in the literature.72,76-79,81-89 To explain 
these observations, three possible theories were proposed: 
 
1) Both diastereoisomers enant-31 and 173 had exactly the same properties and 
consequently appeared to be identical; 
2) A diastereoselective cross-metathesis was achieved, as is documented in the literature, 
via the use of chiral CM catalysts;124 
3) The unwanted isomer 173 decomposed at some point during the reaction or the 
purification process. 
 
4.1 – First investigations 
 
The N-Boc lactam 176 and 177 showed two distinct , but very close set of signals by 1H and 
13C NMRs. However, this difference completely disappeared in the final N-Boc acid enant-31, 
showing only one set of NMR signals, and a very similar optical rotation ([α]23D +15.1, (c = 
1.0, CHCl3)) to the one of the opposite enantiomer reported in the literature ([α]22D -15.1, (c = 
1.0, CHCl3)76) and ([α]23D -15.7, (c = 1.0, CHCl3)79). To explain these observations the existence 
of two blocked rotamers was postulated, as illustrated below (Figure 22).  
 
 
 
Figure 22. Possible barrier originating two rotamers from N-Boc lactam 176.  
 
In order to probe the existence of potential conformers, high temperature 1H NMR 
experiments (C6D6, 20 to 80 °C) of the isomeric mixture of N-Boc protected lactams 176 
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and 177 were carried out. The two sets of signals were expected to merge into one, but 
unfortunately these experiments did not provide any conclusive evidence regarding the 
presence, or not, of rotamers. As the 1H and 13C NMR of the lactams 176 and 177 showed 
very distinct chemical shifts, their separation using chiral HPLC was first attempted. 
However, independently on the columns and the conditions used, a single sharp peak was 
only observed. A HPLC separation of the isomeric mixture of acids enant-31 and 173 was 
then attempted. However, neither HPLC in reverse phase, nor chiral HPLC in normal 
phase enabled the observation of two peaks either. Despite using various columns and 
conditions, a single sharp peak was always observed, suggesting the presence of two 
rotamers resulting from a diastereoselective CM. However, the synthesis of the 
enantiomerically pure lactam 174, appeared necessary to formally demonstrate the 
presence of a single diastereoisomer beyond a doubt. 
 
4.2 – Synthesis of optically pure lactam 174 
 
A large number of methods have been reported for the synthesis of enantiomerically pure 
lactams.125,84,89 They can either be generated through enzymatic125a or crystallographic125b 
resolution methods, using chiral reagents or catalysts,125c or be generated from the chiral 
pool.84,89 The documented cyclisation of 3-methylaspartic acid derivatives84,89 was initially 
investigated, to obtain optically pure β–lactams. The well-known diastereoselective 
methylation was used to prepare the trans-methylated aspartate exclusively, as described 
in the literature.126 However, in our hands this methylation was proved troublesome 
(Scheme 86), resulting in a mixture of diastereoisomers syn-179 and anti-179, as described 
by Chamberlin.81 Furthermore, the mixture could not be cyclised into the β–lactams syn-
180 and anti-180 (Scheme 86).  
 
 
 
Reagents and conditions i, TsCl, TEA, rt, 24 h, THF; ii, KHMDS, THF, -78 °C then MeI, -78 °C to rt, 45%, (1:3) 
syn/anti; iii, tBuMgCl, Et2O. 
 
Scheme 86. Unsuccessful route to optically pure azetidinone anti-180. 
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The issue was finally overcome thanks to methodology described by McCarthy,84,89 which 
was also based on the same type of cyclisation to produce the 4-membered ring (Scheme 
87). The main difference was the use of benzyl esters in place of methyl esters. This better 
leaving group greatly facilitated the cyclisation process, but on the down side, made the 
purification steps more difficult, as benzyl alcohol was liberated in place of methanol. 
Initially, the procedure was rigorously followed as described by McCarthy.84,89 However, 
the instability of crude N-TBS aspartic ester (S)-94 towards extensive manipulations, as 
well as the racemisation at many stages, rapidly appeared as major problems. After 
repeating the McCarthy’s β-lactam synthesis84,89 several times, obtaining partial to total 
racemisation along the way, the whole procedure was modified to insure the formation of 
the final N-Boc protected β-lactam as a single enantiomer (Scheme 87). 
 
The readily accessible and enantiomerically pure (S)-aspartic acid (S)-55 was firstly 
dibenzylated. The resulting benzyl diester (S)-93 was then N-TBS protected to give the 
fragile and unstable intermediate (S)-94, which was used immediately in the cyclisation 
reaction (Scheme 87). The resulting lactam 181 was then gently reduced by treatment with 
NaBH4 and LiBr with control of the temperature, yielding the alcohol (S)-95 in modest 
yield. The Swern oxidation, which represented one of the most sensitive steps regarding 
epimerisation, was performed by addition of triethylamine at -78 °C and led to optically 
pure aldehyde 182. However, as demonstrated later, this reaction should have been 
operated with DIPEA to suppress completely any risk of racemisation (Section IV-2.3.3). 
 
The resulting aldehyde 182 was first olefinated with Ph3CH2I and LiHMDS, but the 
procedure led to the total decomposition. Alternatively, the treatment of aldehyde 182 
with Petasis reagent allowed the preparation of vinyl lactam 152 with complete 
conversion as observed by NMR analyses. However, vinyl lactam 152 was isolated in very 
low yield as it decomposed during the purification by flash column chromatography over 
neutralised silica. This decomposition was completely unexpected as this purification 
process had previously been used with excellent success, with exactly the same conditions 
to provide the racemic vinyl lactam (±)-152 in nearly quantitative yield. The degradation 
was thought to be a result of the action of silica and Petasis derivatives combined together. 
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Reagents and conditions i, BnOH, p-TsOH, Δ, 6 h; ii, TBSCl, TEA, DMAP, DCM, rt, overnight; iii, tBuMgCl, 
Et2O, -78 °C to rt, overnight; iv, NaBH4, LiBr, water, THF, < 28 °C, 9% (4 steps); v, (COCl)2, DMSO, TEA, 
DCM, -78 °C; vi, Petasis reagent, THF, Δ, 2.5 h, 22% (2 steps); vii, n-BuLi, THF, -78 °C, then MeI, 78%, trans 
only; viii, KF, MeOH, 0 °C, 55% (2 steps); ix, (Boc)2O, DMAP, TEA, DCM, rt, overnight, 65%. 
 
Scheme 87. Synthesis of the optically pure azetidinone 174. 
 
The next part of the synthesis was achieved following the same conditions previously 
described for the synthesis of racemic lactam (±)-174 (Scheme 76 & 84), which provided 
the enantiopure N-Boc lactam 174 in modest to good yield. Comparison of HPLC traces of 
optically pure lactam 174 with its racemic version (±)-174 allowed the determination of an 
excellent enantiomeric excess (ee = 98%). Although, the new method ensured the 
formation of the final N-Boc protected β-lactam as a single enantiomer, the synthesis of 
lactam 174 was completed in very low yields. The lack of time prevented us from 
optimising the whole process. 
 
4.3 – Coupling toward enantiopure N-Boc-ADDA chain 
 
To compare the results in a rigorous and scientific manner, the final cross metathesis 
couplings were set up in parallel, and performed under strictly identical conditions with 
enantiopure N-Boc lactam 174 and the racemic N-Boc lactam (±)-174 obtained from the 
[2+2] cycloaddition. Both N-Boc lactam sets were coupled to diene (E)-117 using the same 
methodology as before, which provided the (E,E)-N-Boc heterodimers 176 and [176 + 177] 
exclusively in similar yields (Scheme 88). At this stage, the difference between the two sets 
of (E,E)-heterodimers 176 and [176 + 177] was clearly visible by NMR analyses. This 
formally proved that compound 176, obtained from the CM coupling of the diene (E)-117 
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with the racemic lactam (±)-174 (Section III-3.2) was definitely not a mixture of two 
rotamers, but only a mixture of two diastereoisomers [176 + 177]. Thus, the 
diastereoselective metathesis theory was formally disproved, but not the one involving 
potential decomposition of the undesired diastereoisomer 177, which was still realistic. 
 
 
 
 
 
Reagents and conditions i, HGII (20 mol%), toluene, Δ, 14 h, 61%; ii, HGII (20 mol%), toluene, Δ, 14 h, 69% 
 
Scheme 88. Synthesis of heterofimers 176 and [176+177]. 
 
Both sets of N-Boc protected lactams 176 and [176 + 177] were brought to the carboxylic 
acid stage, by treatment with LiOH (Scheme 89 & 90). Purification of the resulting 
isomeric mixture of acids enant-31 and 173 by flash column chromatography over 
neutralised silica gel with triethylamine, provided the unwanted ammonium salts 183 and 
[183 + 184], which interestingly presented significant differences by NMR analysies, 
revealing clearly the presence of both diastereoisomers. A quick acidic work-up of the 
ammonium salts cleanly generated the free carboxylic acids enant-31 and [enant-31 + 173] 
(Schemes 89 & 90). 
 
 
 
Reagents and conditions i, LiOH, THF, rt, 90 min, triethylamine, 94%; ii, acidic work-up, 90% 
 
Scheme 89. Synthesis of enantiomerically pure enantio-N-Boc-ADDA enant-31. 
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Reagents and conditions i, LiOH, THF, rt, 90 min, triethylamine, 90%; ii, acidic work-up, 88% 
 
Scheme 90. Synthesis of diastereoisomeric mixture of acids enant-31 and 173. 
 
More interestingly, at this point, the two sets of acids enant-31 and [enant-31+173] became 
impossible to differenciate by 1H or 13C NMR, as it was the case before (Section III-3.2). 
The spectral differences between both diastereoisomers enant-31 and 173 were almost 
impossible to observe. A very large expansion of the NMR data was necessary to reveal a 
couple of very close doubled signals, which could not have been seen without a fine 
comparison with the enantiomerically pure carboxylic acid enant-31. These observations 
finally confirmed that both diastereoisomers enant-31 and 173 had almost identical 
physical and spectral properties, and that no decomposition of the undesired 
diastereoisomer 173 had occurred. Importantly, the [α]D of enantiopure enantio-N-Boc-
ADDA chain enant-31 obtained ([α]26D +23.8, (c = 1.0, CHCl3)) did not match very well 
with the literature ([α] D -19, (c = 0.0547, CHCl3)85 and ([α] D -13.3, (c = 0.73, CHCl3)72). 
Strangely, the optical rotations extracted from the literature85,72 were closer to the optical 
rotation of the diastereoisomeric mixture [enant-31+173] than the actual enantiomerically 
pure enantio-N-Boc-ADDA enant-31, casting doubt on the authenticity of some of the data 
previously reported in the literature. 
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5 – BRIEF CONCLUSION 
 
The synthesis of the enantio-N-Boc-ADDA enant-31 was successfully completed, and the 
first part of our work was published in 2008.127 Our investigations demonstrated that 
cross-metathesis was an efficient (E,E)-selective technique to construct the ADDA 
framework. But more importantly, our results filled the gap caused by the lack of data in 
the literature (expansion of NMR spectra, and optical rotations), and illustrated the real 
complexity of such an apparently simple compound as the ADDA chain. 
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RESULTS & DISCUSSION 
 
 
 
-------  PART IV – SYNTHESIS OF ENANTIO-ISO-ADDA CHAIN  ------- 
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Figure 23. enantio-N-TAC-iso-ADDA 115 
 
The synthesis of enantio-N-TAC-iso-ADDA chain 115 (Figure 23) was carried out in 
parallel with the synthesis of the enantio-N-Boc-ADDA enant-31. Well before the previous 
cross-metathesis was made to work, the initial approach was envisaged through an 
alkyne-alkyne organometallic coupling (Section III-2.2), which had never been used to 
generate the ADDA framework. However, this strategy was rapidly discarded as the 
required aldehyde intermediate could not be generated (see section 1.2.2). In the 
meantime, the cross-metathesis methodology utilised to synthesise enantio-N-Boc-ADDA 
enant-31 gave the first promising results, and was therefore considered as a better 
approach towards enantio-N-TAC-iso-ADDA 115 (Figure 23). The convergent synthesis of 
enantio-N-TAC-iso-ADDA 115 employed the same diene (E)-117, which was prepared 
through the same process presented earlier (section 1.1 and 1.2, Schemes 51, 57, 62, 66). 
Consequently, the next part of the discussion will essentially focus on the synthesis of the 
right hand side CM amino-partner. 
 
1 – SYNTHESIS OF THE AMINO UNIT 
 
1.1 – Epimerisation of trans- β-lactam (±)-153 to cis- β-lactam (±)-185 
 
It was first tried to take advantage of the β-lactam chemistry developed earlier (section 
4.3.1) to generate the cis-relationship required in the iso-ADDA framework. To acheive this 
goal, the isomerisation of racemic N-TBS protected β-lactam (±)-153 to racemic cis-lactam 
(±)-185, was envisaged through the mechanism presented below (Scheme 91). 
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Reagents and conditions i, n-BuLi, THF, -78 °C then H2O, -78 °C to rt. 
 
Scheme 91. First isomerisation mechanism of trans-azetidinone (±)-153. 
 
However, treatment of the N-TBS β-lactam (±)-153 with n-BuLi followed by quenching 
with water did not form any of the epimerized lactam (±)-185. The proposed mechanism 
was consequently re-envisaged to account for these observations, as presented below 
(Scheme 92). 
 
 
 
Reagents and conditions i, n-BuLi, THF, -78 °C then H2O, -78 °C to rt. 
 
Scheme 92. Second isomerisation mechanism of trans-azetidinone (±)-153. 
 
However, it should be noted that quenching with deuterated water did not produce 
observable disappearance of the proton in α-position of the carbonyl under any 
conditions, putting a serious doubt on the actual formation of the anion. 
 
1.2 – Synthesis of trichloroacetamide 122 
 
As cis-β-lactam (±)-185 could not be prepared, a different approach was designed to access 
the required cis-stereochemistry present in the enantio-iso-ADDA. The synthesis started 
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with the readily available and enantiomerically pure propionate 186, which was trityl-
protected, and subsequently reduced to the alcohol 187 (Scheme 93). 
 
 
 
 
Reagents and conditions i, TrCl, TEA, DCM, 0°C to rt, overnight, 100%; ii, LAH, Et2O, -30 °C to rt, 
overnight, 97%. 
 
Scheme 93. Synthesis of the diol 187. 
 
This protecting group was thought to be bulky enough to reduce the risk of racemisation 
of the mono-protected diol 187, by protecting group migration between both hydroxyls of 
diol 187 (Scheme 94). The other reason for the choice of trityl protecting group was to 
improve the diastereoselectivity of the aza-Claisen rearrangement (Schemes 43 & 44), as 
discussed later in this paragraph. 
 
  
 
Scheme 94. Racemisation of a monoprotected diol by protecting group migration. 
 
The alcohol 187 was oxidised to the aldehyde intermediate, which was subsequently 
olefinated to give the conjugated methyl ester 188 through a Wittig olefination. The (E)-
double bond isomer was obtained exclusively, as corroborated by NMR analysis,128 and 
the ester was reduced to the allylic alcohol 189 by treatment with Dibal-H (Scheme 95). 
 
 
 
Reagents and conditions i, (COCl)2, DMSO, TEA, DCM, -78 °C; ii, Ph3P=C(CH3)COOMe, DCM, Δ, 3 days, 
90% (2 steps); iii, Dibal-H, Et2O, 0 °C, 2 h, 78%. 
 
Scheme 95. Synthesis of the allylic alcohol 189. 
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As the intermediates 188, 189, 121 and 122 (Schemes 95 & 97) possessed optical rotation 
close to zero, the enantiomeric excess of allylic alcohol 189 was measured by chiral HPLC, 
to confirm that no racemisation occurred during the synthesis. The migration of the trityl 
group (Scheme 94), the triethylamine-based Swern oxidation (see Section IV-2.3.3 for 
further details), or the Wittig olefination, as described by Beatty,76 were all likely to cause 
epimerisation. The racemic allylic alcohol (±)-189 was prepared through the chemistry 
developed above (Scheme 95) from the readily accessible symmetrical diol 190 (Scheme 
96). The comparison of the HPLC traces of both allylic alcohols 189 and (±)-189 confirmed 
that no epimerization occurred during the synthesis of 189 (ee = 98%) (Schemes 93 & 95). 
 
 
 
Reagents and conditions i, TrCl, TEA, rt, 2 days, 88%; ii, (COCl)2, DMSO, TEA, DCM, -78 °C; 
iii, Ph3P=C(CH3)COOMe, DCM, Δ, 3 days, 87% (2 steps); iv, Dibal-H, Et2O, 0 °C, 2 h, 42%. 
 
Scheme 96. Synthesis of racemic allylic alcohol (±)-189. 
 
The alcohol 189 was then converted to the trichloroacetimidate 121 by treatment with 
trichloroacetonitrile under basic conditions (Scheme 97). The trichloroacetimidate 121 was 
subjected to a palladium-catalysed aza-Claisen rearrangement, which was attempted 
using various conditions in order to improve the diastereoisomeric ratio of 
trichloroacetamides 122 and 191. The best results were obtained in dry dichloromethane 
with p-benzoquinone, and trichloroacetamides 122 and 191 were obtained in a (4:1) 
diastereoisomeric ratio (Scheme 97). A one-pot version was also developed and proved to 
be extremely efficient. Nevertheless, it is worth mentioning that the one-pot procedure 
required the use of twice as much palladium catalyst and p-benzoquinone as the classical 
two-step protocol (Scheme 97).  
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Reagents and conditions i, Cl3CCN, DBU, DCM, -78 °C, 3 h, 97%; ii, PdCl2(MeCN)2, p-
benzoquinone, DCM, rt 24 h, 89%, 122/191 (4:1); iii, PdCl2(MeCN)2, p-
benzoquinone, DCM, rt, 24 h, 95% (2 steps), 122/191 (4:1). 
 
Scheme 97. Synthesis of trichloroacetamides 122 and 191. 
 
Both trichloroacetamides 122 and 191 were easily separable by recrystallisation, which 
allowed structural data to be obtained by X-Ray crystallography, and thus confirmed the 
syn-stereochemistry of the major desired diastereoisomer 122 (Figure 24). It is worth 
noting that minor anti-isomer 191 could have potentially been used to generate the ADDA 
chain via a subsequent CM coupling with the opposite enantiomer of the diene (E)-117.  
 
 
 
Figure 24. Crystal structure of the dimeric allylic amine 122. 
 
1.3 – The aza-Claisen rearrangement 
 
The Aza-Claisen rearrangement, commonly known as the Overman rearrangement, is a 
thermal or metal-catalysed [3,3]-sigmatropic rearrangement of allylic trichloroacetimidates 
to allylic trichloroacetamides (Scheme 98). Since its first development by Overman,129 the 
reaction has found widespread use in synthetic organic chemistry to generate allylic 
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amines.130 Like other [3,3]-sigmatropic rearrangements, the reaction pathway progresses 
via a concerted suprafacial pathway involving a highly ordered chair-like transition 
state.131 The metal-catalysed reaction follows a stepwise pathway involving intramolecular 
amino palladation of the alkene followed by reductive elimination to generate the amide 
products (Scheme 98).  
 
 
 
Scheme 98. General palladium-mediated aza-Claisen rearrangement. 
 
The palladium(II)-catalysed version of this reaction is carried out under extremely mild 
conditions allowing the isolation of products in high yields and excellent regio- and 
stereoselectivities.131 However, the mechanism by which the diasteroselectivity of aza-
Claisen rearrangement of allylic trichloroacetimidates can be explained is still under 
debate, and some results are contradictory.130b,132 The diastereoselectivity appears to be 
influenced by steric bulk, but also by chelation between the substrate and the 
palladium(II) catalyst.130b,132 In these cases both effects probably participate together to 
give the diastereoselectivity observed in our rearrangement reaction, and several 
assumptions can be made to explain the observed (4:1) ratio of syn- and anti-
diasteroisomers 122 and 191. 
 
The biggest steric effects are due to the trityl group, causing the thricloroacetimidate 121 
to adopt a zig-zag geometry which places the trityl group as far as possible from the rest 
of the chain. However, the diastereocontrol of the reaction will be essentially dictated by 
the small difference of size between the competing substituents directly attached to the 
allylic carbon; that is to say the CH3 and the CH2O groups. As the carbon-oxygen bond is 
longer than a carbon-carbon bond, it is possible to considerate the methyl group as the 
bulkier of the two, although the difference is not massive. On the other hand, the 1,3-
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allylic strain caused by the methyl group has to be taken into account as shown in Scheme 
99 and discussed by Sutherland.130e Thus, sterics will direct the palladium to the face 
opposite to the methyl group. The nitrogen should then insert to the opposite face of the 
bulky [palladium + ligands], forming the syn-trichloroacetamide 122 as the major isomer. 
 
 
 
Scheme 99. Proposed explanation of aza-Claisen diastereoselectivity. 
 
The diastereoselectivity observed in our example could also be explained through a 
chelation controlled transition state between the oxygen and the palladium, as described 
by Sutherland.130b,130e However, the presence of the trityl group is likely to prevent this 
chelation from taking place, and further investigations would be required to completely 
explain the diastereoselectivity observed in this aza-Claisen rearrangement. 
 
It is also worth mentioning that the diasteroselectivity of our rearrangement reaction 
could be optimised through the use of chiral catalyst, as was shown in some literature 
examples.130a,133 
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1.4 - The initial alkyne-alkyne approach 
 
1.2.1 Possible coupling methods available 
 
While the cross-metathesis methodology was being investigated to complete the synthesis 
of the enantio-ADDA chain enant-31, an alkyne-alkyne coupling technique (Scheme 102) 
was also taken into consideration in parallel to form the 1,3-(E,E)-diene of the ADDA 
scaffold. However, a significant number of methods were also available, as listed below: 
 
- Wittig and Horner-Wadsworth-Emmons olefination (Scheme 100)72,74-78,84,85,89 
 
 
 
Scheme 100. Wittig-type couplings.72,74-78,84,85,89 
 
- Stille, Sonogashira, Suzuki and Negishi couplings (Scheme 101)79,81-83,87 
 
 
 
Scheme 101. Palladium-catalysed couplings.79,81-83,87 
 
- Alkyne-alkyne titanium catalysed couplings (Scheme 102)90 
 
 
 
Scheme 102. alkyne-alkyne coupling. 
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Alkyne-alkyne coupling (Scheme 102),90 which had never been used to construct the 
ADDA side chain, represented an attractive route to access the enantio-iso-ADDA, and was 
preferably proposed for our novel approach. However, the efficient organometallic 
couplings listed above (Schemes 100 & 101) were also envisaged as they had already 
proved to lead successfully to the ADDA framework in the literature.72,74-79,81-85,89 All of 
these coupling methods had one thing in common, as they all required the aldehyde 
intermediate 192, accessible from olefin 122 (Scheme 103). 
 
 
 
Reagents and conditions i, CrCl2, n-Bu3SnCHBr2, LiI, THF, DMF; ii, CHI3, CrCl2, THF then (n-
Bu3Sn)2, Pd(PPh3)4; iii, TMSCHN2, n-BuLi, THF; iv, Corey-Fuchs conditions; v, CrCl2, THF, 
Cl2CHB(OR)2, LiI; vi, CHI3, CrCl2, THF. 
 
Scheme 103. General method for the convertion of aldehyde 192 into suitable organometallic 
coupling partners. 
 
 1.2.2 Synthesis of aldehyde 192 
 
The first route was envisaged through ozonolytic cleavage of the double bond of olefin 
122 (Scheme 104). In order to find the best conditions without consuming too much of the 
precious trichloroacetamide 122, test reactions were all carried out on the (4:1) mixture of 
diastereoisomers 122 and 191. Treatment of olefins 122 and 191 with ozone, induced the 
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complete disappearance of starting material according to TLC analyses, nevertheless no 
traces of expected aldehydes 192 and 197 were detected by NMR. A large number of 
condition modifications (solvents, concentration, reaction time) failed to give the desired 
aldehydes 192 and 197, and alternatively the crude ozonolyzed mixture previously 
quenched with triphenylphosphine oxide, showing no aldehyde signals by NMR, was 
taken on crude to the following reaction. However, not surprisingly, no desired 
compounds were retrieved either. The aldehyde was presumably formed, but was too 
unstable to be isolated. To prove the formation of the aldehyde, a stream of argon was 
bubbled through the final bluish mixture of ozonolysed olefins 122 and 191, and the 
coulourless mixture was subsequently quenched with NaBH4 without any prior work-up. 
After purification by flash column chromatography, the alcohols 198 and 199 were 
isolated in poor yield, thus demonstrating that the unstable aldehydes 192 and 197 were 
actually well formed during the process (Scheme 104). 
 
 
 
Reagents and conditions i, O3, EtOH, DCM, -78 °C, 75 min then DMS or PPh3; ii, O3, EtOH, DCM, -
78 °C, 75 min then NaBH4, -78 °C to rt, 20 h, 31%, syn/anti (4:1). 
 
Scheme 104. Evidence of the formation of aldehydes 192 and 197. 
 
Alternatives to ozonolytic cleavage, such as the use of NaIO4 to cleave a 1,2-diol,134 were 
first envisaged, before it was decided to focus our attention on the ambitious cross-
metathesis, which appeared as a better approach. 
 
 
2 – FIRST CROSS-METATHESIS COUPLINGS 
 
Unlike other couplings which require additional synthetic steps to prepare suitable 
partners, cross-metathesis only requires alkene functions, which are present in the final 
heterodimer. As a result, cross-metathesis methodology represented the most direct way 
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to link the ADDA aromatic containing unit to olefin 122, without changing its already 
optimized synthesis. 
 
2.1 – First investigations towards cross-metathesis of trichloroacetamide 122 
 
 
 
Reagents and conditions i, Schrock’s catalyst (10 mol%), DCM, 40 °C, 16 h, 98%. 
 
Scheme 105. Use of N-TAC and O-Tr protected allylic amine in cross-metathesis.135 
 
A successful cross-metathesis reaction published by Blechert (Scheme 105),135 and using a 
very similar trichloroacetamide 201 to ours 122, was reproduced between a (3:1) isomeric 
mixture of diene (E)-139 and (Z)-139 and a (4:1) isomeric mixture of trichloroacetamides 
122 and 191 (Scheme 106 only the major diastereoisomers are drawn). The CM couplings were 
performed using similar reaction conditions to those described by Blechert,135 but also 
using the same conditions developed for our previous successful metathesis reactions. 
 
 
 
Reagents and conditions i, GII (12 mol%), DCM, Δ, 1 h; ii, silica, 15% (2 steps). 
 
 
Scheme 106. First cross-metathesis between diene (E)-139 and acyclic allylic amine 122. 
 
Unfortunately, the semi-pure heterodimer 203 (mixture of isomers) could only be isolated 
in very small quantities using the CM conditions described above (Scheme 106). A second 
purification by flash column chromatography caused the complete loss of the trityl 
protecting group, and afforded alcohol 204 (mixture of isomers) (Scheme 106). As a result, 
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the trityl-protected heterodimer 203 was only characterized by 1H NMR and LRMS. The 
reaction was re-attempted under the same conditions, but failed to give the heterodimer 
203. Although the reaction appeared rather temperamental and ineffective, these first 
results were rather encouraging, and extensive modifications, such as the transformation 
of the trichloroacetimidate 122, were envisaged. 
 
2.2 – Proposed modifications of trichloroacetamide 122 
 
A large number of possibilities were available to modify the steric hindrance and the 
electronics of the trichloroacetamide 122. This number was limited to four general 
structures (Figure 25), which were retained for their properties, but also for their relative 
ease of synthesise from the trichloroacetamide 122. 
 
 
 
Figure 25. General structure of possible CM partners originated from trichloroacetamide 122. 
 
With a dozen of CM analogues (including various protecting groups) to test with 5 
different commercially available catalysts, under different conditions, at least 60 cross-
metathesis reactions would have been necessary to screen all combinations. For obvious 
time and economical reasons, selection was refined, based on the empirical observations 
listed below: 
 
1) Hindered allylic amine containing trichloroacetamide and trityl groups were shown 
undergo CM couplings in excellent yield and very high (E)-selectivity (Scheme 105).135 
However, the tricloroacetamide 201 was coupled to rather small allylic trimethylsilane 
200, used in a large excess. In our case, these protecting groups were suspected of making 
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the olefin 122 too hindered and less reactive. Consequently the use of one of these two 
protecting groups at a time was preferred. 
2) It has been established as a “dogma” that efficient metathesis reactions are suppressed 
in the presence of basic amines due to their ability to coordinate to metal-alkylidene 
complexes and to interfere unproductively with catalytic activity.136 For this reason, fully 
unprotected amines were discarded from our screening. 
3) Synthesis of the β-lactam from the trichloroacetamide 122 would have added far too 
many steps to the synthesis to be realistic, and it was therefore not considered as a suitable 
CM partner this time. 
 
As a result of the application of the empirical criteria listed above, the modifications were 
limited to the following most promising structures (Figure 26): 
 
 
 
Figure 26. Selected structure of CM partners originated from trichloroacetamide 122. 
 
The strategy was to synthesise analogues of the compounds listed above (Figure 26), and 
try to couple them with the diene (E)-117, using the same conditions as employed in the 
previous successful metathesis reactions. The candidates giving the best results were then 
subjected to optimisation. 
 
2.3 – Synthesis of modified trichloroacetamide 122 analogues 
 
2.3.1 Synthesis of alcohol 205 
 
A number of conditions (aq. conc. HCl, TFA, TFAA, amberlyst, CuSO4) failed to cleave the 
trityl group, until the use of p-TsOH enabled the isolation of a multi-gram quantity of the 
desired alcohol 205 in modest yield. Although being extensively used at the start, this 
scalable process required a very tricky purification, and a more efficient alternative was 
sought. Treatment of an isomeric mixture of trityl-protected trichloroacetamides 122 and 
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191 with a freshly made sat. solution of HCl in ethyl acetate yielded alcohols 205 and 206 
in modest yield (Scheme 107). Although the process was much cleaner than the p-TsOH-
mediated trityl-deprotection reaction, undesired acetates 207 and 208 resulting from the 
transesterification, were also formed in low yield during the reaction. 
 
 
 
Reagents and conditions i, HCl in EtOAc, DCM, rt, 30 min, 47% 122/191 (2.5:1), 8% 207/208 (2.5:1). 
 
Scheme 107. Trityl removal with HCl in ethyl acetate. 
 
Finally, the reaction was significantly optimized through the use of anhydrous 
hydrochloric acid in diethyl ether, which provided the clean alcohol 205 in quantitative 
yield from trichloroacetamide 122 (Scheme 108). 
 
 
 
Reagents and conditions i, HCl in Et2O, DCM, rt, 1 h, 100%. 
 
Scheme 108. Trityl removal with HCl in diethyl ether. 
 
2.3.2 Synthesis of carbamates 209 and 213 
 
2.3.2.1 – Through internal cyclisation 
The preparation of carbamate 209 was initially envisaged to be accomplished by 
nucleophilic cyclisation of the free hydroxyl onto the trichloroacetamide moiety. As 
illustrated below, this efficient and rapid process is well-reported in the literature137 for the 
generation of five-membered cyclic carbamates137 and six-membered cyclic carbamates,138 
(Schemes 109 & 110). 
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Reagents and conditions i, Na2CO3, DMF, 40 min, Δ, 93%. 
 
Scheme 109. Synthesis of 6-membered carbamate.138b 
 
 
Reagents and conditions i, 88% HCOOH, no further details provided. 
 
Scheme 110. Synthesis of 6-membered carbamate.138c 
 
However, application of the reported conditions137,138 to alcohol 205 all failed to give the 
desired carbamate 209, and resulted in no reaction and/or partial decomposition instead 
(Scheme 111). Various acidic and basic conditions including the use of DBU, KHMDS, 
TMSOTf, nBuLi and tBuOK were also unsuccessful to give the desired carbamate 209. 
 
 
 
Scheme 111. Unsuccesful cyclisation of alcohol 205 to carbamate 209 
 
2.3.2.2 – Through external cyclisation 
A classical alternative, using triphosgene, was finally proposed to access the unprotected 
carbamate 209 from the free aminoalcohol 210. The preparation of the aminoalcohol 210 
was envisaged from the transformation of trichloroacetamide 122 via two possible routes 
(Scheme 112). The first approach started with the deprotection of the trityl-protected 
alcohol 122 followed by the cleavage of its trichloroacetamide group, whereas the second 
method proceeded the other way round (Scheme 112). 
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Reagents and conditions i, p-TsOH, EtOH; ii, KOH, iPrOH. 
 
 
Scheme 112. General procedures to free aminoalcohol 210. 
 
The bottom pathway was proved to be much more efficient than the top one, and was 
consequently preferred (Scheme 112). However, the volatility of the unprotected 
aminoalcohol 210, and the uncontrolled formation of unidentified side products from time 
to time, made both routes highly temperamental.  
 
Trichloroacetamide 122 was deprotected to give the amine 211, which was subsequently 
treated with potassium hydroxide to provide the volatile aminoalcohol 210, in poor to 
modest yield (Scheme 112). The resulting crude aminoalcohol 210 was then converted to 
the 6-membered carbamate 209, in modest yield, by treatment with triphosgene (Scheme 
113). As the first metathesis reaction (section 3.3) had been significantly optimised via the 
N-Boc protection of lactam (±)-119, it was also decided to convert the free carbamate 209 to 
its N-Boc protected version. It should be noted that, unlike carbamate 209, which was also 
generated as a single diastereoisomer, carbamate 213 was generated as a (3:1) 
diastereoisomeric mixture only, as it was originated from a (3:1) isomeric mixture of 
trichloroacteamides 122 and 191 (Scheme 113). 
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Reagents and conditions i, KOH, iPrOH, Δ, 3 h; ii, p-TsOH, EtOH, overnight; iii, 
triphosgene, DBU, rt, 2 h, 18% (3 steps); iv, KOH, iPrOH, Δ, 2 h; v, p-TsOH, EtOH, 
rt, overnight; vi, triphosgene, DBU, rt, 2 h, 21% (3 steps); vii, (Boc)2O, DMAP, TEA, 
DCM, rt, overnight, 81%. 
 
Scheme 113. Synthesis of carbamates 209 and 213. 
 
Interestingly, primary NMR and mass spectrometry analyses (LRMS), suggested the 
formation of orthoacid 212 as an important side product, resulting from the treatment of 
trichloroacetamide 122 with potassium hydroxide (Figure 27). Against the odds, this very 
unclean by-product, stemming from the nucleophilic substitution of the chlorines by 
hydroxyl groups, proved to be fairly stable. However, the purification of the side product 
appeared impossible, and thus its structure could not be confirmed. 
 
 
 
Figure 27. Undesired orthoacid 212. 
 
As it will be discussed later (sections 2.4.1 & 2.4.2) the use of carbamates 209 and 213 as 
CM partners gave disappointing results, and as a result, their synthesis was abandoned, 
and left unoptimized. Hence, the following interesting alternative, involving an internal 
nucleophilic cyclisation of the hydroxyl onto the trichloroacetamide carbonyl was not 
utilised (Scheme 114). 
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Reagents and conditions i, HCl in Et2O, 100%; ii, triphosgene, DBU, DCM. 
 
Scheme 114. Synthesis of N-TAC carbamate 214. 
 
2.3.3 Synthesis of ester 221 
 
A very clever one-pot procedure reported by P. J. Walsh138c was firstly utilised to convert 
tritylated alcohols to carboxylic acids, which are essential intermediates to the synthesis of 
esters (Scheme 115). The procedure consisted in using the Jones oxidation to cleave the 
trityl group off chemoselectively, and oxidise the resulting alcohol to the carboxylic acid in 
one-pot (Scheme 115).  
 
 
 
Reagents and conditions i, Jones oxidation conditions, 85-95%. 
 
Scheme 115. One-pot synthesis of carboxylic acids from trityl-protected alcohols. 
 
Although the substrates utilised were very similar to ours (olefin 122), in our hands, the 
application of this procedure, under several conditions, failed to give the desired 
carboxylic acid 215 from the tritylated alcohol 122 (Scheme 116). Very surprisingly this 
reaction afforded traces of unwanted lactone 216 as a single diastereoisomer (Scheme 
116). The data of lactone 216 was compared with a similar lactone 74 (Scheme 28), which 
had already been reported as a side product in the Mann’s ADDA synthesis in 1997.82 It 
should be noticed that this unoptimised reaction might represent an attractive novel one-
pot route, involving four transformations, to the synthesis of protected aminolactones. 
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Reagents and conditions i,CrO3, H2SO4, H2O, acetone, DCM, rt, overnight, 3% 216. 
 
Scheme 116. One-pot synthesis to acid 215 and lactone 216. 
 
A mechanism (Scheme 117) involving an anti-Markovnikov addition of the hydroxyl 
group to the double bond of the olefin 122 was suggested to account for the formation of 
the lactone 216. 
 
 
Reagents and conditions i,CrO3, H2SO4, H2O, acetone, DCM, rt, overnight, 3% 216. 
 
Scheme 117. Proposed mechanism of the synthesis of aminolactone 216. 
 
In order to reduce the addition and the oxidation of the hydroxyl group on the double-
bond, the deprotection of the trityl group was first operated. The Jones oxidation was then 
carried out on the alcohol 205, but this still surprisingly gave the unwanted lactone 216, 
casting a serious doubt on the proposed mechanism above (Scheme 117). 
 
Another attempt using PDC, previously successfully utilised for the synthesis of 
ADDA,83,87 did not give access to the carboxylic acid 215 either. Further investigation of 
the literature revealed that PtO2 was often considered as a reliable alternative to resistant 
oxidations of primary alcohols to carboxylic acids.137a However, due to technical 
difficulties involved in this procedure, a more classical and straightforward alternative 
was envisaged. 
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Instead, the trichloroacetamide 122 was trityl-deprotected using anhydrous acidic 
conditions to give the primary alcohol 205, which was then oxidised to carboxylic acid 215 
via a Swern oxidation, immediately followed by Pinnick oxidation (Scheme 118). 
Interestingly, the original Swern oxidation procedure, involving the use of anhydrous 
triethylamine, epimerized the aldehyde intermediate, yielding an inseparable 
diastereoisomeric mixture of acids 215 and 220 in a (5:3) ratio, which could either be 
purified or, as was more commonly preferred, used into the following esterification 
reaction without any further purification (Scheme 118). It is important to mention that 
both diastereoisomers 215 and 220 could not be separated through reverse phase HPLC 
techniques. The esterification was first attempted with a commercially available solution 
of TMS-diazomethane, which provided a (5:3) mixture of methyl esters 221 and 222, as 
well as an unwanted (5:3) mixture of TMS-methyl esters 223 and 224 (Scheme 118).  
 
 
 
Reagents and conditions i, (COCl)2, DMSO, TEA, DCM, -78°C; ii, tBuOH, NaClO2, 
NaH2PO4, 2-methyl-2-butene, rt, overnight, 96% syn/anti (5:3) (2 steps); iii, TMSCH2N2, 
Et2O, rt, overnight, 27% (221 + 222), 42% (223 + 224). 
 
Scheme 118. Synthesis of methyl esters 221 and 222. 
 
Surprisingly, the silicon-carbon bond was stronger than expected, and a number of 
conditions (KF, TBAF, HF.pyridine) all failed to cleave the TMS group off. Saponification 
of the esters 223 and 224 did not give any satisfactory results either. After a subsequent 
purification by flash column chromatography, the methyl esters 221 and 222 were easily 
isolated in poor yield, and both diastereosisomers were successfully separated by reverse 
phase semi-preparative HPLC. This epimerisation afforded a platform from which the two 
major ADDA isoforms, enantio-N-TAC-ADDA 225 and enantio-N-TAC-iso-ADDA 115, 
could be easily accessed via the same synthesis (Scheme 119). 
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Scheme 119. Generation of enantio-N-TAC-ADDA 225 and enantio-N-TAC-iso-ADDA 115 from 
methyl esters 221 and 222. 
 
To prevent the epimerisation from occurring, the primary alcohol was alternatively 
oxidised with commercially available Dess-Martin periodinane, which is well-known to 
suppress undesirable epimerisations often observed during triethylamine-based Swern 
oxidations.139 The Dess-Martin oxidation easily led to the final methyl ester 221 in pretty 
good yield as a unique syn-diasteroisomer. However, the use of DMP induced the 
formation of aromatic side products, like iodobenzoic acid, which made the purification of 
the final methyl ester 221 or the prior intermediates, extremely difficult. This is the reason 
why the Swern oxidation was alternatively operated with DIPEA (Scheme 120), which is 
also known to limit or suppress the epimerisation risk.139 The DIPEA-based process thus 
cleanly provided the carboxylic acid 215 in excellent yield, and as a single diasteroisomer, 
which was not purified but converted straight into the methyl ester 221 by treatment with 
diazomethane, generated in situ from MNNG (Scheme 120). This sequence afforded the 
final methyl ester 221 in very good yield and no epimerisation at all, and this procedure 
was therefore used to generate the desired diastereoisomer 221 selectively. 
 
 
 
Reagents and conditions i, (COCl)2, DMSO, DIPEA, DCM, -78°C; ii, tBuOH, NaClO2, NaH2PO4, 2-
methyl-2-butene, rt, 1 h, iii, CH2N2, Et2O, 30 min, then AcOH, 69% (3 steps). 
 
Scheme 120. Synthesis of methyl ester 221 as a single diastereoisomer. 
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2.4 - Towards the successful cross coupling 
 
2.4.1 CM/HWE coupling sequence 
 
The coupling methodology between the aromatic-containing unit and the amino partner 
was first envisaged using the HWE olefination previously employed to synthesise diene 
(E)-139 (Scheme 62). The methodology was the same used for the synthesis of phosphine 
oxides (±)-154 to (±)-157 (Scheme 77). The preparation of phosphine oxides 226 to 231 was 
attempted under various cross-metathesis coupling conditions, utilising the phosphine 
oxides 142 and 143 with the allylic amines 122 and 209, which were the only partners 
available at that time. It should be noted that test CM couplings were all attempted in 
toluene, at room temperature, and were then allowed to warm up slowly to 110 °C. 
Althought different ratio of CM partners, various CM catalysts, and additives such as 
titanium isopropoxide were employed, none of the conditions allowed successful 
preparation of the heterodimers listed below (Scheme 121). 
 
 
 
Reagents and conditions i, various conditions, 0%. 
 
Scheme 121. Unsuccessful cross-metathesis towards the synthesis of heterodimers 226 to 231. 
 
2.4.2 Cross-metathesis of 1,3-dienes with allylic amines 
 
As a result of the previous disappointing results, the initial cross metathesis was 
attempted. The first coupling reactions were tried with compounds 205, 209, and 213 (as a 
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(3:1) mixture of syn- and trans-213 isomers) with either dienes (E)-117 and (E)-139, using 
second generation Hoveyda-Grubbs catalysts, in toluene at reflux (Scheme 122). 
Unfortunately none of them led to efficient coupling. The alcohol 205 did not give any 
heterodimer 232 at all, unlike the carbamates 209 and 213, which led to traces of 
heterodimers 233 and 234, according to preliminary analyses (233 was not detected by 
mass spectroscopy, HMRS 234 (FAB) observed (M+Na)+ 466.2563, calculated for 
C26H37NO5Na 466.2569). However due to the microscale used in these test CM reactions, 
the compounds 233 and 234 could not possibly be isolated and characterized. 
 
 
 
Reagents and conditions i, HGII, toluene, Δ. 
 
Scheme 122. Synthesis of CM heterodimers 232, 233, and 234. 
 
Further modifications of the CM conditions did not help improve the yields, and 
therefore, the final derivative 221 became the focus of attention. The advantage of using 
the ester 221 was pretty obvious, as it required minimal transformation to access the 
ADDA framework, once coupled to the diene (E)-117. The CM coupling was first tried 
with a (5:3) isomeric mixture of methyl esters 221 and 222 using the second generation 
Hoveyda-Grubbs catalyst, in toluene at reflux. The first micro-scale attempts were pretty 
disappointing but encouraging, so the process was repeated and scaled up to provide the 
heterodimers 235 and 236 in 20% yield (Scheme 123). 
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Reagents and conditions i, HGII (21 mol%), toluene, Δ, 24 h, 20%. 
 
Scheme 123. Synthesis of CM heterodimers 235 and 236. 
 
2.4.3 Optimisation of CM coupling with ester 221 
 
Although the yield of the cross-metathesis products was very poor, the ester 221 was by 
far the best CM coupling partner tested for the synthesis of enantio-iso-ADDA chain. The 
optimization through the use of a fully protected tertiary amine was first envisaged, as 
basic amines are known to reduce metathesis catalyst reactivity.136 Furthermore, the full 
protection of the β-lactam 119 nitrogen as its N-Boc equivalent 174 had previously been 
shown to improve the reactivity of CM partners (Section III-3.3). The N-Boc and N-Ac 
protecting groups were selected, and diverse protection conditions were tested on both 
ester 221 and trityl-protected alcohol 122 (Scheme 124) through the use of various base 
such as TEA, DMAP, KH, and nBuLi followed by addition of (Boc)2O or freshly distilled 
acetic anhydride at different temperatures. Although the protection of trichloroacetamide 
appeared relatively straightforward at first sight,140 none of the conditions screened led to 
the fully protected amines. The delocalisation of the nitrogen lone pair, in addition to the 
steric hindrance of N-TAC protected amines 221 and 122 were assumed to make the 
protection difficult.  
 
 
 
Scheme 124. Unsucessful N-Ac and N-Boc protections of trichloroacetamide 122 and 221. 
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In all cases (entries 1 to 7), the starting amine remained always unreacted, although traces 
of decomposition products were generally detected too. However, the screening 
illustrated the stability and the resistance of the trichloroacetamides 122 and 221 towards 
such harsh conditions.  
 
The N-protection option was given up, and a different approach was attempted. 
Trichloroacetamide group removal, or preparation of esters analogues (such as t-butyl or 
benzyl esters), were both realistic options. However, it was initially preferred to start with 
the modification of the conditions (solvents, temperature, additives, etc) previously 
employed (Scheme 123). To acheive this goal, a wide range of anhydrous solvents, 
including toluene, DCM, DCE, THF, acetonitrile and diethyl ether, were used, with the 
second generation Hoveyda-Grubbs catalyst, and under reflux to couple the diene (E)-117 
with a (5:3) diastereoisomeric mixture of methyl esters 221 and 222 (Scheme 125). 
Gratifyingly, the coupling performed in anhydrous THF quickly showed significant 
promising changes by TLC and NMR analysis, compared with the other test reactions. 
This reaction was reliably repeated, and scaled up to confirm the formation of the 
heterodimers 235 and 236 in excellent yield and total (E,E) selectivity (Scheme 125). 
 
 
 
Reagents and conditions i, HGII (21 mol%), THF, Δ, 24 h, 90%. 
 
Scheme 125. Optimisation of CM leading to enantio-N-TAC-iso-ADDA methyl ester 235 and enantio-
N-TAC-ADDA methyl ester 236. 
 
The cross-coupling was then successfully repeated with each single diastereoisomer 221 
and 222 separately, and provided the heterodimers 235 and 236 separately in comparable 
efficiency. Both heterodimers were obtained as single (E,E)-double bond isomers, and 
were fully characterised. 
 
The preparation of the final enantio-N-TAC-iso-ADDA chain 115, as its carboxylic acid 
form, was then proposed through the mild saponification of the methyl ester 235 by 
treatment with LiOH. This reaction, never reported before in the presence of N-TAC 
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protecting group, was rather ambitious as both the ester and the trichloroacetimidate 
moieties are sensitive to base. In addition, the substrate was expected to be potentially 
sensitive to epimerisation of the stereocentre next to the methyl ester function. The 
reaction was firstly attempted with the methyl ester 221, which provided the carboxylic 
acid 215 with an exceptional 95% yield, and without epimerization (Scheme 126). To the 
best of our knowledge, this was the first efficient and chemoselective saponification of N-
TAC protected esters, and should contribute to expanding the scope of N-TAC protecting 
groups in organic chemistry. 
 
 
 
Reagents and conditions i, LiOH, THF, rt, 1 h, 95%. 
 
Scheme 126. Saponification of methyl ester 221 to carboxylic acid 215. 
 
The same procedure was then successfully applied to the (5:3) isomeric mixture of 
heterodimers 235 and 236, to give the expected carboxylic acids 115 and 237 in a good 71% 
yield (Scheme 127). 
    
 
 
Reagents and conditions i, LiOH, THF, 1 h, 95%. 
 
Scheme 127. Synthesis of enantio-N-TAC-iso-ADDA 115 and enantio-N-TAC-ADDA 237. 
 
The synthesis of the enantio-N-TAC-iso-ADDA was published as the synthesis of its 
methyl ester derivative 235, and consequently, the saponification was not repeated on 
each diasteroisomer 235 and 236 separately. 
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2.5 – Isolation of CM homodimers 
 
The remaining fractions, free of desired heterodimers, resulting from previous 
purifications of CM reactions were combined, and purified to recover some precious 
starting olefins, but also to isolate any residual traces of undesired dimers. Among the 
significant number of CM olefins used, these purifications allowed the isolation of 
milligram quantities of homodimers 238, (±)-239, (±)-240E and (±)-240Z only (Figure 28). 
Unlike the olefin 180, which was observed as two isomers (presumably E and Z), 238, (±)-
239 have been isolated as their single (E)-double bond isomers. Although the presence of 
traces of (Z)-isomer of olefins 238, (±)-239 was suspected, it could not be confirmed, as the 
majority of impurity NMR signals were unresolved.  
 
 
 
Figure 28. CM homodimers isolated and characterised. 
 
 
3 – BRIEF CONCLUSION 
 
The synthesis of enantio-N-TAC-iso-ADDA methyl ester 235 was successfully completed 
and published in the literature.127 It represents the first synthesis of the iso-ADDA 
framework, as well as a useful platform from which new protein phosphatase inhibitors 
containing iso-ADDA residue, might be synthesised, and subsequently biologically tested. 
Our approach demonstrated once again the efficiency of cross-metathesis chemistry, 
which should extend its scope as a superb tool for carbon-carbon coupling method. The 
chemistry developed should be easily scaled up, and utilised to generate the enantio-N-
TAC-iso-ADDA 115 and enantio-N-TAC-ADDA 237 though the same approach, and on 
multigram scale. 
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4 – RING CLOSING METATHESIS ALTERNATIVE 
 
Before the cross-metathesis methodology was proved to work, the synthesis of ester 242 
from carboxylic acid 215 and dienol 241, followed by a ring closing metathesis (RCM), was 
thought to be an alternative route towards the synthesis of enantio-N-TAC-iso-ADDA 115 
(Scheme 128). A subsequent opening of the 10-membered ring, followed with the 
isomerisation of the (E,Z)-double bond isomer to the (E,E)-isomer, as described by 
Toogood,72 would have then been used to isolate the enantio-iso-ADDA 115 (Scheme 128).  
 
 
 
Scheme 128. RCM alternative towards enantio-N-TAC-iso-ADDA 115. 
 
As the cross-metathesis methodology was subsequently shown to lead successfully to 
both isomeric ADDA enant-31 and 115, the RCM alternative was rapidly considered 
irrelevant. However, it represented a synthetic challenge that we proposed to investigate. 
Although the generation of rings via RCM is now a well known technique, the generation 
of 10-membered rings has already been demonstrated to be a disfavoured process, due to 
entropy and inherent ring strain,141 and only a very few RCM reactions have been 
reported to give this ring size.141 In addition, the synthesis of 10-membered rings 
containing the (E,Z)-1,3-diene motif has not been acheived to date, although these 
frameworks are present in natural products.142 These features made this synthetic target a 
very ambitious and challenging project to us. 
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The (2.5:1) isomeric mixture of alcohol (E)-241 and (Z)-241 was prepared from the 
treatment of a (2.5:1) isomeric mixture of TBS-protected dienes (E)-139 and (Z)-139 with 
TBAF (Scheme 129).  
 
 
 
Reagents and conditions i, TBAF, THF, rt, 15 min, 95%. 
 
Scheme 129. Synthesis of dienols (E)-241 and (Z)-241. 
 
However, the two isomers (E)-241 and (Z)-241 were not separated, and the mixture was 
used directly into the first RCM test reactions. The reason for this was to determine 
whether or not the RCM of one of the double bond isomers was favoured over the other. 
 
A nucleophilic esterification between the isomeric mixture of dienols (E)-241 and (Z)-241, 
and the racemic lactam (±)-153, was initially attempted to form the ester linkage (Scheme 
130). Unfortunately, even after a long reaction time no coupling product was observed. 
 
 
 
Reagents and conditions i, MeMgBr, THF, -78 °C to rt, overnight. 
 
Scheme 130. Unsuccessful synthesis of trienes 245 and 246. 
 
The firstly suggested coupling between dienols (E)-241 and (Z)-241 and carboxylic acid 
215 (Scheme 128), was then attempted through the Yamaguchi procedure. Gratifyingly, 
 - 137 - 
the reaction gave the esters (E)-247 and (Z)-247 in good yield, but as a complex mixture of 
isomers, resulting from the potential epimerisation of the stereocentre next to the carbonyl 
of the anhydride intermediate, as was previously observed for the epimerization of acid 
215 (Section IV-2.3.3) (Scheme 131). 
 
 
 
Reagents and conditions i, 2,4,6-trichlorobenzoyl chloride, DMAP, DIPEA, THF, toluene, rt, 2 h, 78%. 
 
Scheme 131. Synthesis of triene 247 and 248. 
 
The (E)- and (Z)-isomeric mixture of esters 247 and 248 was treated with second 
generation Hoveyda-Grubbs catalyst in tetrahydrofuran, at reflux, but only starting 
material was observed. A last attempt, in toluene, at reflux, fully consumed the starting 
ester, and yielded a crude oil possessing a very complex NMR profile. Unfortunately, 
none of the isomeric macrocycle 249 was detected by mass spectrometry (Scheme 132). 
 
 
 
Reagents and conditions i, HGII (20 mol%), THF or toluene, Δ, 24 h. 
 
Scheme 132. Unsuccessful synthesis of 10-membered ring diene 249. 
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Due to lack of time, the whole process was not further investigated, and the structure of 
the undesired isomers generated under the Yamaguchi esterification (Scheme 131) could 
not be determined in time. However, the preliminary results tend to confirm that 10-
membered rings containing the (E,Z)-1,3-diene cannot be accessed easily through the 
employed RCM methodology.  
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CONCLUSION 
 
Enantio-N-Boc-ADDA chain enant-31 has been successfully synthesised in modest yield,127 
but due to the recent discoveries made through the use of enantiomerically pure β-lactam 
174, the whole synthesis needs to be optimized. Conversely, the efficient convergent 
synthesis of enantio-N-TAC-iso-ADDA methyl ester 235 has already been well optimised. 
Our approach allowed the isolation of the aromatic containing fragment (E)-117 in 28% 
overall yield in 7 steps, while the synthesis of the amino containing unit 221 was obtained 
in 36% yield over 10 synthetic steps. Our approach, terminated through the use of a 
successful cross-metathesis coupling, which enabled the isolation of enantio-N-TAC-iso-
ADDA methyl ester 235 in 25% overall yield after 18 steps from commercially available 
starting material. Hence, ranking our approach among the best syntheses towards the 
ADDA scaffold reported to date. However, our results are by no means comparable to the 
Rinehart’s linear synthesis, which yielded the ADDA chain in an excellent 40% overall 
yield in 13 steps.  
 
However, more importantly, we demonstrated the importance of cross-metathesis 
methodology as a key technique for the generation of (E,E)-1,3-diene motif, in good yield 
and with total (E)-selectivity. The results obtained have extended the scope of cross-
metathesis methodology beyond the synthesis of ADDA, in coupling efficiently 1,3-dienes 
with allylic amines, which are both electron rich olefins. Moreover it is also worth noticing 
that CM couplings were achieved with almost equimolar ratio between CM partners, thus 
by-passing the classical CM distribution discussed in section III-2.1.1. Additionally, low 
amounts of catalysts (< 10 mol%) were required, with preliminary evidence that smaller 
loadings (< 5 mol%) do not dramatically affect the coupling reaction. 
 
Both syntheses of enantio-N-Boc-ADDA enant-31 and enantio-N-TAC-iso-ADDA 115 
involve the use of stable intermediates made through robust and reliable chemistry. Every 
single intermediate (except aldehyde 134) was shown to be stable upon storage at room 
temperature, and was often taken on crude to the following reaction. It should also be 
noted that distillation techniques (via Kugelrohr apparatus) could be employed as an 
alternative to rather difficult purification by flash column chromatography for multi-gram 
scale cross-metathesis reactions. These qualities should offer the opportunity to scale-up 
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the synthetic process, and prepare multi-gram quantities of both ADDA isoforms in little 
amount of time. Hence, the next part of the project, which is the synthesis of isomeric 
ADDA-containing analogues, should be now possible from this synthetic platform. 
Furthermore, it is worth mentioning that access to multi-gram quantities of enantio-ADDA 
1 and enantio-iso-ADDA 2 might allow the use of high throughput screening techniques to 
prepare and test a broad range of ADDA-containing analogues. 
 
The synthesis and biological test of such ADDA-containing analogues might give a better 
understanding of the bioactivity related to the ADDA profile. As an ultimate goal, our 
research might lead to the discovery of potent and selective novel ADDA-containing 
protein phosphatase inhibitors, which might help elucidate biological pathways, and 
access new drug therapies. 
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EXPERIMENTAL PART 
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1 – GENERAL INFORMATION 
 
1.1 – General procedure and material 
 
 All reactions were performed under inert argon atmosphere unless otherwise stated. 
Anhydrous tetrahydrofuran, diethyl ether, dichloromethane, and toluene were purified 
through a solvent purification system. All reagents were used as received and the solvents 
were evaporated under reduced pressure at 60 C, unless otherwise stated. Flash column 
chromatography was performed using silica gel (Silica Gel 60, 40-63 micron) as the 
stationary phase. TLC was performed on aluminium sheets pre-coated with silica. The 
plates were visualised by the quenching of UV fluorescence (max254nm) and/or by 
staining with, anisaldehyde, potassium permanganate, phosphomolybdic acid or iodine 
followed by heating. 
 
It is important to mention that the vast majority of test reactions, were in a first instance 
operated with isomeric mixtures of starting olefins such as compounds 122 and 191 (4:1), 
(E)-139 and (Z)-139 (3:1) or (E)-117 and (Z)-117 (3:1). In these cases, it resulted in the 
isolation of complex isomeric mixtures of heterodimers where only the major 
heterodimers formed were identified, characterized and reported in the experimental part. 
However, every successful reaction necessary to the synthesis of final enantio-N-Boc-
ADDA enant-31 and enantio-N-TAC-iso-ADDA 115 was optimized, reproduced, and then 
scaled-up in using diastereo- and enantiomerically pure starting material.  
 
1.2 – Characterisations & data collection 
 
Proton magnetic resonance spectra (1H NMR) and carbon magnetic resonance spectra (13C 
NMR) were respectively recorded at 400MHz and 100MHz on Bruker AV 400 and DPX 
400. Chemical shifts () are reported in parts per million (ppm), and are referenced to the 
residual solvent peak, which is generally deuterochloroform (1H- 7.26 and 13C- 77.0 
ppm), unless otherwise stated.  The order of citation in parentheses is (1) number of 
equivalent nuclei (by integration), (2) multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, qn = quintet, m = multiplet, b = broad, vb = very broad, app = apparent), and (3) 
coupling constant (J) quoted in Hertz. 
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Optical rotations were determined as solutions in chloroform, irradiating wwith the 
sodium D line (λ = 589 nm) using an JASCO DIP-370 digital polarimeter. [α]D values are 
given in units 10-1 degcm2g-1. 
 
Infrared (IR) spectra were recorded on JASCO FTIR 410 spectrometer, as thin films on 
NaCl plates, and in the range 4000-600 cm-1. Only significant absorptions (max) are 
reported in wavenumbers (cm-1). 
 
Mass spectra and accurate mass measurements were obtained by fast atom bombardment 
(FAB), electrospray ionisation (ES), electronical impact (EI) or chemical ionization (CI), on 
JEOL JMS-700 spectrometer operating at a resolution of 15000 full widths at half height.   
 
Melting points were determined using a Mel-Temp II melting point apparatus. 
 
1.3 - Crystallographic data collection 
 
X-ray data for trichloroacetamide 122 were collected at 100 K on a Rigaku R-Axis RAPID 
Image Plate diffractometer equipped with an Oxford Cryosystems Cryostream low-
temperature device and using graphite monochromated Mo Kα radiation (λ = 0.71069 Å) 
radiation Data reduction was carried out using CrystalClear software version 1.4.0 
[CRYSTALCLEAR 1.4.0. Rigaku, 9009 New Trails Dr., The Woodlands, Texas 77381, USA, 
1998]. The structures was solved by direct methods using the program SHELXS 
[SHELXS86. Sheldrick, G.M. (1986). Program for the solution of crystal structures. Univ. of 
Göttingen, Germany] and refined using full-matrix least-squares refinement on F (I > 2σI) 
using CRYSTALS [Betteridge, P.W.; Carruthers, J.R.; Cooper, R.I.; Prout, K.; Watkin, D.J. J. 
Appl. Cryst., 2003, 36, 1487]. All non-hydrogen atoms were refined anisotropically. H 
atoms were placed in geometrically calculated positions and refined as riding groups, 
except for the atoms involved in hydrogen bonding, which were located on a difference 
map in each case, and their positions allowed to refine. CCDC 699929 contains the 
supplementary crystallographic data for this paper. This data can be obtained free of 
charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. The Cif is supplied as Electronic Supplementary 
Information.  
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2 - PROCEDURES & DATA 
 
 
(2R,3R,4E,6E,8R,9R)-3-(tert-Butoxycarbonylamino)-9-methoxy-2,6,8-trimethyl-10-
phenyldeca-4,6-dienoic acid (enantio-N-Boc-ADDA), enant-31 and (2S,3S,4E,6E,8R,9R)-3-
(tert-Butoxycarbonylamino)-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid, 
173. First procedure yielding the carboxylic acids in quantitative yield: A solution of a 
(1:1) diastereoisomeric mixture of N-Boc protected lactams 176 and 177 (1:1, 55 mg, 130 
µmol) in THF (3 mL) was treated with an aq. solution of LiOH (1.0 M, 600 µL, 600 µmol) at 
room temperature. The reaction was stirred at room temperature until completion (5 h), 
and then quenched by the sequential addition of water (2.4 mL) and glacial acetic acid (0.3 
mL). The resulting mixture was extracted with diethyl ether (3 x 20 mL), and the combined 
organic phases were dried over anhydrous sodium sulfate. The solvent was removed 
under reduced pressure to give a yellow oil (70 mg) which was purified by flash 
chromatography (silica gel, 0-10% methanol in dichloromethane) to give enantio-N-Boc-
ADDA enant-31 and 173 (1:1) as a clear and very viscous light yellowish oil (58 mg, 100%). 
 
 
(2R,3R,4E,6E,8R,9R)-3-(tert-Butoxycarbonylamino)-9-methoxy-2,6,8-trimethyl-10-
phenyldeca-4,6-dienoic acid (enantio-N-Boc-ADDA chain) enant-31: A solution of the 
single diastereoisomer 176 (40 mg, 97 µmol) in THF (2.2 mL) was treated with LiOH (1.0 M 
aq, 450 µL, 450 µmol) at room temperature. After stirring the reaction for 90 min, water 
(1.7 mL) was added and the solution was acidified by addition of glacial acetic acid (0.2 
mL), before being extracted with ethyl acetate (3 x 20 mL). The combined organics were 
dried over anhydrous sodium sulfate, and then concentrated under reduced pressure to 
give a viscous yellow oil (61 mg). Purification by flash column chromatography (silica gel, 
0.5% TEA, 0-10% methanol in dichloromethane) gave the triethylammonium salt of 
enantio-N-Boc-ADDA 183 contaminated with an slight excess of triethylamine, as a clear 
and very viscous light yellowish oil (49 mg, 94%) which could be fully characterised. The 
pure triethylammonium salt was dissolved in chloroform (50 mL) and was washed with 
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acidic water (10 mL of H2O + 1.0 mL of 1.0 M HCl) to regenerate the carboxylic acid enant-
31. The organic layer was then dried over anhydrous sodium sulfate, and concentrated 
under reduced pressure. This quick work up afforded the single diastereoisomer of the 
free enantio-N-Boc-ADDA enant-31 as a very viscous colourless clear oil (38 mg, 90%).  
 
183. 1H NMR (400MHz, CDCl3) δ 0.98 (3H, d, J = 6.5 Hz, 8-CCH3), 1.20 (9H, t, J = 7.3 Hz, 3 
x CH3), 1.20 (3H, hidden m, 2-CCH3), 1.43 (3H, s, OC(CH3)3), 1.58 (3H, s, 6-CCH3), 2.56 (2H, 
m, 8-CH + 2-CH), 2.64 (1H, dd, J = 14.0, 7.5 Hz, 10-CH), 2.78 (1H, dd, J = 13.9, 4.1 Hz, 10-
CH’), 2.98 (6H, q, J = 7.3 Hz, 3 x CH2), 3.15 (1H, m, 9-CH), 3.20 (3H, s, OCH3), 4.22 (1H, 
appbs, 3-CH), 5.32 (1H, d, J = 9.7 Hz, 7-CH), 5.54 (1H, unresolved dd, J = 14.7, 3.6 Hz, 4-
CH), 6.09 (1H, bs, NH), 6.16 (1H, d, J = 15.7 Hz, 5-CH), 7.16-7.26 (5H, m, ArH); 13C NMR 
(100MHz, CDCl3) δ 8.3 ((NCH2CH3)3), 12.7 (6-CCH3), 15.5 (2-CCH3), 16.3 (8-CCH3), 28.4 
(OC(CH3)3), 36.6 (8-CH), 38.2 (10-CH2), 44.8 ((NCH2CH3)3), 44.9 (2-CH), 54.9 (3-CH), 58.6 
(OCH3), 78.6 (OC(CH3)3), 86.9 (9-CH), 125.8 (4-CH), 127.3 (ArCHpara), 128.1 (ArCHortho), 
129.4 (ArCHmeta), 132.7 (6-CIV), 134.7 (7-CH), 134.8 (5-CH), 139.3 (ArCIV), 156.5 (HNCOO), 
180.0 (10-C=O); [α]26D +23.2, (c = 1.0, CHCl3); 
 
enant-31. 1H NMR (400MHz, CDCl3) δ 1.03 (3H, d, J = 6.7 Hz, 8-CCH3), 1.25 (3H, d, J = 7.4 
Hz, 2-CCH3), 1.45 (3H, s, OC(CH3)3), 1.61 (3H, s, 6-CCH3), 2.60 (1H, m, 8-CH), 2.67 (1H, dd, 
J = 13.9, 7.5 Hz, 10-CH), 2.77 (1H, m, 2-CH), 2.79 (2H, dd, J = 13.9, 4.5 Hz, 10-CH’), 3.19 
(1H, m, 9-CH), 3.23 (3H, s, OCH3), 4.39 (1H, appbs, 3-CH), 5.25 (1H, bs, NH), 5.39 (1H, d, J 
= 9.8 Hz, 7-CH), 5.48 (1H, dd, J = 15.7, 6.1 Hz, 4-CH), 6.20 (1H, d, J = 15.6 Hz, 5-CH), 7.17-
7.29 (5H, m, ArH); 13C NMR (100MHz, CDCl3) δ 12.7 (6-CCH3), 14.6 (2-CCH3), 16.2 (8-
CCH3), 28.4 (OC(CH3)3), 36.7 (8-CH), 38.3 (10-CH2), 44.1 (2-CH), 54.1 (3-CH), 58.6 (OCH3), 
79.8 (OC(CH3)3), 87.0 (9-CH), 125.1 (4-CH), 125.9 (ArCHpara), 128.2 (ArCHortho), 129.4 
(ArCHmeta), 132.5 (6-CIV), 135.9 (7-CH), 136.5 (5-CH), 139.4 (ArCIV), 155.5 (HNCOO), 179.4 
(10-COOH); [α]26D +23.8, (c = 1.0, CHCl3); IR (thin film) max = 3419, 3334, 3029, 2972, 2929, 
2605, 2534, 1709, 1169, 740, 701 cm-1; HRMS (CI) observed (M+H)+ 432.2749, calculated for 
C25H38O5N 432.2750. Data was in full agreement with the one of the opposite 
enantiomer.72,74-86 
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(2R,3R,4E,6E,8R,9R)-3-(tert-Butoxycarbonylamino)-9-methoxy-2,6,8-trimethyl-10-
phenyldeca-4,6-dienoic acid (enantio-N-Boc-ADDA chain) enant-31, and 
(2S,3S,4E,6E,8R,9R)-3-(tert-Butoxycarbonylamino)-9-methoxy-2,6,8-trimethyl-10-
phenyldeca-4,6-dienoic acid, 173: A solution of a (1:1) mixture of diastereoisomers 176 
and 177 (50 mg, 120 µmol) in THF (2.5 mL) was treated with LiOH (1.0 M aq, 500 µL, 500 
µmol) at room temperature. After stirring the reaction for 90 min, water (2.0 mL) was 
added and the solution was acidified by addition of glacial acetic acid (25 µL), before 
being extracted with ethyl acetate (3 x 20 mL). The combined organic phases were dried 
over anhydrous sodium sulfate, and then concentrated under reduced pressure to give a 
viscous yellow oil (72 mg). Purification by flash column chromatography (silica gel, 0.5% 
TEA, 0-10% methanol in dichloromethane) gave the triethylammonium carboxylate salts 
183 and 184 as a clear and very viscous light yellowish oil (58 mg, 90%) which could be 
fully characterised. The pure triethylammonium salts 183 and 184 were dissolved in 
chloroform (50 mL) and were washed with acidic water (10 mL of H2O + 1.0 mL of 1.0M 
HCl) to regenerate the carboxylic acids enant-31 and 173. The organic layer was then dried 
over anhydrous sodium sulfate, and concentrated under reduced pressure to afford the 
inseparable diastereoisomeric mixture of carboxylic acids enant-31 and 173 as a very 
viscous colourless clear oil (46 mg, 88%).  
  
183 and 184. 1H NMR (400MHz, CDCl3) δ 0.98 and 0.99 (6H, 2 x d, J = 6.6 Hz, 8-CCH3 + 8’-
CCH3), 1.19 (18H, t, J = 7.3 Hz, 3 x CH3 + 3 x CH3’), 1.19 (6H, hidden m, 2-CCH3 + 2’-CCH3), 
1.42 (6H, s, OC(CH3)3 + OC(CH3)3’), 1.57 and 1.58 (6H, 2 x d, J = 0.9 Hz, 6-CCH3 + 6’-CCH3), 
2.56 (4H, m, 8-CH + 8’-CH + 2-CH + 2’-CH), 2.64 (2H, dd, J = 14.0, 7.5 Hz, 10-CH + 10’-
CH), 2.78 (2H, 2 x unresolved dd, J = 13.9 Hz, 10-CH” + 10’-CH”), 2.97 (12H, q, J = 7.3 Hz, 
3 x CH2 + 3 x CH2’), 3.14 (2H, m, 9-CH + 9’-CH), 3.19 and 3.20 (6H, 2 x s, OCH3 + OCH3’), 
4.20 (2H, appbs, 3-CH + 3’-CH), 5.31 (2H, d, J = 9.7 Hz, 7-CH + 7’-CH), 5.54 (1H, bd, J = 
14.8 Hz, 4-CH + 4’-CH), 6.16 (2H, hidden, NH), 6.16 and 6.17 (2H, 2 x d, J = 15.5 Hz, 5-CH 
+ 5’-CH), 7.15-7.26 (10H, m, ArH + ArH’); 13C NMR (100MHz, CDCl3) δ 8.4 ((NCH2CH3)3 + 
(NCH2CH3)3’), 12.7 (6-CCH3 + 6’-CCH3), 15.6 (2 peaks, 2-CCH3 + 2’-CCH3), 16.3 and 16.4 (8-
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CCH3 + 8’-CCH3), 28.4 (OC(CH3)3), 36.6 and 36.7 (8-CH + 8’-CH), 38.2 (10-CH2 + 10’-CH2), 
44.8 ((NCH2CH3)3), 45.0 and 45.1 (2-CH + 2’-CH), 54.9 and 55.0 (3-CH + 3’-CH), 58.6 (OCH3 
+ OCH3’), 78.5 (OC(CH3)3 + OC(CH3)3’), 86.9 and 87.0 (9-CH + 9’CH), 125.8 (4-CH + 4’CH), 
127.6 (2 peaks, ArCHpara + ArCHpara’), 128.1 (ArCHortho + ArCHortho’), 129.4 (2 peaks, 
ArCHmeta + ArCHmeta’), 132.8 (2 peaks, 6-CIV + 6-CIV’), 134.5 (7-CH + 7’-CH), 134.7 (5-CH + 
5’-CH), 139.3 and 139.4 (ArCIV + ArCIV’), 156.0 (2 peaks, HNCOO + HNCOO’), 180.2 (10-
C=O + 10’-C=O); [α]26D +15.8, (c = 1.0, CHCl3); 
    
enant-31 and 173. 1H NMR (400MHz, CDCl3) δ 1.03 and 1.04 (6H, 2 x d, J = 6.7 Hz, 8-CCH3 
+ 8’-CCH3), 1.25 (6H, d, J = 7.4 Hz, 2-CCH3 + 2’-CCH3), 1.45 (6H, s, OC(CH3)3 + OC(CH3)3’), 
1.61 (6H, s, 6-CCH3 + 6’-CCH3), 2.60 (2H, m, 8-CH + 8’-CH), 2.70 (2H, dd, J = 14.0, 7.4 Hz, 
10-CH + 10’-CH), 2.67 (2H, 2 x dd, J = 13.9, 7.5 and 14.0, 7.6 Hz, 10-CH + 10’-CH), 2.74 (2H, 
m, 2-CH + 2’-CH), 2.80 (2H, 2 x unresolved dd, J = 13.9, 3.8 Hz, 10-CH” + 10’-CH”), 3.19 
(2H, m, 9-CH, 9’-CH), 3.23 (6H, s, OCH3 + OCH3’), 4.39 (2H, appbs, 3-CH + 3’-CH), 5.25 
(2H, bs, NH + NH’), 5.39 (2H, d, J = 9.8 Hz, 7-CH + 7’-CH), 5.48 (2H, dd, J = 15.7, 6.1 Hz, 4-
CH + 4’-CH), 6.20 (2H, 2 x d, J = 15.6 Hz, 5-CH + 5’-CH), 7.17-7.29 (10H, m, ArH + ArH’); 
13C NMR (100MHz, CDCl3) δ 12.7 (6-CCH3 + 6’-CCH3), 14.5 (2-CCH3 + 2’-CCH3), 16.2 (8-
CCH3 + 8’-CCH3), 28.3 (OC(CH3)3 + OC(CH3)3’), 36.6 (2 peaks, 8-CH + 8’-CH), 38.2 (2 peaks, 
10-CH2 + 10’-CH2), 44.1 (2-CH + 2’-CH), 54.4 (3-CH + 3’CH), 58.6 (OCH3 + OCH3’), 79.5 
(OC(CH3)3 + OC(CH3)3’), 87.0 (2 peaks, 9-CH + 9’-CH), 125.1 (4-CH + 4’-CH), 125.9 
(ArCHpara + ArCHpara’), 128.1 (ArCHortho + ArCHortho’), 129.4 (ArCHmeta + ArCHmeta’), 132.5 
(6-CIV + 6-CIV’), 135.9 (7-CH + 7’-CH), 136.5 (5-CH + 5’-CH), 139.3 (ArCIV + ArCIV’), 155.7 
(HNCOO + HNCOO’), 179.9 (10-COOH + 10’-COOH); [α]26D +19.3, (c = 1.0, CHCl3); IR 
(thin film) max = 3419, 3334, 3029, 2972, 2929, 2605, 2534, 1709, 1169, 740, 701 cm-1; HRMS 
(CI) observed (M+H)+ 432.2749, calculated for C25H38O5N 432.2750. 
 
 
(4S)-N-(tert-Butyldimethylsilyl)-4-(hydroxymethyl)azetidinone, (S)-95: A suspension of 
(L)-aspartic acid (S)-55 (16.5 g, 124 mmol) in regular toluene (600 mL) was treated with 
benzyl alcohol (124 mL, 1.20 mol) and p-toluenesulfonic acid (25.8 g, 136 mmol). The 
mixture was refluxed under vigorous stirring until no more water was formed in the 
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Dean-Stark apparatus (6 h). The half of the solvent was then evaporated under reduced 
pressure and 40-60 petroleum ether was then added until no more white solid 
precipitated. The suspension was filtered, and the white solid was dissolved in chloroform 
(1 L). The new resulting suspension was filtered one more time to provide a clear filtrate 
containing the final benzyl ester free of any starting reagents. The solvents were 
evaporated under vacuum to afford the benzyl ester (S)-93 (35.6 g) in good purity as a 
white solid, which was used into the next step without any further purification. The 1H 
and 13C NMRs data agreed with those reported in the literature.146 
A solution of crude benzyl ester (S)-93 (35.6 g) in dry dichloromethane (400 mL) was 
treated with DMAP (8.9 g, 72 mmol) and a solution of TBSCl (13.8 g, 92 mmol) in 
anhydrous dichloromethane (50 mL). The mixture was then treated by the dropwise 
addition of a solution of anhydrous triethylamine (12.8 ml, 92 mmol) in anhydrous 
dichloromethane (50 mL) over 40 min at room temperature. The mixture was stirred 
overnight, the majority of the solvent was evaporated off under vacuum, and 40-60 
petroleum ether was added to the resulting mixture to precipitate the ammonium and 
pyridinium salts, which were discarded after filtration. The filtrate was concentrated 
under reduced pressure (< 40 °C) to afford the crude N-TBS protected amine (S)-94 (33.3 g) 
as a viscous and colourless clear oil, which was also used into the next reaction without 
any further purification. The 1H and 13C NMRs data agreed with those reported in the 
literature.147 
A portion of crude N-TBS protected amine (S)-94 (14.1 g) was dissolved in anhydrous 
diethyl ether (600 mL), cooled down to -78 °C and treated by the slow addition of tBuMgCl 
(15 mL, 2.0 M in diethyl ether, 30 mmol) over 10 min. The reaction mixture was then 
slowly allowed to warm up to room temperature, and was stirred overnight before being 
quenched by addition of methanol (20 mL). The mixture was filtrated through Celite, 
which was thoroughly washed with diethyl ether (600 mL), and the half of the solvent was 
removed in vacuo (< 45 °C). The resulting organic solution (~ 600 mL) was then washed 
with water (3 x 250 mL), and the organic layer was dried over anhydrous sodium sulfate. 
Evaporation of the diethyl ether under reduced pressure (< 45 °C) yielded the crude 
azetidinone 181 (11.0 g) as a viscous yellow to orange oil. Although the crude could be 
used into the next reaction without any further purification, removal of the equivalent of 
benzyl alcohol liberated during the cyclisation was readily acheived by flash column 
chromatography (silica gel, 1% TEA, 20-50% ethyl acetate in 40-60 petroleum ether). The 
semi-pure azetidinone 181 (3.09 g) was isolated as a viscous yellowish clear oil, which was 
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used into the next reaction without any further purification. The 1H and 13C NMRs data 
agreed with those reported in the literature.147 
A suspension of sodium borohydride (480 mg, 12.7 mmol) in tetrahydrofuran (30 mL) and 
an aq. solution of lithium bromide (1.1 g, 13 mmol) in water (7.2 mL) were placed in the 
same dropping funnel, and added dropwise over a period of 40 min to a solution of the 
semi-pure lactam 181 (3.09 g) in tetrahydrofuran (30 mL) at such a rate that the internal 
temperature did not rise above 28 °C. The mixture was then stirred at room temperature 
until completion as indicated by TLC analysis. The reaction was quenched with a sat. aq. 
solution of ammonium chloride (30 mL), and the aqueous layer was extracted with ethyl 
acetate (2 x 60 mL) and dichloromethane (60 mL). The phases were separated, and the 
organic extracts were combined, dried over anhydrous sodium sulfate, and concentrated 
under reduced pressure. The crude yellow viscous oil (3.07 g) was then purified by flash 
chromatography (silica gel, 0.5% TEA, 20-40% ethyl acetate in 40-60 petroleum ether) to 
afford the pure alcohol (S)-95 (1.03 g, 9% over 4 steps) as a viscous yellowish clear oil. The 
1H and 13C NMRs data agreed with those reported for the opposite enantiomer.148 [α]25D -
72.0, (c = 1.0, CHCl3). 
 
 
(2S,3R,4E,6E,8R,9R)-9-Methoxy-2,6,8-trimethyl-10-phenyl-3-(2,2,2-
trichloroacetamido)deca-4,6-dienoic acid (enantio-iso-N-TAC-ADDA), 115 and 
(2R,3R,4E,6E,8R,9R)-9-Methoxy-2,6,8-trimethyl-10-phenyl-3-(2,2,2-
trichloroacetamido)deca-4,6-dienoic acid, 237. A solution of a (1:1) mixture of methyl 
esters 235 and 236 (85 mg, 173 µmol) in tetrahydrofuran (2.0 mL) was treated with an aq. 
solution of lithium hydroxide (1.5 mL, 1.0 M, 1.5 mmol) at room temperature. The reaction 
was left overnight under vigorous stirring, and was subsequently quenched by addition of 
an aq. solution of HCl (1.0 M, 1.8 mL). The phases were separated, and the aqueous layer 
was extracted with dichloromethane (3 x 5 mL) and ethyl acetate (10 mL). The organic 
fractions were combined, and dried over anhydrous sodium sulfate. The solvents were 
evaporated under reduced pressure, and the resulting very viscous orange oil (72 mg) was 
purified by flash column chromatography (silica gel, 80% ethyl acetate in 40-60 petroleum 
spirit). The pure mixture of carboxylic acids 115 and 237 was obtained as an extremely 
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viscous and clear yellowish oil (59 mg, 71%). 1H NMR  (400MHz, CDCl3) δ 1.03 and 1.04 
(6H, 2 x d, J = 6.7 and 6.8 Hz, 3-CCH3 + 3’-CCH3), 1.26 and 1.34 (6H, 2 x d, J = 7.2 Hz, 9-
CCH3 + 9’-CCH3), 1.62 (6H, 2 x d, J = 1.2 Hz, 5-CCH3 + 5’-CCH3), 2.62 (2H, m, 3-CH + 3’-
CH), 2.67 and 2.70 (2H, 2 x dd, J = 7.6, 3.5 and 7.5, 3.5 Hz, 1-CH + 1’-CH), 2.79 (2H, 2 x dd, J 
= 14.0, 4.7 Hz, 1-CH” + 1’-CH”), 2.92 (2H, m, 9-CH + 9’-CH), 3.21 (2H, m, 2-CH + 2’-CH), 
3.24 and 3.25 (6H, 2 x s, OCH3 + OCH3’), 4.62 (2H, m, 8-CH + 8-CH’), 5.41-5.51 (4H, m, 7-
CH + 7’-CH + 4-CH + 4’-CH), 6.27 and 6.30 (2H, 2 x d, J = 15.3 and 15.4 Hz, 6-CH + 6’-CH), 
7.17-7.28 (10H, m, ArH + ArH’), 7.62 and 7.80 (2H, bd, J = 8.8 and 8.9 Hz, NH + NH’), 9.58 
(2H, vbs, OH + OH’); 13C NMR (100MHz, CDCl3) δ 12.7 (5-CCH3 + 5’-CCH3), 13.6 and 15.2, 
(9-CCH3 + 9’-CCH3), 16.1 (3-CCH3 + 3’-CCH3), 36.7 (3-CH + 3’-CH), 38.2 (1-CH2 + 1’-CH2), 
42.8 and 43.3 (9-CH + 9’-CH), 55.1 and 55.4 (8-CH + 8’-CH), 58.6 (2 peaks, OCH3 + OCH3’), 
86.9 and 87.0 (2-CH + 2’-CH), 92.7 and 92.8 (CCl3 + C’Cl3), 120.0 and 122.6 (4-CH + 4’-CH), 
126.0 (ArCHpara + ArCH’para), 128.2 (ArCHortho + ArCH’ortho), 129.3 (ArCHmeta + ArCH’meta), 
132.2 (5-CIV), 137.3 and 138.1 (7-CH + 7’-CH), 137.6 and 140.0 (6-CH + 6’-CH), 139.2 
(ArCIV), 160.9 and 161.7 (Cl3CC=O + Cl3CC’=O), 178.4 and 179.5 (10-C=O + 10’-C=O). 
 
 
((2R,3R)-3-Benzyl-2-methyloxiran-2-yl)methanol, 116. To flame-dried 4 Å molecular 
sieves (32 g in powder) in a round bottom flask was added dry dichloromethane (250 mL), 
followed by freshly distilled D(-)-DIPT (13.55 mL, 14.95 g, 63.80 mmol). After cooling to -
30 °C, freshly distilled Ti(OiPr)4 (17.82 mL, 17.11 g, 60.19 mmol) was added, and the 
reaction was allowed to stir at -30 °C for 30 min. After the addition of t-BuOOH (5.5 M in 
decanes, 64.0 mL, 352 mmol) at -25 °C, the solution was left to stir for a further hour at -30 
°C before being treated with a solution of alcohol 125 (27.7 g, 171 mmol) in anhydrous 
dichloromethane (250 mL). The reaction was stirred 1 h at -30 °C, then allowed to warm 
up slowly to room temperature overnight, before being quenched by addition of water 
(800 mL) followed by an aq. solution of sodium hydroxide (30%) sat. with NaCl (175 mL 
total volume). The resultant milky mixture was filtered through cotton wool and sand (2 
kg), and then washed with diethyl ether (1000 mL) and dichloromethane (1000 mL). The 
phases were separated and the aqueous layer was washed with dichloromethane (250 
mL). The organic extracts were combined, dried over anhydrous sodium sulfate and 
concentrated under vacuum to afford a viscous oil (51.3 g). Purification of the resulting 
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crude residue by flash column chromatography (silica gel, 30% ethyl acetate in 40-60 
petroleum ether) afforded the pure desired epoxide 116 (28.7 g, 95%, ee = 90%) as a clear 
and colourless viscous oil.  The enantiomeric excess was determined through HPLC 
analysis with a Chiracel IB column using hexanes:isopropanol (99:1) at a flow rate of 0.75 
mL/min (retention time (2R,3R) = 28.85 min; (2S,3S) = 25.55 min). 1H NMR (400MHz, 
CDCl3) δ 1.45 (3H, s, CH3), 2.06 (1H, bs, OH), 2.90 (1H, dd, J = 14.7, 6.2 Hz, 4-CH), 3.00 (1H, 
dd, J = 14.7, 6.4 Hz, 4-CH’), 3.33 (1H, t, J = 6.3 Hz, 3-CH), 3.61 (1H, d, J = 12.3 Hz, 1-CH), 
3.73 (1H, d, J = 12.3 Hz, 1-CH’), 7.26-7.38 (5H, m, ArCH); 13C NMR (100MHz, CDCl3) δ 14.5 
(CH3), 34.7 (4-CH2), 60.3 (3-CH), 61.4 (2-CIV), 65.3 (1-CH2), 126.7 (ArCHpara), 128.7 
(ArCHortho), 128.8 (ArCHmeta), 137.6 (ArCIV); [α]25D +23.2, (c = 1.0, CHCl3); IR (thin film) max 
= 3419, 3029, 2965, 2926, 2870, 1496, 1454, 1038, 742, 700 cm-1; HRMS (EI) observed M+ 
178.0995, calculated for C11H14O2 178.0994. 
 
 
((2R,3R,4E)-2-Methoxy-3,5-dimethylhepta-4,6-dienyl)benzene, (E)-117. A solution of O-
TBS protected diene (E)-139 (544 mg, 1.65 mmol) in anhydrous THF (30 mL) was 
transferred into a round bottom flask containing flame-activated powdered 4 Å molecular 
sieves (2 g). The suspension was treated with tetrabutylammonium fluoride (1.0 M in THF, 
4.90 mL, 4.90 mmol), and the resulting reaction mixture was stirred at room temperature 
until completion as indicated by TLC analysis (15 min). The mixture was quenched with 
water (40 mL), and then extracted with ethyl acetate (2 x 20 mL). The organic extracts were 
combined, dried over anhydrous sodium sulfate, and the solvents were removed under 
vacuum. The resulting brown oil (447 mg) was then taken on crude to the next reaction 
without any further purification. 
Neat KH (1.2 g, 30 mmol) was mixed with anhydrous THF (90 mL), and the resulting 
suspension was treated with the crude dienol at 0 °C. The reaction mixture was then 
stirred under argon at 0 °C for 20 min, and iodomethane (1.60 mL, 3.65 g, 25.7 mmol) was 
incorporated after having been filtered through a small pad of basic alumina. The solution 
was then allowed to slowly warm up to room temperature, and the reaction was stirred at 
room temperature until completion as indicated by TLC analysis (2 h). The reaction was 
carefully quenched by the slow addition of a sat. aq. solution of NaHCO3 (70 mL), the 
phases were separated, and the aqueous layer was extracted with diethyl ether (30 mL). 
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The organic extract was dried over anhydrous magnesium sulfate, and the solvent was 
removed under reduced pressure. The crude yellow oil (433 mg) obtained was then 
purified by flash column chromatography (silica gel, 70% toluene in 40-60 petroleum 
ether) to afford diene (E)-117 as a colourless and clear viscous oil (347 mg, 91% over 2 
steps). 1H NMR (400MHz, CDCl3) δ 1.05 (3H, d, J = 6.7 Hz, 3-CCH3), 1.65 (3H, d, J = 1.2 Hz, 
5-CCH3), 2.57-2.66 (1H, m, 3-CH), 2.70 (1H, dd, J = 13.9, 7.4 Hz, 1-CH), 2.83 (1H, dd, J = 
13.9, 4.5 Hz, 1-CH’), 3.19-3.23 (1H, m, 2-CH), 3.24 (3H, s, OCH3), 4.97 (1H, d, J = 10.7 Hz, 7-
CH), 5.11 (2H, dd, J = 17.4, 0.3 Hz, 7-CH’), 5.41 (1H, d, J = 9.8 Hz, 4-CH), 6.38 (1H, ddd, J = 
17.4, 10.6, 0.6 Hz, 6-CH), 7.17-7.30 (5H, m, ArH); 13C NMR (100MHz, CDCl3) δ 11.9 (5-
CCH3), 16.2 (3-CCH3), 36.6 (3-CH), 38.2 (1-CH2), 58.6 (OCH3), 86.9 (2-CH), 111.1 (7-CH2), 
125.9 (ArCHpara), 128.1 (ArCHortho), 129.4 (ArCHmeta), 133.7 (5-CIV), 135.8 (4-CH), 139.4 
(ArCIV), 141.6 (6-CH); [α]25D -2.6, (c = 1.0, CHCl3); IR (thin film) max = 3027, 2955, 2928, 
2871, 1454, 1096, 700 cm-1; HRMS (CI) observed (M+H)+ 231.1745, calculated for C16H23O 
231.1749. 
 
 
The procedure employed for the synthesis of (E)-117, was repeated on a (3:1) mixture of 
TBS 1,3-dienes (E)-139 and (Z)-139, and provided a mixture of methoxy 1,3-dienes (E)-117 
and (Z)-117 in identical yields. Both diastereoisomers were then successfully separated by 
flash chromatography (silica gel, 70% toluene in 40-60 petroleum spirit), and the methoxy 
1,3-diene (Z)-117 was isolated as a colourless clear viscous oil. 1H NMR (400MHz, CDCl3) 
δ 1.06 (3H, d, J = 6.9 Hz, 3-CCH3), 1.74 (3H, d, J = 1.2 Hz, 5-CCH3), 2.63 (1H, dd, J = 13.7, 
5.9 Hz, 1-CH), 2.71 (1H, m, 3-CH), 2.83 (1H, dd, J = 13.7, 7.2 Hz, 1-CH’), 3.31 (1H, m, 2-
CH), 3.32 (3H, s, OCH3), 5.00 (1H, d, J = 10.7 Hz, 7-CH), 5.15 (2H, dd, J = 17.4, 0.3 Hz, 7-
CH’), 5.57 (1H, d, J = 9.7 Hz, 4-CH), 6.46 (1H, ddd, J = 17.4, 10.7, 0.5 Hz, 6-CH), 7.19-7.32 
(5H, m, ArH); 13C NMR (100MHz, CDCl3) δ 11.9 (5-CCH3), 16.9 (3-CCH3), 35.5 (3-CH), 38.1 
(1-CH2), 58.5 (OCH3), 86.8 (2-CH), 110.8 (7-CH2), 125.9 (ArCHpara), 128.2 (ArCHortho), 129.3 
(ArCHmeta), 134.2 (5-CIV), 134.3 (4-CH), 139.4 (ArCIV), 141.7 (6-CH); [α]25D -4.2, (c = 1.0, 
CHCl3). IR (thin film) max = 3032, 2966, 2930, 2865, 1455, 1101, 699 cm-1. 
 
 - 153 - 
 
4-Acetoxyazetidinone, ()-118. Freshly distilled vinyl acetate 148 (286 mL, 267 g, 3.10 mol) 
was treated with chlorosulfonyl isocyanate 149 (50.0 mL, 81.3 g, 574 mmol) at 0 °C. The 
reaction was followed by 1H NMR, and the maximum conversion was obtained after 1 h, 
when the reaction mixture started to turn yellow. The reaction was then cooled down to -
78 °C, and cannulated into a 2 L conical flask containing a previously made mixture of 
sodium bicarbonate (130 g, 1.54 mol), sodium sulfite (90 g, 710 mmol), ice (250 g, 13.9 mol) 
and water (250 g, 13,9 mol). The transfer was made in an air vessel which was 
imperatively kept below 0 °C throughout the transfer, and the mixture was stirred until 
the bubbling ceased (1 h), before being poured into a separating funnel. The phases were 
separated, and the organic layer was extracted with water (5 x 150 mL). The combined 
aqueous extracts were extracted with dichloromethane (3 x 150 mL) followed by saturation 
of the aqueous phase with sodium chloride. The saturated aqueous solution was then 
extracted with dichloromethane (2 x 150 mL) and ethyl acetate (150 mL).  The combined 
organic layers were dried over anhydrous sodium sulfate, and concentrated (< 30 °C) 
under reduced pressure to give the desired azetidinone ()-118 as a viscous light yellow 
oil, which was shown pure by 1H NMR analysis, and was used in the next step without 
any further purification (17.8 g, 24%). Data fully agreed with those reported in the 
literature.145 
 
 
()-(3R,4R)-3-Methyl-4-vinylazetidin-2-one, ()-119. A solution of N-TBS protected 
vinylazetidinone ()-153 (8.78 g, 39.0 mmol) in methanol (300 mL) was treated by the slow 
addition of potassium fluoride (4.22 g, 72.6 mmol) at 0 °C.  The reaction mixture was 
stirred for 10 min, and the solvent was evaporated under reduced pressure to yield a 
crude orange/brown oil (5.57 g), which was purified by flash column chromatography 
(silica gel, 50% ethyl acetate in 40-60 petroleum ether) to afford the pure desired 
azetidinone ()-119 as a clear, colourless and slightly viscous oil (3.77 g, 87%). 1H NMR 
(400MHz, CDCl3) δ 1.34 (3H, d, J = 7.4 Hz, CH3), 2.92 (1H, qdd, J = 7.4, 2.3, 1.0 Hz, 3-CH), 
3.72 (1H, dm, J = 7.2 Hz, 4-CH), 5.17 (1H, dappt, J = 10.2, 0.9 Hz, 6-CH), 5.30 (1H, dappt, J = 
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17.1, 1.0 Hz, 6-CH’), 5.92 (1H, ddd, J = 17.1, 10.2, 7.1 Hz, 5-CH), 6.12 (1H, s, NH); 13C NMR 
(100MHz, CDCl3) δ 12.7 (CH3), 53.3 (3-CH), 58.2 (4-CH), 116.9 (6-CH2), 137.1 (5-CH), 171.3 
(2-C=O); IR (thin film) max = 3471, 3253, 3087, 3008, 2968, 2931, 2873, 1750, 1644, 1176, 926 
cm-1; HRMS (CI) observed (M+H)+ 112.0760, calculated for C6H10ON 112.0762. 
 
 
(3R,4R)-1-(tert-Butyldimethylsilyl)-3-methyl-4-vinylazetidin-2-one, 119: The N-TBS 
protected azetidinone 152 (92 mg, 430 µmol) was dissolved in dry tetrahydrofuran (10 
mL), and the solution was cooled down to -78 °C. n-BuLi (2.0 M, 600 µL, 600 µmol) was 
then incorporated slowly, and the mixture was stirred for 10 min at -78 °C, before adding 
iodomethane (150 µL, 2.41 mmol) through a short pad of basic alumina. The reaction was 
stirred for a further 10 min and then worked up by adding methanol (300 µL) followed by 
a sat. aq. solution of ammonium chloride (3.5 mL) at -78 °C. The mixture was then filtered 
through a pad of Celite, washed with diethyl ether (200 mL), and concentrated in vacuo to 
afford a yellow oil as the crude azetidinone 153 (196 mg), which was then used into the 
next reaction without any further purification. 
The crude N-TBS protected vinylazetidinone 153 (196 mg) was dissolved in methanol (5 
mL) and the solution was cooled down to 0 °C. Potassium fluoride (75 mg, 1.3 mmol) was 
slowly added to the reaction, which was stirred for 10 min. The solvent was evaporated 
under reduced pressure, and the crude residue (131 mg) was purified by flash column 
chromatography (silica gel, 30% ethyl acetate in 40-60 petroleum ether) to afford the pure 
desired azetidinone 119 as a clear, colourless and slightly viscous oil (27 mg, 55% over 2 
steps). Data were in full agreement with those reported for the racemic azetidinone ()-119 
[α]29D +6.2, (c = 1.0, CHCl3). 
 
 
(R)-(-)-3-Trityloxy-2-methylpropionate, 120. To a solution of (R)-(-)-3-hydroxy-2-
methylpropionate 186 (91.0 mg, 0.77 mmol) in anhydrous dichloromethane (5 mL) was 
added anhydrous triethylamine (170 µL, 1.22 mmol) at room temperature. After stirring 
the mixture at room temperature for 5 min, the solution was cooled down to 0 °C and a 
previously prepared solution of tritylchloride (279 mg, 1.00 mmol) in dry dichloromethane 
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(1 mL) was added slowly. The reaction was allowed to warm up to room temperature, and 
stirred overnight. The mixture was then quenched by the addition of a sat. aq. solution of 
ammonium chloride (4 mL), and extracted with dichloromethane (2 x 5 mL). The 
combined organic extracts were washed with brine (5 mL), dried over anhydrous sodium 
sulfate, and concentrated under vacuum to afford a sticky yellowish oil (324 mg). 
Purification by flash column chromatography (silica gel, 1% TEA, elution gradient 0-20% 
ethyl acetate in 40-60 petroleum ether) yielded the pure trityl-protected ester 120 as a 
sticky, clear and colourless oil (277 mg, 100%), which tends to form white crystals upon 
storage. For multigram scales the ester 120 was taken on crude in the next reaction without 
any purification. The spectroscopic data was in full agreement with the one reported in the 
literature.143 [α]25D –19.7, (c = 1.0, CHCl3). 
 
 
(4S,2E)-5-Trityloxy-4-methylpent-2-enyl 2,2,2-trichloroacetimidate, 121. To a -78 °C 
solution of allylic alcohol 189 (73.2 mg, 204 µmol) in anhydrous dichloromethane (5 mL) 
was added trichloroacetonitrile (30 µL, 0.3 mmol) and DBU (6.2 µL, 40 µmol). The mixture 
was slowly allowed to warm up to room temperature, where it was stirred under argon 
until completion as indicated by TLC analysis (3 h). The reaction was quenched by 
addition of water (5 mL), and diluted with diethyl ether (20 mL). The phases were 
separated, and the aqueous layer was extracted with ethyl acetate (20 mL). The organic 
extracts were combined, and dried over anhydrous sodium sulfate before being 
concentrated under vacuum to afford a crude yellowish oil (121 mg). Purification of the 
oily residue by flash column chromatography (silica gel, 1% TEA, elution gradient 0-5% 
ethyl acetate in 40-60 petroleum ether) afforded the desired trichloroacetimidate 121 (99 
mg, 97%) as a sticky colourless oil. 1H NMR (400MHz, CDCl3) δ 1.06 (3H, d, J = 6.8 Hz, 
CH3), 2.53 (1H, appsept, J = 6.5 Hz, 4-CH), 2.99 (1H, dd, J = 8.7, 6.2 Hz, 5-CH), 3.03 (1H, dd, 
J = 8.7, 6.7 Hz, 5-CH’), 4.78 (2H, d, J = 6.1 Hz, 1-CH2), 5.72 (1H, dtd, J = 15.6, 6.1, 0.9 Hz, 2-
CH), 5.88 (1H, bdd, J = 15.6, 7.0 Hz, 3-CH), 7.21-7.46 (15H, m, ArH), 8.29 (1H, s, NH); 13C 
NMR (100MHz, CDCl3) δ 16.8 (CH3), 37.1 (3-CH), 67.8 (5-CH2), 69.9 (1-CH2), 86.2 (OCPh3), 
91.5 (CCl3), 122.6 (2-CH), 126.8 (ArCHpara), 127.7 (ArCHortho), 128.7 (ArCHmeta), 139.3 (3-
CH), 144.2 (ArCIV), 162.6 (C=N); [α]24.5D -1.4, (c = 1.0, CHCl3); IR (thin film) max = 3342, 
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3087, 3059, 3023, 2961, 2926, 2871, 1661, 1490, 1448, 1307, 1290, 1218, 1073, 974, 797, 763, 
707, 649 cm-1. 
 
   
2,2,2-Trichloro-N-((3R,4S)-5-trityloxy-4-methylpent-1-en-3-yl)acetamide, 122; and 2,2,2-
Trichloro-N-((3R,4R)-5-trityloxy-4-methylpent-1-en-3-yl)acetamide, 191. A solution of 
trichloroacetimidate 121 (9.84 g, 19.6 mmol) in anhydrous dichloromethane (435 mL) was 
treated with p-benzoquinone (3.12 g, 28.9 mmol) and bis(acetonitrile)dichloropalladium (II) 
(460 mg, 1.77 mmol, 9.1 mol%). The reaction was stirred at room temperature until TLC 
analysis indicated completion (24 h). An initial filtration of the reaction mixture through a 
short pad of silica was then used to remove the main colouring agent, and the silica pad 
was subsequently flushed with diethyl ether and the combined organic flushes were 
concentrated to afford crude residue that was purified by flash column chromatography 
(silica gel, 1% TEA, 10% ethyl acetate in 40-60 petroleum ether) to afford the desired 
terminal alkenes 122 and 191 as a mixture of two syn- and anti-diastereoisomers (4:1) (8.71 
g, 89%) as a very viscous and clear light brown oil. The two diastereoisomers 122 and 191 
were separated successfully by recrystallisation (ethanol:40-60 petroleum ether) to afford 
122 as a white powder. 
 
One-pot procedure: To a 0 °C solution of allylic alcohol 189 (812 mg, 2.27 mmol) in 
anhydrous dichloromethane (50 mL) was added DBU (67 µL, 0.4 mmol) followed by 
trichloroacetonitrile (320 µL, 3.19 mmol). The reaction was then allowed to warm up to 
room temperature, where it was stirred until completion as indicated by TLC analysis (2 
h). p-Benzoquinone (315 mg, 2.91 mmol) and bis(acetonitrile)dichloropalladium (II) (63 mg, 
0.24 mmol, 10.7 mol%) were then quickly incorporated into the reaction at the same time, 
and the reaction was stirred under argon for 5 h. At this time, extra p-benzoquinone (158 
mg, 1.46 mmol) and bis(acetonitrile)dichloropalladium (II) (47 mg, 0.18 mmol, 8.0 mol%) 
were incorporated, and the reaction was stirred at room temperature for 2 days, before the 
reaction mixture was filtered through a pad of silica gel, which was then flushed with 
diethyl ether. Evaporation under reduced pressure of the organic solvent afforded a crude 
dark brown oil (1.46 g), which was purified by flash column chromatography (silica gel, 
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1% TEA, 10% ethyl acetate in 40-60 petroleum ether) to provide the expected terminal 
alkenes 122 and 191 (1.08 g, 95% over two steps) as a viscous and clear light brown oil. As 
in the two-pot procedure, the pure terminal alkenes 122 and 191 were obtained as a (4:1) 
mixture of syn- and anti-diastereoisomers, which could be separated by recrystallisation to 
afford 122 as a white powder (ethanol:40-60 petroleum ether). 
 
122. 1H NMR (400MHz, CDCl3) δ 0.82 (3H, d, J = 7.2 Hz, CH3), 2.12 (1H, m, 4-CH), 3.12 
(1H, t, J = 9.8 Hz, 5-CH), 3.26 (1H, dd, J = 10.0, 4.0 Hz, 5-CH’), 4.43 (1H, m, 3-CH), 5.12 (1H, 
appdt, J = 10.4, 1.2 Hz, 1-CH), 5.14 (1H, appdt, J = 17.1, 1.3 Hz, 1-CH’), 5.52 (1H, ddd, J = 
17.0, 10.4, 6.1 Hz, 2-CH), 7.23-7.45 (15H, m, ArH), 7.76 (1H, d, J = 8.1 Hz, NH); 13C NMR 
(100MHz, CDCl3) δ 14.4 (CH3), 36.7 (4-CH), 57.2 (3-CH), 65.9 (5-CH2), 87.9 (OCPh3), 92.8 
(CCl3), 117.8 (1-CH2), 127.2 (ArCHpara), 127.9 (ArCHortho), 128.7 (ArCHmeta), 132.4 (2-CH), 
143.3 (ArCIV), 161.1 (C=O); [α]24D -1.6, (c = 1.0, CHCl3); IR (thin film) max = 3368, 3086, 3058, 
3022, 2967, 2927, 2883, 1706, 1492, 1448, 1218, 1036, 821, 759, 707, 633 cm-1; M.p. 140 °C. 
 
191. 1H NMR (400MHz, CDCl3) δ 1.24 (3H, d, J = 7.1 Hz, CH3), 2.00 (1H, m, 4-CH), 3.12 
(1H, t, J = 9.8 Hz, 5-CH), 3.26 (1H, dd, J = 10.0, 4.0 Hz, 5-CH’), 4.43 (1H, m, 3-CH), 4.98 (1H, 
brd, J = 10.2 Hz, 1-CH), 5.01 (1H, d, J = 17.0 Hz, 1-CH’), 5.49 (1H, partially masked dd, J = 
17.0, 10.2 Hz, 2-CH), 7.23-7.46 (15H, m, ArH), 7.59 (1H, d, J = 7.7 Hz); 13C NMR (100MHz, 
CDCl3) δ 14.9 (CH3), 36.8 (4-CH), 57.5 (3-CH), 64.2 (5-CH2), 87.4 (OCPh3), 92.7 (CCl3), 116.0 
(1-CH2), 127.1 (ArCHpara), 127.9 (ArCHortho), 128.7 (ArCHmeta), 135.0 (2-CH), 143.2 (ArCIV), 
161.7 (C=O). 
 
 
(E)-Ethyl 2-methyl-4-phenylbut-2-enoate, 124. To a stirred solution of commercially 
available phenylacetaldehyde 88 (6.05 g, 504 mmol) in dry benzene (120 mL) was added 
(1-ethoxycarbonylethylidene)-triphenylphosphorane (23.9 g, 660 mmol), and the resultant 
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solution was refluxed overnight. The reaction mixture was concentrated under reduced 
pressure, and the resultant yellow oily residue was washed with 40-60 petroleum ether 
(150 mL) to crush out triphenylphosphine oxide. The suspension was filtered and the solid 
was washed with 40-60 petroleum ether four more times (4 x 150 mL). The combined 
washings were then concentrated under vacuum to give a crude residue (9.34 g), which 
was purified by flash column chromatography (silica gel, 1-2% diethyl ether in petroleum 
ether) to afford (E)-Ethyl 2-methyl-4-phenylbut-2-enoate 124 (8.64 g, 84%) as a clear and 
colourless viscous oil. 1H NMR (400MHz, CDCl3) δ 1.32 (3H, t, J = 7.1 Hz, CH2CH3), 2.00 
(3H, appq, J = 1.4 Hz, 2-CCH3), 3.57 (2H, d, J = 7.6 Hz, 4-CH2), 4.23 (2H, q, J = 7.1 Hz, 
OCH2), 6.96 (1H, tq, J = 7.6, 1.4 Hz, 3-CH), 7.22-7.37 (5H, m, ArH); 13C NMR (100MHz, 
CDCl3) δ 12.6 (2CCH3), 14.3 (CH2CH3), 34.9 (4-CH2), 60.6 (OCH2), 126.4 (ArCHpara), 128.5 
(2-CIV), 128.6 (ArCHmeta), 128.7 (ArCHortho), 139.1 (ArCIV), 140.0 (3-CH), 168.1 (1-C=O); IR 
(thin film) max = 3029, 2981, 2932, 1710, 1255, 742, 699 cm-1; HRMS (EI) observed M+ 
204.1152, calculated for C13H16O2 204.1150. 
 
 
(E)-2-Methyl-4-phenylbut-2-en-1-ol, 125. To a stirred solution of (E)-Ethyl 2-methyl-4-
phenylbut-2-enoate 124 (2.11 g, 10.3 mmol) in anhydrous diethyl ether (40 mL) was added 
LiAlH4 dropwise (1.0 M in hexanes, 10.0 mL, 10.0 mmol) at 0 °C. The reaction was allowed 
to warm up to room temperature until completion as indicated by TLC (4 h). The reaction 
mixture was quenched at 0 °C by addition of water (2 mL) and aq. sodium hydroxide 
(20%, 1 mL). The work-up was continued by the further addition of water (40 mL) and aq. 
sodium hydroxide (20%, 20 mL). The mixture was stirred for 30 min after which, the 
mineral solid precipitate was filtrated, and washed with diethyl ether (120 mL). The 
organic extracts were dried over anhydrous sodium sulfate, and concentrated under 
vacuum to give a crude residue (1.71 g). Flash column chromatography (silica gel, 60% 
diethyl ether in 40-60 petroleum ether) provided the desired alcohol 125 (1.51 g, 90%) as a 
clear and colourless viscous oil.  1H NMR (400MHz, CDCl3) δ 1.80 (3H, s, CH3), 1.98 (1H, 
bs, OH), 3.42 (2H, d, J = 7.4 Hz, 4-CH2), 4.04 (2H, s, 1-CH2), 5.64 (1H, tq, J = 7.4, 1.4 Hz, 3-
CH), 7.23-7.33 (5H, m, ArH); 13C NMR (100MHz, CDCl3) δ 13.8 (CH3), 33.9 (4-CH2), 68.6 (1-
CH2), 124.6 (3-CH), 126.0 (ArCHpara), 128.4 (ArCHmeta), 128.6 (ArCHortho), 135.7 (2-CIV), 
141.0 (ArCIV); IR (thin film) max = 3324, 3027, 2915, 2860, 1493, 1453, 1016, 741, 698 cm-1; 
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HRMS (EI) observed M+ 162.1043, calculated for C11H14O 162.1045. Data was in full 
agreement with the one reported in the literature.149 
 
 
(((2R,3R)-3-Benzyl-2-methyloxiran-2-yl)methoxy)(tert-butyl)dimethylsilane, 126. A 
solution of epoxide 116 (207 mg, 1.16 mmol) in anhydrous N,N-dimethylformamide (6 mL) 
was treated with imidazole (237 mg, 3.48 mmol), and stirred until homogeneous.  The 
reaction mixture was treated with TBSCl (277 mg, 1.84 mmol), and stirred under argon 
until completion as indicated by TLC analysis (2 h). The reaction was quenched by the 
addition of a (1:1) mixture of diethyl ether/water (14 mL total volume). The mixture was 
then slightly acidified by addition of aq. HCl (1.0 M, 1.5 mL) before the two phases were 
separated. The organic extracts were washed with water (10 mL) and brine (10 mL) after 
which, the combined ether extracts were then dried over anhydrous sodium sulfate, and 
subsequently concentrated under vacuum to yield a dark yellow crude oil (331 mg). Flash 
column chromatography (silica gel, 30% ethyl acetate in hexane) gave the desired silyl 
protected epoxide 126 (325 mg, 95%) as a clear and colourless viscous oil. 1H NMR 
(400MHz, CDCl3) δ -0.03 (3H, s, SiCH3), 0.00 (3H, s, SiCH3), 0.84 (9H, s, SiC(CH3)3), δ 1.36 
(3H, s, 2-CH3), 2.78 (1H, dd, J = 14.8, 6.7 Hz, 4-CH), 2.93 (1H, dd, J = 14.8, 6.0 Hz, 4-CH’), 
3.09 (1H, appt, J = 6.3 Hz, 3-CH), 3.52 (1H, d, J = 11.1 Hz, 1-CH), 3.57 (1H, d, J = 11.1 Hz, 1-
CH’), 7.18-7.28 (5H, m, ArH); 13C NMR (100MHz, CDCl3) δ -5.4 (SiCH3), 14.4 (2-CCH3), 18.3 
(SiC(CH3)3), 25.9 (SiC(CH3)3), 34.7 (4-CH2), 61.2 (3-CH), 61.3 (2-CIV), 68.0 (1-CH2), 126.5 
(ArCHpara), 128.6 (ArCHortho), 128.7 (ArCHmeta), 137.8 (ArCIV); [α]25D -2.5, (c = 1.0, CHCl3); IR 
(thin film) max = 2929, 2857, 1689, 1471, 1461, 1255, 1096, 837 cm-1; HRMS (CI) observed 
(M+H)+ 293.1935, calculated for C17H29O2Si 293.1937. 
 
 
(E)-2-Methyl-4-phenylbut-2-enal, 128. The procedures employed for the synthesis of 
aldehydes 127 and 134 produced small variable amounts of conjugated aldehyde 128 as a 
side product, which could be isolated after a subsequent purification by flash column 
chromatography (silica gel, 1% TEA, 20% dichloromethane in 40-60 petroleum ether). 1H 
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NMR (400MHz, CDCl3) δ 1.88 (3H, s, CH3), 3.70 (2H, d, J = 7.4 Hz, 4-CH2), 6.65 (1H, td, J = 
7.4, 0.9 Hz, 3-CH), 7.19-7.36 (5H, m, ArH), 9.44 (1H, s, 1-CHO); 13C NMR (100MHz, CDCl3) 
δ 9.4 (2-CCH3), 35.2 (4-CH2), 126.7 (ArCHpara), 128.5 (ArCHmeta), 128.8 (ArCHortho), 138.2 (2-
CIV), 139.5 (ArCIV), 152.2 (3-CH), 195.1 (1-CH=O); IR (thin film) max = 3063, 3028, 2957, 
2926, 2854, 2818, 2715, 1686, 1644, 1494, 1454, 1072, 1005, 752, 699; HRMS (CI) observed 
(M+H)+ 161.0966, calculated for C11H13O 161.0969. Data was in full agreement with the one 
reported in the literature.149c,150 
 
 
((2R,3R)-5,5-Dibromo-3-methyl-1-phenylpent-4-en-2-yloxy)trimethylsilane, 131. A -78 °C 
solution of epoxide 126 (202 mg, 691 µmol) and DIPEA (271 mg, 365 µL, 2.10 mmol) in 
anhydrous dichloromethane (20 mL) was treated by addition of TMSOTf (467 mg, 380 µL, 
2.10 mmol). After being stirred for 10 min at -78 °C, the reaction was poured into a 
separating funnel containing a (1:1) mixture of diethyl ether and NaHPO4 (1.0 M, 100 mL 
in total). The phases were thoroughly mixed up, and subsequently separated. The organic 
layer was then washed with an additional portion of water (50 mL), isolated and dried 
over anhydrous sodium sulfate. Evaporation of solvent under reduced pressure gave the 
crude aldehyde 127 (387 mg) as a single diastereoisomer. 
A -78 °C solution of carbon tetrabromide (348 mg, 1.05 mmol) in anhydrous 
dichloromethane (5 mL) was slowly treated by the slow addition of a solution of 
triphenylphosphine (468 mg, 1.78 mmol) in dichloromethane (5 mL). The reaction mixture 
was stirred for 30 min at -78 °C before being treated with a previously prepared solution 
of crude aldehyde 127 (289 mg) in dry dichloromethane (5 mL). The mixture was stirred, 
and allowed to slowly warm up to room temperature overnight after which, the reaction 
was quenched and worked-up by addition of 40-60 petroleum spirit (3 x 100 mL) followed 
each time by filtration. The filtrates were combined, and concentrated in vacuo to provide a 
crude viscous and colourless oil (256 mg). NMR analysis proved the crude to be a (3:1) 
mixture of the TMS-protected alkenol 131 and free alkenol 132. Purification by flash 
column chromatography (silica gel, 1% TEA, 100% 40-60 petroleum spirit) gave the pure 
TMS-protected alkenol 131 (68 mg, 24%) and free alkenol 132 (71 mg, 31%) both as viscous, 
clear and colourless oils. The conjugated dibromoolefin 133 (13 mg, 6%), formed during 
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the process as a minor side product, could also be isolated by flash column 
chromatography (silica gel, 1% TEA, 100% 40-60 petroleum spirit). 
 
131. 1H NMR (400MHz, CDCl3) δ -0.10 (9H, s, Si(CH3)3), 1.07 (3H, d, J = 6.8 Hz, 3-CCH3), 
2.52 (1H, m, 3-CH), 2.67 (1H, dd, J = 13.5, 8.1 Hz, 1-CH), 2.79 (1H, dd, J = 13.5, 4.8 Hz, 1-
CH’), 3.83 (1H, dt, J = 8.1, 4.8 Hz, 2-CH), 6.32 (1H, d, J = 9.5 Hz, 4-CH), 7.17-7.31 (5H, m, 
ArH); 13C NMR (100MHz, CDCl3) δ 0.0 (Si(CH3)3), 13.7 (3-CCH3), 41.8 (1-CH2), 43.6 (3-CH), 
76.3 (2-CH), 88.3 (5-CIV), 126.3 (ArCHpara), 128.3 (ArCHmeta), 129.6 (ArCHortho), 138.8 
(ArCIV), 141.9 (4-CH); [α]23D -7.0, (c = 1.0, CHCl3); IR (thin film) max = 3085, 3064, 3028, 
2957, 2875, 1622, 1604, 1496, 1455, 1366, 1251, 1216, 1107, 1019, 932, 886, 841, 750, 699 cm-1; 
HRMS (CI) observed (M+H)+ 404.9888, calculated for C15H23OSi79Br2 404.9885.  
 
(2R,3R)-5,5-Dibromo-3-methyl-1-phenylpent-4-en-2-ol, 132. 1H NMR (400MHz, CDCl3) δ 
1.13 (3H, d, J = 6.8 Hz, CH3), 1.64 (1H, vbs, OH), 2.60 (1H, m, 3-CH), 2.65 (1H, dd, J = 13.8, 
9.5 Hz, 1-CH), 2.87 (1H, dd, J = 13.7, 3.5 Hz, 1-CH’), 3.74 (1H, ddd, J = 9.4, 5.8, 3.5 Hz, 2-
CH), 6.43 (1H, d, J = 9.6 Hz, 4-CH), 7.21-7.35 (5H, m, ArH); 13C NMR (100MHz, CDCl3) δ 
13.9 (CH3), 41.5 (1-CH2), 43.8 (3-CH), 74.7 (2-CH), 89.0 (5-CIV), 126.7 (ArCHpara), 128.7 
(ArCHmeta), 129.3 (ArCHortho), 138.0 (ArCIV), 141.0 (4-CH); [α]22D -12.8, (c = 1.0, CHCl3); IR 
(thin film) max = 3550, 3422, 3085, 3059, 3027, 2973, 2928, 2875, 1724, 1603, 1495, 1454, 1371, 
1261, 1214, 1093, 1076, 1032, 989, 850, 822783, 746, 700 cm-1; HRMS (CI) observed (M-OH)+ 
314.9365, calculated for C12H1379Br2 314.9384. 
 
(E)-(5,5-Dibromo-3-methylpenta-2,4-dienyl)benzene, 133. 1H NMR (400MHz, CDCl3) δ 
1.99 (3H, d, J = 0.8 Hz, CH3), 3.46 (2H, d, J = 7.5 Hz, 1-CH2), 5.84 (1H, tappqn, J = 7.5, 1.3 
Hz, 2-CH), 6.99 (1H, s, 4-CH), 7.19-7.33 (5H, m, ArH); 13C NMR (100MHz, CDCl3) δ 15.4 
(CH3), 34.3 (1-CH2), 86.4 (5-CIV), 126.1 (ArCHpara), 128.4 (ArCHmeta), 128.5 (ArCHortho), 132.4 
(3-CIV), 133.5 (2-CH), 139.8 (ArCIV), 140.5 (4-CH); IR (thin film) max = 3085, 3062, 3027, 
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2954, 2926, 2855, 1603, 1495, 1453, 1264, 831, 773, 739, 698 cm-1; HRMS (CI) observed 
(M+H)+ 314.9342, calculated for C12H1379Br2 314.9384. 
 
 
(2R,3R)-5,5-Dibromo-3-methyl-1-phenylpent-4-en-2-ol, 132. Procedure A: A solution of 
TMS-protected alcohol 131 (65.3 mg, 160 µmol) in anhydrous tetrahydrofuran (5 mL) was 
treated with TBAF (176 µL, 1.0 M in THF, 176 µmol) at room temperature. The mixture 
quickly turned orange, and was left 3 h under stirring and argon. An additional portion of 
TBAF (64 µL, 1.0 M in THF, 64 µmol) was incorporated and the reaction was stirred for an 
extra 1 h. The reaction mixture was diluted with ethyl acetate (10 mL), and quenched with 
a sat. aq. solution of sodium chloride (10 mL). The phases were separated and the aqueous 
layer was extracted with ethyl acetate (2 x 10 mL). The organic fractions were combined, 
and dried over anhydrous magnesium sulphate, before being concentrated under reduced 
pressure to give the crude alcohol 132 as a viscous yellow oil (56 mg). Purification by flash 
chromatography (silica gel, 100% 40-60 petroleum spirit) afforded the pure alcohol 132 as a 
viscous yellow oil (17 mg, 32%).  
 
Procedure B: A -78 °C solution of TBS-protected epoxyalcohol 126 (371 mg, 1.27 mmol) and 
DIPEA (492 mg, 663 µL, 3.81 mmol) in anhydrous dichloromethane (45 mL) was treated 
with TMSOTf (847 mg, 689 µL, 3.81 mmol). After being stirred 15 min at -78 °C, the 
reaction was poured into a separating funnel containing a 1:1 mixture of diethyl ether and 
NaHPO4 (1.0 M, 100 mL in total). The phases were thoroughly mixed up, and subsequently 
separated. The organic layer was then washed with an additional portion of water (50 
mL), isolated, and dried over anhydrous sodium sulfate. Evaporation of solvent under 
reduced pressure gave the crude aldehyde 134 (458 mg) as a single diastereoisomer. 
A -78 °C solution of carbon tetrabromide (682 mg, 2.06 mmol) in anhydrous 
dichloromethane (12 mL) was slowly treated by the slow addition of a solution of 
triphenylphosphine (954 mg, 3.64 mmol) in dichloromethane (12 mL). The reaction 
mixture was stirred for 30 min at -78 °C, before a previously prepared solution of crude 
aldehyde 134 (458 mg) in dry dichloromethane (12 mL) was added. The resulting reaction 
mixture was then allowed to slowly warm up to room temperature, and was then 
quenched by the sequential addition of 40-60 petroleum spirit (3 x 300 mL), followed each 
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time by an appropriate filtration. Evaporation of the solvent in vacuo provided a crude oil 
(406 mg), which was used in the next step without further purification. 
A fraction of the crude oil (270 mg) was dissolved in anhydrous tetrahydrofuran (8 mL), 
and the resulting solution was treated at room temperature by addition of anhydrous 
pyridine (1.05 g, 1.07 mL, 13.2 mmol) followed by a solution of hydrogen fluoride pyridine 
(158 mg, 144 µL, 7.91 mmol, 70% HF). The mixture was stirred at room temperature for 2.5 
h, and was quenched by the dropwise and careful addition of a sat. aq. solution of sodium 
bicarbonate (55 mL). The phases were separated, and the aqueous layer was extracted with 
ethyl acetate (2 x 50 mL) and dichloromethane (100 mL). The obtained organic phases 
were washed with an acidic sat. aq. solution of sodium chloride (50 mL + 3.4 mL of HCl 
1.0 M), and subsequently separated. The combined organic layers were dried over 
anhydrous magnesium sulphate, and evaporation of the solvents under vacuum provided 
the crude alcohol 132 as a viscous oil (269 mg). Purification by flash column 
chromatography (silica gel, 0-10% ethyl acetate in 40-60 petroleum spirit) yielded the pure 
alcohol 132 as a clear, and colourless viscous oil (98 mg, 23% over 3 steps). 
 
Procedure C: A solution of TBS-protected alcohol 126 (497 mg, 1.11 mmol) in anhydrous 
tetrahydrofuran (30 mL) was treated by addition of TBAF (1.66 mL, 1.0 M in THF, 1.66 
mmol) at room temperature. The mixture quickly turned orange, and was stirred under 
argon overnight. The reaction mixture was diluted with ethyl acetate (50 mL), and 
quenched by adding a sat. aq. solution of sodium chloride (50 mL). The phases were 
separated, and the aqueous layer was extracted with ethyl acetate (2 x 50 mL), before the 
organic fractions were combined, and dried over anhydrous magnesium sulfate. 
Evaporation of the solvents under reduced pressure gave the crude alcohol as a sticky 
orange oil (860 mg), which was purified through an initial flash column chromatography 
(silica gel, 0-5% ethyl acetate in 40-60 petroleum spirit). A second purification of the 
resulting semi-pure product by flash column chromatography (silica, 40% ethyl acetate in 
40-60 petroleum spirit) afforded the pure alcohol 132 as a viscous yellow oil (301 mg, 81%). 
1H NMR (400MHz, CDCl3) δ 1.13 (3H, d, J = 6.8 Hz, CH3), 1.64 (1H, vbs, OH), 2.60 (1H, m, 
3-CH), 2.65 (1H, dd, J = 13.8, 9.5 Hz, 1-CH), 2.87 (1H, dd, J = 13.7, 3.5 Hz, 1-CH’), 3.74 (1H, 
ddd, J = 9.4, 5.8, 3.5 Hz, 2-CH), 6.43 (1H, d, J = 9.6 Hz, 4-CH), 7.21-7.35 (5H, m, ArH); 13C 
NMR (100MHz, CDCl3) δ 13.9 (CH3), 41.5 (1-CH2), 43.8 (3-CH), 74.7 (2-CH), 89.0 (5-CIV), 
126.7 (ArCHpara), 128.7 (ArCHmeta), 129.3 (ArCHortho), 138.0 (ArCIV), 141.0 (4-CH); [α]22D -
12.8, (c = 1.0, CHCl3); IR (thin film) max = 3550, 3422, 3085, 3059, 3027, 2973, 2928, 2875, 
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1724, 1603, 1495, 1454, 1371, 1261, 1214, 1093, 1076, 1032, 989, 850, 822783, 746, 700 cm-1; 
HRMS (CI) observed (M-OH)+ 314.9365, calculated for C12H1379Br2 314.9384. 
 
 
(2S,3R)-3-(tert-Butyldimethylsilyloxy)-2-methyl-4-phenylbutanal, 134. A -78 °C solution 
of epoxyalcohol 126 (1.35 g, 4.60 mmol) in anhydrous dichloromethane (125 mL) was 
sequentially treated with anhydrous DIPEA (2.42 mL, 1.80 g, 13.9 mmol) and TBSOTf (3.19 
mL, 3.67 g, 13.9 mmol). The mixture was then slowly allowed to warm up to -45 °C and 
stirred until completion as indicated by TLC analysis (3 h). The cold mixture was then 
cooled down once again to -78 °C, before being poured into a separating funnel containing 
a (1:1) mixture of diethyl ether and 1.0 M aq. solution of NaHPO4 (100 mL total volume). 
The phases were separated, and the organic layer was then successively washed with 
water (2 x 50 mL) and aq. solution of NaHPO4 (1.0 M, 50 mL). The combined aqueous 
fractions were extracted with diethyl ether (20 mL), and the organic extracts were 
combined, and dried over anhydrous sodium sulfate. The solvents were evaporated under 
reduced pressure to provide a light yellow crude oil (3.25 g), which was purified by flash 
column chromatography (silica gel, 1% TEA, 20% dichloromethane in 40-60 petroleum 
ether) to afford the pure aldehyde 134 as a clear and colourless viscous oil (948 mg, 70%). 
The aldehyde proved unstable standing, and it could not be stored for any periods of time 
without decomposition was observed. The purification by flash column chromatography 
(silica gel, 1% TEA, 20% dichloromethane in 40-60 petroleum ether) also allowed the 
isolation of aldehyde 128 (mg, 8%) and silyl enol ether 135 (mg, 4%) as minor side-
products. 1H NMR (400MHz, CDCl3) δ -0.14 (3H, s, SiCH3), 0.00 (3H, s, SiCH3), 0.85 (9H, s, 
SiC(CH3)3), 1.15 (3H, d, J = 7.0 Hz, 2-CCH3), 2.35 (1H, qd, J = 6.9, 3.0 Hz, 2-CH), 2.80 (2H, d, 
J = 7.0 Hz, 4-CH2), 4.39 (1H, td, J = 7.0, 3.0 Hz, 3-CH), 7.16-7.32 (5H, m, ArH), 9.70 (1H, bs, 
1-CH); 13C NMR (100MHz, CDCl3) δ -4.9 (SiCH3), -4.7 (SiCH3), 7.3 (2-CCH3), 18.0 
(SiC(CH3)3), 25.7 (SiC(CH3)3), 41.2 (4-CH2), 50.5 (2-CH), 73.2 (3-CH), 126.6 (ArCHpara), 128.5 
(ArCHortho), 129.4 (ArCHmeta), 138.0 (ArCIV), 204.9 (1-C=O); [α]25D +37.0, (c = 1.0, CHCl3); IR 
(thin film) max = 3028, 2954, 2929, 2710, 1727, 1254, 1104, 1032, 837, 777, 700 cm-1; HRMS 
(CI) observed (M+H)+ 293.1938, calculated for C17H29O2Si 293.1937. 
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tert-Butyldimethyl((1E,3E)-2-methyl-4-phenylbuta-1,3-dienyloxy)silane, 135. The 
procedures employed for the synthesis of aldehyde 127 and 134 produced small variable 
amounts of conjugated aldehyde 128 as a side product, which could be isolated after a 
subsequent purification by flash column chromatography (silica gel, 1% TEA, 20% 
dichloromethane in 40-60 petroleum ether). 1H NMR (400MHz, CDCl3) δ 0.59 (6H, s, 
Si(CH3)2), 0.98 (9H, s, SiC(CH3)3), 1.87 (3H, d, J = 1.2 Hz, 2-CCH3), 6.39 (1H, d, J = 15.9 Hz, 
4-CH), 6.60 (1H, s, 1-CH), 6.76 (1H, d, J = 15.9 Hz, 3-CH), 7.15-7.41 (5H, m, ArH); 13C NMR 
(100MHz, CDCl3) δ -5.3 (Si(CH3)2), 9.4 (2-CCH3), 18.3 (SiC(CH3)3), 25.6 (SiC(CH3)3), 118.3 (2-
CIV), 123.4 (4-CH), 125.6 (3-CH), 126.2 (ArCHpara), 128.5 (ArCHmeta), 129.7(ArCHortho), 138.5 
(ArCIV), 142.7 (1-CH); IR (thin film) max = 3060, 3027, 2957, 2930, 2886, 2858, 1631, 1253, 
1173, 840 cm-1; LRMS (ESI) observed (M+H)+ 274.20 and LRMS (CI) observed (M+H)+ 
161.2. 
 
 
tert-Butyl((2R,3R)-5,5-dibromo-3-methyl-1-phenylpent-4-en-2-yloxy)dimethylsilane, 
136. A -78 °C solution of epoxide 126 (197 mg, 674 µmol) and DIPEA (261 mg, 352 µL, 2.02 
mmol) in anhydrous dichloromethane (15 mL) was treated with TBSOTf (534 mg, 464 µL, 
2.02 mmol). The mixture was slowly allowed to warm up to -50 °C, and was stirred until 
completion as indicated by TLC analysis (3 h). The reaction was then cooled down to -78 
°C before being poured into a separating funnel containing a (1:1) mixture of diethyl ether 
and an aq. solution of NaHPO4 (1.0 M, 100 mL total volume). The phases were thoroughly 
mixed up, and subsequently separated, before the organic layer was washed with an 
additional portion of water (50 mL). The phases were separated, and the organic fraction 
was isolated, dried over anhydrous sodium sulphate, and concentrated under reduced 
pressure to give the crude aldehyde 134 (289 mg) as a single diastereoisomer. 
A -78 °C solution of carbon tetrabromide (378 mg, 1.14 mmol) in anhydrous 
dichloromethane (5 mL) was slowly treated with the slow addition of a solution of 
triphenylphosphine (549 mg, 2.09 mmol) in dichloromethane (5 mL). The reaction mixture 
was stirred 30 min at -78 °C before being treated with a previously made solution of crude 
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aldehyde 134 (289 mg) in dry dichloromethane (5 mL). The -78 °C reaction mixture was 
then allowed to slowly warm up to room temperature overnight, and the mixture was 
then quenched by the sequential addition of 40-60 petroleum spirit (3 x 100 mL), followed 
each time by an appropriate filtration. Evaporation of solvent in vacuo provided the crude 
dibromoolefin 136 (256 mg) as a viscous colourless oil, which was purified by flash 
column chromatography (silica gel, 1% TEA, 100% hexane) to yield the pure olefin 136 
(202 mg, 67% over 2 steps) as a viscous, clear and colourless oil. 1H NMR (400MHz, CDCl3) 
δ -0.14 (3H, s, SiCH3), -0.11 (3H, s, SiCH3), -0.97 (9H, s, SiC(CH3)3), 1.13 (3H, d, J = 6.9 Hz, 3-
CCH3), 2.54 (1H, m, 3-CH), 2.81 (1H, dd, J = 13.6, 6.9 Hz, 1-CH), 2.86 (1H, dd, J = 13.6, 6.8 
Hz, 1-CH’), 3.99 (1H, td, J = 6.7, 3.5 Hz, 2-CH), 6.43 (1H, d, J = 9.3 Hz, 4-CH), 7.24-7.38 (5H, 
m, ArH); 13C NMR (100MHz, CDCl3) δ -4.9 (CH3), -4.7 (CH3), 12.6 (3-CCH3), 18.1 
(SiC(CH3)3, 25.9 (SiC(CH3)3), 41.4 (1-CH2), 42.4 (3-CH), 75.5 (2-CH), 87.9 (5-CIV), 126.3 
(ArCHpara), 128.3 (ArCHmeta), 129.5 (ArCHortho), 138.4 (ArCIV), 142.3 (4-CH); [α]23D +4.1, (c = 
1.0, CHCl3); IR (thin film) max = 3028, 2954, 2929, 2885, 2856, 1471, 1461, 1255, 1102, 1022, 
836, 775, 760, 700 cm-1; HRMS (CI) observed (M+H)+ 447.0328, calculated for 
C18H29OSi79Br2 447.0354. 
 
 
((2R,3R)-5,5-Dibromo-2-methoxy-3-methylpent-4-enyl)benzene, 137. A solution of 
alcohol 132 (63.5 mg, 189 µmol) in a 2:1 mixture of anhydrous tetrahydrofuran and 
dimethylformamide (0.8 mL + 0.4 mL) was cooled down to 0 °C, and was then treated 
with iodomethane (117 µL, 1.89 mmol) previously filtered trough basic alumina. The 
reaction mixture was then treated with the addition of sodium hydride (23 mg, 60% in oil, 
575 µmol), and was stirred for 5 h at 0 °C. The mixture was then carefully poured into a 
mixture of ice, water (25 mL in total), and ethyl acetate (50 mL). The phases were 
separated, and the organic layer was dried over anhydrous magnesium sulfate. 
Evaporation of the solvent under reduced pressure gave the crude dibromoolefin 137 as a 
yellow to orange viscous oil (68 mg). Three purifications by flash column chromatography 
(silica gel, 15% ethyl acetate in 40-60 petroleum spirit) (silica gel, 1% ethyl acetate in 40-60 
petroleum spirit) (silica gel, 50% dichloromethane in hexane) were necessary to isolate the 
pure methoxydibromoolefin 137 as a clear and colourless viscous oil (28 mg, 43%). 1H 
NMR (400MHz, CDCl3) δ 1.07 (3H, d, J = 6.9 Hz, 3-CCH3), 2.59 (1H, m, 3-CH), 2.74 (1H, dd, 
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J = 13.9, 5.6 Hz, 1-CH), 2.82 (1H, dd, J = 13.9, 7.2 Hz, 1-CH’), 3.26 (3H, s, OCH3), 3.31 (1H, 
m, 2-CH), 6.37 (1H, d, J = 9.5 Hz, 4-CH), 7.21-7.32 (5H, m, ArH); 13C NMR (100MHz, 
CDCl3) δ 13.7 (CH3), 37.9 (1-CH2), 41.6 (3-CH), 58.6 (OCH3), 85.0 (2-CH), 88.6 (5-CIV), 126.2 
(ArCHpara), 128.4 (ArCHmeta), 129.3 (ArCHortho), 138.6 (ArCIV), 141.2 (4-CH); [α]21D -3.3, (c = 
1.0, CHCl3); IR (thin film) max = 3088, 3062, 3025, 2961, 2926, 2875, 2852, 2826, 1737, 1600, 
1495, 1455, 1357, 1261, 1102, 1030, 787, 743, 699 cm-1; HRMS (CI) observed (M-OMe)+ 
314.9370, calculated for C12H1379Br2 314.9384; HRMS (CI) observed (M+H)+ 346.9641, 
calculated for C13H17O79Br2 346.9646. The spectroscopic data was in full agreement with 
this of the opposite enantiomer reported in the literature.81,83,87 
 
 
tert-Butyl((2R,3R,4E)-3,5-dimethyl-1-phenylhepta-4,6-dien-2-yloxy)dimethylsilane, (E)-
139 and tert-Butyl((2R,3R,4Z)-3,5-dimethyl-1-phenylhepta-4,6-dien-2-
yloxy)dimethylsilane, (Z)-139. A -78 °C solution of phosphine oxide 142 (1.20 g, 4.68 
mmol) in anhydrous THF (16 mL) was treated with the dropwise addition of n-butyl 
lithium (2.5 M in hexanes, 1.8 ml, 4.5 mmol). The reaction was stirred for 20 min at -78 °C 
before a solution of freshly distilled HMPA (1.65 mL, 1.70 g, 9.48 mmol) in dry THF (5 mL) 
was incorporated. A solution of aldehyde 134 (913 mg, 3.11 mmol) in anhydrous THF (5 
mL) was then added dropwise, and the reaction mixture was stirred at -78 °C until 
completion as indicated by TLC analysis (15 min). The reaction was quenched with water 
(20 mL), and the two phases were separated. The organic layer was sequentially washed 
with water (2 x 20 mL), and sat. aq. solution of LiBr (2 x 20 mL), and dried over anhydrous 
sodium sulfate. The solvent was evaporated in vacuo to give a viscous yellow oil (1.69 g), 
which was then purified by flash column chromatography (silica gel, 1% TEA, 20% 
dichloromethane in 40-60 petroleum ether) to afford 565 mg of the pure O-TBS protected 
diene (E)-139 and 188 mg of the minor diene (Z)-139 as colourless, clear and viscous oils 
(753 mg, 73% overall yield). 
 
(E)-139. 1H NMR (400MHz, CDCl3) δ -0.26 (3H, s, SiCH3), 0.02 (3H, s, SiCH3), 0.87 (9H, s, 
SiC(CH3)3), 1.00 (3H, d, J = 6.8 Hz, 3-CCH3), 1.56 (3H, d, J = 1.2 Hz, 5-CCH3), 2.45-2.54 (1H, 
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m, 3-CH), 2.69 (1H, dd, J = 13.6, 6.4 Hz, 1-CH), 2.82 (1H, dd, J = 13.6, 6.0 Hz, 1-CH’), 3.78 
(1H, appq, J = 6.2 Hz, 2-CH), 4.93 (1H, d, J = 10.8 Hz, 7-CH), 5.07 (1H, d, J = 17.4 Hz, 7-
CH’), 5.42 (1H, d, J = 9.7 Hz, 4-CH), 6.34 (1H, ddd, J = 17.4, 10.7, 0.4 Hz, 6-CH), 7.15 -7.28 
(5H, m, ArCH); 13C NMR (100MHz, CDCl3) δ -4.8 (SiCH3), -4.5 (SiCH3), 11.8 (5-CCH3), 15.2 
(3-CCH3), 18.1 (SiC(CH3)3), 25.9 (SiC(CH3)3), 37.1 (3-CH), 41.7 (1-CH2), 77.3 (2-CH), 110.7 (7-
CH2), 126.0 (ArCHpara), 128.1 (ArCHortho), 129.7 (ArCHmeta), 132.9 (5-CIV), 136.9 (ArCIV), 
139.1 (4-CH), 141.8 (6-CH); [α]20D +23.0, (c = 1.0, CHCl3); IR (thin film) max = 3027, 2956, 
2928, 2856, 1254, 1100, 1085, 835, 774, 699 cm-1. 
 
(Z)-139. 1H NMR (400MHz, CDCl3) δ -0.15 (3H, s, SiCH3), 0.00 (3H, s, SiCH3), 0.87 (9H, s, 
SiC(CH3)3), 0.98 (3H, d, J = 6.8 Hz, 3-CCH3), 1.68 (3H, s, 5-CCH3), 2.51-2.56 (1H, m, 3-CH), 
2.65 (2H, dd, J = 8.4, 1.3 Hz, 1-CH2), 3.76-3.80 (1H, m, 2-CH), 4.96 (1H, d, J = 10.7 Hz, 7-
CH), 5.11 (1H, d, J = 17.4 Hz, 7-CH’), 5.58 (1H, d, J = 9.6 Hz, 4-CH), 6.44 (1H, dd, J = 17.4, 
10.7 Hz, 6-CH), 7.06-7.28 (5H, m, ArH); 13C NMR (100MHz, CDCl3) δ -4.8 (SiCH3), -4.6 
(SiCH3), 12.1 (5-CCH3), 16.9 (3-CCH3), 18.1 (SiC(CH3)3), 25.9 (SiC(CH3)3), 37.2 (3-CH), 41.3 
(1-CH2), 77.4 (2-CH), 110.7 (7-CH2), 126.0 (ArCHpara), 128.2 (ArCHortho), 129.7 (ArCHmeta), 
133.9 (5-CIV), 134.8 136.9 (ArCIV), 139.4 (4-CH), 142.0 (6-CH); [α]25D -11.8, (c = 1.0, CHCl3). 
IR (thin film) max = 3027, 2956, 2928, 2856, 1254, 1100, 1085, 835, 774, 699 cm-1. 
 
 
1-Methylallyldiphenylphosphine oxide, 142. Procedure A: A solution of 
diphenylphosphine chloride (6.20 g, 5.19 mL, 28.1 mmol) in anhydrous diethyl ether (30 
mL) was added slowly at 0 °C to a stirred solution of crotyl alcohol 140 (2.01 g, 27.7 mmol) 
and anhydrous pyridine (5.1 mL, 64.8 mmol) in dry diethyl ether (15 mL). After stirring 
the reaction for 1 h, the resulting suspension was filtered, and the filtrate was evaporated 
under reduced pressure. The crude oil (8.86 g) was then heated at 130 °C for 1 h under 
argon. Diethyl ether (2 x 250 mL) was added to the crude resulting oil under vigorous 
stirring, leaving a black sticky residue at the bottom of the flask. The ethereal layer was 
isolated, and concentrated under reduced pressure to give a brown sticky oil, which was 
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purified by flash column chromatography (silica gel, 100% ethyl acetate) to obtain the pure 
phosphine oxide 142 as a white powder (1.44 g, 20%). 
 
Procedure B: A -78 °C solution of commercially available allyldiphenylphosphine oxide 
143 (5.64 g, 23.3 mmol) in anhydrous tetrahydrofuran (120 mL) was treated with the slow 
addition of n-BuLi (10.2 mL, 2.5 M in hexanes, 25.6 mmol). The mixture immediately 
turned dark red, and was stirred for 20 min at -78 °C before iodomethane (16.4 g, 7.20 mL, 
116 mmol) was incorporated into the reaction through a short pad of basic alumina. The 
reaction was stirred under argon for 2 h at -78 °C, and then quenched by the careful 
addition of water (100 mL). Dichloromethane (100 mL) and additional water (100 mL) 
were added, and the resulting mixture was stirred vigorously overnight. The phases were 
separated, and the organic layer was dried over anhydrous sodium sulfate, and then 
concentrated in vacuo. The resulting crude oil (6.35 g) was purified by flash column 
chromatography (silica gel, 100 % ethyl acetate) to afford the desired phosphine oxide 142 
(5.1 g, 85%) contaminated with 1,1-Dimethylallyldiphenylphosphine oxide 144 (1.0 g, 15%) 
as a white powder. 1H NMR (400MHz, CDCl3) δ 1.27 (3H, dd, JH-P = 16.1 Hz, J = 7.1 Hz, 
CH3), 3.18 (1H, appdqn, JH-P = 11.6 Hz, J = 7.2 Hz, 1-CH), 5.03 (1H, dd, J = 17.3 Hz, JH-P = 4.6 
Hz, 3-CH), 5.08 (1H, dd, J = 10.5 Hz, JH-P = 3.6 Hz, 3-CH’), 5.82 (1H, m, 2-CH), 7.39-7.49 
(6H, m, ArHmeta + ArHpara), 7.73-7.80 (4H, m, ArHortho); 13C NMR (100MHz, CDCl3) δ 12.5 
(d, JC-P = 3.6 Hz, CH3), 38.6 (d, JC-P = 68.9 Hz, 1-CH), 118.2 (d, JC-P = 11.2 Hz, 3-CH2), 128.2 
(d, JC-P = 11.5 Hz, ArCHmeta), 128.5 (d, JC-P = 11.4 Hz, ArCHmeta), 131.1 (d, JC-P = 8.6 Hz, 
ArCHortho), 131.3 (d, JC-P = 8.5 Hz, ArCHortho), 131.5 (d, JC-P = 96.6 Hz, ArCIV),  131.5 (d, JC-P = 
2.7 Hz, ArCHpara), 131.5 (d, JC-P = 2.7 Hz, ArCHpara), 131.9 (d, JC-P = 94.8 Hz, ArCIV), 134.0 (d, 
JC-P = 6.7 Hz, 2-CH); M.p. 85 °C. Data was in full agreement with the one reported in the 
literature.151 
 
1H NMR (400MHz, CDCl3) δ 1.30 (6H, d, JH-P = 14.7 Hz, 2 x CH3), 5.08 (1H, partially hidden 
m, 3-CH), 5.22 (1H, ddd, J = 10.7, 0.9 Hz, JH-P = 3.7 Hz, 3-CH’), 5.95 (1H, ddd, J = 17.4, 10.7 
Hz, JH-P = 4.9 Hz, 2-CH), 7.39-7.49 (6H, hidden m, ArHmeta + ArHpara), 7.89-7.94 (4H, m, 
ArHortho); 13C NMR (100MHz, CDCl3) δ 21.6 (d, JC-P = 0.9 Hz, 2 x CH3), 40.9 (d, JC-P = 67.9 
Hz, 1-CH), 115.6 (d, JC-P = 10.3 Hz, 3-CH2), 128.0 (d, JC-P = 11.1 Hz, ArCHmeta), 131.5 (d, JC-P = 
2.8 Hz, ArCHpara), 132.2 (d, JC-P = 8.0 Hz, ArCHortho), ArCIV and 2-CH unresolved; 
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(3R,4S,5R,6R)-6-(tert-Butyldimethylsilyloxy)-3-(diphenylphosphoryl)-3,5-dimethyl-7-
phenylhept-1-en-4-ol, 145. A -78 °C solution of phosphine oxide 142 (6.08 g, 23.7 mmol) in 
anhydrous diethyl ether (400 mL) was treated by addition of n-BuLi (11.1 mL, 2.3 M in 
hexanes, 25.5 mmol). The dark red reaction mixture was stirred for 1 h at -78 °C before 
being treated with freshly distilled hexamethylphosphoramide (9.58 g, 9.3 mL, 53.5 mmol). 
The reaction was stirred for 15 min at -78 °C, and was then cooled down to -100 °C. At this 
temperature, a -78 °C solution of aldehyde 134 (4.48 g, 15.3 mmol) in anhydrous diethyl 
ether (200 mL) was cannulated into the reaction, and the resulting mixture was stirred for 
a further 30 min at -100 °C. The reaction was quenched at -100 °C by addition of water 
(11.5 mL), and then allowed to warm up to room temperature. The phases were separated 
and the organic layer was washed with water (2 x 115 mL), followed by a sat. aq. LiBr 
solution (2 x 115 mL). The combined aqueous layers were finally extracted with diethyl 
ether (300 mL), and the combined organic fractions were concentrated under reduced 
pressure to yield to a crude viscous oil (8.05 g). Purification by flash column 
chromatography (silica, 1% TEA, 0-30% ethyl acetate in 40-60 petroleum spirit) enabled the 
isolation of the pure TBS-protected dienol 139 as a 3:1 mixture of (E)-139 and (Z)-139 
double-bond isomers (1.18 g, 23%) as well as the phosphinyl alcohol 145 as a white solid 
(445 mg, 5%). It should be noted that the side product 145 failed to diffract during 
crystallographic assays. 1H NMR (400MHz, CDCl3) δ -0.75 (3H, s, SiCH3), -0.26 (3H, s, 
SiCH3), 0.59 (9H, s, SiC(CH3)3), 0.98 (3H, d, J = 7.1 Hz, 5-CCH3), 1.37 (3H, d, JH-P = 16.3 Hz, 
3-CCH3), 1.70 (1H, m, 5-CH), 2.60 (1H, dd, J = 13.9, 8.9 Hz, 7-CH), 2.97 (1H, dd, J = 13.9, 3.0 
Hz, 7-CH’), 3.49 (1H, m, 6-CH), 4.51 (1H, d, J = 10.3 Hz, 4-CH), 5.17 (1H, ddd, J = 17.5, 0.8 
Hz, JH-P = 5.3 Hz, 1-CH), 5.31 (1H, ddd, J = 10.8, 0.9 Hz, JH-P = 4.8 Hz, 1-CH’), 5.61 (1H, ddd, 
J = 17.5, 10.8 Hz, JH-P = 4.9 Hz, 2-CH), 5.70 (1H, bs, OH), 7.05-7.21 (6H, m, ArHmeta + ArHpara 
(Ph2PO)), 7.45-7.58 (4H, m, ArHortho (Ph2PO)), 7.95-8.06 (5H, m, ArH); 13C NMR (100MHz, 
CDCl3) δ -6.0 (SiCH3), -4.5 (SiCH3), 11.7 (d, JC-P = 13.8 Hz, 3-CCH3 ), (5-CCH3 was not 
observed), 17.7 (SiC(CH3)3), 25.9 (SiC(CH3)3), 39.3 (7-CH2), 39.4 (d, JC-P = 10.4 Hz, 5-CH), 
49.2 (d, JC-P = 64.3 Hz, 3-CIV), 69.1 (d, JC-P = 3.7 Hz, 4-CH), 78.5 (6-CH), 117.5 (d, JC-P = 11.2 
Hz, 1-CH2), 125.6 (ArCHpara), 127.8 (ArCHortho), 128.2 (d, JC-P = 11.2 Hz), 128.5 (d, JC-P = 11.2 
Hz), 130.0 (d, JC-P = 92.5 Hz, ArCIV (Ph2PO)), 130.0 (ArCHmeta), 130.3 (d, JC-P = 91.3 Hz, 
 - 171 - 
ArCIV (Ph2PO)), 131.9 (d, JC-P = 2.6 Hz), 132.0 (d, JC-P = 2.7 Hz), 132.2 (d, JC-P = 7.3 Hz), 132.4 
(d, JC-P = 8.2 Hz), 138.2 (d, JC-P = 3.5 Hz, 2-CH), 140.4 (ArCIV);(*) [α]25D +56.7, (c = 1.0, CHCl3); 
IR (thin film) max = 3333, 3060, 2956, 2928, 2885, 2856, 1437, 1256, 1153, 1111, 1065, 930, 834, 
698 cm-1; HRMS (FAB) observed (M+H)+ 549.2957, calculated for C33H46O3SiP 549.2954. (*) 
The JP-H couplings for the 1H and 13C NMRs are consistent with JP-H couplings reported in the 
literature.152 
 
 
(4R,5R,E)-Ethyl 5-(tert-butyldimethylsilyloxy)-2,4-dimethyl-6-phenylhex-2-enoate, 146. 
A -78 °C solution of epoxyalcohol 126 (604 mg, 2.07 mmol) in anhydrous dichloromethane 
(125 mL) was sequentially treated with anhydrous DIPEA (1.41 mL, 1.04 g, 8.04 mmol) and 
TBSOTf (1.92 mL, 2.19 g, 8.27 mmol). The mixture was then slowly allowed to warm up to 
-40 °C, and stirred until completion as indicated by TLC analysis (4.5 h). The cold mixture 
was then cooled down once again to -78 °C, before being poured into a separating funnel 
containing a (1:1) mixture of diethyl ether and 1.0 M aq. solution of NaHPO4 (40 mL total 
volume). The phases were separated, and the organic layer was then successively washed 
with water (2 x 20 mL) and aq. solution of NaHPO4 (1.0 M, 2 x 20 mL). The combined 
aqueous fractions were extracted with diethyl ether (20 mL), and the organic extracts were 
combined, and dried over anhydrous sodium sulfate. The solvents were evaporated under 
reduced pressure to provide a light yellow crude oil (701 mg), which was used 
immediately into the next reaction without any further purification. 
A fraction of the crude oil (141 mg) was dissolved in anhydrous dichloromethane (5 mL), 
and the resulting solution was treated with (1-ethoxycarbonylethylidene)-
triphenylphosphorane (290 mg, 80.4 mmol). The reaction mixture was refluxed for 2 days 
before being cooled down to room temperature, and quenched by addition of 40-60 
petroleum ether (50 mL). The precipitate formed was filtered out and the process was 
repeated until no further phosphine oxide could be forced out of solution. Subsequent 
evaporation of the organic filtrates provided a very sticky orange oil (208 mg), which 
could be used without any further purification in the next step. Purification by flash 
column chromatography (silica gel, 1% TEA, 0-50% dichloromethane in 40-60 petroleum 
ether) yielded the pure ethyl ester 146 (84 mg, 54% over two steps) as an extremely viscous 
colourless oil. 1H NMR (400MHz, CDCl3) δ -0.11 (3H, s, CH3), 0.10 (3H, s, CH3), 0.98 (9H, s, 
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SiC(CH3)3), 1.13 (3H, d, J = 6.8 Hz, 4-CCH3), 1.38 (3H, t, J = 7.1 Hz, OCH2CH3), 1.73 (3H, d, J 
= 1.4 Hz, 2-CCH3), 2.57 (1H, m, 4-CH), 2.83 (1H, dd, J = 13.6, 6.3 Hz, 6-CH), 2.91 (1H, dd, J 
= 13.6, 6.6 Hz, 6-CH’), 3.92 (1H, td, J = 6.4, 4.2 Hz, 5-CH), 4.25 (1H, dq, J = 7.2, 7.1 Hz, 
OCHCH3), 4.26 (1H, dq, J = 7.2, 7.1 Hz, OCH’CH3) 6.81 (1H, dq, J = 10.1, 1.4 Hz, 3-CH), 
7.24-7.38 (5H, m, ArH); 13C NMR (100MHz, CDCl3) δ -4.8 (SiCH3), -4.7 (SiCH3), 12.3 (2-
CCH3), 13.9 (4-CH3), 14.3 (OCH2CH3), 18.1 (SiC(CH3)3), 25.9 (SiC(CH3)3), 37.4 (4-CH), 41.6 
(6-CH2), 60.4 (OCH2), 76.4 (5-CH), 126.2 (ArCHpara), 126.7 (2-CIV), 128.2 (ArCHortho), 129.6 
(ArCHmeta), 138.6 (ArCIV), 145.4 (3-CH), 168.2 (1-C=O); [α]23D +32.9, (c = 1.0, CHCl3); IR 
(thin film) max =  3027, 2956, 2929, 2898, 2857, 1712, 1462, 1366, 1254, 1082, 1032, 837, 776 
cm-1; HRMS (CI) observed (M+H)+ 377.2509, calculated for C22H37O3Si 377.2512. 
 
 
(4R,5R,E)-5-(tert-Butyldimethylsilyloxy)-2,4-dimethyl-6-phenylhex-2-en-1-ol, 147. A 
solution of ester 146 (1.54 g, 4.09 mmol) in anhydrous diethyl ether (100 mL) was cooled 
down to -78 °C, and treated with a solution of LAH (10.0 mL, 1.0 M in diethyl ether, 10.0 
mmol). The reaction was stirred for 30 min at -78 °C, and was then quenched by the 
careful addition of ethyl acetate (10 mL). The thick mixture was subsequently washed with 
water (3 x 100 mL), and the organic layer was dried over anhydrous sodium sulfate. 
Concentration under reduced pressure provided the crude alcohol 147 as a viscous oil 
(1.55 g). Purification by flash column chromatography (silica, 1% TEA, 10% ethyl acetate in 
40-60 petroleum spirit) yielded the pure alcohol 147 as a clear and colourless viscous oil 
(1.25 g, 91%). 1H NMR (400MHz, CDCl3) δ -0.15 (3H, s, SiCH3), 0.08 (3H, s, SiCH3), 0.96 
(9H, s, SiC(CH3)3), 1.07 (3H, d, J = 6.8 Hz, 4-CCH3), 1.31 (1H, bt, J = 5.7 Hz, OH), 1.58 (3H, 
d, J = 1.2 Hz, 2-CCH3), 2.51 (1H, m, 4-CH), 2.80 (1H, dd, J = 13.6, 6.4 Hz, 6-CH), 2.89 (1H, 
dd, J = 13.6, 6.2 Hz, 6-CH’), 3.85 (1H, td, J = 6.2, 5.0 Hz, 5-CH), 4.03 (2H, d, J = 4.7 Hz, 1-
CH2), 5.40 (1H, dq, J = 9.7, 1.2 Hz, 3-CH), 7.24-7.36 (5H, m, ArH); 13C NMR (100MHz, 
CDCl3) δ -4.8 (SiCH3), -4.5 (SiCH3), 13.7 (2-CCH3), 15.6 (4-CCH3), 18.1 (SiC(CH3)3), 25.9 
(SiC(CH3)3), 36.9 (4-CH), 41.7 (6-CH2), 69.0 (1-CH2), 77.4 (5-CH), 126.0 (ArCHpara), 128.1 
(ArCHortho), 129.7 (ArCHmeta), 129.8 (3-CH), 133.8 (2-CIV), 139.3 (ArCIV); [α]22D +8.1, (c = 1.0, 
CHCl3); IR (thin film) max = 3324, 3028, 2956, 2928, 2857, 1471, 1461, 1254, 1081, 1056, 1041, 
1006, 835, 774, 699 cm-1; HRMS (CI) observed (M+H)+ 377.2402, calculated for 
C20H35O2Si 335.2406. 
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()-4-Vinylazetidin-2-one, ()-151. Acetoxyazetidinone ()-118 (27.1 g, 210 mmol) was 
dissolved in water (110 mL), treated with sodium phenyl sulfinate (35.0 g, 213 mmol), and 
the mixture was refluxed for 20 min. The yellow reaction mixture was then cooled down 
to room temperature, and was then extracted with dichloromethane (5 x 150 mL). The 
combined extracts were dried over anhydrous sodium sulfate, and the solvent was 
removed under reduced pressure to give the pure sulfone intermediate as a white powder 
(36.6 g, 173 mmol, 82%), which was used in the next reaction without any further 
purification. 
A -78 °C solution of sulfone (36.6 g, 172 mmol) in anhydrous THF (620 mL) was treated 
with vinyl magnesium bromide (1.0 M in THF, 426 mL, 426 mmol), and the reaction was 
vigorously stirred at -78 °C for 30 min. The mixture was allowed to warm up to 0 °C, and 
was stirred for a further 50 min. The reaction was then warmed up to room temperature 
and stirred for 2 h, before being quenched with a sat. aq. solution of ammonium chloride 
(185 mL), and stirred for 15 min. The crude mixture was then filtered through cotton wool, 
the two resulting phases were separated, and the aqueous layer was extracted with 
dichloromethane (3 x 500 mL). The combined organic extracts were collected, dried over 
anhydrous sodium sulfate, and the solvents were evaporated under vacuum to give a 
crude orange/brown oil. The crude product was purified by flash column 
chromatography (silica gel, 50% ethyl acetate in 40-60 petroleum ether) to give the pure 
vinylazetidinone ()-151 as a colourless and slightly viscous oil (15.0 g, 90%). 
 
1H NMR (400MHz, CDCl3) δ 3.22 (1H, dd, J = 15.5, 2.3 Hz, 3-CH), 3.31 (1H, dd, J = 15.5, 5.0 
Hz, 3-CH’), 4.73 (1H, dd, J = 5.0, 2.3 Hz, 4-CH), 6.47 (1H, bs, NH), 7.62-7.66 (2H, m, 
ArHmeta), 7.73-7.78 (1H, m, ArHpara) 7.93-7.96 (2H, m, ArHortho); 13C NMR (100MHz, CDCl3) 
δ 41.6 (3-CH2), 64.8 (4-CH), 129.3 (ArCHortho), 129.7 (ArCHmeta), 134.6 (ArCIV), 135.0 
(ArCHpara), 164.4 (2-C=O); IR (thin film) max = 3490, 3253, 3017, 2923, 2852, 1769, 1313, 1148 
cm-1; HRMS (CI) observed (M+H)+ 212.0374, calculated for C9H10O3NS 212.0381; M.p. 157 
°C. Data was in full agreement with the one reported in the literature.153 
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()-151. 1H NMR (400MHz, CDCl3) δ 2.67 (1H, dq, J = 14.8, 1.3 Hz, 3-CH), 3.17 (1H, ddd, J 
= 14.8, 5.2, 2.0 Hz, 3-CH’), 4.07-4.11 (1H, m, 4-CH), 5.14 (1H, dt, J = 10.2, 0.9 Hz, 6-CH), 5.28 
(1H, dt, J = 17.0, 1.0 Hz, 6-CH’), 5.88 (1H, ddd, J = 17.0, 10.2, 7.0 Hz, 5-CH), 6.68 (1H, s, 
NH); 13C NMR (100MHz, CDCl3) δ 44.9 (4-CH), 49.4 (3-CH2), 116.9 (6-CH2), 137.5 (5-CH), 
168.1 (2-C=O); IR (thin film) max = 3471, 3263, 2986, 2924, 1761 cm-1; LRMS (CI) (M+H)+ 
98.18 (100%). Data was in full agreement with the one reported in the literature.154 
 
 
()-1-(tert-Butyldimethylsilyl)-4-vinylazetidin-2-one, ()-152. A solution of 
vinylazetidinone ()-151 (100 mg, 1.03 mmol) in dry dichloromethane (10 mL) was treated 
with triethylamine (215 µL, 156 µg, 1.54 mmol) and TBSOTf (409 mg, 336 µL, 1.55 mmol) at 
room temperature. The reaction mixture was stirred for 10 min, and the solvent was 
evaporated under reduced pressure. The resulting crude orange oil was immediately 
purified by flash column chromatography (silica gel, 10% ethyl acetate in 40-60 petroleum 
ether) to afford the desired N-TBS protected azetidinone ()-152 as a clear, colourless and 
slightly viscous oil (215 mg, 98%). 1H NMR (400MHz, CDCl3) δ 0.17 (3H, s, SiCH3), 0.21 
(3H, s, SiCH3), 0.94 (9H, s, SiC(CH3)3), 2.75 (1H, dd, J = 15.4, 2.8 Hz, 3-CH), 3.29 (1H, dd, J = 
15.4, 5.6 Hz, 3-CH’), 3.99 (1H, ddd, J = 8.8, 5.6, 2.8 Hz, 4-CH), 5.16 (1H, dd, J = 10.0, 0.8 Hz, 
6-CH), 5.27 (1H, dq, J = 17.1, 0.7 Hz, 6-CH’), 5.84 (1H, ddd, J = 17.1, 10.1, 8.9 Hz, 5-CH); 13C 
NMR (100MHz, CDCl3) δ -5.7 (SiCH3), -5.5 (SiCH3), 18.9 (SiC(CH3)3), 26.2 (SiC(CH3)3), 45.4 
(3-CH2), 51.7 (4-CH), 117.5 (6-CH2), 139.7 (5-CH), 172.3 (2-C=O); IR (thin film) max = 3475, 
3084, 2954, 2929, 2858, 1749 cm-1; HRMS (CI) observed (M+H)+ 212.1468, calculated for 
C11H22ONSi 212.1471. 
 
 
(S)-1-(tert-Butyldimethylsilyl)-4-vinylazetidin-2-one, 152. A -78 °C solution of oxalyl 
chloride (220 µL, 2.56 mmol) in anhydrous dichloromethane (8 mL) was treated with the 
slow addition of anhydrous dimethylsulfoxide (335 µL, 4.72 mmol), and the resulting 
mixture was stirred for 30 min under argon. A solution of alcohol (S)-95 (424 mg, 1.97 
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mmol) in dry dichloromethane (15 mL) was then added slowly at -78 °C, and the mixture 
was stirred for a further 30 min at -78 °C. Anhydrous triethylamine (600 µL, 4.31 mmol) 
was then incorporated slowly, and the reaction was allowed to warm up to room 
temperature over 1 h. The reaction was then quenched by addition of a sat. aq. solution of 
ammonium chloride (15 mL), followed by water (20 mL). The phases were separated, and 
the aqueous layer was extracted with ethyl acetate (50 mL). The combined organic extracts 
were dried over anhydrous sodium sulfate, and concentrated under vacuum to afford the 
crude aldehyde 182 as a viscous orange oil (430 mg). The crude aldehyde, proved to be 
clean by 1H NMR, was then used into the next reaction without any further purification. 
A solution of the crude aldehyde 182 (430 mg) in anhydrous tetrahydrofuran (15 mL) was 
treated with a solution of Petasis’s reagent in toluene (11 mL, 10 g, 2.4 mmol).  The mixture 
was refluxed for 2.5 h under argon before being worked up by addition of 40-60 petroleum 
ether (100 mL) to precipitate the titanium derivatives. After a subsequent filtration, the 
filtrate was concentrated under reduced pressure to give a viscous orange oil (965 mg). 
This oil was then purified by flash column chromatography (silica gel, 1% TEA, 10% ethyl 
acetate in 40-60 petroleum ether) to afford the pure vinyl azetidinone 152 (92 mg, 22%) as a 
viscous yellow oil. Unfortunately, the compound 152 proved to be unstable to the 
purification conditions. Data were in full agreement with those reported for the racemic 
azetidinone (±)-152. [α]25D -16.0, (c = 1.0, CHCl3). 
 
 
()-(3R,4R)-1-(tert-Butyldimethylsilyl)-3-methyl-4-vinylazetidin-2-one, ()-153. A -78 °C 
solution of N-TBS protected azetidinone ()-152 (7.73 g, 36.4 mmol) in anhydrous THF (400 
mL) was treated with the slow addition of n-BuLi (2.5 M, 28.4 mL, 710 mmol).  The 
reaction was stirred for 10 min at -78 °C, and was then quenched by addition of 
iodomethane (7.52 mL, 17.2 g, 121 mmol) previously filtered through a short pad of basic 
alumina. The reaction mixture was stirred at -78 °C for a further 10 min and then worked 
up by the sequential addition of methanol (12.9 mL), and sat. aq. solution of ammonium 
chloride (169 mL). The crude mixture was then filtered through a pad of Celite and 
washed with diethyl ether (400 mL).  The solvent was removed under vacuum, and the 
crude yellow oil (16.97 g) was purified by flash column chromatography (silica gel, 10% 
ethyl acetate in 40-60 petroleum ether) to provide the pure methylated azetidinone ()-153 
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as a clear, colourless and slightly viscous oil (6.43 g, 78%). 1H NMR (400MHz, CDCl3) δ 
0.14 (3H, s, SiCH3), 0.21 (3H, s, SiCH3), 0.93 (9H, s, SiC(CH3)3), 1.28 (3H, d, J = 7.4 Hz, 3-
CCH3), 2.88 (1H, qd, J = 7.4, 2.5 Hz, 3-CH), 3.56 (1H, dd, J = 8.9, 2.5 Hz, 4-CH), 5.13 (1H, 
dd, J =  10.1, 1.0 Hz, 6-CH), 5.24 (1H, dq, J = 17.6, 0.6 Hz, 6-CH’), 5.82 (1H, ddd, J = 17.6, 
10.1, 8.9 Hz, 5-CH); 13C NMR (100MHz, CDCl3) δ -5.6 (SiCH3), -5.5 (SiCH3), 13.2 (3-CCH3), 
18.3 (SiC(CH3)3), 26.2 (SiC(CH3)3), 53.2 (3-CH), 60.7 (4-CH), 117.3 (6-CH2), 139.2 (5-CH), 
176.1 (2-C=O); IR (thin film) max = 3474, 3084, 2958, 2929, 2858, 1744 cm-1; HRMS (CI) 
observed (M+H)+ 226.1626, calculated for C12H24ONSi 226.1627. 
 
 
()-(E)-7-(Diphenylphosphoryl)oct-5-enyl acetate, 159. Second generation Grubbs catalyst 
(24 mg, 28 µmol, 6 mol%) was added to a solution of 1-methylallyldiphenylphosphine 
oxide 142 (120 mg, 468 µmol) and hexenyl acetate 158 (250 µL, 221 mg, 1.55 mmol) in 
anhydrous dichloromethane (2.0 mL). The reaction was refluxed for 24 h, and cooled 
down to room temperature before the solvent was evaporated under reduced pressure. 
The resulting dark residue (391 mg) was purified by flash chromatography (silica gel, 
100% ethyl acetate) to afford the heterodimer 159 (90 mg, 52%), and the starting phosphine 
oxide 142 (20 mg) as an inseparable mixture. The semi-pure homodimer 161 was also 
isolated as a slightly viscous, clear and colourless oil (215 mg, 54%). Both olefins 159 and 
161 were obtained as their (E)-double bond isomer almost exclusively, with traces of side-
products which could not be formally attributed to the (Z)-isomers, as their NMR signals 
were mostly unresolved. 1H NMR (400MHz, CDCl3) δ 1.24 (2H, m, 3-CH2), 1.25 (3H, dd, JH-
P = 16.2 Hz, J = 7.1 Hz, 7-CCH3), 1.35 (2H, m, 2-CH2), 1.91 (2H, m, 4-CH2), 2.00 (3H, s, 
OOCCH3), 3.11 (2H, appdqn or m, 7-CH), 3.90 (2H, t, J = 6.6 Hz, 1-CH2), 5.39 (2H, m, 5-CH 
+ 6-CH), 7.38-7.47 (6H, m, ArHmeta + ArHpara), 7.70-7.80 (4H, m, ArHortho); 13C NMR 
(100MHz, CDCl3) δ 13.3 (d, JC-P = 3.4 Hz, 7-CCH3), 20.9 (OOCCH3), 25.3 (d, JC-P = 3.0 Hz, 3-
CH2), 27.6 (2-CH2), 32.0 (d, JC-P = 1.9 Hz, 4-CH2), 37.7 (d, JC-P = 69.5 Hz, 7-CH2), 64.2 (1-
CH2), 126.1 (d, JC-P = 7.0 Hz, 5-CH), 128.1 (d, JC-P = 11.3 Hz, ArCHmeta), 128.4 (d, JC-P = 11.2 
Hz, ArCHmeta), 131.1 (d, JC-P = 8.6 Hz, ArCHortho), 131.4 (partially hidden d, JC-P = 8.6 Hz, 
ArCHortho), 131.5 (d, JC-P = 96.6 Hz, ArCIV), 131.5 (d, JC-P = 2.7 Hz, ArCHpara), 131.5 (d, JC-P = 
2.7 Hz, ArCHpara), 131.9 (d, JC-P = 94.8 Hz, ArCIV), 134.0 (d, JC-P = 11.5 Hz, 6-CH), 171.0 
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(C=O); IR (thin film) max = 3423, 3055, 2973, 2932, 2875, 2852, 1735, 1637, 1438, 1372, 1245, 
1183, 1119, 1046, 721, 692 cm-1; HRMS (CI) observed (M+H)+ 371.1782, calculated for 
C22H28O3P 371.1776. 
 
 
(E)-7-(Diphenylphosphoryl)hept-5-enyl acetate, 160.122 Second generation Grubbs catalyst 
(24 mg, 28 µmol, 6 mol%) was added to a solution of allyldiphenylphosphine oxide 143 
(120 mg, 495 µmol) and hexenyl acetate 158 (250 µL, 221 mg, 1.55 mmol) in anhydrous 
dichloromethane (2.0 mL). The reaction was refluxed for 24 h before it was cooled down to 
room temperature, and the solvent was evaporated under reduced pressure. The dark 
residue (395 mg) was purified by flash column chromatography (silica gel, 30% ethyl 
acetate in 40-60 petroleum ether) to give the heterodimer 160 as a very viscous black oil 
(183 mg) as well as the unclean homodimer 161 as a slightly viscous, clear and colourless 
oil (191 mg). Further purification by flash column chromatography of the heterodimer 160 
(silica gel, 0-100% ethyl acetate in chloroform) and the homodimer 161 (silica gel, 100% 
chloroform) gave the analytically pure heterodimer 160 (148 mg, 84%), and an improved 
sample of homodimer 161 (150 mg, 38%). Both olefins 159 and 161 were obtained as their 
(E)-double bond isomer almost exclusively, with traces of side-products which could not 
be formally attributed to the (Z)-isomers, as their NMR signals were mostly unresolved. 
1H NMR (400MHz, CDCl3) δ 1.22 (2H, qn, J = 7.5 Hz, 3-CH2), 1.38 (2H, m, 2-CH2), 1.91 (2H, 
m, 4-CH2), 1.97 (3H, s, OOCCH3), 3.03 (2H, dd, J = 14.1, 5.8 Hz, 7-CH2), 3.90 (2H, t, J = 6.6 
Hz, 1-CH2), 5.41 (2H, m, 5-CH + 6-CH), 7.38-7.48 (6H, m, ArHmeta + ArHpara), 7.65-7.72 (4H, 
m, ArHortho); 13C NMR (100MHz, CDCl3) δ 20.8 (CH3), 25.1 (d, JC-P = 3.1 Hz, 3-CH2), 27.6 (2-
CH2), 31.9 (d, JC-P = 2.1 Hz, 4-CH2), 34.6 (d, JC-P = 69.4 Hz, 7-CH2), 64.1 (1-CH2), 118.5 (d, JC-P 
= 9.2 Hz, 5-CH), 128.3 (d, JC-P = 11.6 Hz, ArCHmeta), 130.8 (d, JC-P = 9.1 Hz, ArCHortho), 131.5 
(d, JC-P = 2.7 Hz, ArCHpara), 132.4 (d, JC-P = 98.3 Hz, ArCIV), 136.5 (d, JC-P = 11.8 Hz, 6-CH), 
170.9 (C=O); IR (thin film) max = 3437, 3056, 2937, 2858, 2218, 1735, 1438, 1388, 1366, 1244, 
1185, 1120, 1043, 970, 730, 718, 696 cm-1; HRMS (CI) observed (M+H)+ 357.1624, calculated 
for C21H26O3P 357.1620. 
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(E)-Dec-5-ene-1,10-diyl diacetate, 161.122 1H NMR (400MHz, CDCl3) δ 1.37 (2H, appqn, J = 
7.5 Hz, 3-CH2), 1.58 (2H, appqn, J = 7.0 Hz, 2-CH2), 1.97 (2H, m, 4-CH2), 2.00 (3H, s, CH3), 
4.01 (2H, t, J = 6.7 Hz, 1-CH2), 5.35 (1H, m, 5-CH); 13C NMR (100MHz, CDCl3) δ 20.9 (CH3), 
25.7 (3-CH2), 27.9 (2-CH2), 32.0 (4-CH2), 64.3 (1-CH2), 130.1 (5-CH), 171.0 (C=O); 
 
 
(E)-1,4-Bis(diphenylphosphoryl)but-2-ene, 162.122 To a solution of commercially available 
allyldiphenylphosphine oxide 143 (3.15 g, 13.0 mmol) in anhydrous dichloromethane (56 
mL) was added second generation Grubbs catalyst (230 mg, 0.27 mmol, 2.1 mol%). The 
reaction mixture was then refluxed for 24 h, allowed to cool down, and then quenched by 
incorporation of diethyl ether (100 mL). The mixture was filtered and the resulting white 
solid was washed with more diethyl ether (100 mL). The process was repeated until no 
white solid was isolated out from the filtrate. The white solid (2.08 g, 70%) was proved to 
be the pure homodimer 162 by NMR analysis. 1H NMR (400MHz, CDCl3) δ 3.02 (2H, ddd, 
JH-P = 10.7 Hz, J = 3.8, 1.7 Hz, 1-CH2), 5.55 (1H, m, 2-CH), 7.36-7.47 (6H, m, ArHmeta + 
ArHpara), 7.59-7.63 (4H, m, ArHortho); 13C NMR (100MHz, CDCl3) δ 34.9 (dd, JC-P = 70.7, 4.0 
Hz, 1-CH2), 124.8 (appt, JC-P = 15.6 Hz, 2-CH), 128.5 (appt, JC-P = 5.8 Hz, ArCHmeta), 130.7 
(appt, JC-P = 4.6 Hz, ArCHortho), 131.7 (appbs, ArCHpara), 132.7 (d, partially hidden, ArCIV); 
IR (thin film, Nujol) max = 1438, 1408, 1183, 1119, 1105, 1061, 984, 842, 828, 764, 743, 718, 
693, 560, 510, 428 cm-1; HRMS (FAB) observed (M+H)+ 457.1484, calculated for 
C28H27O2P2 457.1486; M.p. 140 °C. 
 
 
()-(3R,4R)-4-((E)-3-(Diphenylphosphoryl)prop-1-enyl)-3-methylazetidin-2-one, ()-163.  
Procedure A: Second generation Grubbs catalyst (10 mg, 12 µmol, 9.4 mol%) was added to 
a solution of β-lactam ()-119 (41.4 mg, 369 µmol) and allyldiphenyphosphine oxide 143 
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(30.2 mg, 124 µmol) in anhydrous toluene (2.0 mL). The reaction mixture was heated at 65 
°C for 21 h, and was then treated with additional allyldiphenyphosphine oxide 143 (20 mg, 
83 µmol), and second generation Grubbs catalyst (10 mg, 12 µmol, 9.4 mol%). After stirring 
the reaction for 17 h at 80 °C, the majority of the toluene was evaporated under reduced 
pressure, and the resulting crude solution was then purified by flash column 
chromatography (silica gel, 0-50% methanol in ethyl acetate). The pure heterodimer ()-
163 was obtained as a light brownish sticky oil (46 mg, 69%).  
 
Procedure B: Second generation Hoveyda-Grubbs catalyst (18 mg, 29 µmol, 31 mol%) was 
added to a solution of β-lactam ()-119 (33.3 mg, 297 µmol) and allyldiphenyphosphine 
oxide 143 (24 mg, 94 µmol) in anhydrous toluene (1.5 mL). After stirring the reaction for 13 
h at 80 °C, the majority of the toluene was evaporated under reduced pressure, and the 
resulting crude solution was then purified by flash column chromatography (silica gel, 
100% ethyl acetate) to give the pure heterodimer ()-163 as a light brownish sticky oil (24 
mg, 78%). 1H NMR (400MHz, CDCl3) δ 1.22 (3H, d, J = 7.4 Hz, CH3), 2.62 (1H, appbq, J = 
7.4 Hz, CHCH3, 3-CH), 3.11 (2H, m, 7-CH2), 3.60 (1H, d, J = 7.5 Hz, 4-CH), 5.52 (1H, ddd, J 
= 15.1, 7.4 Hz, JH-P = 4.5 Hz, 5-CH), 5.73 (1H, m, 6-CH), 6.02 (1H, bs, NH), 7.47-7.55 (6H, m, 
ArHmeta + ArHpara), 7.68-7.73 (4H, m, ArHortho); 13C NMR (100MHz, CDCl3) δ 12.5 (CH3), 
34.4 (d, JC-P = 68.1 Hz, 7-CH2), 53.2 (d, JC-P = 2.9 Hz, 3-CH), 57.2 (d, JC-P = 2.3 Hz, 4-CH), 
121.6 (d, JC-P = 9.3 Hz, 5-CH), 128.6 (d, JC-P = 11.8 Hz, ArCHmeta), 128.6 (d, JC-P = 11.8 Hz, 
ArCHmeta), 130.8 (d, JC-P = 9.2 Hz, ArCHortho), 130.9 (d, JC-P = 9.2 Hz, ArCHortho), 132.0 (d, JC-P 
= 3.0 Hz, ArCHpara), 132.0 (d, JC-P = 2.9 Hz, ArCHpara), 132.0 (d, JC-P = 99.6 Hz, ArCIV), 132.1 
(d, JC-P = 99.3 Hz, ArCIV), 135.5 (d, JC-P = 11.3 Hz, 6-CH), 170.9 (2-C=O); IR (thin film) max = 
3419, 3213, 3059, 2965, 2929, 2229, 1747, 1663, 1438, 1177, 1121, 969, 721, 696 cm-1; HRMS 
(CI) observed (M+H)+ 326.1302, calculated for C19H21O2NP 326.1310.  
 
 
()-(3R,4R)-1-(tert-Butyldimethylsilyl)-4-((E)-3-(diphenylphosphoryl)prop-1-enyl)-3-
methylazetidin-2-one, ()-164. Second generation Hoveyda-Grubbs catalyst (55 mg, 88 
µmol, 5.0 mol%) was added to a solution of N-TBS protected β-lactam ()-153 (399 mg, 1.77 
mmol) and allyldiphenyphosphine oxide 143 (429 mg, 1.77 mmol) in anhydrous toluene 
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(13.5 mL). The reaction mixture was heated at 80 °C for 16 h until some additional second 
generation Hoveyda-Grubbs catalyst (55 mg, 88 µmol, 5.0 mol%) was added. After stirring 
the reaction for 17 h at 80 °C, the majority of the toluene was evaporated under reduced 
pressure. The crude resulting solution was then purified by flash column chromatography 
(silica gel, 1% TEA, 100% ethyl acetate). The pure heterodimer ()-164 was obtained as a 
light brownish sticky oil (242 mg, 31%). 1H NMR (400MHz, CDCl3) δ -0.02 (3H, s, SiCH3), 
0.06 (3H, s, SiCH3), 0.84 (9H, s, SiC(CH3)3), 1.15 (3H, d, J = 7.4 Hz, 3-CHCH3), 2.56 (1H, qd, J 
= 7.4, 2.5 Hz, 3-CH), 3.04 (1H, tdd, JH-P = 14.0 Hz, J = 7.9, 1.0 Hz, 7-CH), 3.16 (1H, tdd, JH-P = 
14.8 Hz, J = 6.9, 1.1 Hz, 7-CH’), 3.45 (1H, dd, J = 8.9, 2.4 Hz, 4-CH), 5.45 (1H, ddd, J = 15.3, 
9.0 Hz, JH-P = 4.3 Hz, 5-CH), 5.72 (1H, m, 6-CH), 7.40-7.52 (6H, m, ArHmeta + ArHpara), 7.63-
7.75 (4H, m, ArHortho); 13C NMR (100MHz, CDCl3) δ -5.8 (Si(CH3)2), 13.0 (3-CHCH3), 18.2 
(SiCIV), 26.1 (SiC(CH3)3), 34.4 (d, JC-P = 68.4 Hz, 7-CH2), 53.3 (d, JC-P = 2.9 Hz, 3-CH), 59.4 (d, 
JC-P = 2.2 Hz, 4-CH), 121.6 (d, JC-P = 9.2 Hz, 6-CH), 128.4 (d, JC-P = 11.8 Hz, ArCHmeta), 128.6 
(d, JC-P = 11.7 Hz, ArCHmeta), 130.8 (d, JC-P = 9.2 Hz, ArCHortho), 130.8 (d, JC-P = 9.2 Hz, 
ArCHortho), 131.8 (d, JC-P = 2.7 Hz, ArCHpara), 131.9 (d, JC-P = 2.7 Hz, ArCHpara), 132.1 (d, JC-P 
= 99.7 Hz, ArCIV), 132.3 (d, JC-P = 98.7 Hz, ArCIV), 137.2 (d, JC-P = 11.4 Hz, 5-CH), 175.8 (2-
C=O); IR (thin film) max = 3448, 3056, 2957, 2928, 2899, 2857, 2220, 1737, 1438, 1289, 1254, 
1182, 1120, 997, 840, 824, 730, 696, 549 cm-1; HRMS (CI) observed (M+H)+ 440.2168, 
calculated for C25H35O2NSiP 440.2175. 
 
 
(2E,4E,6E)-2-Methylnona-2,4,6-trienamide, 166. A -78 °C solution of phosphine oxide (±)-
207 (30 mg, 92 µmol) in anhydrous tetrahydrofuran (2.5 mL) was treated with the slow 
addition of LiHMDS (93 µL, 1.06 M in THF, 99 µmol). The reaction was stirred for 20 min 
at -78 °C, and distilled HMPA (52 mg, 50 µL, 0.3 mmol) was then added. The reaction 
mixture was stirred for a further 5 min, before freshly distilled propanal (58 mg, 72 µL, 1.0 
mmol) was incorporated. The reaction was allowed to warm up slowly to room 
temperature, and was stirred overnight under argon. The reaction was then quenched 
with the careful addition of water (10 mL). The phases were separated and the organic 
phase was washed one more time with water (10 mL). The organic layer was dried over 
anhydrous sodium sulfate, and the solvent was removed under reduced pressure to afford 
the crude triene 166 as an extremely viscous yellowish oil. Purification by flash column 
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chromatography (silica gel, 70-100% ethyl acetate in 40-60 petroleum ether) yielded the 
pure triene 166 as a very viscous clear and colourless oil (10 mg, 66%). 1H NMR (400MHz, 
CDCl3) δ 1.04 (3H, t, J = 7.4 Hz, 9-CH3), 1.97 (3H, d, J = 1.0 Hz, 2-CIVCH3), 2.16 (2H, appqn, 
J = 7.4 Hz, 8-CH2), 5.58 (2H, vbs, NH2), 5.93 (1H, dt, J = 15.2, 6.6 Hz, 7-CH), 6.17 (1H, ddt, J 
= 15.1, 10.3, 1.4 Hz, 6-CH), 6.36 (1H, dd, J = 14.8, 11.2 Hz, 4-CH), 6.48 (1H, dd, J = 14.8, 10.5 
Hz, 5-CH), 6.99 (1H, dd, J = 11.1, 1.1 Hz, 3-CH); 13C NMR (100MHz, CDCl3) δ 13.0 (9-CH3), 
13.2 (2-CIVCH3), 25.9 (8-CH2), 125.2 (4-CH), 127.6 (2-CH), 129.2 (6-CH), 135.4 (3-CH), 139.4 
(5-CH), 140.6 (7-CH), 170.9 (1-C=O); IR (thin film) max = 3365, 3201, 3029, 2964, 2924, 2879, 
2848, 1655, 1619, 1596, 1581, 1458, 1405, 1379, 1285, 1180, 1154, 1113, 1030, 986, 797, 738 cm-
1; HRMS (CI) observed (M+H)+ 166.1231, calculated for C10H16NO 166.1232. 
 
 
(3R,4R)-4-((1E,3E,5R,6R)-6-(tert-Butyldimethylsilyloxy)-3,5-dimethyl-7-phenylhepta-1,3-
dienyl)-3-methylazetidin-2-one, 167, (3S,4S)-4-((1E,3E,5R,6R)-6-(tert-
Butyldimethylsilyloxy)-3,5-dimethyl-7-phenylhepta-1,3-dienyl)-3-methylazetidin-2-one, 
168. Second generation Hoveyda-Grubbs catalyst (35 mg, 56 µmol, 11 mol%) was 
incorporated into a solution of TBS-protected dienol (E)-139 (173 mg, 523 μmol) and β-
lactam (±)-119 (56 mg, 500 µmol) in anhydrous toluene (4 mL). The reaction mixture was 
stirred at 80 °C for 2 days. The majority of the toluene was evaporated under reduced 
pressure, and the resulting crude solution was then purified by flash column 
chromatography (silica gel, 1% TEA, 0-30% ethyl acetate in 40-60 petroleum spirit). 
Purification enabled the recovery of the dienol (E)-139 (102 mg, 59% of recovery) as well as 
the pure (1:1) isomeric mixture of heterodimers 167 and 168 as a light brownish sticky oil 
(77 mg, 37%, 87% borsm). 1H NMR (400MHz, CDCl3) δ -0.26 (6H, s, SiCH3 + SiCH’3), -0.03 
(6H, s, SiCH3 + SiCH’3), 0.87 (18H, s, SiC(CH3)3 + SiC(CH’3)3), 0.99 (6H, d, J = 6.8 Hz, 3-
CCH3 + 3’-CCH3), 1.34 (6H, 2 x d, J = 7.4 and 7.5 Hz, 9-CCH3 + 9’-CCH3), 1.56 (6H, 2 x s, 5-
CCH3 + 5’-CCH3), 2.50 (2H, m, 3-CH + 3’-CH), 2.68 (2H, dd, J = 13.5, 6.6 Hz, 1-CH + 1’-
CH), 2.81 (2H, dd, J = 13.5, 5.9 Hz, 1-CH” + 1’-CH”), 2.93 (2H, m, 9-CH + 9’-CH), 3.78 (4H, 
m, 2-CH + 8-CH + 2’-CH + 8’-CH), 5.45 (2H, d, J = 9.7 Hz, 4-CH + 4’-CH), 5.55 (2H, dd, J = 
15.5, 8.0 Hz, 7-CH + 7’-CH), 5.92 (2H, bd, J = 8.9 Hz, NH + NH’), 6.23 (2H, d, J = 15.5 Hz, 6-
CH + 6’-CH), 7.14-7.28 (10H, m, ArCH + ArCH’); 13C NMR (100MHz, CDCl3) δ -4.8 (SiCH3 
+ SiC’H3), -4.5 (SiCH3 + SiC’H3), 12.6 (2 peaks, 9-CCH3 + 9’CCH3), 12.7 (2 peaks, 5-CCH3 + 
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5’-CCH3), 15.2 (3-CCH3 + 3’-CCH3), 18.1 (SiC(CH3)3 + SiC’(CH3)3), 25.9 (SiC(CH3)3 + 
SiC(C’H3)3), 37.2 (2 peaks, 3-CH + 3’-CH),  41.5 (1-CH2 + 1’-CH2), 53.8 (9-CH + 9’-CH), 58.3 
(2 peaks, 8-CH + 8’-CH), 77.3 (underneath CHCl3 peaks, 2-CH + 2’-CH), 125.2 (2 peaks, 7-
CH + 7’-CH), 126.0 (ArCHpara + ArC’Hpara), 128.1 (ArCHortho + ArC’Hortho), 129.7 (ArCHmeta 
+ ArC’Hmeta), 131.5 (5-CIV + 5’-CIV), 137.5 (2 peaks, 4-CH + 4’-CH) 137.9 (2 peaks, 6-CH + 6’-
CH), 139.0 (2 peaks, ArCIV + ArC’IV), 171.4 (C=O + C’=O); IR (thin film) max = 3390, 3029, 
2957, 2929, 2856, 1752,1495, 1472, 1455, 1378, 1360, 1255, 1175, 1097, 1083, 1060, 1030, 966, 
937, 874, 836, 809, 775, 738, 701 cm-1; HRMS (CI) observed (M+H)+ 414.2829, calculated for 
C25H40O2NSi 414.2828. 
 
 
 (3R,4R)-4-((1E,3E,5R,6R)-6-Methoxy-3,5-dimethyl-7-phenylhepta-1,3-dienyl)-3-
methylazetidin-2-one, 169 and (3S,4S)-4-((1E,3E,5R,6R)-6-Methoxy-3,5-dimethyl-7-
phenylhepta-1,3-dienyl)-3-methylazetidin-2-one, 170: To a solution of freshly purified 
diene (E)-117 (140 mg, 608 µmol) and vinylazetidinone ()-119 (70.1 mg, 630 µmol) in dry 
toluene (8 mL) was added second generation Hoveyda-Grubbs (60 mg, 16 mol%). The 
mixture was then refluxed overnight, and the solvent was evaporated under reduced 
pressure to afford the crude product as a black viscous oil (298 mg). The black crude oil 
was purified by flash column chromatography (silica gel, 10-50% ethyl acetate in 40-60 
petroleum ether) to afford the semi-pure desired heterodimer 169 and 170 as a colourless 
and very viscous oil (71 mg, 37%, 79% borsm) which was used in the next reaction without 
any further purification. 1H NMR (400MHz, CDCl3) δ 1.03 (6H, d, J = 6.7 Hz, 3-CCH3 + 3’-
CCH3), 1.33 and 1.34 (6H, 2 x d, J = 7.5 and 7.3 Hz, 9-CCH3 + 9’-CCH3), 1.48 (9H, bs, 5-
CCH3 + 5’-CCH3), 2.61 (2H, m, 3-CH + 3’-CH), 2.68 (2H, dd, J = 13.9, 7.5 Hz, 1-CH + 1’-
CH), 2.80 (2H, dd, J = 13.9, 4.6 Hz, 1-CH” + 1’-CH”), 2.93 (2H, appq, J = 7.4 Hz, 9-CH + 9’-
CH), 3.20 (2H, m, 2-CH + 2’-CH), 3.24 (6H, s, OCH3 + OCH3’), 3.78 (2H, dd, J = 7.9, 1.8 Hz, 
8-CH + 8’-CH), 5.44 (2H, d, J = 9.9 Hz, 4-CH + 4’-CH), 5.59 (2H, dd, J = 15.6, 7.9 Hz, 7-CH + 
7’-CH), 6.13 (2H, d, J = 4.3 Hz, NH), 6.27 (2H, d, J = 15.5, 6-CH + 6’-CH), 7.18-7.29 (10H, m, 
ArH + ArH’); 13C NMR (100MHz, CDCl3) δ 12.6 (5-CCH3 + 5’-CCH3), 16.1 (2 peaks, 3-CCH3 
+ 3’-CCH3), 22.1 (9-CCH3 + 9’-CCH3), 36.5 (2 peaks, 3-CH + 3’-CH), 38.1 (2 peaks, 1-CH2 + 
1’-CH2), 53.7 (9-CH + 9’-CH), 58.2 (8-CH + 8’-CH), 58.6 (2 peaks, OCH3 + OCH3’), 86.8 (2 
peaks, 2-CH + 2’-CH), 125.6 (7-CH + 7’-CH), 125.9 (ArCHpara), 128.1 (2 peaks, ArCHortho), 
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129.3 (ArCHmeta), 132.2 (2 peaks, 5-CIV + 5’-CIV), 136.7 and 136.8 (4-CH + 4’-CH), 137.2 and 
137.3 (6-CH + 6’-CH), 139.2 (2 peaks, ArCIV), 171.4 (10-C=O); [α]24D +18.5, (c = 1.0, CHCl3); 
IR (thin film) max = 3264, 3086, 3062, 3027, 2965, 2929, 2871, 2826, 1754, 1454, 1372, 1112, 
966, 750, 701 cm-1; HRMS (CI) observed (M+H)+ 314.2121, calculated for C20H28O2N 
314.2120. 
 
 
 (S)-4-((1E,3E,5R,6R)-6-Methoxy-3,5-dimethyl-7-phenylhepta-1,3-dienyl)azetidin-2-one, 
171 and (R)-4-((1E,3E,5R,6R)-6-Methoxy-3,5-dimethyl-7-phenylhepta-1,3-
dienyl)azetidin-2-one, 172. Second generation Hoveyda-Grubbs catalyst (23 mg, 37 µmol, 
10 mol%) was added to a solution of methoxydienol (E)-117 (84 mg, 360 μmol) and β-
lactam (±)-151 (56 mg, 580 µmol) in anhydrous dichloromethane (3 mL). The reaction 
mixture was refluxed for 10 h before being cooled down to room temperature. The solvent 
was evaporated under reduced pressure, and the crude resulting oil (165 mg) was then 
purified by flash column chromatography (silica gel, 1% TEA, 0-50% ethyl acetate in 40-60 
petroleum spirit) to provide the semi-pure isomeric mixture of heterodimers 171 and 172 
(23 mg). A second purification by flash column chromatography (silica gel, 10% ethyl 
acetate in chloroform) afforded the cleaner isomeric mixture of heterodimers 171 and 172 
contaminated with starting β-lactam (±)-151 (4 mg) and as a viscous clear and colourless 
oil (12 mg, 11%). 1H NMR (400MHz, CDCl3) δ 1.03 and 1.04 (6H, 2 x d, J = 6.7 and 6.8 Hz, 
3-CCH3 + 3’CCH3), 1.65 and 1.66 (6H, 2 x s, 5-CCH3 + 5’-CCH3), 2.61 (2H, m, 3-CH + 3’-
CH), 2.68 (2H, dd, J = 13.9, 6.9 Hz, 1-CH + 1’-CH), 2.72 (4H, m, 9-CH + 9’-CH), 2.80 (2H, 
dd, J = 13.9, 4.5 Hz, 1-CH” + 1’-CH”), 3.17-3.27 (2H, m, 2-CH + 2’-CH), 3.23 and 3.24 (3H, 2 
x s, OCH3 + OCH3’), 4.19 (2H, 2 x ddd, J = 7.7, 5.2, 2.6 Hz, 8-CH + 8’-CH), 5.44 (2H, bd, J = 
9.8 Hz, 4-CH + 4’-CH), 5.59 (2H, dd, J = 15.4, 7.7 Hz, 7-CH + 7’-CH), 5.95 (2H, vbs, NH + 
NH’), 6.28 (2H, d, J = 15.5 Hz, 6-CH + 6’-CH), 7.15-7.29 (10H, m, ArH + ArH’); 13C NMR 
(100MHz, CDCl3) δ 12.7 (5-CCH3 + 5’-CCH3), 16.1 (2 peaks, 3-CCH3 + 3’CCH3), 36.6 (3-CH 
+ 3’-CH), 38.1 (2 peaks, 1-CH2 + 1’-CH2), 45.6 (9-CH + 9’-CH), 49.5 (8-CH + 8’-CH), 58.6 (2 
peaks, OCH3 + OCH3’), 86.8 (2-CH + 2’-CH), 125.9 (7-CH + 7’-CH), 126.0 (ArCHpara + 
ArC’Hpara), 128.2 (ArCHortho + ArC’Hortho), 129.4 (ArCHmeta + ArC’Hmeta), 132.2 (5-CH + 5’-
CH), 137.0 (2 peaks, 4-CH + 4’-CH), 137.4 (2 peaks, 6-CH + 6’-CH), 139.2 (ArCIV), 167.6 (2 
peaks, C=O); IR (thin film) max = 3259, 3084, 3029, 2980, 2961, 2927, 2871, 2830, 1757, 1645, 
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1454, 1412, 1372, 1353, 1262, 1245, 1182, 1112, 1083, 966, 749, 701 cm-1; HRMS (CI) observed 
(M+H)+ 300.1961, calculated for C19H26O2N 300.1964. 
 
 
()-(3R,4R)-3-Methyl-2-oxo-4-vinyl-azetidine-1-carboxylic acid tert-butyl ester, ()-174. A 
room temperature solution of lactam ()-119 (47 mg, 420 µmol) in anhydrous 
dichloromethane (10 mL) was sequentially treated with anhydrous triethylamine (56 µL, 
40 µg, 0.4 µmol), DMAP (50 mg, 410 µmol) and (Boc)2O (96 mg, 440 µmol). The resulting 
reaction mixture was stirred overnight, and then concentrated under reduced pressure. 
The resulting crude yellow oil (151 mg) was purified by flash column chromatography 
(silica gel, 0.5% TEA, 10% ethyl acetate in 40-60 petroleum spirit) to give the pure desired 
N-Boc protected lactam ()-174 as a clear and colourless viscous oil (89 mg, 100%). 1H 
NMR (400MHz, CDCl3) δ 1.34 (3H, d, J = 7.5 Hz, 3-CCH3), 1.48 (9H, s, OC(CH3)3), 2.91 (1H, 
qd, J = 7.5, 3.0 Hz, 3-CH), 3.96 (1H, dd, J = 7.7, 3.0 Hz, 4-CH), 5.27 (1H, d, J = 10.3 Hz, 6-
CH), 5.36 (1H, d, J = 17.1 Hz, 6-CH’), 5.86 (1H, ddd, J = 17.1, 10.3, 7.7 Hz, 5-CH); 13C NMR 
(100MHz, CDCl3) δ 12.2 (3-CCH3), 27.9 (OC(CH3)3), 51.1 (3-CH), 61.2 (4-CH), 83.1 
(OC(CH3)3), 118.7 (6-CH2), 134.7 (5-CH), 147.8 (O-C=O), 168.1 (2-C=O); IR (thin film) max = 
3086, 2979, 2934, 1808, 1724, 1339, 1156 cm-1; HRMS (CI) observed (M+H)+ 212.1283, 
calculated for C11H18O3N 212.1287. 
 
 
(3R,4R)-tert-Butyl 3-methyl-2-oxo-4-vinylazetidine-1-carboxylate, 174: To a solution of 
lactam 119 (27 mg, 240 µmol) in dry dichloromethane (6 mL) was added anhydrous 
triethylamine (34 µL, 240 µmol), DMAP (31 mg, 250 µmol) and (Boc)2O (60 mg, 280 µmol) 
at room temperature. The mixture was stirred overnight and then directly concentrated to 
afford a yellow crude oil (83 mg), which was purified by flash column chromatography 
(silica gel, 0.5% TEA, 10% ethyl acetate in 40-60 petroleum spirit) to give the pure desired 
N-Boc protected lactam 174 as a clear and colourless viscous oil (33 mg, 65%, ee = 98%). 
The enantiomeric excess was determined through HPLC analysis with a Chiralcel OJH 
column using hexane:isopropanol (99:1) at a flow rate of 0.75 mL/min. Data were in full 
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agreement with those reported for the racemic azetidinone ()-174. [α]25D -39.0, (c = 1.0, 
CHCl3). 
 
 
(±)-(3S,4S)-3-Methyl-1-(2,2,2-trichloroacetyl)-4-vinylazetidin-2-one, (±)-175. A solution of 
β-lactam (±)-119 (244 mg, 2.20 mmol) in anhydrous dichloromethane (10 mL) was cooled 
down to -78 °C. The reaction mixture was then sequentially treated with anhydrous 
triethylamine (444 mg, 612 µL, 4.39 mmol) and trichloroacetyl chloride (803 mg, 493 µL, 
4.42 mmol). Completion was reached within 10 min, as indicated by TLC analysis, and the 
reaction was then quenched by addition of a sat. aq. solution of sodium bicarbonate (2 
mL). The phases were separated, and the organic layer was dried over anhydrous sodium 
sulfate. The solvent was evaporated under reduced pressure, and the resulting solid was 
diluted in dichloromethane (50 mL) and washed with water (2 x 10 mL). The organic layer 
was dried one more time over anhydrous sodium sulfate, and concentrated in vacuo to 
provide the crude N-TAC protected β-lactam (±)-175 as an orange to brown viscous oil 
(961 mg). Purification by flash column chromatography (silica gel, 10% ethyl acetate in 40-
60 petroleum spirit) gave the pure N-TAC protected β-lactam (±)-175 as a clear and 
colourless viscous oil (561 mg, 100%), which turns brown when exposed to temperatures 
above 45°C. 1H NMR (400MHz, CDCl3) δ 1.44 (3H, d, J = 7.5 Hz, CH3), 3.13 (1H, qd, J = 7.5, 
3.6 Hz, 3-CH), 4.22 (1H, dd, J = 7.4, 3.5 Hz, 4-CH), 5.39 (1H, dd, J = 10.3, 0.6 Hz, 5-CH), 5.48 
(1H, dd, J = 17.1, 0.7 Hz, 6-CH), 5.93 (1H, ddd, J = 17.3, 10.3, 7.4 Hz, 6-CH’); 13C NMR 
(100MHz, CDCl3) δ 12.8 (CH3), 50.9 (3-CH), 61.1 (4-CH), 91.2 (CCl3), 120.1 (6-CH2), 133.0 (5-
CH), 157.5 (CCl3C=O), 164.2 (2-C=O); IR (thin film) max = 3089, 2975, 2935, 2875, 1811, 
1713, 1281 cm-1; HRMS (CI) observed (M+H)+ 255.9705, calculated for 
C8H9NO2Cl3 255.9699. 
 
 
(2R,3R)-tert-Butyl 2-((1E,3E,5R,6R)-6-methoxy-3,5-dimethyl-7-phenylhepta-1,3-dienyl)-3-
methyl-4-oxoazetidine-1-carboxylate, 176. To a solution of freshly purified diene (E)-117 
(30 mg, 130 µmol) and N-Boc protected vinylazetidinone 174 (45 mg, 210 µmol, ee = 90%) 
 - 186 - 
in dry toluene (2.0 mL) was added second generation Hoveyda-Grubbs catalyst (16 mg, 20 
mol%). The mixture was then refluxed overnight (14 h), and then cooled down to room 
temperature. The solvent was evaporated under reduced pressure to afford a black 
viscous oil which was diluted with diethyl ether (10 mL), and filtered to remove the 
catalyst derivatives. Concentration of the filtrate under reduced pressure gave a very 
viscous brownish oil (76 mg). The black crude oil was purified by flash column 
chromatography (silica gel, 1% TEA, 0-20% ethyl acetate in 40-60 petroleum ether) to 
afford the pure single diasteroisomer 176 as a clear and very viscous yellowish oil (33 mg, 
61%). 1H NMR (400MHz, CDCl3) δ 1.04 (3H, d, J = 6.7 Hz, 3-CCH3), 1.35 (3H, d, J = 7.4 Hz, 
9-CCH3), 1.49 (9H, s, OC(CH3)3), 1.64 (3H, d, J = 1.2 Hz, 5-CCH3), 2.61 (1H, m, 3-CH), 2.69 
(1H, d, J = 7.5 Hz, 1-CH), 2.80 (1H, d, J = 4.6 Hz, 1-CH’), 2.94 (1H, m, 9-CH), 3.19 (1H, m, 2-
CH), 3.23 (3H, s, CH3, OCH3), 4.03 (1H, dd, J = 8.1, 3.0 Hz, 8-CH), 5.46 (1H, d, J = 9.8 Hz, 4-
CH), 5.55 (1H, dd, J = 15.4, 8.1 Hz, 7-CH), 6.34 (1H, d, J = 15.5, 6-CH), 7.17-7.29 (5H, m, 
ArH); 13C NMR (100MHz, CDCl3) δ 12.3 (9-CCH3), 12.7 (5-CCH3), 16.1 (3-CCH3), 28.0 
(OC(CH3)3), 36.6 (3-CH), 38.1 (1-CH2), 51.6 (9-CH), 58.6 (9-CH), 61.4 (8-CH3), 82.9 
(OC(CH3)3), 86.9 (2-CH), 123.0 (7-CH), 126.1 (ArCHpara), 128.1 (ArCHortho), 129.3 129.4 
(ArCHmeta), 132.2 (5-CIV), 137.2 (4-CH), 139.2 (6-CH), 139.3 (ArCIV), 147.8 (O-C=O), 168.4 
(10-C=O); [α]24D +24.9, (c = 1.0, CHCl3); IR (thin film) max = 3422, 3029, 2976, 2931, 2875, 
2362, 2342, 1810, 1723, 1333, 1157, 1104 cm-1; HRMS (CI) observed (M+H)+ 413.2646, 
calculated for C25H35O4N 413.2657. 
 
    
(2R,3R)-tert-Butyl 2-((1E,3E,5R,6R)-6-methoxy-3,5-dimethyl-7-phenylhepta-1,3-dienyl)-3-
methyl-4-oxoazetidine-1-carboxylate, 176 and (2S,3S)-tert-Butyl 2-((1E,3E,5R,6R)-6-
methoxy-3,5-dimethyl-7-phenylhepta-1,3-dienyl)-3-methyl-4-oxoazetidine-1-
carboxylate, 177. To a solution of freshly purified diene (E)-117 (30 mg, 130 µmol) and a 
mixture of N-Boc protected vinylazetidinone (±)-174 (52 mg, 250 µmol) in dry toluene (2.0 
mL) was added second generation Hoveyda-Grubbs catalyst (17 mg, 20 mol%). The 
mixture was refluxed overnight (14 h), and the solvent was evaporated under reduced 
pressure to afford a black viscous oil which was diluted with diethyl ether (10 mL), and 
filtered to remove the catalyst derivatives. Concentration of the filtrate under reduced 
pressure gave a very viscous brownish oil as crude (78 mg). The black crude oil was 
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purified by flash column chromatography (silica gel, 1% TEA, 0-20% ethyl acetate in 40-60 
petroleum ether) to afford the pure mixture of two inseparable diastereoisomers 176 and 
177 as a clear and very viscous yellowish oil (37 mg, 69%). 
176. 1H NMR (400MHz, CDCl3) δ 1.04 (3H, d, J = 6.7 Hz, 3-CCH3), 1.35 (3H, d, J = 7.4 Hz, 9-
CCH3), 1.49 (9H, s, OC(CH3)3), 1.64 (3H, d, J = 1.2 Hz, 5-CCH3), 2.61 (1H, m, 3-CH), 2.69 
(1H, d, J = 7.5 Hz, 1-CH), 2.80 (1H, d, J = 4.6 Hz, 1-CH’), 2.94 (1H, m, 9-CH), 3.19 (1H, m, 2-
CH), 3.23 (3H, s, CH3, OCH3), 4.03 (1H, dd, J = 8.1, 3.0 Hz, 8-CH), 5.46 (1H, d, J = 9.8 Hz, 4-
CH), 5.55 (1H, dd, J = 15.4, 8.1 Hz, 7-CH), 6.34 (1H, d, J = 15.5, 6-CH), 7.17-7.29 (5H, m, 
ArH); 13C NMR (100MHz, CDCl3) δ 12.3 (9-CCH3), 12.7 (5-CCH3), 16.1 (3-CCH3), 28.0 
(OC(CH3)3), 36.6 (3-CH), 38.1 (1-CH2), 51.6 (9-CH), 58.6 (9-CH), 61.4 (8-CH3), 82.9 
(OC(CH3)3), 86.9 (2-CH), 123.0 (7-CH), 126.1 (ArCHpara), 128.1 (ArCHortho), 129.3 129.4 
(ArCHmeta), 132.2 (5-CIV), 137.2 (4-CH), 139.2 (6-CH), 139.3 (ArCIV), 147.8 (O-C=O), 168.4 
(10-C=O); 
177. 1H NMR (400MHz, CDCl3) δ 1.03 (3H, d, J = 6.7 Hz, 3’-CCH3), 1.36 (3H, d, J = 7.5 Hz, 
9’-CCH3), 1.48 (9H, s, OC(CH3)3’), 1.66 (3H, d, J = 1.2 Hz, 5’-CCH3), 2.60 (1H, m, 3’-CH), 
2.66 (1H, d, J = 7.5 Hz, 1’-CH), 2.81 (1H, d, J = 4.6 Hz, 1-CH”), 2.95 (1H, m, 9’-CH), 3.19 
(1H, m, 2’-CH), 3.24 (3H, s, OCH3’), 4.03 (1H, dd, J = 8.1, 3.0 Hz, 8’-CH), 5.45 (1H, d, J = 9.7 
Hz, 4’-CH), 5.54 (1H, dd, J = 15.4, 8.1 Hz, 7’-CH), 6.33 (1H, d, J = 15.5 Hz, 6’-CH), 7.17-7.29 
(5H, m, ArH’); 13C NMR (100MHz, CDCl3) δ 12.3 (9’-CCH3), 12.6 (5’-CCH3), 16.0 (3’-CCH3), 
28.0 (OC(CH3)3’), 36.7 (3’-CH), 38.2 (1’-CH2), 51.7 (9’-CH), 58.7 (OCH3’), 61.3 (8’-CH3), 82.9 
(OC(CH3)3’), 86.8 (2’-CH), 123.1 (7’-CH), 126.0 (ArCHpara’), 128.2 (ArCHortho’), 129.4 
(ArCHmeta’), 132.1 (5-CIV’), 137.4 (4’-CH), 139.1 (6’-CH), 139.2 (ArCIV’), 147.9 (O-C=O’), 
168.5 (10’-C=O); [α]24D +9.1, (c = 1.0, CHCl3); IR (thin film) max = 3422, 3029, 2976, 2931, 
2875, 2362, 2342, 1810, 1723, 1333, 1157, 1104 cm-1; HRMS (CI) observed (M+H)+ 413.2646, 
calculated for C25H35O4N 413.2657. 
 
   
(2S,3R)-dimethyl 2-methyl-3-(4-methylphenylsulfonamido)succinate, trans-179 and 
(2R,3R)-dimethyl 2-methyl-3-(4-methylphenylsulfonamido)succinate, syn-179. Solid 
tosyl chloride (3.67 g, 19.2 mmol) was added to a solution of methylester 178 (2.53 g, 12.8 
mmol) in anhydrous tetrahydrofuran (130 mL) at room temperature. The resulting 
mixture was then treated with the slow addition of anhydrous triethylamine (4.46 mL, 32.0 
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mmol), and was stirred at room temperature for 24 h under argon. Additional anhydrous 
triethylamine was added (1.0 mL, 7.2 mmol), and the suspension was stirred for an extra 1 
h. The reaction was filtered through Celite, and flushed with ethyl acetate (300 mL total 
volume). The filtrate was then washed with water (3 x 40 mL), the aqueous layers were 
combined, and extracted with ethyl acetate (40 mL). The organic layers were combined, 
dried over anhydrous sodium sulphate, and concentrated in vacuo to yield a crude oil, 
which was then dissolved in diethyl ether (150 mL), and filtered. The filtrate was 
concentrated under vacuum, the resulting oil was then dissolved in 40-60 petroleum spirit 
(150 mL), and the precipitate formed was filtered out. The solid residue was washed with 
40-60 petroleum spirit (3 x 100 mL), and dried to give N-tosyl protected dimethylaspartate 
as a white solid (5.176 g), which was used without any further purification. 
A fraction of the crude dimethylaspartate (787 mg) was dissolved in anhydrous 
tetrahydrofuran (8 mL). The solution was cooled down to -78 °C, and was treated by the 
slow addition of KHMDS (11 mL, 1.0 M in THF, 11 mmol). After stirring the mixture for 
1.5 h at -78 °C, iodomethane (190 µL, 3.05 mmol) was added through a pad of basic 
alumina. The reaction was allowed to slowly warm up to room temperature, and was 
stirred for 14 h under argon. The mixture was quenched by the addition of a 1.0 M aq. 
solution of HCl to pH 3 and was then extracted with ethyl acetate (3 x 20 mL). The 
combined organic extracts were dried over anhydrous magnesium sulfate, and were 
concentrated under vacuum. Purification of the resulting crude oil (816 mg) by flash 
column chromatography (silica gel, 20-50% ethyl actetate in 40-60 petroleum spirit) 
provided the pure methylated dimethylaspartates trans-179 and syn-179 as a very viscous, 
clear and colourless oil (368 mg, 45%). The aspartates trans-179 and syn-179 were isolated 
as a 3:1 mixture of two inseparable syn- and anti-diastereoisomers. 
  
 1H NMR (400MHz, CDCl3) δ 2.42 (3H, s, ArCH3), 2.84 (1H, dd, J = 17.1, 4.9 Hz, 2-CH), 2.96 
(1H, dd, J = 17.1, 4.3 Hz, 2-CH’), 3.59 (3H, s, OCH3), 3.66 (3H, s, OCH3), 4.14 (1H, dt, J = 8.1, 
4.6 Hz, 1-CH), 5.65 (1H, d, J = 8.0 Hz, NH), 7.30 (2H, d, J = 8.0 Hz, ArHmeta), 7.74 (2H, d, J = 
8.3 Hz, ArHortho). The data was in full agreement with the one reported in the literature.155 
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trans-179. 1H NMR (400MHz, CDCl3) δ 1.26 (3H, d, J = 7.2 Hz, 2-CCH3), 2.41 (3H, s, 
ArCH3), 3.14 (1H, dq, J = 7.3, 3.1 Hz, 2-CH), 3.48 (3H, s, OCH3), 3.65 (3H, s, OCH3), 4.08 
(1H, dd, J = 9.5, 4.1 Hz, 1-CH), 5.60 (1H, d, J = 9.5 Hz, NH), 7.29 (2H, d, J = 8.0 Hz, 
ArHmeta), 7.73 (2H, d, J = 8.3 Hz, ArHortho); 13C NMR (100MHz, CDCl3) δ 13.5 (2-CCH3), 21.5 
(ArCH3), 42.2 (2-CH), 52.1 (OCH3), 52.6 (OCH3), 57.7 (1-CH), 127.2 (ArCHortho), 129.4 
(ArCHmeta), 136.8 (ArCIVpara), 143.5 (ArCIVipso), 170.2 (C=O), 173.4 (C=O). The data was in 
full agreement with the one previously reported in the literature.126 
 
syn-179. 1H NMR (400MHz, CDCl3) δ 1.18 (3H, d, J = 7.2 Hz, CH3), 2.41 (3H, s, ArCH3), 
3.14 (1H, qd, J = 7.2, 4.9 Hz, 2-CH), 3.52 (3H, s, OCH3), 3.62 (3H, s, OCH3), 4.24 (1H, dd, J = 
9.6, 4.9 Hz, 1-CH), 5.52 (1H, d, J = 9.6 Hz, NH), 7.29 (2H, d, J = 8.0 Hz, ArHmeta), 7.72 (2H, d, 
J = 8.0 Hz, ArHortho); 13C NMR (100MHz, CDCl3) δ 12.3 (2-CCH3), 21.5 (ArCH3), 42.7 (2-
CH), 52.1 (OCH3), 52.7 (OCH3), 57.4 (1-CH), 127.2 (ArCHortho), 129.5 (ArCHmeta), 136.5 
(ArCIVpara), 143.6 (ArCIVipso), 170.3 (C=O), 172.5 (C=O); IR (thin film) max = 3277, 3029, 2987, 
2954, 2882, 1736, 1598, 1438, 1341, 1266, 1210, 1163, 1092, 1092, 1019, 816, 664 cm-1; HRMS 
(CI) observed (M+H)+ 330.1006, calculated for C14H20NO6S 330.1011.  
 
 
(2S)-3-Trityloxy-2-methylpropan-1-ol, 187. A solution of crude ester 120 (36.5 g, P = 69%, 
70.2 mmol) in anhydrous diethyl ether (1100 mL), cooled down to -30 °C was cautiously 
treated with small portions of solid lithium aluminium hydride (6.09 g, 16.0 mmol). The 
reaction was then allowed to warm up to room temperature, and the mixture was stirred 
overnight. The mixture was quenched slowly and carefully by the addition of water (6 
mL), followed by a solution of sodium hydroxide (15%wt, 6 mL). More water (18 mL) was 
then incorporated, and the mixture was stirred until a white precipitate formed. The 
mixture was filtered through Celite, and the solid was washed with ethyl acetate (1000 
mL) until no product remained in the solid as indicated by TLC analysis. The organic 
filtrate was then dried over anhydrous sodium sulfate, and the solvents were evaporated 
under reduced pressure. Evaporation under high vacuum afforded the crude alcohol 187 
as an extremely viscous yellowish oil (37.5 g) that have a tendancy to crystallise. 
Purification by flash column chromatography (silica gel, 1% TEA, 20% ethyl acetate, 10% 
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dichloromethane in 40-60 petroleum ether) provided alcohol 187 as an extremely viscous 
and yellowish clear oil (22.7 g, 97%), which can crystallize as a white powder after 
prolonged storage under high vacuum. Note: commercially available solutions of LiAlH4 
in diethyl ether can also be used with comparable yields (91%). The spectroscopic data 
was in full agreement with the one reported in the literature.144 [α]26D -32.7, (c = 1.0, 
CHCl3). 
 
 
(2E,4S)-Methyl 5-trityloxy-4-methylpent-2-enoate, 188. A -78 °C solution of oxalyl 
chloride (414 µL, 4.89 mmol) in anhydrous dichloromethane (10 mL) was treated by the 
slow addition of anhydrous dimethylsulfoxide (845 µL, 11.9 mmol), and the mixture was 
stirred for 45 min under argon. A previously prepared solution of alcohol 187 (797 mg, 
2.40 mmol) in dry dichloromethane (5 mL) was then added slowly at -78 °C and the 
resulting mixture was stirred for 1 h at –78 °C. The reaction was treated with anhydrous 
triethylamine (1.50 mL, 10.88 mmol), and the solution was stirred for a further 45 min at -
78 °C. The reaction was then poured into a separation funnel containing acidic water (20 
mL H2O + 7 mL 1.0 M HCl). The layers were separated, and the organic fraction was 
washed with water (50 mL). The organic phase was dried over anhydrous sodium sulfate, 
and concentrated under vacuum to afford a very sticky yellowish oil (1.06 g), which was 
shown to be clean by 1H NMR, and was used immediately without any further 
purification.  
The crude was dissolved in dry dichloromethane (50 mL, regular dichloromethane was 
preferred when the reaction was carried out in larger scale), and 
Methyl(triphenylphosphoranylidene) (1.76 g, 5.26 mmol) was then added. The resulting 
mixture was refluxed under argon for 3 days before being cooled down to room 
temperature and worked up by the addition of enough 40-60 petroleum ether to force the 
triphenylphosphine oxide to precipitate out. The solid was discarded after filtration, and 
the process was repeated until no further triphenylphosphine oxide could be forced out of 
solution. Subsequent evaporation of the organic filtrates provided a very sticky orange oil 
(930 mg), which could be used without any further purification in the next step. 
Purification by flash column chromatography (silica gel, 1% TEA, 10% ethyl acetate in 40-
60 petroleum ether) yielded an analytically pure sample of the methyl ester 188 (835 mg, 
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90% over two steps) as an extremely viscous colourless oil. 1H NMR (400MHz, CDCl3) δ 
1.04 (3H, d, J = 6.8 Hz, 3-CCH3), 2.58 (1H, appsept, J = 6.8 Hz, 3-CH), 3.02 (1H, dd, J = 8.6, 
6.3 Hz, 4-CH), 3.04 (1H, dd, J = 8.8, 6.7 Hz, 4-CH’), 3.69 (3H, s, OCH3), 5.82 (1H, appdd, J = 
15.8, 0.8 Hz, 1-CH), 6.92 (1H, dd, J = 15.8, 7.3 Hz, 2-CH), 7.17-7.41 (15H, m, ArH); 13C NMR 
(100MHz, CDCl3) δ 16.2 (3-CCH3), 37.2 (3-CH), 51.4 (OCH3), 67.1 (4-CH2), 86.4 (OCPh3), 
120.4 (1-CH), 126.9 (ArCHpara), 127.7 (ArCHortho), 128.6 (ArCHmeta), 144.0 (ArCIV), 151.9 (2-
CH), 167.1 (C=O); [α]25D -3.4, (c = 1.0, CHCl3); IR (thin film) max = 3087, 3059, 3023, 2963, 
2952, 2915, 2872, 1720, 1658, 1598, 1491, 1448, 1437, 1275, 1218, 1196, 1180, 1153, 1072, 1033, 
983, 765, 707, 632 cm-1; HRMS (EI) observed M+ 386.1886, calculated for C26H26O3 386.1882. 
 
 
(4S,2E)-5-Trityloxy-4-methylpent-2-en-1-ol, 189. A 0 °C solution of ester 188 (17.15 g, 44.37 
mmol) in anhydrous diethyl ether (1400 mL) was treated with the slow addition of Dibal-
H (1.0 M in hexanes, 121 mL, 121 mmol). The resulting mixture was then immediately 
allowed to warm up slowly to room temperature where it was stirred under argon until 
completion as indicated by TLC analysis (2 h). The reaction was then quenched by the 
dropwise addition of water (100 mL), followed by aq. solution of HCl (1.0 M, 10 mL). Ethyl 
acetate (500 mL) was added to the mixture, and the two phases were separated. The 
organic layer was subsequently washed with water (300 mL), acidic water (250 mL of 
water + 50 mL of HCl 1.0 M), and finally with water (300 mL) one last time. The aqueous 
layers were then combined, and extracted with ethyl acetate (300 mL). The combined 
organic fractions were then dried over anhydrous sodium sulfate, and the solvent was 
evaporated under vacuum to yield a crude sticky yellowish oil residue (15.22 g). This 
crude oil was purified by flash column chromatography (silica gel, 1% TEA, 20% ethyl 
acetate, 10% dichloromethane in 40-60 petroleum ether) to give the desired allylic alcohol 
189 (12.41 g, 78%, ee = 99%) as a clear yellowish oil. The enantiomeric excess was 
determined through Chiral HPLC analysis with a Chiracel AD column using 
hexane:isopropanol (99:1) at a flow rate of 0.75 mL/min (retention time (R) 27.62 min; (S) 
31.86 min). The allylic alcohol 189 can also be obtained in very good yield with minimal 
intermediate purification from methyl ester 186 (18.51 g, 78% from 188, 71% from (R)-(-)-3-
hydroxy-2-methylpropionate 186). 1H NMR (400MHz, CDCl3) δ 1.07 (3H, d, J = 6.8 Hz, 
CH3), 1.26 (1H, bs, OH), 2.50 (1H, appsept, J = 6.4 Hz, 4-CH), 2.95 (1H, dd, J = 8.7, 6.7 Hz, 
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5-CH), 3.03 (1H, dd, J = 8.7, 6.4 Hz, 5-CH’), 4.09 (2H, bs, 1-CH2), 5.65 (2H, m, 2-CH + 3-
CH), 7.21-7.46 (15H, m, ArH); 13C NMR (100MHz, CDCl3) δ 17.1 (CH3), 36.9 (3-CH), 63.7 (5-
CH2), 68.0 (1-CH2), 86.2 (OCPh3), 126.8 (ArCHpara), 127.6 (ArCHortho), 128.5 (2-CH), 128.7 
(ArCHmeta), 135.6 (3-CH), 144.2 (ArCIV); [α]23D +3.6, (c = 1.0, CHCl3); 3580, 3375, 3087, 3059, 
3022, 2961, 2952, 2913, 2870, 1597, 1491, 1448, 1218, 1071, 973, 753, 707, 633 cm-1. Not 
detected through mass spectroscopy techniques. 
 
 
2,2,2-Trichloro-N-((2S,3S)-1-hydroxy-3-methyl-4-(trityloxy)butan-2-yl)acetamide, 198 and 
2,2,2-Trichloro-N-((2R,3S)-1-hydroxy-3-methyl-4-(trityloxy)butan-2-yl)acetamide 199. A 
stream of ozone was bubbled through a solution of (4:1) mixture of olefins 122 and 191 
(161 mg, 320 µmol) in a mixture of ethanol (10 mL) and dichloromethane (2 mL) at -78 °C. 
After bubbling O3 into the reaction mixture for 75 min at -78 °C, the light bluish solution 
was purged with argon until clean, and was then quenched with the slow and careful 
addition of sodium borohydride (40 mg, 1.06 mmol) at -78 °C. The reaction mixture was 
then allowed to warm up to room temperature overnight (20 h). The solvents were 
removed under reduced pressure and the white residual solid was dissolved in 
dichloromethane (30 mL). The resulting solution was washed with water (10 mL) and 
brine (10 mL), and the organic layer was dried over anhydrous sodium sulfate before 
being concentrated in vacuo. The crude mixture of alcohols 198 and 199, obtained as a very 
viscous brownish oil (115 mg), was purified by flash column chromatography (silica gel, 
1% TEA, 50% ethyl acetate in 40-60 petroleum ether) to afford the pure alcohols 198 and 
199 in a (4:1) ratio, as an extremely viscous clear and colourless oil (50 mg, 31%).  
198. 1H NMR (400MHz, CDCl3) δ 1.06 (3H, d, J = 7.2 Hz, CH3), 2.15 (1H, m, 3-CH), 2.79 
(1H, dd, J = 8.3, 4.4 Hz, OH), 3.13 (1H, dd, J = 10.1, 6.8 Hz, 4-CH), 3.17 (1H, dd, J = 10.1, 3.7 
Hz, 4-CH’), 3.54 (1H, ddd, J = 11.8, 8.3, 3.5 Hz, 1-CH), 3.71 (1H, appdt, J = 11.8, 4.2 Hz, 1-
CH’), 3.88 (1H, m, 2-CH), 7.10 (1H, bd, J = 8.2 Hz, NH), 7.24-7.46 (15H, m, ArH); 13C NMR 
(100MHz, CDCl3) δ 14.7 (CH3), 35.1 (3-CH), 55.3 (2-CH), 61.7 (1-CH2), 65.0 (4-CH2), 66.5 
(CPh3), 87.7 (CCl3), 127.3 (ArCHpara), 128.1 (ArCHortho), 128.5 (ArCHmeta), 143.2 (ArCIV), 
164.3 (C=O);  
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199. 1H NMR (400MHz, CDCl3) δ 1.15 (3H, d, J = 7.1 Hz, CH3), 2.15 (1H, m, 3-CH), 2.45 
(1H, dd, J = 6.5, 7.4 Hz, OH), 3.20 (2H, m, 4-CH2), 3.46 (1H, m, 1-CH), 3.56 (1H, mostly 
masked, 1-CH’), 3.94 (1H, m, 2-CH), 7.22 (1H, mostly masked d, NH), 7.24-7.46 (15H, m, 
ArH); 13C NMR (100MHz, CDCl3) δ 15.7 (CH3), 34.4 (3-CH), 55.7 (2-CH), 63.7 (1-CH2), 64.6 
(4-CH2), 66.5 (CPh3), 87.6 (CCl3), 127.3 (ArCHpara), 128.1 (ArCHortho), 128.5 (ArCHmeta), 143.3 
(ArCIV), 165.1 (C=O); IR (thin film) max = 3396, 3303, 3088, 3060, 3017, 2969, 2927, 2882, 
1677, 1525, 1491, 1448, 1218, 1067, 1034, 900, 811, 763, 747, 707, 633 cm-1; Not detected by 
mass spectrometry. 
 
   
N-((2S,3R,4E,6E,8R,9R)-9-(tert-Butyldimethylsilyloxy)-2,6,8-trimethyl-10-phenyl-1-
(trityloxy)deca-4,6-dien-3-yl)-2,2,2-trichloroacetamide, 203 and N-((2S,3R,4E,6E,8R,9R)-9-
(tert-Butyldimethylsilyloxy)-1-hydroxy-2,6,8-trimethyl-10-phenyldeca-4,6-dien-3-yl)-
2,2,2-trichloroacetamide, 204. Second generation Grubbs catalyst (5 mg, 6 µmol, 12 mol%) 
was added to a solution of (3:1) isomeric mixture of TBS-protected dienol (E)-139 and (Z)-
139 (16 mg, 48 µmol) and a (4:1) isomeric mixture of olefins 122 and 191 (49 mg, 97 µmol) 
in anhydrous dichloromethane (2 mL). The reaction mixture was refluxed for 1 h, and was 
then cooled down to room temperature. The solvent was evaporated under reduced 
pressure, and the resulting crude oil (70 mg) was then purified by flash column 
chromatography (silica gel, 1% TEA, 20% dichloromethane in 40-60 petroleum spirit). 
Purification enabled the isolation of the unclean heterodimer 203 (32 mg) as the major 
diastereoisomer of a complex isomeric mixture plus the unconsumed starting 
trichloroacetimidates 122 and 191. A second purification by flash column chromatography 
(silica gel, 1% TEA, 100% chloroform) degraded the expected trichloroacetimidate 203 to 
the unexpected free alcohol 204, which was obtained as a very viscous brownish oil (4 mg, 
15%). As the reaction afforded a complex mixture of diastereoisomers, only the major 
isomers 203 and 204 are reported. 
203. 1H NMR (400MHz, CDCl3) δ -0.27 (3H, s, SiCH3), -0.07 (3H, s, SiCH3), 0.80 (3H, d, J = 
7.1 Hz, 2-CCH3), 0.86 (9H, s, SiC(CH3)3), 1.00 (3H, d, J = 6.8 Hz, 8-CCH3), 1.38 (3H, d, J = 0.9 
Hz, 6-CCH3), 2.20 (1H, m, 2-CH), 2.45 (1H, m, 8-CH), 2.67 (1H, dd, J = 13.9, 6.3 Hz, 10-CH), 
2.78 (1H, dd, J = 13.6, 6.2 Hz, 10-CH’), 3.02 (1H, appt, J = 9.7 Hz, 1-CH), 3.23 (1H, dd, J = 
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9.7, 3.9 Hz, 1-CH’), 3.74 (1H, m, 9-CH), 4.44 (1H, td, J = 8.0, 2.6 Hz, 3-CH), 5.11 (1H, dd, J = 
15.6, 7.1 Hz, 4-CH), 5.36 (1H, d, J = 9.5 Hz, 7-CH), 6.10 (1H, d, J = 15.6 Hz, 5-CH), 7.24-7.44 
(20H, d, J = 7.4 Hz, ArH), 7.78 (1H, d, J = 8.4 Hz, NH); LRMS (FAB) observed M+ 804. No 
further characterisation could be collected, as the compound 203 degraded to 204. 
204. 1H NMR (400MHz, CDCl3) δ -0.24 (3H, s, SiCH3), -0.04 (3H, s, SiCH3), 0.85 (3H, 
partially masked d, 2-CCH3), 0.87 (9H, s, SiC(CH3)3), 1.00 (3H, d, J = 6.8 Hz, 8-CCH3), 1.55 
(3H, s, 6-CCH3), 2.16 (1H, m, 2-CH), 2.27 (1H, m, OH), 2.48 (1H, m, 8-CH), 2.70 (1H, dd, J = 
14.2, 6.4 Hz, 10-CH), 2.80 (1H, dd, J = 13.5, 6.3 Hz, 10-CH’), 3.52 (1H, m, 1-CH), 3.63 (1H, 
m, 1-CH’), 3.77 (1H, appdd, J = 10.6, 5.9 Hz, 9-CH), 4.65 (1H, m, 3-CH), 5.45 (2H, m, 4-CH 
+ 7-CH), 6.22 (1H, d, J = 15.7 Hz, 5-CH), 7.10-7.32 (5H, m, ArH), 7.74 (1H, bd, J = 8.3 Hz, 
NH); 13C NMR (100MHz, CDCl3) δ -4.8 (SiCH3), -4.5(SiCH3), 12.4 (2-CCH3), 12.6 (6-CCH3), 
14.9 (8-CCH3), 18.1 (SiC(CH3)3), 25.9 (SiC(CH3)3), 37.0 (8-CH), 39.4 (2-CH), 41.7 (10-CH2), 
55.3 (3-CH), 65.2 (1-CH2), 77.2 (9-CH partially masked by CHCl3 peaks), (CCl3 unresolved), 
121.3 (4-CH), 126.0 (ArCHpara), 128.1 (ArCHortho), 129.7 (ArCHmeta), 131.4 (6-CIV), 137.9 (5-
CH), 138.1 (7-CH), 139.0 (ArCIV), 161.6 (C=O); IR (thin film) max = 3456, 3426, 3326, 3028, 
2957, 2929, 2882, 2856, 16700, 1513, 1471, 1461, 1377, 1363, 1254, 1099, 1083, 909, 825, 735 
cm-1; Not detected by mass spectrometry. 
 
 
2,2,2-Trichloro-N-((3R,4S)-5-hydroxy-4-methylpent-1-en-3-yl)acetamide, 205. A solution 
of trytil-protected alcohol 122 (545 mg, 1.08 mmol) in dichloromethane (5 mL) was treated 
with the slow addition of a commercially available solution of HCl in anhydrous diethyl 
ether (1.0 M, 2.0 mL, 2.0 mmol) at room temperature. The reaction was stirred for 1 h, and 
was then concentrated under vacuum without any prior work up. The crude viscous oil 
(550 mg) was purified by flash column chromatography (silica gel, elution gradient 5-10% 
ethyl acetate in 40-60 petroleum ether) to give the desired alcohol 205 (281 mg, 100%) as a 
very viscous, clear and colourless oil. 1H NMR (400MHz, CDCl3) δ 0.86 (3H, d, J = 7.1 Hz, 
CH3), 2.18 (1H, m, 4-CH), 2.28 (1H, dd, J = 5.5, 4.7 Hz, OH), 3.53 (1H, apptd, J = 10.6, 4.6 
Hz, 5-CH), 3.65 (1H, m, 5-CH’), 4.62 (1H, m, 3-CH), 5.28 (1H, dm, J = 17.2 Hz, 1-CH), 5.28 
(1H, dm, J = 10.6 Hz, 1-CH’), 5.86 (1H, ddd, J = 17.1, 10.7, 5.4 Hz, 2-CH), 7.80 (1H, bs, NH); 
13C NMR (100MHz, CDCl3) δ 12.3 (CH3), 38.6 (4-CH), 55.7 (3-CH), 65.1 (5-CH2), 92.8 (CCl3), 
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117.3 (1-CH2), 133.4 (2-CH), 161.8 (C=O); [α]24D +15.6, (c = 1.0, CHCl3); IR (thin film) max = 
3468, 3427, 3321, 3085, 3017, 2966, 2934, 2882, 1698, 1644, 1516, 1241, 1036, 994, 928, 823, 
757, 735, 683, 666 cm-1; HRMS (CI) observed (M+H)+ 260.0007, calculated for 
C8H13O2NCl3 260.0012.  
 
 
(2S,3R)-2-Methyl-3-(2,2,2-trichloroacetamido)pent-4-enyl acetate, 207 and (2S,3S)-2-
Methyl-3-(2,2,2-trichloroacetamido)pent-4-enyl acetate, 208. A solution of a (2.5:1) 
isomeric mixture of trityl-protected alkenols 122 and 191 (589 mg, 1.17 mmol) in 
anhydrous dichloromethane (5 mL) was treated with a freshly made sat. solution of HCl in 
ethyl acetate (2.0 mL). After 10 min of stirring at room temperature, an additional portion 
of HCl was added (2.0 mL), followed by a third one (2.0 mL) 10 min later. After a further 
20 min of stirring at room temperature, the solvents were evaporated under reduced 
pressure, and the resulting crude oil (630 mg) was purified by two consecutive flash 
chromatography columns (silica gel, 10% ethyl acetate in 40-60 petroleum spirit). The 
(2.5:1) isomeric mixture of alcohols 205 and 206 were isolated as an extremely viscous clear 
and colourless oil (142 mg, 47%) as well as the undesired acetates 207 and 208 as a very 
viscous colourless oil (29 mg, 8%).  
207. 1H NMR (400MHz, CDCl3) δ 1.01 (3H, d, J = 7.1 Hz, 2-CCH3), 2.09 (3H, s, OOCCH3), 
2.23 (1H, m, 2-CH), 3.96 (1H, dd, J = 11.4, 8.6 Hz, 1-CH), 4.09 (1H, dd, J = 11.4, 4.9 Hz, 1-
CH’), 4.56 (1H, m, 3-CH), 5.28 (1H, ddd, J = 17.0, 1.6, 0.9 Hz, 5-CH), 5.30 (1H, ddd, J = 10.6, 
1.5, 0.9 Hz, 5-CH’), 5.80 (1H, ddd, J = 17.1, 10.6, 5.6 Hz, 4-CH), 7.13 (1H, vbd, J = 6.4 Hz, 
NH); 13C NMR (100MHz, CDCl3) δ 13.1 (2-CCH3), 20.9 (OOCCH3), 36.1 (2-CH), 55.6 (3-
CH), 66.0 (1-CH2), 92.9 (CCl3), 117.7 (5-CH2), 133.0 (4-CH), 161.1 (Cl3CC=O), 170.5 (OC=O); 
208. 1H NMR (400MHz, CDCl3) δ 1.06 (3H, d, J = 7.1 Hz, 2-CCH3), 2.08 (3H, s, OOCCH3), 
2.23 (1H, m, 2-CH), 4.04 (1H, dd, J = 11.5, 4.2 Hz, 1-CH), 4.20 (1H, dd, J = 11.5, 5.7 Hz, 1-
CH’), 4.56 (1H, m, 3-CH), 5.23 (1H, ddd, J = 3.7, 1.7, 0.8 Hz, 5-CH), 5.27 (1H, m, mostly 
masked, 5-CH’), 5.81 (1H, ddd, J = partially masked, 10.4, 5.2 Hz, 4-CH), (NH not 
observed); 13C NMR (100MHz, CDCl3) δ 14.1 (2-CCH3), 20.9 (OOCCH3), 36.2 (2-CH), 56.0 
(3-CH), 65.7 (1-CH2), 92.9 (CCl3), 116.7 (5-CH2), 134.7 (4-CH), 161.6 (Cl3CC=O), 170.8 
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(OC=O); IR (thin film) max = 3415, 3338, 3085, 2970, 2935, 1714, 1517, 1240, 1038, 835, 822, 
682 cm-1; HRMS (CI) observed (M+H)+ 302.0110, calculated for C10H15O3NCl3 302.0118. 
 
   
(4R,5S)-5-Methyl-4-vinyl-1,3-oxazinan-2-one, syn-209 and (4S,5S)-5-Methyl-4-vinyl-1,3-
oxazinan-2-one, trans-213. A flask open to the air, containing a (3:1) mixture of 
trichloroacetimidate 122 and 191 (4.63 g, 9.21 mmol) in solution in iso-propanol (55 mL), 
was treated with potassium hydroxide (4.28 g, 107 mmol). The reaction was then refluxed, 
causing it to turn green then milky/turbid after 30 min. After being stirred for 2 h under 
reflux to the open air, an additional portion of potassium hydroxide (2.0 g, 50 mmol) was 
poured into the flask. The reaction was refluxed for an extra 2 h before being concentrated 
under reduced pressure. The resulting residue was then diluted in water (90 mL), and the 
phases were separated. The aqueous layer was then extracted with dichloromethane (200 
mL), then ethyl acetate (200 mL), and the organic phases were combined, before being 
dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting crude 
amines syn-211 and trans-211 (3.05 g) were obtained as a sticky brownish oil, which was 
used in the next reaction step without any further purification. 
A solution of a (3:1) mixture of trityl-protected aminoalcohols syn-211 and trans-211 (3.05 
g) in ethanol (200 mL) was treated with p-toluenesulfonic acid monohydrate (3.61 g, 19.0 
mmol) at room temperature and open to the air. The reaction was stirred overnight, and 
was then quenched by incorporating potassium hydroxide (1.65 g, 41.3 mmol) to the 
mixture. A precipitate of p-toluenesulfonic acid potassium salt was formed and separated 
out by filtration. The precipitate was washed thoroughly with ethyl acetate (200 mL), and 
the filtrate was concentrated under reduced pressure (< 45 °C) to give the crude volatile 
aminoalcohols syn-210 and trans-210 as a very sticky brown oil (4.53 g). The residue was 
subjected to a quick filtration through a short pad of silica gel, monitored by TLC analysis 
of the effluent. The silica gel was first flushed with 40-60 petroleum spirit to remove the 
trityl derivatives then with ethyl acetate and methanol to retrieve the free aminoalcohols 
syn-210 and trans-210. This process provided, after evaporation of the solvents in vacuo, 
the crude mixture of free aminoalcohols syn-210 and trans-210 in a (3:1) ratio, as a 
yellowish oil (1.90 g), which was used without any further purification. 
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The (3:1) mixture of aminoalcohols syn-210 and trans-210 (1.90 g, 3:1) was dissolved in 
anhydrous dichloromethane (300 mL), and was transferred into a round-bottomed-flask 
containing pre-activated 4Å molecular sieves (7 g). DBU (153 mg, 150 µL, 1.00 mmol) was 
incorporated to the solution at room temperature, which was then treated with the slow 
addition of a pre-made solution of triphosgene (1.80 g, 6.07 mmol) in anhydrous 
dichloromethane (50 mL). The reaction mixture was stirred at room temperature for 2 h 
and additional DBU (102 mg, 100 µL, 669 µmol) was added. The reaction was stirred for an 
extra 30 min and the solvent was evaporated under reduced pressure. The resulting 
residue was dissolved in ethyl acetate (200 mL), and the organic solution was then washed 
with a basic sat. aq. solution of sodium chloride (2 x 100 mL + 1.0 g, 25 mmol KOH each). 
The organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuo to 
give the crude carbamates syn-209 and trans-209 as a brown slightly viscous oil (1.78 g). 
Purification by flash column chromatography (silica gel, 1% TEA, 80-100% ethyl acetate in 
40-60 petroleum spirit) yielded a (3:1) mixture of carbamates syn-209 and trans-209 as a 
light brown very viscous oil (274 mg, 21% over 3 steps). 
syn-209. 1H NMR (400MHz, CDCl3) δ 0.93 (3H, d, J = 6.8 Hz, CH3), 1.80 (1H, m, 2-CH), 3.48 
(1H, appt, J = 7.9 Hz, 3-CH), 3.85 (1H, dd, J = 10.9, 9.9 Hz, 1-CH), 4.15 (1H, dd, J = 11.0, 3.8 
Hz, 1-CH’), 5.64 (1H, ddd, J = 17.3, 10.1, 7.4 Hz, 4-CH), 6.28 (1H, bs, NH); 13C NMR 
(100MHz, CDCl3) δ 12.8 (2-CCH3), 31.2 (2-CH), 60.3 (3-CH), 70.4 (1-CH2), 118.7 (5-CH2), 
136.5 (4-CH), 154.0 (C=O);  
trans-209. 1H NMR (400MHz, CDCl3) δ 0.90 (3H, d, J = 7.1 Hz, CH3’), 2.24 (1H, m, 2’-CH), 
3.93 (1H, dd, J = 10.9, 8.8 Hz, 1’-CH), 3.96 (1H, completely hidden m, 3’-CH), 4.06 (1H, 
ddd, J = 10.9, 3.6, 0.9 Hz, 1’-CH”), 5.74 (1H, ddd, J =  17.6, 9.9, 6.1 Hz, 4’-CH), 6.52 (1H, bs, 
NH’); 13C NMR (100MHz, CDCl3) δ 11.3 (2’-CCH3), 29.5 (2’-CH), 56.0 (3’-CH), 69.1 (1’-
CH2), 118.3 (5’-CH2), 134.3 (4’-CH), 154.0 (C=O); IR (thin film) max = 3378, 3257, 3122, 3092, 
3062, 2973, 2933, 1705, 1478, 1438, 1270, 1180, 1144, 1119, 1069, 925, 733, 701 cm-1; HRMS 
(CI) observed (M+H)+ 142.0864, calculated for C7H12O2N 142.0868. 
 
 
(4R,5S)-5-Methyl-4-vinyl-1,3-oxazinan-2-one, 209. A solution of trichloroacetimidate 122 
(519 mg, 1.03 mmol) in iso-propanol (6 mL), in an open-air flask, was treated by addition of 
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potassium hydroxide (480 mg, 12.0 mmol). The reaction was then refluxed, initially turned 
orange, and became milky and turbid after 30 min. After stirring the reaction for 3 h under 
reflux whilst open to the air, the mixture was concentrated under reduced pressure. The 
resulting residue was then diluted with water (10 mL) and extracted with ethyl acetate (3 x 
20 mL). The organic phases were combined, dried over anhydrous sodium sulphate, and 
concentrated in vacuo. The resulting crude amine 211 (399 mg) was obtained as a sticky 
dark yellow oil, which was split in two, and a portion of it was used into the next reaction 
without any further purification. 
To a solution of crude trityl protected aminoalcohol 211 (136 mg) in ethanol (20 mL) was 
added p-toluenesulfonic acid monohydrate (250 mg, 1.31 mmol) at room temperature and 
open to the air. The reaction was stirred overnight, and was quenched by incorporating 
potassium hydroxide (1.0 g, 25 mmol) to the mixture. A precipitate of p-toluenesulfonic 
acid potassium salt was formed, and removed by filtration. The solution was mixed with a 
sat. aq. solution of sodium chloride (10 mL), and the mixture was thoroughly extracted 
with ethyl acetate (3 x 20 mL) and dichloromethane (20 mL). The organic extracts were 
combined, dried over anhydrous sodium sulfate and then concentrated under reduced 
pressure. The resulting volatile crude aminoalcohol 210 was obtained as a very sticky 
brown oil (175 mg) contaminated with p-toluenesulfonic acid. The residue was then 
subjected to a quick filtration through a short pad of silica, monitored by TLC analysis of 
the effluent. The silica was first flushed with 40-60 petroleum spirit, then with ethyl acetate 
and finally with methanol to retrieve the aminoalcohol 210. This process provided, after 
evaporation of the solvents in vacuo, the crude aminoalcohol 210 as a yellowish oil (133 
mg), which was used without any further purification. 
A solution of crude aminoalcohol 210 (133 mg) in anhydrous dichloromethane (20 mL) 
was transferred into a round-bottomed-flask containing pre-activated 4Å molecular sieves 
(1 g) under argon. DBU (10 mg, 10 µL, 66 µmol) was incorporated to the solution at room 
temperature, and the reaction was treated with the slow addition of a pre-made solution of 
triphosgene (126 mg, 425 µmol) in anhydrous dichloromethane (5 mL). The mixture was 
stirred at room temperature for 2 h, the solvent was then evaporated under reduced 
pressure and the crude residue was dissolved in ethyl acetate (20 mL). The organic 
solution was then washed with a basic sat. aq. solution of sodium chloride (2 x 10 mL + 0.1 
g, 25.0 mmol KOH each). The phases were separated and the organic layer was dried over 
anhydrous sodium sulphate, and concentrated in vacuo to give the crude carbamate 209 as 
a brown slightly viscous oil (120 mg). Purification by flash column chromatography (silica 
 - 199 - 
gel, 1% TEA, 80-100% ethyl acetate in 40-60 petroleum spirit) yielded the pure carbamate 
209 as a light brown very viscous oil (82 mg, 18% over 3 steps).  
 
211.  1H NMR (400MHz, CDCl3) δ 0.75 (3H, d, J = 6.9 Hz, CH3), 1.28 (2H, vbs, NH2), 1.81 
(1H, m, 2-CH), 2.96 (2H, m, 1-CH2), 3.44 (1H, m, 3-CH), 4.89 (1H, dd, J = 10.4, 0.9 Hz, 5-
CH), 4.98 (1H, dd, J = 16.3, 0.9 Hz, 5-CH’), 5.64 (1H, ddd, J = 16.7, 10.4, 6.0 Hz, 4-CH), 7.12 
(3H, m, ArHpara), 7.19 (6H, m, ArHortho), 7.36 (6H, m, ArHmeta); 13C NMR (100MHz, CDCl3) 
δ 12.0 (CH3), 38.8 (2-CH), 55.4 (3-CH), 65.7 (1-CH2), 86.4 (OCPh3), 113.7 (5-CH2), 126.8 
(ArCHpara), 127.6 (ArCHortho), 128.6 (ArCHmeta), 141.5 (4-CH), 144.1 (ArCIV). 
 
210.  1H NMR (400MHz, CDCl3) δ 0.84 (3H, d, J = 7.1 Hz, CH3), 1.89 (1H, m, 2-CH), 2.27 
(3H, vbs, NH2 + OH), 3.61-3.68 (3H, m, 3-CH + 1-CH2), 5.16 (1H, bdt, J = 6.3, 1.1 Hz, 5-
CH2), 5.19 (1H, appd, J = 1.1 Hz, 5-CH’), 5.93 (1H, m, 4-CH); 13C NMR (100MHz, CDCl3) δ 
11.7 (CH3), 38.6 (2-CH), 58.5 (3-CH), 67.4 (1-CH2), 115.0 (5-CH2), 139.6 (4-CH). 
 
209. 1H NMR (400MHz, CDCl3) δ 0.98 (3H, d, J = 6.8 Hz, CH3), 1.87 (1H, m, 2-CH), 3.53 
(1H, appt, J = 8.1 Hz, 3-CH), 3.91 (1H, appt, J = 10.5 Hz, 1-CH), 4.21 (1H, dd, J = 11.0, 3.9 
Hz, 1-CH’), 5.27 (1H, d, J = 3.3 Hz, 5-CH), 5.31 (1H, d, J = 10.2 Hz, 5-CH’), 5.51 (1H, bs, 
NH), 5.69 (1H, ddd, J = 17.3, 10.1, 7.5 Hz, 4-CH); 13C NMR (100MHz, CDCl3) δ 12.9 (CH3), 
31.4 (2-CH), 60.7 (3-CH), 70.6 (1-CH), 119.1 (5-CH2), 136.7 (4-CH), 153.7 (C=O); [α]24D -21.2, 
(c = 1.0, CHCl3); IR (thin film) max = 3378, 3257, 3122, 3092, 3062, 2973, 2933, 1705, 1478, 
1438, 1270, 1180, 1144, 1119, 1069, 925, 733, 701 cm-1; HRMS (CI) observed (M+H)+ 
142.0864, calculated for C7H11NO2 142.0852. 
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(4R,5S)-tert-Butyl 5-methyl-2-oxo-4-vinyl-1,3-oxazinane-3-carboxylate, syn-213 and 
(4S,5S)-tert-Butyl 5-methyl-2-oxo-4-vinyl-1,3-oxazinane-3-carboxylate, trans-213. To a 
solution of a (3:1) isomeric mixture of free carbamate syn-209 and trans-209 (54 mg, 380 
µmol) in anhydrous dichloromethane (6 mL) was added sequentially anhydrous 
triethylamine (36 mg, 50 µL, 360 µmol), DMAP (45 mg, 370 µmol) and a pre-made solution 
of di-tert-butyl dicarbonate (87 mg, 400 µmol) in dry dichloromethane (3 mL). The mixture 
was left under stirring overnight, and was quenched by addition of water (5 mL). The 
phases were separated, and the organic layer was washed two more times with water (2 x 
5 mL). The aqueous layers were combined, and extracted with diethyl ether (10 mL). All 
organic fractions were combined, dried over anhydrous sodium sulfate, and concentrated 
in vacuo. The resulting very viscous light brown oil (136 mg) was finally purified by flash 
column chromatography (silica gel, 1% TEA, 10-50% ethyl acetate in 40-60 petroleum 
ether) to afford the pure (3:1) isomeric mixture of N-Boc protected carbamates syn-209 and 
trans-209 as a slightly viscous and clear light yellow oil (75 mg, 81%).  
syn-209. 1H NMR (400MHz, CDCl3) δ 0.98 (3H, d, J = 7.0 Hz, 2-CCH3), 1.50 (9H, s, 
OC(CH3)3), 2.41 (1H, m, 2-CH), 3.98 (1H, appt, J = 11.3 Hz, 1-CH), 4.10 (1H, ddd, J = 10.8, 
4.7, 1.6 Hz, 1-CH’), 4.69 (1H, bappt, J = 5.0 Hz, 3-CH), 5.29 (1H, d, J = 16.8 Hz, 5-CH), 5.38 
(1H, d, J = 10.5 Hz, 5-CH’), 5.80 (1H, ddd, J = 16.9, 10.5, 6.2 Hz, 4-CH); 13C NMR (100MHz, 
CDCl3) δ 12.2 (CH3), 27.8 (OC(CH3)3, 30.6 (2-CH), 59.8 (3-CH), 69.0 (1-CH2), 83.7 (OCtBu), 
119.4 (5-CH2), 131.7 (4-CH), 148.9 (C=O Boc), 151.5 (C=O). 
trans-209. 1H NMR (400MHz, CDCl3) δ 1.17 (3H, d, J = 7.0 Hz, 2-CCH3), 1.50 (9H, s, 
OC(CH3)3), 2.04 (1H, m, 2-CH), 3.92 (1H, ddd, J = 10.7, 5.7, 0.6 Hz, 1-CH), 4.26 (1H, dd, J = 
10.8, 3.5 Hz, 1-CH’), 4.37 (1H, bappt, J = 4.7 Hz, 3-CH), 5.22 (1H, d, J = 16.5 Hz, 5-CH), 5.38 
(1H, d, J = 10.6 Hz, 5-CH’), 5.79 (1H, ddd, J = 16.8, 10.6, 6.2 Hz, 4-CH); 13C NMR (100MHz, 
CDCl3) δ 15.1 (CH3), 27.8 (OC(CH3)3, 32.3 (2-CH), 62.4 (3-CH), 68.9 (1-CH2), 83.7 (OCtBu), 
116.6 (5-CH2), 136.6 (4-CH), 148.9 (C=O Boc), 151.9 (C=O); IR (thin film) max = 3088, 2980, 
2935, 1788, 1737, 1472, 1458, 1409, 1367, 1289, 1255, 1154, 1116, 1015, 918, 853, 775 cm-1; 
HRMS (CI) observed (M+H)+ 242.1389, calculated for C12H20O4N 242.1392. 
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(2S,3R)-2-Methyl-3-(2,2,2-trichloroacetamido)pent-4-enoic acid, 215. A solution of methyl 
ester 221 (170 mg, 590 µmol) in tetrahydrofuran (3.1 mL) was treated with an aq. solution 
of lithium hydroxide (1.0 M, 4.3 mL) at room temperature. After 1 h under stirring, the 
reaction was quenched by addition of an aq. solution of HCl (5.7 mL, 1.0 M, 5.7 mmol). 
Phases were separated, and the aqueous layer was extracted with ethyl acetate (10 mL). 
The organic fractions were combined, and dried over anhydrous magnesium sulfate. The 
solvents were evaporated under reduced pressure, and the crude viscous orange oil (156 
mg) was purified by flash column chromatography (silica gel, 30-50% ethyl acetate in 40-
60 petroleum spirit). The pure carboxylic acid 215 was obtained as a single 
diastereoisomer, and as an extremely viscous and clear orange oil (147 mg, 91%), that 
tends to form white crystals upon prolonged storage. 1H NMR (400MHz, CDCl3) δ 1.23 
(3H, d, J = 7.3 Hz, CH3), 2.87 (1H, qd, J = 7.2, 4.8 Hz, 4-CH), 4.54 (1H, m, 3-CH), 5.27 (1H, 
appdt, J = 10.3, 0.9 Hz, 1-CH), 5.30 (1H, appdt, J = 17.1, 1.0 Hz, 1-CH’), 5.80 (1H, ddd, J = 
17.0, 10.4, 6.6 Hz, 2-CH), 7.72 (1H, bd, J = 8.9 Hz, NH), 9.40 (1H, vbs, OH); 13C NMR 
(100MHz, CDCl3) δ 13.3 (CH3), 42.4 (4-CH), 55.3 (3-CH), 92.4 (CCl3), 119.2 (1-CH2), 131.9 (2-
CH), 161.2 (Cl3CC=O), 178.4 (5-C=O); [α]24D +29.2, (c = 1.0, CHCl3); IR (thin film) max = 
3411, 3344, 3201, 3088, 3021, 2986, 2927, 2855, 2651, 2552, 1709, 1510, 1265, 1216, 823, 755, 
668 cm-1. HRMS (CI) observed (M+H)+ 273.9794, calculated for C8H11O3NCl3 273.9805. 
 
 
2,2,2-Trichloro-N-((4R,5S)-5-methyl-2-oxotetrahydro-2H-pyran-4-yl)acetamide, 216. A 
solution of trityl-protected alcohol 122 (1.11 g, 2.20 mmol) in acetone (40 mL) and 
dichloromethane (40 mL) was cooled down to 0 °C and treated by the dropwise addition 
of a previously made solution of Jones’s reagent (1.3 mL H2O + 2 mL H2SO4 conc. + 330 mg, 
3.30 mmol CrO3). The reaction was slowly allowed to warm up to room temperature, and 
was stirred overnight. Filtration through a pad of Celite, followed by concentration of the 
filtrate in vacuo provided an aqueous solution, which was extracted with dichloromethane 
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(2 x 100 mL). The combined organic layers were in turn washed with a sat. aq. solution of 
sodium bicarbonate and the resulting aqueous fraction was acidified to pH = 2 by addition 
of an aq. solution of 2.0 M HCl. The acidic aqueous layer was then extracted with 
dichloromethane (2 x 100 mL). The organic fractions were combined, and dried over 
anhydrous magnesium sulfate. Evaporation of the solvents under reduced pressure 
afforded a crude oil (864 mg), which was purified twice by flash column chromatography 
(silica gel, 1% methanol, 0.5% acetic acid in dichloromethane) (silica gel, 0.5% acetic acid, 
40% ethyl acetate in 40-60 petroleum spirit) to isolate the lactone 216 as a very viscous, 
clear, and colourless oil (20 mg, 3%). 1H NMR (400MHz, CDCl3) δ 1.09 (3H, d, J = 6.7 Hz, 
CH3), 2.16 (1H, m, 5-CH), 2.56 (1H, dd, J = 17.8, 8.2 Hz, 3-CH), 3.06 (1H, dd, J = 17.8, 7.0 
Hz, 3-CH’), 3.98 (1H, dd, J = 11.4, 10.7 Hz, 6-CH), 4.06 (1H, appqn, J = 8.4 Hz, 4-CH), 4.36 
(1H, dd, J = 11.7, 4.6 Hz, 6-CH’), 6.94 (1H, bd, J = 6.6 Hz, NH); 13C NMR (100MHz, CDCl3) 
δ 13.5 (CH3), 34.3 (5-CH), 35.4 (3-CH2), 50.6 (4-CH), 71.7 (6-CH2), 92.2 (CCl3), 161.9 
(CCl3C=O), 169.2 (2-C=O); [α]24D -19.2, (c = 1.0, CHCl3); IR (thin film) max = 3415, 3330, 
3020, 2973, 2935, 1708, 1523, 1216, 1048, 756 cm-1; HRMS (CI) observed (M+H)+ 273.9795, 
calculated for C8H11O3NCl3 273.9805. 
 
 
(2R,3R)-2-Methyl-3-(2,2,2-trichloroacetamido)pent-4-enoic acid, 215 and (2R,3R)-2-
Methyl-3-(2,2,2-trichloroacetamido)pent-4-enoic acid, 220. A -78 °C solution of oxalyl 
chloride (113 µL, 1.34 mmol) in anhydrous dichloromethane (12 mL) was treated by the 
slow addition of anhydrous dimethylsulfoxide (191 µL, 2.69 mmol), and the resulting 
mixture was stirred at -78 °C for 45 min. A previously prepared solution of alcohol 205 
(210 mg, 806 µmol) in dry dichloromethane (6 mL) was then slowly added and the 
reaction was stirred for a further 1 h at -78 °C. The reaction was treated with anhydrous 
triethylamine (521 µL, 3.74 mmol), and the reaction was allowed to warm up to room 
temperature and stirred for a further 1 h. The reaction was quenched by addition of water 
(10 mL), and the phases were separated. The organic layer was washed with water (2 x 10 
mL) and the combined aqueous fractions were extracted with ethyl acetate (10 mL). The 
combined organic extracts were dried over anhydrous sodium sulfate, and concentrated 
under vacuum to afford the crude aldehyde (237 mg) as a viscous orange oil, and as a (5:3) 
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mixture of (syn:anti) diastereomers. The crude aldehyde was solubilised in tert-butanol (4.5 
mL) and 2-methyl-2-butene (695 µL, 6.56 mmol) was added. This resulting solution was 
then treated slowly with a freshly made aq. solution of sodium chlorite (555 mg, 6.14 
mmol) and sodium phosphate monobasic dehydrate (816 mg, 5.23 mmol) in water (2.2 mL 
total volume) at room temperature. The reaction mixture was stirred overnight at room 
temperature, and subsequently quenched by the dropwise addition of conc. HCl (200 µL). 
The acidic mixture was then extracted with ethyl acetate (3 x 15 mL) and dichloromethane 
(30 mL), and the combined organic extracts were dried over magnesium sulphate. The 
solvent was removed under reduced pressure to give the crude mixture of acids 215 and 
220 (545 mg) as a viscous yellow oil. Purification by flash chromatography (silica gel, 20% 
ethyl acetate in 40-60 petroleum ether) afforded the carboxylic acids 215 and 220 (213 mg, 
96%) as an inseparable mixture of diastereomers (syn:anti, 5:3) as a viscous, clear and 
colourless oil. 
 
215. 1H NMR (400MHz, CDCl3) δ 1.27 (3H, d, J = 7.3 Hz, CH3), 2.85 (1H, m, 4-CH), 4.55 
(1H, m, 3-CH), 5.33 (1H, appdt, J = 10.3, 0.9 Hz, 1-CH), 5.35 (1H, appdt, J = 17.1, 1.0 Hz, 1-
CH’), 5.84 (1H, ddd, J = 17.0, 10.3, 6.6 Hz, 2-CH), 7.59 (1H, bd, J = 8.0 Hz, NH), 8.32 (1H, 
vbs, OH); 13C NMR (100MHz, CDCl3) δ 13.3 (CH3), 42.5 (4-CH), 55.3 (3-CH), 92.6 (CCl3), 
119.4 (1-CH2), 131.9 (2-CH), 161.2 (Cl3CC=O), 178.8 (5-C=O); IR (thin film) max = 3411, 
3344, 3201, 3088, 3021, 2986, 2927, 2855, 2651, 2552, 1709, 1510, 1265, 1216, 823, 755, 668 cm-
1. HRMS (CI) observed (M+H)+ 273.9794, calculated for C8H11O3NCl3 273.9805. 
 
220. 1H NMR (400MHz, CDCl3) δ 1.35 (3H, d, J = 7.3 Hz, CH3), 2.87 (1H, m, 4-CH), 4.56 
(1H, m, 3-CH), 5.19 (1H, brdd, J = 10.5, 1.2 Hz, 1-CH), 5.24 (1H, dd, J = 15.9, 1.2 Hz, 1-CH’), 
5.84 (1H, partially hidden m, 2-CH), 7.77 (1H, ddd, J = 15.9, 10.5, 5.3 Hz, NH), 8.32 (1H, 
vbs, OH); 13C NMR (100MHz, CDCl3) δ 15.0 (CH3), 42.6 (4-CH), 54.9 (3-CH), 91.9 (CCl3), 
117.5 (1-CH2), 134.3 (2-CH), 161.9 (Cl3CC=O), 180.0 (5-C=O). 
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(2S,3R)-Methyl 2-methyl-3-(2,2,2-trichloroacetamido) pent-4-enoate, 221. A -78 °C 
solution of oxalyl chloride (156 µL, 1.84 mmol) in anhydrous dichloromethane (3 mL) was 
treated with dimethylsulfoxide (317 µL, 4.46 mmol) and the mixture was stirred at -78 °C 
for 45 min. A previously prepared solution of alcohol 205 (235 mg, 902 µmol) in dry 
dichloromethane (2 mL) was then added slowly, and the resulting mixture was stirred at -
78 °C for a further 1 h. The reaction was then treated slowly with anhydrous DIPEA (550 
µL, 3.16 mmol), and the reaction was stirred for an extra 45 min at -78 °C. The reaction was 
then poured into an extraction funnel containing acidic water (8 ml H2O + 2.6 mL 1.0 M 
HCl). The phases were separated, and the organic fraction was washed with water (20 mL) 
one more time. The organic layer was dried over anhydrous sodium sulfate and 
concentrated under vacuum to afford the desired aldehyde intermediate as a viscous 
yellowish oil (311 mg). 
The crude aldehyde intermediate was dissolved in tert-butanol (5.0 mL) and 2-methyl-2-
butene (773 µL, 7.30 mmol) was added to the solution. The mixture was then slowly 
treated with a freshly made aq. solution of sodium chlorite (621 mg, 6.87 mg) and sodium 
phosphate monobasic dehydrate (913 mg, 5.85 mmol) in water (2.5 mL) at room 
temperature. The reaction mixture was stirred until completion as indicated by TLC 
analysis (1 h) and was then quenched by the dropwise addition of conc. HCl (220 µL). 
Water (10 mL) was added to the solution, and the aqueous layer was extracted with ethyl 
acetate (2 x 10 mL). The organic fractions were combined, and were dried over magnesium 
sulfate before being evaporated under reduced pressure to give the crude acid 215 (299 
mg) as a very viscous yellow oil. 
A 0°C 3.0 M aq. solution of sodium hydroxide (13 mL) topped up with diethyl ether (19 
mL) was carefully treated by the addition of small portions of a suspension of N-methyl–
N’-nitro-N-nitrosoguanidine (MNNG) (1.0 g in total, 50% in water, 3.4 mmol). After the 
bubbling has ceased (10 min), the yellow ethereal solution of diazomethane was 
transferred slowly and carefully using a polished glass pipette to a solution of the crude 
carboxylic acid 215 (299 mg) in diethyl ether (6 mL) at room temperature in an open air 
round bottom flask. The yellow solution was then stirred until completion as indicated by 
TLC analysis (30 min), and was subsequently quenched by the careful dropwise addition 
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of acetic acid (150 µL, 2.62 mmol). After stirring the acidic mixture for 30 min, the solvent 
was evaporated under reduced pressure to give the crude methyl ester 221 (359 mg) as a 
viscous yellow oil. Purification by flash column chromatography (silica gel, elution 
gradient 0-10% ethyl acetate in 40-60 petroleum ether) provided the pure methyl ester 221 
as a single diastereomer (180 mg, 69% over 3 steps), and as a colourless viscous oil. 
 
1H NMR (400MHz, CDCl3) δ 1.22 (3H, d, J = 7.5 Hz, CH3), 2.78 (1H, qd, J = 7.4, 4.2 Hz, 4-
CH), 4.65 (1H, m, 3-CH), 5.28 (2H, m, 1-CH2), 5.82 (1H, ddd, J = 17.10, 10.3, 6.7 Hz, 2-CH), 
7.41 (1H, bd, J = 8.9 Hz, NH), 9.66 (1H, s, CHO); 13C NMR (100MHz, CDCl3) δ 10.4 (CH3), 
48.9 (4-CH), 54.4 (3-CH), 92.4 (CCl3), 119.1 (1-CH2), 132.6 (2-CH), 161.1 (Cl3CC=O), 203.4 (5-
C=O). 
 
215. 1H NMR (400MHz, CDCl3) δ 1.23 (3H, d, J = 7.3 Hz, CH3), 2.87 (1H, qd, J = 7.2, 4.8 Hz, 
4-CH), 4.54 (1H, m, 3-CH), 5.27 (1H, appdt, J = 10.3, 0.9 Hz, 1-CH), 5.30 (1H, appdt, J = 
17.1, 1.0 Hz, 1-CH’), 5.80 (1H, ddd, J = 17.0, 10.4, 6.6 Hz, 2-CH), 7.72 (1H, bd, J = 8.9 Hz, 
NH), 9.40 (1H, vbs, OH). 
 
221. 1H NMR (400MHz, CDCl3) δ 1.21 (3H, d, J = 7.3 Hz, CH3), 2.84 (1H, qd, J = 7.3, 4.7 Hz, 
4-CH), 3.70 (3H, s, OCH3), 4.51 (1H, m, 3-CH), 5.26 (1H, appdt, J = 10.3, 1.0 Hz, 1-CH), 5.28 
(1H, appdt, J = 17.1, 1.0 Hz, 1-CH’), 5.77 (1H, ddd, J = 17.0, 10.3, 6.6 Hz, 2-CH), 7.71 (1H, 
bd, J = 7.2 Hz, NH); 13C NMR (100MHz, CDCl3) δ 13.4 (CH3), 42.5 (4-CH), 52.1 (OCH3), 55.5 
(3-CH), 92.6 (CCl3), 118.9 (1-CH2), 132.2 (2-CH), 160.9 (Cl3CC=O), 173.8 (5-C=O); [α]24D 
+65.6, (c = 1.0, CHCl3); IR (thin film) max = 3419, 3029, 2965, 2926, 2870, 1496, 1454, 1038, 
742, 700 cm-1; HRMS (ESI) observed (M+H)+ 287.9956, calculated for 
C9H13O3NCl3 287.9955. 
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(2S,3R)-Methyl 2-methyl-3-(2,2,2-trichloroacetamido) pent-4-enoate, 221 and (2R,3R)-
Methyl 2-methyl-3-(2,2,2-trichloroacetamido)pent-4-enoate, 222. A solution of a (5:3) 
diastereoisomeric mixture of acids 215 and 220 (210 mg, 770 µmol) in anhydrous diethyl 
ether (4.5 mL) was treated with the dropwise addition of a commercial solution of TMS-
diazomethane in hexanes (0.8 mL, 2.0 M, 1.6 mmol). The resulting yellow solution was 
stirred overnight, and was subsequently quenched by the sequential and careful addition 
of glacial acetic acid (180 µL, 2.62 mmol) and potassium fluoride (50 mg, 860 µmol). After 
the mixture was stirred for 10 min, the solution was treated with an aq. solution of HCl 
(1.0 M, 2 x 10 mL), and the layers were subsequently separated. The organic phase was 
dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced 
pressure to afford the crude esters 221 and 222 (359 mg) as a yellow oil. Purification by 
flash column chromatography (silica gel, elution gradient 0-10% ethyl acetate in 40-60 
petroleum ether) provided the desired methyl esters 221 and 222 as a viscous, clear oil and 
as an inseparable (5:3) mixture of syn- and anti-diastereomers (60 mg, 27%). The TMS-
methyl esters 223 and 224 (115 mg, 42%, d.r. 5:3) were also isolated as an inseparable 
mixture of diastereomers. 
The diastereomeric mixture was then loaded onto a semi-preparative HPLC under reverse 
phase conditions as a MeCN/H2O (50:50) stock solution (C18 column). The separation was 
achieved using the following elution profile: initial elution gradient increased the 
acetonitrile concentration from 25% to 45% over 20 min. The concentration was kept at 
45% for 55 min and was then increased from 45% to 95% over 5 min. Finally, the 
concentration was kept at 95% for an additional 10 min at which point the run was 
terminated. Methyl ester 221 was isolated after 52.85 min.  Methyl ester 222 was isolated 
after 55.90 min. Finally, the enriched fraction containing TMS methylene ester 223 was 
isolated after 68.48 min (syn:anti 7.5:1.0). In all cases, the optimized detection wavelength 
was 214 nm.  
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221. 1H NMR (400MHz, CDCl3) δ 1.21 (3H, d, J = 7.3 Hz, 4-CH3), 2.84 (1H, qd, J = 7.3, 4.7 
Hz, 4-CH), 3.70 (3H, s, OCH3), 4.51 (1H, m, 3-CH), 5.26 (1H, appdt, J = 10.3, 1.0 Hz, 1-CH), 
5.28 (1H, appdt, J = 17.1, 1.0 Hz, 1-CH’), 5.77 (1H, ddd, J = 17.0, 10.3, 6.6 Hz, 2-CH), 7.71 
(1H, bd, J = 7.2 Hz, NH); 13C NMR (100MHz, CDCl3) δ 13.4 (CH3), 42.5 (4-CH), 52.1 
(OCH3), 55.5 (3-CH), 92.6 (CCl3), 118.9 (1-CH2), 132.2 (2-CH), 160.9 (Cl3CC=O), 173.8 (5-
C=O); [α]24D +65.6, (c = 1.0, CHCl3); IR (thin film) max = 3419, 3029, 2965, 2926, 2870, 1496, 
1454, 1038, 742, 700 cm-1; HRMS (ESI) observed (M+H)+ 287.9956, calculated for 
C9H13O3NCl3 287.9955. 
 
222. 1H NMR (400MHz, CDCl3) δ 1.30 (3H, d, J = 7.2 Hz, 4-CH3), 2.84 (1H, qd, J = 7.2, 3.8 
Hz, 4-CH), 3.71 (3H, s, OCH3), 4.55 (1H, m, 3-CH), 5.20 (1H, ddd, J = 10.5, 1.5, 0.5 Hz, 1-
CH), 5.27 (1H, ddd, J = 17.2, 1.6, 0.5 Hz, 1-CH’), 5.80 (1H, ddd, J = 17.2, 10.5, 5.2 Hz, 2-CH), 
8.02 (1H, bd, J = 5.6 Hz, NH); 13C NMR (100MHz, CDCl3) δ 15.3 (CH3), 42.4 (4-CH), 52.1 
(OCH3), 55.2 (3-CH), 92.8 (CCl3), 116.9 (1-CH2), 134.7 (2-CH), 161.9 (Cl3CC=O), 175.7 (5-
C=O); [α]24D +26.8, (c = 1.0, CHCl3). 
 
(2S,3R)-(Trimethylsilyl)methyl-2-methyl-3-(2,2,2-trichloroacetamido)pent-4-enoate, 223. 
1H NMR (400MHz, CDCl3) δ 0.07 (9H, s, Si(CH3)3), 1.23 (3H, d, J = 7.3 Hz, 4-CCH3), 2.84 
(1H, qd, J = 7.3, 4.6 Hz, 4-CH), 3.77 (1H, d, J = 14.1 Hz, OCH3), 3.88 (1H, d, J = 14.1 Hz, 
OCHSiMe3), 4.51 (1H, m, OCH’SiMe3), 5.28 (1H, appdt, J = 10.4, 1.0 Hz, 1-CH), 5.31 (1H, 
appdt, J = 17.2, 1.0 Hz, 1-CH’), 5.79 (1H, ddd, J = 17.1, 10.4, 6.7 Hz, 2-CH), 7.85 (1H, bd, J = 
7.4 Hz, NH); 13C NMR (100MHz, CDCl3) δ -3.1 (Si(CH3)3), 13.8 (4-CCH3), 42.7 (4-CH), 55.8 
(OCH2), 58.6 (3-CH), 92.7 (CCl3), 119.1 (1-CH2), 132.2 (2-CH), 161.0 (Cl3CC=O), 174.3 (5-
C=O). [α]24D +41.9, (c = 1.0, CHCl3) enriched fraction (syn:anti 7.5:1.0). 
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(2R,3R)-(Trimethylsilyl)methyl-2-methyl-3-(2,2,2-trichloroacetamido)pent-4-enoate, 224. 
1H NMR (400MHz, CDCl3) δ 0.06 (9H, s, Si(CH3)3), 1.29 (3H, d, J = 7.2 Hz, 4-CCH3), 2.84 
(1H, qd, J = 7.2, 3.8 Hz, 4-CH), 3.81 (1H, s, OCH3), 3.82 (1H, s, OCHSiMe3), 4.51 (1H, m, 
OCH’SiMe3), 5.20 (1H, ddd, J = 10.4, 1.5, 0.6 Hz, 1-CH), 5.26 (1H, ddd, J = 17.1, 1.5, 0.6 Hz, 
1-CH’), 5.79 (1H, ddd, J = 17.1, 10.4 Hz, 1 unresolved coupling, 2-CH), 8.14 (1H, bd, J = 8.2 
Hz, NH); 13C NMR (100MHz, CDCl3) δ -3.1 (Si(CH3)3), 15.5 (4-CCH3), 42.5 (4-CH), 55.2 
(OCH2), 58.6 (3-CH), 92.8 (CCl3), 116.8 (1-CH2), 134.9 (2-CH), 162.0 (Cl3CC=O), 175.6 (5-
C=O). IR (thin film) max = 3340, 2958, 1718, 1509, 1298, 1252, 1180, 1154, 843, 822, 681 cm-1; 
HRMS (FAB+) observed (M+H)+ 360.0355, calculated for C12H21O3NCl3Si 360.0356. 
 
 
(2S,3R,4E,6E,8R,9R)-Methyl 9-methoxy-2,6,8-trimethyl-10-phenyl-3-(2,2,2-
trichloroacetamido)deca-4,6-dienoate (enantio-N-TAC-iso-ADDA methyl ester), 235; and 
(2R,3R,4E,6E,8R,9R)-Methyl 9-methoxy-2,6,8-trimethyl-10-phenyl-3-(2,2,2-
trichloroacetamido)deca-4,6-dienoate (enantio-N-TAC-ADDA methyl ester), 236.  
General procedure: Neat methoxy diene (E)-117 (140 mg, 608 µmol) and the (5:3) 
diastereomeric mixture of methyl esters 221 and 222 (263 mg, 911 µmol) were placed in a 
round bottom flask equipped with a reflux condenser, and wrapped up in aluminium foil. 
Second generation Hoveyda-Grubbs catalyst (40 mg, 64 µmol, 7.0 mol%) was then quickly 
introduced to the reaction followed by the fast addition of anhydrous tetrahydrofuran (20 
mL). The mixture was then immediately placed in an oil bath pre-heated at 110 °C, and the 
reaction mixture was refluxed under argon until completion as indicated by TLC analysis 
(24 h). The reaction was cooled down to room temperature, and was then diluted with 
hexanes (30 mL), which caused the catalyst derivatives to crash out of solution. Filtration 
of the solid residue, followed by concentration of the remaining organic solvent under 
reduced pressure afforded a crude light brown oil. [Note: When dealing with microscale 
amounts, a better work-up procedure involves the simple evaporation of the solvent 
under vacuum followed by purification of the crude residue]. The crude oil was purified 
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by flash column chromatography (silica gel, elution gradient 0-10% ethyl acetate in 40-60 
petroleum ether) to afford the heterodimers 235 and 236 as a light brown and very sticky 
clear oil. A second purification by flash column chromatography (silica gel, 100% toluene) 
was necessary to give the analytically pure heterodimers 235 and 236 (269 mg, 90%) as an 
inseparable (5:3) mixture of diastereomers. 
The same procedure was repeated for the successful cross coupling of each individual 
diastereomerically pure ester 235 and 236. 
Enantio-N-TAC-iso-ADDA methyl ester, 235. 1H NMR (400MHz, CDCl3) δ 1.03 (3H, d, J = 
6.8 Hz, 3-CCH3), 1.23 (3H, d, J = 7.3 Hz, 9-CCH3), 1.62 (3H, d, J = 1.2 Hz, 5-CCH3), 2.61 (1H, 
m, 3-CH), 2.68 (1H, dd, J = 13.9, 7.4 Hz, 1-CH), 2.79 (1H, dd, J = 13.9, 4.6 Hz, 1-CH’), 2.88 
(1H, qd, J = 7.2, 4.5 Hz, 9-CH), 3.20 (1H, m, 2-CH), 3.24 (3H, s, 2-COCH3), 3.73 (3H, s, 10-
COOCH3), 4.57 (1H, apptm, J = 7.9 Hz, 8-CH), 5.42 (1H, dd, J = 15.3, 7.5 Hz, 7-CH), 5.43 
(1H, d, J = 10.6 Hz, 4-CH), 6.28 (1H, d, J = 15.6 Hz, 6-CH), 7.17-7.29 (5H, m, ArH), 7.72 (1H, 
d, J = 8.8 Hz, NH); 13C NMR (100MHz, CDCl3) δ 12.7 (5-CCH3), 13.7 (9-CCH3), 16.1 (3-
CCH3), 37.7 (3-CH), 38.2 (1-CH2), 43.0 (9-CH), 52.1 (COOCH3), 55.7 (8-CH), 58.6 (2-COCH3), 
86.8 (2-CH), 92.8 (CCl3), 120.3 (4-CH), 126.0 (ArCHpara), 128.2 (ArCHortho), 129.4 (ArCHmeta), 
132.2 (ArCIV), 137.4 (7-CH), 139.3 (5-CIV), 139.7 (6-CH), 160.8 (Cl3CC=O), 174.2 (10-C=O); 
[α]24D +12.4, (c = 1.0, CHCl3); IR (thin film) max = 3408, 3356, 3029, 2980, 2953, 2935, 2879, 
1718, 1509, 1456, 1266, 1200, 822, 739, 702 cm-1; HRMS (ESI) observed (M+H)+ 490.1313, 
calculated for C23H31O4NCl3 490.1313. 
Enantio-N-TAC-ADDA methyl ester, 236. 1H NMR (400MHz, CDCl3) δ 1.03 (3H, d, J = 6.8 
Hz, 3’-CCH3), 1.30 (3H, d, J = 7.2 Hz, 9’-CCH3), 1.60 (3H, d, J = 0.9 Hz, 5’-CCH3), 2.60 (1H, 
m, 3’-CH), 2.67 (1H, dd, J = 13.9, 7.5 Hz, 1’-CH), 2.79 (1H, dd, J = 13.9, 4.6 Hz, 1’-CH”), 2.86 
(1H, qd, J = 7.2, 4.0 Hz, 9’-CH), 3.18 (1H, m, 2’-CH), 3.23 (3H, s, 2’-COCH3), 3.72 (3H, s, 10’-
COOCH3), 4.59 (1H, m, 8’-CH), 5.41 (1H, d, J = 9.5 Hz, 7’-CH), 5.44 (1H, dd, J = 15.8, 6.5 
Hz, 4’-CH), 6.24 (1H, d, J = 15.6 Hz, 6’-CH), 7.17-7.29 (5H, m, ArH’), 8.01 (1H, d, J = 9.0 Hz, 
NH’); 13C NMR (100MHz, CDCl3) δ 12.7 (5’-CCH3), 15.3 (9’-CCH3), 16.1 (3’-CCH3), 36.7 (3’-
CH), 38.2 (1’-CH2), 43.3 (9’-CH), 52.1 (COOCH3’), 55.3 (8’-CH), 58.7 (2’-COCH3), 86.9 (2’-
CH), 92.9 (CCl3’), 122.9 (4’-CH), 126.0 (ArCHpara’), 128.2 (ArCHortho’), 129.4 (ArCHmeta’), 
132.1 (ArCIV’), 137.2 (7’-CH), 137.6 (6’-CH), 139.3 (5’-CIV), 161.7 (Cl3CC=O’), 175.9 (10’-
C=O); [α]24D +11.2, (c = 1.0, CHCl3). 
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((2R,3R,4E,6E,8E,10R,11R)-2,11-Dimethoxy-3,5,8,10-tetramethyldodeca-4,6,8-triene-1,12-
diyl)dibenzene, 238. 1H NMR (400MHz, CDCl3) δ 1.05 (3H, d, J = 6.7 Hz, 3-CCH3), 1.70 
(3H, d, J = 1.1 Hz, 5-CCH3), 2.62 (1H, appdt, J = 9.7, 6.7 Hz, 3-CH), 2.70 (1H, dd, J = 13.9, 7.5 
Hz, 1-CH), 2.84 (1H, dd, J = 13.9, 4.5 Hz, 1-CH’), 3.20 (1H, m, 2-CH), 3.25 (3H, s, OCH3), 
5.43 (1H, dd, J = 9.8, 1.1 Hz, 4-CH), 6.20 (1H, bs, 6-CH), 7.17-7.29 (5H, m, ArH); 13C NMR 
(100MHz, CDCl3) δ 12.7 (5-CCH3), 16.4 (3-CCH3), 36.8 (3-CH), 38.3 (1-CH2), 58.6 (OCH3), 
87.1 (2-CH), 125.9 (ArCHpara), 128.1 (ArCHortho), 129.5 (ArCHmeta), 131.6 (6-CH), 133.6 (5-
CIV), 135.1 (4-CH), 139.4 (ArCIV); [α]23D = + 15.0 ° (C = 1.0, CHCl3); IR (thin film) max = 3086, 
3063, 3027, 3007, 2962, 2928, 2871, 2857, 2827, 2245, 1721, 1496, 1455, 1375, 1265, 1217, 1106, 
1082, 909, 759, 732, 701 cm-1; HRMS (CI) observed (M+H)+ 433.3105, calculated for 
C30H41O2 433.3107. 
 
 
(3R,3'R,4R,4'R)-4,4'-((E)-Ethene-1,2-diyl)bis(3-methylazetidin-2-one), (±)-239. 1H NMR 
(400MHz, CDCl3) δ 1.32 (3H, d, J = 7.4 Hz, CH3), 2.89 (1H, qm, J = 7.4 Hz, 2-CH), 3.74 (1H, 
appsex, J = 2.0 Hz, 3-CH), 5.81 (1H, m, 4-CH), 6.55 (1H, bd, J = 8.8 Hz, NH); 13C NMR 
(100MHz, CDCl3) δ 12.6 (CH3), 53.4 (2-CH), 56.9 (3-CH), 131.6 (4-CH), 171.4 (1-C=O); IR 
(thin film) max = 3260, 2968, 2927, 2875, 1735, 1721, 1458, 1383, 1363, 1174, 971, 831, 740, 704 
cm-1. 
 
   
 ()-(3R,3'R,4R,4'R)-tert-Butyl 4,4'-((E)-ethene-1,2-diyl)bis(3-methyl-2-oxoazetidine-1-
carboxylate), ()-240E and  ()-(3R,3'R,4R,4'R)-tert-Butyl 4,4'-((Z)-ethene-1,2-diyl)bis(3-
methyl-2-oxoazetidine-1-carboxylate), ()-240Z. (E/Z = 1:1) 1H NMR (400MHz, CDCl3) δ 
1.36 and 1.37 (6H, d, J = 7.5 Hz, CH3), 1.49 and 1.50 (18H, s, OC(CH3)3), 2.94 (2H, m, 3-CH), 
4.02 (2H, m, 4-CH), 5.85 and 5.86 (2H, d, J = 2.2 Hz, 5-CH); 13C NMR (100MHz, CDCl3) δ 
12.3 and 12.4 (2 x CH3), 27.9 (2 x OC(CH3)3), 51.4 (2 x 3-CH), 59.5 and 59.8 (2 x 4-CH), 83.4 
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(2 x OCMe3), 130.8 and 131.1 (2 x 5-CH), 147.7 and 147.8 (2 x COOtBu), 167.7 (2 x 2-C=O); 
IR (thin film) max = 2974, 2932, 2874, 1806, 1723, 1477, 1456, 1369, 1337, 1315, 1259, 1158, 
1102, 1069, 952, 913, 846, 797, 772, 733 cm-1; Not detected by mass spectroscopy. 
 
  
(2R,3R,E)-3,5-Dimethyl-1-phenylhepta-4,6-dien-2-ol, (E)-241, and (2R,3R,Z)-3,5-
Dimethyl-1-phenylhepta-4,6-dien-2-ol, (Z)-241. A (2.5:1) isomeric mixture of O-TBS 
protected dienes (E)-139 and (Z)-139 (450 mg, 1.36 mmol) was dissolved in anhydrous 
THF (25 mL), and was transferred into a round bottom flask containing flame-activated 
powdered 4Å molecular sieves (2 g). The suspension was treated with 
tetrabutylammonium fluoride (1.0 M in THF, 4.0 mL, 4.0 mmol), and the resulting reaction 
mixture was stirred at room temperature until completion (15 min). The mixture was then 
quenched with water (40 mL), and the reaction extracted with ethyl acetate (2 x 20 mL). 
The organic extracts were combined, dried over anhydrous sodium sulfate, and the 
solvents were removed under vacuum. The resulting brown oil (368 mg) was then purified 
by flash column chromatography (silica gel, 10% ethyl acetate in 40-60 petroleum ether) to 
afford a (2.5:1) isomeric mixture of dienols (E)-241 and (Z)-241 as a colourless and clear 
viscous oil (280 mg, 95%).  
(E)-241. 1H NMR (400MHz, CDCl3) δ 1.11 (3H, d, J = 6.7 Hz, 3-CCH3), 1.59 (1H, d, J = 4.3 
Hz, OH), 1.78 (3H, d, J = 1.1 Hz, 5-CCH3), 2.56 (1H, dd, J = 13.8, 9.4 Hz, 3-CH), 2.61-2.67 
(1H, m, 1-CH), 2.91 (1H, dd, J = 13.8, 3.1 Hz, 1-CH’), 3.64 (1H, m, 2-CH), 5.00 (1H, d, J = 
10.7 Hz, 7-CH), 5.15 (2H, d, J = 17.4, 7-CH’), 5.44 (1H, d, J = 9.8 Hz, 4-CH), 6.41 (1H, dd, J = 
17.4, 10.6 Hz, 6-CH), 7.20-7.33 (5H, m, ArH); 13C NMR (100MHz, CDCl3) δ 12.2 (5-CCH3), 
16.4 (3-CCH3), 38.6 (3-CH), 41.6 (1-CH2), 76.7 (2-CH), 111.4 (7-CH2), 126.4 (ArCHpara), 128.5 
(ArCHortho), 129.3 (ArCHmeta), 134.2 (5-CIV), 135.2 (4-CH), 138.8 (ArCIV), 141.5 (6-CH). 
(Z)-241. 1H NMR (400MHz, CDCl3) δ 1.09 (3H, d, J = 6.8 Hz, 3’-CCH3), 1.62 (1H, d, J = 2.9 
Hz, OH’), 1.77 (3H, d, J = 1.1 Hz, 5’-CCH3), 2.56-2.67 (2H, masked, 3’-CH and 1’-CH), 2.85 
(1H, dd, J = 13.7, 3.8 Hz, 1’-CH”), 3.72 (1H, m, 2’-CH), 5.00 (1H, masked, 7’-CH), 5.15 (2H, 
masked, 7’-CH”), 5.52 (1H, d, J = 9.8 Hz, 4’-CH), 6.44 (1H, dd, J = 17.4, 10.4 Hz, 6’-CH), 
7.20-7.33 (5H, m, ArH’); 13C NMR (100MHz, CDCl3) δ 17.2 (5’-CCH3), 25.6 (3’-CCH3), 38.1 
(3’-CH), 41.1 (1’-CH2), 76.4 (2’-CH), 111.4 (7’-CH2), 126.3 (ArCHpara’), 128.4 (ArCHortho’), 
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129.3 (ArCHmeta’), 134.0 (5’-CIV), 135.2 (4’-CH), 138.8 (ArCIV’), 141.5 (6’-CH); HRMS (CI) 
observed (M+H)+ 217.1587, calculated for C15H21O 217.1592. 
 
 
(2S,3R)-((2R,3R,E)-3,5-Dimethyl-1-phenylhepta-4,6-dien-2-yl) 2-methyl-3-(2,2,2-
trichloroacetamido)pent-4-enoate, (E)-247. To a solution of carboxylic acid 215 (130 mg, 
474 µmol) in anhydrous tetrahydrofuran (8 mL) was added DIPEA (122 µL, 700 µmol) and 
2,4,6-trichlorobenzoyl chloride (141 mg, 90.2 µL, 576 µmol). The reaction was stirred 40 
min at room temperature before being treated with additional anhydrous triethylamine 
(36.3 mg, 50.3 µL, 359 µmol). After stirring for 80 min, the suspension was diluted with 
hexane (20 mL), and filtered through a short pad of Celite. The Celite was flushed with 
hexane (80 mL in total), and the solvent was evaporated under reduced pressure. The 
resulting crude residue was placed into a round-bottomed-flask and carefully dried under 
high vaccum. Anhydrous toluene (8 mL) was added to the dry residue under argon, and 
this solution was treated with a solution of a (2.5:1) isomeric mixture of dienols (E)-241 
and (Z)-241 (150 mg, 693 µmol) and DMAP (80 mg, 660 µmol) in dry toluene (3 mL). The 
reaction turned quickly into a cloudy suspension, which was stirred at room temperature 
for 2 h, before being filtered through a short pad of Celite. After flushing the Celite with 
hexane (80 mL), the solvents were evaporated and the crude oil (469 mg) was purified by 
flash column chromatography (silica gel, 100% chloroform). The pure ester (E)-247 was 
isolated as the major isomer of a complex mixture of inseparable minor isomers, and as an 
extremely viscous clear and colourless oil (175 mg, 78%). It is worth noticing that the 
excess of dienol was easily recovered during the chromatographic separation. 1H NMR 
(400MHz, CDCl3) δ 1.02 (3H, d, J = 6.7 Hz, 3-CCH3), 1.18 (3H, d, J = 7.3 Hz, 9-CCH3), 1.71 
(3H, d, J = 0.8 Hz, 5-CCH3), 2.63-2.82 (3H, m, 1-CH + 9-CH + 3-CH), 2.97 (1H, dd, J = 14.3, 
4.2 Hz, 1-CH’), 4.39 (1H, m, 10-CH), 5.02 (1H, d, J = 10.7 Hz, 7-CH), 5.12-5.24 (4H, m, 7-CH’ 
+ 2-CH + 12-CH2), 5.30-5.47 (2H, m, 4-CH + 11-CH), 6.37 (1H, m, 6-CH), 7.14-7.27 (5H, m, 
ArH), 7.68 (1H, bd, J = 8.6 Hz, NH); 13C NMR (100MHz, CDCl3) δ 12.2 (5-CCH3), 13.9 (9-
CCH3), 16.6 (3-CCH3), 36.2 (3-CH), 38.2 (1-CH2), 42.6 (9-CH), 55.7 (10-CH), 78.8 (2-CH), 92.7 
(CCl3), 112.1 (7-CH2), 119.4 (12-CH2), 126.6 (ArCHpara), 128.4 (ArCHortho), 129.1 
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(ArCHmeta), 131.9 (11-CH), 133.2 (4-CH), 134.9 (5-CIV), 137.2 (ArCIV), 141.1 (6-CH), 160.9 
(Cl3CC=O), 173.0 (O-C=O); IR (thin film) max = 3407, 3352, 3088, 3066, 3025, 2972, 2924, 
2875, 1718, 1499, 1456, 1217, 1157, 756 cm-1; HRMS (CI) observed (M+H)+ 472.1215, 
calculated for C23H29NO3Cl3 472.1213. 
 
3 - COSY CORRELATIONS 
 
 
 
 
HA HB JAB values 
1 2 7.5 Hz 
1’ 2 4.6 Hz 
2 3 undefined 
3 4 9.8 Hz 
3 3-CCH3 6.7 Hz 
4 5-CCH3 1.2 Hz 
6 7 15.4 Hz 
7 8 8.1 Hz 
8 9 3.0 Hz 
9 9-CCH3 7.4 Hz 
 
 
 
 
HA HB JAB values 
1’ 2’ 7.5 Hz 
1” 2’ 4.6 Hz 
2’ 3’ undefined 
3’ 4’ 9.7 Hz 
3’ 3’-CCH3 6.7 Hz 
4’ 5’-CCH3 1.2 Hz 
6’ 7’ 15.4 Hz 
7’ 8’ 8.1 Hz 
8’ 9’ 3.0 Hz 
9’ 9’-CCH3 7.4 Hz 
 
 
 
HA HB JAB values 
2 2-CCH3 7.4 Hz 
2 3 unseen 
3 4 6.1 Hz 
3 NH undefined 
4 5 15.6 Hz 
7 6-CCH3 undefined 
7 8 9.8 Hz 
8 8-CCH3 6.7 Hz 
8 9 undefined 
9 10 7.5 Hz 
9 10’ 4.5 Hz 
 
 
 
HA HB JAB values 
2 2-CCH3 7.4 Hz 
2 3 unseen 
3 4 6.1 Hz 
3 NH undefined 
4 5 15.6 Hz 
7 6-CCH3 undefined 
7 8 9.8 Hz 
8 8-CCH3 6.7 Hz 
8 9 undefined 
9 10 7.5 Hz 
9 10’ 3.8 Hz 
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